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Summary 
Evidence-based medicine (EBM) is a contemporary practice paradigm with a focus on 
improving outcomes of diagnosis and treatment through effective integration of the best 
available evidence, practitioners’ expertise and individual patients’ preference. In this project, 
Chinese herbal medicine (CHM) for insomnia is used as an example to illustrate the available 
evidence and identify CM practitioners’ attitudes, knowledge, skills, behaviours and barriers 
towards evidence-based practice (EBP). Understanding and addressing these factors will 
contribute to the enhancement of the practice of Chinese medicine (CM) as well as to set the 
priorities for CM education, research and policy development. 
CHM is increasingly used for insomnia in China and worldwide, and has been extensively 
researched and used in clinical practice. Therefore, it is a suitable exemplar providing insight 
into EBM in the context of CM practice. Insomnia is the most common sleep-wake disorder 
with notable health, social and economic burden. Cognitive and behavioural therapy for 
insomnia (CBT-i) and pharmacotherapy are commonly used to manage symptoms. However, 
many sufferers seek complementary and alternative medicine (CAM) to improve their sleep 
and to manage daytime dysfunction. As a form of CAM, Chinese medicine has a long history 
of use for insomnia and continues to be frequently utilised. Emerging preclinical and clinical 
evidence suggests that CHM may be beneficial for improving sleep quality. Despite the 
frequent use of CHM for insomnia it remains largely unclear if CM doctors use EBM to 
inform their clinical practice. Therefore, this project uses a step-wise approach to understand, 
firstly, the best available evidence of CHM for insomnia and secondly, to what extent is the 
evidence being translated into clinical practice.   
The present study consists of four components: 1) a systematic review (SR) of randomised 
controlled trials (RCTs); 2) a systematic analysis of the historical literature; 3) a quantitative 
survey of CM practitioners; and 4) a qualitative interview of CM practitioners. 
Part One: Current Clinical Evidence of CHM for Insomnia: A Systematic Review and 
Meta-Analysis 
This SR with meta-analysis answers the following research questions:  
 15 
 Does CHM produce beneficial effects in people with insomnia in terms of sleep 
quality?’  
 Does CHM cause any adverse events in people with insomnia and, if so, what is the 
nature of the adverse events?’ 
Seventy-nine RCTs involving 7, 886 participants were included in the SR and 76 in the meta-
analyses. Findings from this review revealed that CHM improves subjective sleep quality and 
quantity in people with insomnia. There was no significant difference between CM and the 
placebo with respect to the frequency and severity of adverse events. Firm conclusions could 
not be drawn on the comparative effectiveness between CHM and benzodiazepine drugs or 
psychotherapy due to heterogeneity and risks of bias in the included RCTs. 
Part Two: Traditional Use of CHM for Insomnia: A Systematic Analysis of the 
Historical Literature 
This part of the research answers the following research questions:  
 What Chinese herbal formulae and individual herbs had been referenced and indicated 
for the treatment of insomnia in the historical literature?’ 
  Is there a difference between traditional and contemporary use of CHM for insomnia 
and, if so, what are the implications for research and practice?’ 
The analysis revealed that there were 729 citations involving multi-herb formulae of CHM 
for insomnia. These herbal formulae were used for people with insomnia based on the CM 
diagnostic framework. Gender, age and concurrent conditions affected the formulae selection. 
There has been strong continuity with regard to the clinical application of the most common 
CHM formulae and herbs for insomnia. Varied CHM formulae might be used according to 
the distinct phenotypes, stages and severity of insomnia that were traditionally identified as a 
‘Syndrome’ or ‘pattern’. By taking together the empirical use, contemporary practice and 
evidence, Suan zao ren tang and Wen dan tang were the most frequently used and potentially 
promising candidates for further evaluation and therapeutic development. 
Part Three: A Quantitative Survey of CM Practitioners Assessing the EBP of CHM for 
Insomnia 
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This part of the research answers the following research question:  
 What are the CM practitioners’ attitudes, knowledge, skills, behaviours and barriers 
related to the EBP of CHM for insomnia? 
A quantitative survey of CM practitioners from the two large academic bodies of CM in 
Guangdong Province (China) was undertaken. Most survey participants showed positive 
attitudes to EBM and acknowledged the necessity of applying EBM in the field of CHM for 
insomnia. More than half of the participants remained conservative about their overall 
knowledge and skills of EBM. Less than half of participants believed they had implemented 
EBP of CHM for insomnia, but they appeared to be inactive in seeking clinical practice 
guidelines to assist in their decision-making. The top barriers to EBP included insufficient 
high-quality evidence, inadequate research skills to understand EBM and a lack of 
generalisability of the research findings to patients. Thirteen potential factors were identified 
that related to EBP of CHM for insomnia. The logistic regression and factor analysis 
determined the essential factors explaining the behaviours related to EBP of CHM for 
insomnia, including motivation and goals and the knowledge and skills associated with EBM. 
Part Four: A Qualitative Interview of CM Practitioners Exploring Their Perspectives 
on EBM and EBP of CHM for Insomnia 
The final part of the research explores in greater details the way CM practitioners perceived 
EBM and their behaviours related to EBP of CHM for insomnia. 
A qualitative interview of the CM practitioners was conducted. All the interviewees showed 
positive attitudes to EBM and acknowledged the benefits of EBP of CHM for insomnia. 
Interviewees demonstrated their understanding of EBM was in line with the commonly 
understood definition. Also, they understood the importance of critical thinking when they 
applied senior practitioners’ experience in practice, though they acknowledged the benefits of 
apprenticeship to improving clinical practice. The barriers to applying contemporary 
evidence in CM practice were explained within the context of the directness, quality and 
production of evidence. As a unique characteristic of CM, the principle ‘individualised 
treatment’ was considered to influence the decision-making and utilisation of CM evidence in 
EBP. The interviewees indicated that they updated their knowledge of conventional medicine 
by reading the latest research and clinical practice guidelines. However, they updated their 
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CM knowledge by reading the historical literature and apprenticeship to meet needs of 
enhancing their clinical practice because of their similarity to clinical scenarios. 
Based on findings from Parts 3 and 4, a theoretical framework useful for evidence-based CM 
practice (EBCMP) was constructed by mixed analyses of the quantitative survey (Part 3) and 
qualitative interview (Part 4). The framework included four factors to improve EBCMP, 
namely, 1) motivation and goals for EBM, 2) belief about the consequence of EBM, 3) 
fundamental training of EBM and 4) capacity of EBP. It also included two CM-specific 
obstacles to EBCMP, namely, 1) the indirectness of CM evidence and 2) the low-quality 
evidence of CM. 
Conclusion 
CHM has a long history of treating insomnia and related symptoms. The key formulae and 
individual herbs have been consistently used in both ancient and contemporary practice. A 
meta-analysis indicated that there was promising evidence on the benefit of CHM formulae 
for improving subjective sleep quality and quantity. When compared with current 
pharmacotherapy and/or psychotherapy, the effectiveness of CHM was uncertain due to the 
risk of bias and heterogeneity of the RCTs included in the analyses. Hence, caution should be 
given when translating these findings into clinical decision making. 
A survey and an interview of CM practitioners demonstrated their overall positive attitudes 
towards EBP on CHM for insomnia. Capacity building on EBM and the quality of clinical 
evidence of CM have been identified as major gaps for promoting EBP. Based on these 
findings, a theoretical framework has been proposed for enhancing EBCMP. Further 
evaluation on the effectiveness of this framework is required to strengthen the EBP in CHM 
for insomnia. Knowledge gained from this process will be transferrable to the global 
development of CM as a form of EBP that meets the public expectation of evidence 
generation, evaluation and translation (eGET). 
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Chapter 1. Introduction 
1.1. Background 
Insomnia is a common sleep-wake disorder that is characterised by dissatisfaction with sleep 
quantity or quality with predominant complaints of difficulty in falling asleep, maintaining 
sleep or early wakening despite adequate time and opportunity of sleep (1). It is prevalent 
globally (2), resulting in notable physical, psychological and socio-economic impairments 
(3). Cognitive and behavioural therapy for insomnia (CBT-i) is currently recommended as the 
first-line treatment that is supported by growing evidence of greater benefit and less harm (4). 
The short-term use of pharmacotherapy is also considered for people with insomnia when 
CBT-i is not producing a satisfactory outcome or when it is not available (5). 
Chinese medicine (CM) has a long history of being utilised to treat insomnia (6). Though CM 
has a unique theory explaining the pathogenesis of insomnia, the major differences between a 
conventional and CM diagnosis are the extent of clinically bothersome symptoms and 
severity of insomnia (7). The CM diagnosis does not quantify the duration of symptoms or 
nights with impairment. 
Chinese herbal medicine (CHM) is one of the most common CM therapies for insomnia (8). 
It can be prescribed along or co-administrated with conventional treatments (9). Recently, its 
use has gradually increased as a form of complementary and alternative medicine (CAM) in 
the Western world (10). Though the mechanism of CHM for insomnia is not fully elucidated, 
many pharmacological studies suggest that it mainly targets the neurotransmitter gamma-
aminobutyric acid (GABA) pathway (11). Growing clinical evidence also reveals its potential 
benefit in safely improving the subjective sleep measurements among the people with 
insomnia (12). Considering its public popularity and emerging research, various governing 
societies have started evaluating the evidence and grading the recommendation strength of 
CHM for insomnia in clinical practice guidelines (13, 14). 
1.2. Rationale 
There is an unmet need to improve the sleep quality and associated daytime symptoms of 
people with insomnia. CHM has been used in China for thousands of years to treat clinical 
conditions such as insomnia, and it continues to be utilised in both the East and West. By 
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critical evaluating its historical literature, contemporary clinical evidence as well as the 
current practice, the extent of its effect and usefulness can be elucidated. 
In today’s China, the clinical evidence-based practice (EBP) guidelines specific to CHM for 
insomnia have been developed to assist CM practitioners’ clinical decision-making (15). 
However, its use takes a different view regarding the evidence hierarchy compared to the 
traditional use of CHM. CM theory and practice emphasises anecdotal evidence and 
experience from senior practitioners, while EBP prioritises clinical trials of interventions. 
Thus, a research question generated from this distinction is whether CM practitioners 
specialised in CHM for insomnia are well prepared for EBP. 
A national survey conducted in mainland China indicated that most CM practitioners had 
heard of evidence-based medicine (EBM) and supported its use but admitted they had 
insufficient knowledge of EBM and seldom incorporated it into their daily practice (16). An 
interview of CM practitioners in Europe investigating their understanding of EBM concluded 
that the application of the complete EBM process in CM practice was completely absent (17). 
These studies evaluated a broad range of CM practitioners from different specialities but the 
use of EBM in a single area was not undertaken. Focusing on one speciality or disease, such 
as insomnia, may provide a detailed explanation of the behaviours and issues surrounding the 
application of EBP in a clinical setting. 
To inform the EBP of CHM for insomnia, it is necessary to identify CM practitioners’ 
attitudes, understandings, knowledge, skills, behaviours and barriers to EBP. This will also 
help to develop an appropriate direction for CM education, research and policymaking. 
1.3. Aims and Research Questions 
Overall, this study is to evaluate the traditional knowledge, contemporary clinical evidence, 
CM practitioners’ EBP and associated perspectives in the field of CHM for insomnia. The 
specific aims and relevant research questions are: 
1) To systematically evaluate the efficacy and safety of CHM treatment for insomnia. 
• Does CHM produce beneficial effects in the people with insomnia in terms of 
sleep quality and quantity? 
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• Does CHM cause any adverse events in people with insomnia, and, if so, what is 
the nature of the adverse events? 
2) To systematically analyse the historical use of CHM for insomnia. 
• What Chinese herbal formula and herbs have been referenced and indicated for 
the treatment of insomnia in the historical literature? 
• Is there a difference between traditional use and contemporary evidence of CHM 
for insomnia and, if so, what are the implications for research and practice? 
3) To survey a representative sample of CM practitioners to identify their attitudes, 
knowledge and behaviours related to EBP of CHM for insomnia. 
• What are the numeric overviews of attitudes, knowledge and behaviours related to 
EBP among CM practitioners who specialise in insomnia treated with CHM? 
• What are CM practitioners’ barriers to EBP of CHM for insomnia? 
4) To explore CM practitioners’ opinions on EBM and EBP of CHM for insomnia. 
• What are CM practitioners’ in-depth understandings of EBM? 
• What are the in-depth explanations to CM practitioners’ attitudes, knowledge, 
behaviours and barriers related to EBP of CHM for insomnia? 
5) To further generate a theory explaining the evidence-based CM practice (EBCMP) 
among CM practitioners. 
• What are the essential factors explaining the behaviours related to EBCMP? 
1.4. Significance 
The best available clinical evidence of CHM for insomnia identified by the SR will improve 
future EBCMP. The similarities and differences between traditional use and contemporary 
evidence found by analysing the historical literature will outline the unique characteristics of 
EBCMP and direct future research. By incorporating the quantitative survey and qualitative 
interview, the overview of CM practitioners’ attitudes, knowledge and behaviours related to 
EBP of CHM for insomnia will generate a theory explaining EBCMP. To summarise, the 
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whole study will inform better practice, education and research directions for CM by 
investigating the typical case ‘CHM for insomnia’. 
1.5. Scope and Organisation of the Thesis 
Insomnia is understood as a disorder but was previously viewed as a complaint. This 
difference might affect its conceptualisation from research and clinical perspectives. The 
onset of insomnia may be situational and resolved when the cause is withdrawn, whereas 
insomnia as a disorder should be diagnosed according to standard criteria and systematically 
treated. In this thesis, insomnia is defined as a disorder. Though an ideal EBP incorporates 
the best available evidence, clinical expertise and patients’ values and preferences, the thesis 
investigates EBP only from the perspective of evidence and practice. The contribution from 
patients’ values and preferences will be researched in the future. 
This thesis includes eight chapters: 
Chapter 1 introduces the background, rationale, aims, research questions and significance of 
the PhD research as well as outlines the whole thesis. 
Chapter 2 comprises an overview of insomnia, including its definition, epidemiology, 
pathogenesis, diagnosis and treatments. In addition to conventional treatments, such as CBT-i 
and pharmacotherapy, the CM therapies for insomnia are also described. 
Chapter 3 presents a SR of RCTs on CHM for insomnia, including detailed methods and the 
results of meta-analyses. The findings are also discussed. 
Chapter 4 describes a systematic search and evaluation of the pre-contemporary literature 
within The Encyclopaedia of Traditional Chinese Medicine 5th edition to reveal the historical 
use of CHM for insomnia. The identification of search terms, citation categorisation and 
coding, analyses of Chinese herbal formulae and associated factors are presented. The 
comparison between traditional use and contemporary evidence is also discussed. 
Chapter 5 discusses the methodological issues and data-analysis framework of a mixed-
method design, consisting of a quantitative survey and a qualitative interview. The 
development of the survey instrument and pilot study is also included. This chapter informs 
the specific design and methods used in Chapter 6 and Chapter 7. 
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Chapter 6 presents a quantitative survey of CM practitioners for assessing their attitudes, 
behaviours, knowledge, skills and barriers related to the EBP of CHM for insomnia. In 
addition to describing the numeric measurements, further statistical findings of the 
associations between domains and a multivariate logistic regression model are also 
illustrated. Explanations to the findings and how it forms the qualitative interview (see 
Chapter 7) are discussed. 
Chapter 7 presents a qualitative interview of CM practitioners for their perspectives on EBM 
and EBP of CHM for insomnia. In addition to analysing the interview alone, by incorporating 
the findings from the survey and the interview through triangulation and theorisation are also 
described. 
Chapter 8 summarises and discusses the research findings. It also provides implications for 
the improvement of evidence production, EBM education and CM practice. Limitations and 
future research directions are also described.  
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Chapter 2. Overview of Insomnia Diagnosis and Treatment 
2.1. Introduction 
This chapter comprises an overview of insomnia, including its definition, epidemiology, 
pathogenesis, diagnosis and treatments. In addition to conventional treatments such as CBT-i 
and pharmacotherapy, CM therapy for insomnia is also described because of its long tradition, 
popularity to the public and growing research. 
2.2. Definition of Insomnia 
Insomnia is a common sleep-wake disorder that is characterised by dissatisfaction with sleep 
quantity or quality with predominant complaints of difficulty in falling asleep, maintaining 
sleep or early wakening, leading to daytime distress or functional impairments despite 
adequate time and opportunity of sleep (1). 
Insomnia may occur independently or concurrently with another medical condition (17, 18). 
However, the causal relationship between insomnia and other conditions remains unclear 
(19). Therefore, insomnia can be diagnosed alone or alongside another condition. Whether 
insomnia is diagnosed primarily or not depends on its significance in the overall clinical 
picture. 
Previously, insomnia was usually classified as primary or secondary regarding the cause (20). 
However, given recent developments in research and practice, the concept of insomnia and 
comorbid insomnia are used in this chapter. 
2.3. Epidemiology of Insomnia 
2.3.1. Prevalence 
Around one-third of adults experience insomnia and approximately 6–10 per cent worldwide 
meet the diagnosis for insomnia (2). An international survey conducted in the United States 
(US), France and Japan indicated that almost half of people (48.7%) had chronic insomnia 
(21). Another cross-sectional study conducted in France, the United Kingdom, Germany, 
Italy, Portugal, Spain and Finland reported that 8.5 per cent of people had sleep 
dissatisfaction (22). A 2010 national survey in Australia suggested the overall prevalence of 
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severe insomnia was 6.9 per cent (23). In Shanghai, China, a community survey reported 
around 41.5 per cent of participants had poor sleep quality (24) and in Hong Kong the 
prevalence of insomnia was about 39.4 per cent and affected 2.2 million adults (25). These 
studies show that insomnia affects large numbers of people globally. However, the specific 
prevalence may be affected by different insomnia definitions, screening instruments and 
participant characteristics. 
2.3.2. Natural History 
The onset of insomnia can occur at any time but the first episode is more prevalent in earlier 
life (26). Though insomnia may also have a late-life onset, it is partially explained by the 
onset of health problems with ageing (27). In women, new-onset insomnia commonly occurs 
during menopause (28). Episodic insomnia may develop into chronic or persistent insomnia if 
the initial onset is severe (29). 
2.3.3. Risk Factors 
Risk factors increase vulnerability to insomnia. Epidemiological research shows that women, 
the elderly, psychosocial stressors and people with mental or physical conditions are more 
likely to suffer from insomnia than the general population (30). The Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (1) categorises the risk factors 
as temperamental, environmental, genetic/physiological factors and course modifiers (see 
Figure 2.1). 
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Figure 2.1. Category of risk factors for insomnia 
Note. The figure is edited based on the text from American Psychiatric Association (1 p. 366). 
2.3.4. Health Consequences 
People who suffer with insomnia usually present with daytime cognitive impairments, 
including poor memory and reduced executive functioning (31). Although the association 
between insomnia and other medical conditions has yet to be elucidated, longitudinal studies 
have suggested that compared to good sleepers, people with persistent sleep disturbances are 
associated with a higher risk of developing depression and anxiety (32), type 2 diabetes (33), 
hypertension (34), cardiovascular disease (35) and stroke (36) in the long term. 
2.3.5. Socio-Economic Impact of Insomnia 
The socio-economic impact of insomnia includes impaired work performance, increased 
traffic accidents and enhanced economic costs (38). Epidemiological studies show that the 
complaint of insomnia is the most predictable factor for absenteeism (39) and populations 
with insomnia have double the rate of absenteeism than good sleepers (39, 40). In the 
workplace, low productivity (41), increased errors, poor work efficiency, inability to 
complete complicated tasks (39) and greater work disability (42) are also observed more 
frequently in populations with insomnia than in good sleepers. People with insomnia are 
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more likely to have traffic accidents, which is associated with the side effect of hypnotic 
medications (43). 
The economic costs of insomnia consist of direct costs, such as charges for clinic visits, sleep 
assessments and therapy specific for insomnia, and indirect costs, such as payments for 
insomnia-related morbidity and costs associated with social impairments (44). The economic 
burden is notable. Taking the US as an example, estimates of the total annual cost of 
insomnia ranges from 28.1 billion USD to 216.6 billion USD (45, 46). 
2.4. Pathophysiology of Insomnia 
Insomnia is often considered a state of hyperarousal experience, although its pathophysiology 
is not fully understood. The arousal state is currently explained by cognitive and 
physiological models. From the cognitive perspective, people with insomnia tend to be 
worried about their inability to sleep and the resultant consequences. This excessive 
negatively toned cognitive activity triggers arousal and distress that may lead to selective 
attention and monitoring of sleep-associated effects (47). Finally, the anxious state and 
abnormal attention result in a distorted perception of sleep and relevant performances (47). 
The physiological model is supported by multifaceted evidence of sleep-wake regulation 
neurotransmitters such as serotonin and GABA; endocrine molecules such as cortisol, 
adrenocorticotropic hormone, melatonin, norepinephrine and IL-6; and polysomnographic 
changes such as the frequent occurrence of non-rapid eye movement (NREM) sleep (48). The 
physiological model informs the discovery of pharmacological agents for insomnia such as 
benzodiazepine receptor agonists (BZRAs). 
In addition to the hyperarousal theory, the 3Ps model—also called the Spielman Model—
including predisposing, precipitating and perpetuating factors are used for the 
conceptualisation of elements that lead to the development and maintenance of insomnia 
(49). Predisposing factors, often presenting before insomnia is manifested, refer to trait-like 
characteristics related to a higher risk of insomnia in vulnerable individuals (50). 
Precipitating factors are life events that act as triggers of insomnia, such as mental illness or 
stress. Perpetuating factors refer to individuals’ thoughts, feelings and behaviours adopted to 
cope with insomnia (50). More and more evidence explains the genetic and epigenetic 
background of insomnia, including familial aggregation with high heritability of insomnia, 
specific genotypes accounting for the phenotypic variance in insomniacs and the mechanisms 
 27 
of sleep regulation, such as clock genes (51). Thus, personal vulnerability might contribute to 
a maladaptive response to acute stressful events and the possibility that the perpetuation of 
insomnia may be caused by the epigenetic alternation of biological processes in addition to 
behavioural factors (51). These new findings inform the phenotype-oriented therapy. 
2.5. Diagnosis of Insomnia 
2.5.1. Diagnostic Procedure 
The diagnostic procedure usually includes a patient review for subjective experiences, a full 
sleep history and medication and substance use as well as physical and mental examinations 
for relevant symptoms and concurrent conditions (3, 52, 53). 
A comprehensive sleep history commonly consists of sleep hygiene behaviour, sleep habits, 
sleep environment, work schedules and circadian factors (54). A mental status examination is 
mandatory because insomnia may occur concurrently with another mental disorder and long-
term insomnia may develop into other mental disorders, such as depression (3, 52, 53). A 
one- or two-week sleep diary is also recommended to review the subjective quantity of sleep 
(3, 52, 53). The measurements of the subjective quantity and quality of sleep in the previous 
month by the Pittsburgh Sleep Quality Index (PSQI) are helpful but not specifically used for 
diagnosis (55). The Insomnia Severity Index (ISI) is also commonly used as a reliable and 
valid tool to grade insomnia severity (56). 
2.5.2. Diagnostic Instrument 
The definition and diagnosis of insomnia has undergone several revisions and updates over 
recent years (20, 57). Currently the diagnostic criteria vary among different countries and 
academic societies (1, 58–60). However, they all generally diagnose insomnia according to 
the clinical assessment of patient complaints, next-day symptoms, functional impairment, 
attack frequency and persistence. 
2.5.2.1. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
The DSM-5 is one of the most widely accepted and up-to-date diagnostic instruments for 
insomnia. It was published by the American Psychiatric Association in 2013 and is different 
to other instruments because it includes chronicity as a requirement for diagnosis and pays 
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attention to comorbid insomnia. Figure 2.2 shows the diagnostic criteria of insomnia 
according to DSM-5 (1). 
 
Figure 2.2. Diagnostic criteria of insomnia disorder 
Note. The figure is edited based on the text from American Psychiatric Association (1 p. 362). 
2.5.2.2. Other Diagnostic Criteria 
The insomnia diagnosis from DSM-5 corresponds to disorders of initiating and maintaining 
sleep (DIMS), coded as G47.00 under the diseases of the nervous system from the World 
Health Organization International Classification of Diseases, 10th version (WHO ICD-10) 
(59). Non-organic insomnia, coded as F51.0, can also be classified under mental and 
behavioural disorders when it dominates the clinical picture yet develops from a basic 
disorder. The International Classification of Sleep Disorders, Third Edition (ICSD-3) (58), is 
another essential diagnostic guide for clinicians dealing with sleep disorders. It was published 
by the American Academy of Sleep Medicine (AACM) in 2014, updating the knowledge of 
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the International Classification of Sleep Disorders, Second Edition (ISCD-2) (61). The 
criteria in ICSD-3 are similar to the descriptions of DIMS in WHO ICD-10, but its 
classification system no longer contains phenotypes for acquired insomnia because they are 
not reliably reproducible in clinical practice. In China, the Chinese Classification and 
Diagnosis of Mental Disease, Third Edition (CCMD-3) (60) applies the same classification of 
insomnia as WHO ICD-10. Although CCMD-3 is the only diagnostic instrument specific to 
mental disorders, the latest Chinese Guideline on Diagnosis and Treatment of Insomnia 
(CGDTI 2017) published by the Chinese Sleep Research Society (CSRS) (62), endorsed the 
ICSD-3 classification of insomnia. 
Insomnia is classified according to disease course and cause (see Table 2.1). These 
classifications are often used together in the clinical setting to establish the full picture of 
insomnia in an individual patient. However, classifying insomnia according to cause appears 
not always reproducible because of the uncertain causal relationship to insomnia. 
Table 2.1. Classification of Insomnia 
Diagnostic 
Standard 
Based on Disease Course Based on Causes of Disease 
DSM-5 
1. Episodic: ≥1 month and <3 months 
2. Persistent: ≥3 months 
3. Recurrent: Two (or more) episodes within 
the space of one year 
1. Insomnia 
2. Insomnia comorbid 
ISCD-3 
1. Short-term insomnia disorder 
2. Chronic insomnia disorder: ≥3 months and occurs at least three times per week 
3. Other insomnia disorder 
CGDTID 2017 
1. Short-term insomnia disorder 
2. Chronic insomnia disorder: ≥3 months and occurs at least three times per week 
3. Other insomnia disorder 
WHO ICD-10 Not applicable  
1. Organic insomnia 
2. Non-organic insomnia 
CCMD-3 Not applicable  
1. Organic insomnia 
2. Non-organic insomnia 
Note. CCMD-3: Chinese Classification and Diagnosis of Mental Disease, Third Edition; CGDTID 2017: 
Chinese Guideline on Diagnosis and Treatment of Insomnia Disorder, published in 2017; DSM-5: Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition; ISCD-3: International Classification of Sleep 
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Disorders, Third Edition; WHO ICD-10: World Health Organization International Classification of Diseases 
(10th version). 
2.5.3. The Assessment of Polysomnography 
Clinical diagnosis of insomnia is made according to patients’ complaints or subjective 
reports, rather than the assessment of polysomnography (PSG) (13). Although laboratory 
studies reveal a remarkable discrepancy between the subjective experience of insomnia and 
the objective polysomnographic measurement in people with insomnia (63), the additional 
value of PSG as a clinical diagnostic criterion remains uncertain. However, it is mandatory 
when differential diagnosis with other sleep disorders, such as sleep apnoea, restless leg 
syndrome and rapid eye movement (REM) sleep behaviour disorder is considered (13). 
2.5.4. Insomnia and Comorbidity 
Insomnia is a common comorbidity of many medical conditions (19). Figures 2.3 and 2.4 
specify the prevalence of medical conditions (i.e., neurologic disease, breathing disease, 
gastrointestinal disease, urinary disease, chronic pain, high blood pressure and heart disease) 
in people with or without insomnia and the prevalence of insomnia in people with or without 
these medical conditions (64). Epidemiological studies also reveal that the prevalence of 
insomnia is high in people with chronic obstructive pulmonary disease (65), diabetes (66), 
osteoarthritis (67), rheumatoid arthritis and fibromyalgia (68). 
 
Figure 2.3. The prevalence of medical conditions in people with or without insomnia  
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Note. The figure is adapted from Table 1 in Taylor DJ, Mallory LJ, Lichstein KL, Durrence HH, Riedel BW, 
Bush AJ (64). 
 
Figure 2.4. The prevalence of insomnia in people with or without other medical 
conditions  
Note. The figure is adapted from Table 2 in Taylor DJ, Mallory LJ, Lichstein KL, Durrence HH, Riedel BW, 
Bush AJ (64). 
Insomnia also frequently occurs concurrently with mental disorders, particularly depression 
and anxiety. Around 40 per cent of people with chronic insomnia are diagnosed with one or 
more mental disorders compared to 16 per cent of good sleepers (69). An epidemiological 
survey found that, compared to those without insomnia, the lifetime prevalence of insomnia 
increases when it is comorbid with major depression, anxiety and substance abuse (70). Many 
studies have found that depression is the mental disorder most appearing in conjunction with 
chronic insomnia (71–74). People with a depression diagnosis are 2.6 times likely to have 
mild insomnia and 8.2 times likely to have severe insomnia than those without depression 
(75). 
The risk relationship appears to be bi-directional and the relationship may change over time. 
It is almost impossible to establish the precise nature of the relationship from the perspectives 
of either epidemiological research or therapy. Therefore, whether insomnia occurs as an 
independent condition or is comorbid with other conditions should be specified when a 
diagnosis of insomnia is considered; however, making the causal attribution between 
insomnia and a comorbid disorder is unnecessary (1). 
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2.6. Insomnia Treatment 
2.6.1. Therapeutic Goals and Principles 
The general goal of insomnia treatment includes enhancing effective sleep duration, 
improving global sleep quality, reducing daytime impairments as well as lowering the risk of 
insomnia developing into a long-term or other medical condition. Some guidelines 
recommend a clinical assessment of therapeutic outcomes that usually takes place once in 
every month, a thorough examination of insomnia status in every six months and an 
evaluation of the recurrence of insomnia six months after treatment withdrawal (62). 
Insomnia is usually approached by multiple strategies, mainly including sleep hygiene 
education, psychotherapy such as CBT-i, pharmacotherapy and CAM (76). 
2.6.2. Sleep Hygiene Education 
Sleep hygiene education refers to teaching people with insomnia about healthy sleep habits 
and encouraging them to follow a set of behavioural and environmental recommendations 
and other sleep-related factors, such as avoiding caffeine before bedtime, eliminating noises, 
managing stress, maintaining a regular sleep-wake schedule and undertaking regular exercise 
training (77). Sleep hygiene education is considered a basic component of insomnia 
management but the benefit of its independent use is not supported by current clinical 
evidence. 
However, there is no an absolute consensus on which strategy should be included in sleep 
hygiene education. Although there are commonly utilised options, the current 
recommendation is unspecific. For example, the consumption of caffeine is not quantified 
and the techniques of stress management in specific circumstances are unclear. These 
problems may also lead to inconsistent implementation and heterogeneous effectiveness. The 
development of individualised sleep hygiene education is further required as people may have 
various lifestyles and sleeping environments. 
2.6.3. Cognitive and Behavioural Therapy for Insomnia 
CBT-i is considered the most effective and safe intervention for either insomnia or comorbid 
insomnia (4, 78). CBT-i uses a multi-modular approach, including behavioural, cognitive and 
educational modules to help people develop healthier skills and habits to improve their sleep 
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(4, 78–79). Specifically, CBT-i usually comprises sleep hygiene education, sleep restriction, 
stimulus control, cognitive therapy and relaxation (79). Figure 2.5 details the individual 
components (76). 
 
Figure 2.5. Components of CBT-i  
Note. The figure is edited based on the texts from Ree M, Junge M, Cunnington D (76). 
The best available evidence suggests that CBT-i presents a significant effect size in insomnia 
severity, sleep efficiency, global scores of PSQI, wakes after sleep onset and sleep-onset 
latency after treatment, but it has the smallest effect size in improving the total sleep duration 
either for insomnia or comorbid insomnia (80). The clinical evidence also reveals an 
improvement of sleep after the implementation of CBT-i by face-to-face, online, telephone or 
self-help (81). In terms of effect size, face-to-face delivery appears superior to the self-help 
approach and at least four sessions of CBT-i seem to be more effective than fewer sessions 
(80). However, considering the prevalence of insomnia and the economic input, self-help 
strategies are still worthwhile in practice (82). 
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2.6.4. Pharmacotherapy 
Clinical practice guidelines suggest that cautious use of pharmacotherapy is considered 
effective for insomnia when CBT-i is unavailable or unsuccessful. Currently, the major drugs 
are BZRAs, including benzodiazepine drugs (BZDs), such as diazepam, and non-BZDs 
(NBZDs), such as zopiclone. Acute use of BZDs has been proven to have a significant 
benefit for insomnia patients (5). A meta-analysis of BZDs reported that short-term use of 
BZDs produced a benefit compared with the placebo in terms of total sleep duration (mean 
difference [MD]: 61.8 minutes, 95% confidence interval [CI]: 37.4 to 86.2. However, adverse 
events, such as dizziness, headache and daytime drowsiness, were reported in the BZD group 
(odds ratio [OR]: 1.8, 95% CI: 1.4 to 2.4) (83). A meta-analysis of the American Food and 
Drug Administration database revealed that NBZDs showed a significant but mild reduction 
in sleep latency (MD: –22 minutes, 95% CI: –33 to –11) compared with the placebo and 
other drugs (84). However, unusual sleep behaviour was reported after taking NBZDs such as 
zolpidem (85). Another meta-analysis revealed that there was no significant difference 
between BZDs and NBZDs in terms of sleep parameters (86). Also, tolerance significantly 
grew with long-term use of BZDs and rebound insomnia was severe on the first withdrawal 
night for both BZDs and NBZDs (87). In terms of adverse effects, NBZDs are safer than 
BZDs because of their shorter half-life and less impairment in sleep structure (88). Sedating 
antidepressants are effective in the short term but contraindications have to be carefully 
considered and its long-term use is not generally recommended (88). 
Other classes of drugs, such as antihistamines, antipsychotics and melatonin receptor 
agonists, have been used for insomnia but are not routinely recommended due to a lack of 
strong evidence. 
2.6.5. Complementary and Alternative Therapies 
CAM such as herbal medicine and acupuncture are popular among insomnia patients. A 
national survey in the US reported that 45.2 per cent of adults with insomnia used more than 
one CAM therapy compared to 30.9 per cent of adults without insomnia (89). Products such 
as melatonin and valerian were most popular (89). A population-based survey in Hong Kong 
showed the prevalence of CAM for insomnia was 12.3 per cent and CHM was most 
commonly used (7.9%) followed by acupuncture (1.7%) (8). Melatonin, one of the most 
commonly used CAM medicines, is a naturally synthesised hormone. It helps control the day-
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night cycle and when taken as a supplement it can be effective for sleep conditions. However, 
research indicates it is more effective for other sleep conditions, such as circadian rhythm 
disorders (90). Valerian, a flowering plant, significantly improved sleep quality compared 
with the placebo but did not improve sleep latency (91). Despite existing treatments for 
insomnia, new treatments with reliable clinical effects and a good risk-benefit ratio are 
needed. In recent years, CM has been increasingly used as a form of CAM in the Western 
world such as in the US, Europe and Australia (10). 
2.6.6. A Summary of Recommendations in Clinical Practice Guidelines 
Insomnia management slightly varies among countries due to the diverse considerations of 
benefit–harm balance, commercial products approved by the food and drug administrations, 
the healthcare system and socio-economic factors. Clinical practice guidelines of insomnia 
treatments developed by the American College of Physicians (ACP), the AASM, the 
European Sleep Research Society (ESRS), the Australasian Sleep Association (AASA), the 
Sleep Health Foundation in Australia and the CSRS are used as representative references in 
the following section. 
Almost all clinical practice guidelines mentioned above recommend CBT-i as a first-line 
treatment for insomnia, particularly chronic insomnia, although they acknowledge the limited 
access to CBT-i due to the lack of well-trained health professionals and inadequate 
promotion. The ESRS recommends pharmacotherapy when CBT-i is ineffective or 
unavailable (13). The ACP recommends clinicians use a shared decision-making approach to 
decide whether to add pharmacological therapy by discussing the benefits, harms and costs of 
medications with patients (14). The CSRS suggests pharmacotherapy could be used in 
addition to etiological treatment, sleep hygiene education and CBT-i according to patients’ 
insomnia status (76). The AASM states there is no definite priority list of pharmacological 
recommendations; however, BZRAs with shorter half-lives—particularly NBZDs—are 
considered to have less harm (92). CAM therapies such as herbal medicine, acupuncture and 
meditative movement, are not generally recommended by the ACP, ESRS and AASA 
guidelines due to a paucity of evidence. Being different from other healthcare systems, the 
clinical practice guidelines launched by mainland China recommended the appropriate use of 
CHM and acupuncture therapy for insomnia according to CM theory and patients’ individual 
syndromes (62). 
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2.7. Chinese Medicine for Insomnia 
CM originated from ancient China, has a history of more than 2,000 years and includes a 
broad range of traditional clinical practices (6, 93, 94). It is based on the observation of 
nature and human life, integrating medical knowledge and the theory of ancient Chinese 
philosophy and is greatly influenced by levels of science and technology and historical 
culture (6, 93, 94). It holds a holistic view of human beings and highlights physiological 
functions (6, 93, 94). 
Chinese philosophy believes each phenomenon could be categorised into Yin and Yang that 
represent two opposite and complementary features (6, 93, 94). Yin is more allocated to 
things that are static, downwards, cold and dark, while Yang is labelled to things with features 
that are dynamic, upwards, hot and bright (6, 93, 94). The Yin and Yang features of a thing 
could be changed when the reference subject is different (86–88). In addition, the percentage 
of the Yin and Yang of one thing is considered consistently changing (6, 93, 94). Thus, the 
essential component for health in CM is to keep harmony between Yin and Yang. From the 
perspective of CM, the imbalance between Yin and Yang is the fundamental pathogenesis of 
all medical conditions (6, 93, 94). 
In CM, Qi is more likely to be energy in modern understanding, which generates and 
transforms life (6, 93, 94). It flows in all organs and channels of the body and plays an 
essential role in human life. Commonly Qi running interiorly, such as blood vessels, is called 
nutrient Qi and Qi flowing exteriorly, such as the skin, is named as defensive Qi (6, 93, 94). 
The former Qi nourishes the body and the latter defends the body from illnesses (6, 93, 94). 
They also regulate sleep and wake cycles as described in the book entitled the Yellow 
Emperor’s Classic on Internal Medicine (in Chinese: 黄帝内经) (6, 93, 94).  
In CM, Mind is a broad range of consciousness, thoughts, cognition and emotions (86–88). 
CM theory states that disturbance of the mind is the pathogenesis of mental disorders (6, 93, 
94). Five viscera of CM include Heart, Liver, Spleen, Lung and Kidney (this is a unique 
understanding that is not equivalent to anatomic parts of the human body in contemporary 
medicine) (6, 93, 94). These viscera are primarily defined by their functions. CM believes 
that Heart is the engine of the circulation system and the mental governor, Liver regulates the 
flow of Qi and stores the blood, Spleen promotes digestion and generates blood, Lung is the 
respiratory channel and Kidney dominates the urinary and reproductive systems (6, 93, 94). 
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CM theory states that the function of Spleen is more influenced by acquired factors while that 
of Kidney is more congenital (6, 93, 94). 
2.7.1. Insomnia Defined by Chinese Medicine 
There have been several stages of evolution of insomnia in CM. The earliest description of 
symptoms related to insomnia was traced back to the Yellow Emperor’s Classic on Internal 
Medicine approximately 1,500 to 2,000 years ago (95–99). The text described the possible 
mechanisms of insomnia. The most representative citation stated that ‘good sleep could not 
be maintained due to dysfunction of the digestive system’, which informed one category of 
syndrome differentiation and formula prescription in later CM practice (100). The second 
milestone was considered the explanation of insomnia aetiology in Doctor Zhongjing 
Zhang’s Discussion of Cold Damage (in Chinese: 伤寒论), published around 220 AD (100). 
He proposed the idea that both anxiety and fatigue might trigger insomnia. Later, in the 
Chinese Ming dynasty (1368–1644), the theory and treatment of insomnia were 
systematically summarised by several eminent doctors, such as in the Collected Treatises of 
Jing-Yue (in Chinese: 景岳全书) (100). In the Qing dynasty (1644–1911), insomnia was 
found more prevalent in the elderly and it was considered associated with Yang deficiency of 
the Kidney (100). 
Traditionally, CM defines insomnia as frequent dissatisfaction with sleep quantity or quality 
without physical disorders (94). This definition changed in modern times as views of modern 
medicine gradually integrated into CM. In the national traditional CM (TCM) standard in 
Chinese, insomnia is defined as a functional disorder characterised by a night-time sleep 
disorder commonly accompanied by some neurological and cardiac symptoms (101). In the 
latest national expert consensus guidelines for CM, insomnia is considered a disorder only 
when it lasts for more than four weeks (102). In the current EBP guidelines for CM, a 
combination of conventional and CM diagnoses is recommended and insomnia caused by 
other mental disorders, such as depression and anxiety, is not included in the guideline (7). 
The major differences between a conventional and CM diagnosis are the extent of clinically 
bothersome symptoms and the severity of insomnia. Generally speaking, it is similar to the 
conventional definition of ‘insomnia without comorbidity’ (100, 103). However, the CM 
diagnosis does not quantify the duration of symptoms or nights with impairment. 
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2.7.2. Aetiology and Pathogenesis of Insomnia in Chinese Medicine 
The contributing factors are slightly different between CM and modern sleep medicine, as 
lifestyle and culture may influence sleep behaviours. For example, consumption of tea is 
more common than coffee in China (104). Chinese people wake up early and take regular 
naps at noon (105). CM theory states that several factors may induce insomnia, including 
improper diets, such as overeating or drinking tea in the evening, excessive emotions and 
changes in mood, such as extreme anger or fright and an imbalance between work and rest 
(100). People who are congenitally weak, suffering from chronic disease and the elderly are 
more likely to be affected by insomnia (100). 
Three CM theories explain the pathogenesis of insomnia (103). ‘The disharmony between Yin 
and Yang’ is considered the fundamental pathogenesis of insomnia: the imbalance between 
sleep (Yin) and awakening (Yang). ‘Irregular circulation of defensive Qi’ is another 
explanation for insomnia occurrence that also incorporates the previous theory. ‘Disturbance 
of mind’ is the most common theory that informs current CM clinical practice for insomnia 
treatment. According to CM theory, insomnia is mainly caused by dysfunction of Heart and 
is also related to the functioning of Liver, Spleen and Kidney (100). The pathways are 
specified in Figure 2.6. 
 
Figure 2.6. Pathways of insomnia from CM perspective  
Note. Graph A presents the theories ‘the disharmony between Yin and Yang’ and the ‘irregular circulation of 
defensive Qi’. The former is considered the fundamental pathogenesis of insomnia: the imbalance between sleep 
(Yin) and awakening (Yang), while the latter specifies the previous theory. Graph B presents the theory 
‘disturbance of mind’. It is the most common theory that informs current CM clinical practice for insomnia 
treatment. When depressed Liver Qi transforms into fire or internal phlegm-heat exists, the mind is disturbed, 
resulting in insomnia. A collection of deficient conditions could also contribute to the disturbance of mind, such 
as dual deficiency of Heart and Spleen, Qi deficiency of Heart and Gallbladder or non-interaction between 
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Heart and Kidney. Stagnation of blood is also involved if the insomnia is incurable or recurrent over an 
extended period (103). Image source © Xiaojia Ni. 
2.7.3. Therapeutic Principles for Insomnia in Chinese Medicine 
CM treatments for insomnia include CHM, acupuncture and other therapies, such as tuina 
and Tai Chi. Treatment principles in CM are established according to the theories of holism 
and syndrome differentiation. The aim is to regain balance between Yin and Yang and to 
tonify deficiency and reduce excess (6). Specifically for insomnia, the strategies for reducing 
excess include soothing Liver and clearing fire, resolving phlegm and clearing heat, while 
those for deficiency include tonifying and replenishing Qi, nourishing blood and 
strengthening Spleen and Kidney (100). In addition, interventions that sedate and calm the 
mind are important as are treatments that promote blood circulation and resolve stasis for 
people with chronic or recurrent insomnia (100). CM also highlights the importance of 
removing causes of the disease and encourages patients to strengthen their physique to avoid 
illness (100). 
If insomnia is caused by a comorbid condition, it is suggested to combine insomnia therapy 
alongside that of the other conditions, thereby managing the root cause and subsequent 
insomnia symptoms (100, 103). The effectiveness of CM treatment is influenced by insomnia 
duration and its contributing factors (100, 103). When insomnia is acute and the cause is 
simple, CM treatment is effective and quick. However, insomnia of a longer duration and 
complicated cause takes more time to recover. Severe and long-standing insomnia takes 
greater effort to obtain a satisfactory result, particularly when it results in other mental 
disorders, such as depression and anxiety (100, 103). 
In CM, maintaining a good mood, regular work-rest schedule and sleep hygiene, including 
sleeping in a quiet room are important for the prevention of insomnia (100, 103). People with 
insomnia are also advised to maintain physical exercise, such as practising Tai Chi, to 
strengthen their physique (100). 
2.7.4. Chinese Herbal Medicine for Insomnia 
2.7.4.1. Clinical Evidence 
There is a growing body of clinical studies on CHM for insomnia. Five SRs and meta-
analyses had evaluated the benefits of CHM alone or in combination with conventional 
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medicine for insomnia (12, 106-109). In terms of global effective rate, CHM alone or as an 
adjunctive therapy was more effective than pharmacotherapies such as BZDs (106–108). 
However, the conclusions were limited by the poor methodological quality and considerable 
heterogeneity. Yeung et al. (12) found that CHM was equal to either the placebo control or 
pharmacotherapy in terms of global effective rate in a meta-analysis of RCTs with a Jadad 
score greater than three points. In addition, the frequency of adverse events associated with 
CHM was similar to that of the placebo and less than that of pharmacotherapy (12). However, 
a firm conclusion could not be drawn due to the small sample size included in the meta-
analysis and poor methodological quality. Yeung et al. (109) also found improved effective 
rates for pattern-based CHM treatments for insomnia, but more studies were required to draw 
a certain conclusion because the methodological designs and diagnostic processes for pattern 
differentiation of the included studies were of low report quality. 
Overall, previous SRs and meta-analyses have shown the promising effect of CHM for 
insomnia. Despite positive statistical results, almost all the previous reviews used effective 
rate as the primary outcome, which is not a validated outcome and very few applied the 
Cochrane Risk of Bias Assessment Tool and the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) method to evaluate the evidence. 
2.7.4.2. Potential Mechanism 
The underlying pharmacological action of CHM in the treatment of insomnia mainly targets 
the neurotransmitter GABA pathway, including modulating GABAA receptors, enhancing 
GABA synthesis by activating glutamic acid decarboxylase and interacting with GABA 
release (11). This mechanism is also shared by many sedative-hypnotic medications such as 
BZDs. 
Unlike chemical drugs, multi-ingredient formulae are widely used in the field of CHM. It is 
based on the theory of Chinese Materia Medica that each herb plays its specific role in a 
recipe and the synergistic effect of all herbs is better than that of the individual components 
(110). The use is also supported by preclinical evidence (111). The modified Xiao-yao-san 
(in Chinese: 加味逍遥散 ; also called Jia-wei-xiao-yao-san or Dan-zhi-xiao-yao-san), 
introduced by the Summary of Internal Medicine (in Chinese: 内科摘要) during the Chinese 
Ming dynasty (110), is a typical formula for insomnia treatment. Both health insurance 
database analyses and the SR suggest it is one of the most common CHM prescriptions for 
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insomnia in clinical practice (9, 12, 112). It is a multi-herb formula containing Mudanpi 
(English name: Moutan cortex; scientific name: Paeonia suffruticosa Andr.; Chinese: 牡丹皮) 
and Zhizi (English name: Gardeniae fructus; Scientific name: Gardenia jasminoides Ellis; 
Chinese name: 栀子) in addition to a full Xiao-yao-san, including Chaihu (English name: 
Bupleuri radix; scientific name: Bupleurum chinense DC. or B. scorzonerifolium Willd. ; 
Chinese: 柴胡), Danggui (English name: Angelicae sinensis radix; scientific name: Angelica 
sinensis (Oliv.) Diels; Chinese: 当归), Baizhu (English name: Atractylodis macrocephalae 
rhizoma; scientific name: Atractylodes macrocephala Koidz.; Chinese: 白术 ), Baishao 
(English name: Paeoniae radix alba; scientific name: Paeonia lactiflora Pall.; Chinese: 白
芍), Fuling (English name: Poria; scientific name: Poria cocos (Schw.) Wolf; Chinese: 茯苓) 
and Gancao (English name: Glycyrrhizae radix et rhizoma; scientific name: Glycyrrhiza 
uralensis Fisch.or Glycyrrhiza. inflata Bat.or Glycyrrhiza. glabra L.; Chinese: 甘草 ). 
According to traditional rules of Chinese herbal theory, Chai hu, mainly used in the 
improvement of mood disorders, is the King of the formula (110). Compared to the original 
Xiao-yao-san, the modified variation is considered more useful for people with a subjective 
feeling of heat because of the add-on effect of Mudanpi and Zhizi (110). Pharmacological 
studies suggest, by a well-established quantitative method, that 12 absorbed constituents are 
responsible for its overall therapeutic effect, including Geniposide, Puerarin, Paeoniflorin, 
Ferulic acid, Liquiritin, Hesperidin, Naringin, Paeonol, Daidzein, Glycyrrhizic acid, Honokiol 
and Magnolol (113). Although few studies are undertaken specifically for insomnia, in an 
animal model of chronic stress the modified Xiao-yao-san revealed its anxiolytic and 
neuroprotective prosperities via attenuating up-regulation of α-synuclein and corticosterone 
as well as down-regulation of protein phosphatase 2A in the hippocampus (114). Regarding 
the original Xiao-yao-san, most of the laboratory experiments showed that it was able to 
ameliorate the depression-like behaviours by regulating the glutamate/glutamine cycle and 
glutamate transporter GLT-1 in the hippocampus of the model induced by chronic 
unpredictable mild stress (115). The original Xiao-yao-san was also able to inhibit the locus 
coeruleus-norepinephrine system in the model with chronic immobilisation stress (116) or 
modulate HPA hyper-activation via down-regulation of corticotrophin-releasing hormone 
receptor 2 in the model with social isolation and chronic unpredictable mild stress (117). The 
above data suggest that the benefit of Xiao-yao-san is more associated with improving 
depression, which is also supported by the clinical evidence (118). 
 42 
Although a multi-herb formula is the therapeutic strategy of CHM in most cases, laboratory 
experiments have demonstrated the sedative and hypnotic functions of individual herbs that 
are considered specific for sleep improvements. The evidence suggests the underlying 
mechanism of CHM specific for sleep improvements is more likely to involve the 
neuroendocrine system (119). The GABA pathway is the essential target of CHM for 
insomnia, including modifying the GABA receptor, increasing GABA synthesis and 
influencing GABA release (11). Suanzaoren (SZR, English: Ziziphusspinosa seeds; scientific 
name: Ziziphus jujube Mill. var. spinosa (Bunge) Hu ex H. F. Chou; Chinese: 酸枣仁) is the 
most common Chinese herb used to calm the mind and reduce insomnia in TCM (120). SZR 
was first documented in the Divine Husbandman's Classic of the Materia Medica (in 
Chinese: 神农本草经), the earliest dictionary of Chinese Materia Medica (c. 206 BC). The 
text reported its sour and neutral properties and its use for limb pain. Later, SZR was found 
useful for improving sleep. In the book Miscellaneous Records of Famous Physicians (in 
Chinese: 名医别录), SZR was prescribed for its effect on worry-induced insomnia. Another 
prominent CM book, the Grand Materia Medica (in Chinese: 本草纲目), published in 1590, 
states that if there is excessive sleep, SZR can be used unprepared and if there is an inability 
to sleep then SZR should be used after being dry fried. A review of its chemistry suggests 
that ingredients from SZR such as sanjoinine A, jujubosides and various flavones all exhibit 
sedative pharmacological activities as GABA agonists (121). Its additional actions, such as 
increasing GABA synthesis and elevating different GABAA receptors, are also identified 
(121). 
2.7.4.3. Clinical Practice 
CHM is commonly used to treat insomnia and the selection of herbs is guided by the 
syndrome differentiation (122). It can be used alone or concurrently with conventional 
medicine, such as pharmacotherapies and psychotherapy (9). In CHM, people sharing the 
same characteristics are often grouped into a syndrome (also called a pattern) to guide 
treatment selection. The ‘Syndrome’ is defined by a collection of symptoms or complaints 
that are considered clinically important from a CM perspective (123). It may not be 
equivalent to a subgroup of people with the same disease severity or duration in conventional 
medicine. 
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Chinese standards and guidelines have also been developed to assist practitioners in their 
clinical decision-making. It is recommended to prescribe a standard herbal formula with 
slight modifications based on individual syndromes (7, 62, 102, 124). Traditional guidelines 
such as expert consensus and EBP guidelines coexist in China. In the evidence-based 
guidelines specific to CM practice for insomnia (7), the level of evidence from Chinese 
herbal formulae was low to moderate, although some of the formulae were strongly 
recommended (see Table 2.2). This evidence and the recommendations have been included in 
the clinical practice guidelines developed for all health professionals (62, 124). However, as a 
CAM, CHM is not conventionally recommended for insomnia management outside China 
due to its poor evidence (13, 14). 
Table 2.2. Evidence and Recommendations of Chinese Herbal Formula for Insomnia 
Formula Name Syndrome 
Level of 
Evidence* 
Recommendation
‡
 
Long-Dan-Xie-Gan-Tang 
(in Chinese：龙胆泻肝汤) 
Depressed Liver Qi 
transforming into fire 
IIIb C 
Huang-Lian-Wen-Dan-Tang 
(in Chinese：温胆汤) 
Internal block of phlegm-heat IIb B 
Huang-Lian-E-jiao-Tang 
(in Chinese：黄连阿胶汤) 
Yin deficiency with effulgent 
fire 
IIb B 
Gui-Pi-Tang 
(in Chinese：归脾汤) 
Dual deficiency of the Heart–
Spleen 
IIb A 
An-Shen-Ding-Zhi-Wan 
(in Chinese：安神定志丸) 
Qi deficiency of Heart–
Gallbladder 
IIIb A 
Jiao-Tai-Wan combined with 
Tian-Wang-Bu-Xin-Dan (in 
Chinese：交泰丸合天王补心
丹) 
Non-interaction between Heart 
and Kidney 
IIIb B 
Dao-Chi-Tang combined with 
Jiao-Tai-Wan 
(in Chinese：导赤汤合交泰丸) 
Intense Heart fire IIb A 
Xue-Fu-Zhu-Yu-Tang 
(in Chinese：血府逐瘀汤) 
Internal obstruction of static 
blood 
IIIb C 
Bao-He-Wan 
(in Chinese: 保合丸) 
Stomach disharmony IV E 
‡ 
Recommendation is made according to grade definition (125); * level of evidence is graded based on 
Liu’s system (126). 
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2.7.5. Other Chinese Medicine Therapies 
Acupuncture therapies, such as needling acupuncture and acupressure of the body or ears, are 
also used for insomnia management. A number of laboratory experiments reveal that 
acupuncture may suppress the central nervous activity via the GABA pathways, which 
explains its sedative and anxiolytic functions (127). A Cochrane SR of RCTs suggested 
therapies relevant to acupuncture potentially improved the sleep quality and quantity of 
people with insomnia compared with no treatment or sham acupuncture despite the 
considerable risk of bias and heterogeneity of the included studies (128). Another SR showed 
that traditional needling acupuncture appeared more effective than benzodiazepine drugs, 
sleep hygiene education or sham acupuncture (129). A meta-analysis concluded that 
acupressure was superior to sham acupressure for people with insomnia (130). Generally, 
acupuncture therapies present potential benefits to people with insomnia; however, a 
conclusion is yet to be determined due to the heterogeneous meta-analyses and only a small 
change in outcomes, often falling short of clinical significance (131). 
In addition to CHM and acupuncture, other CM therapies for insomnia include massage and 
Tai Chi. An RCT showed that back massage provided additional improvements of sleep 
quality to routine care among postpartum women with insomnia (132). A SR also showed Tai 
Chi enhanced sleep quality in terms of PSQI scores compared to various controls (133). 
2.7.6. An Integrative and Individualised Approach for Insomnia Management 
Insomnia management is complex, particularly for persistent and chronic insomnia. Therefore 
a sequential or integrative approach may optimise the therapeutic results (134, 135). 
Integrative insomnia therapies include conventional medication, herbal medicine, 
acupuncture and mind-body therapies (9, 136). 
Individualised therapy is highlighted in CM practice. In 2016, clinical practice guidelines of 
individualised CM for insomnia disorder were published to guide clinical practice (137). The 
guideline details individualised treatments, including CM psychotherapy and CHM 
treatments according to clinical manifestations, personality and the CM syndrome of 
individual insomnia patients, timing and space of an attack of insomnia as well as the results 
of mental or physical status examinations. However, the levels of evidence, grades of 
recommendations of the CM psychotherapies and the whole integrative approach are not 
clearly demonstrated.  
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2.8. Summary 
2.8.1. What was Previously Known? 
Insomnia is prevalent globally. Its understandings and treatments are undergoing change with 
the growth of multidisciplinary research. CM has a long history of being used for insomnia. 
The belief of TCM theory informs its clinical practice. Population-based surveys show that it 
continues to be frequently utilised among the public in both the East and the West. CHM is 
most commonly used as a monotherapy or an adjunct to conventional medicine. 
Pharmacological studies reveal that CHM has sedative-hypnotic profiles and emerging RCTs 
suggest some Chinese herbal formulae show promising benefits to people with insomnia. 
However, it remains unclear the full extent of the CHM effects for insomnia because of poor 
methodological quality of the current evidence. Acknowledging the wide demand of CHM, 
clinical practice guidelines have started, including evidence appraisals of CHM for insomnia 
in the integrative framework of insomnia management. However, the recommendations vary 
between countries or areas. 
2.8.2. What are the Knowledge Gaps? 
1) Does contemporary clinical evidence support the use of CHM for insomnia 
management with respect to its benefit and harm? 
2) What is the comparative effectiveness between CHM and other therapies such as 
CBT-i and pharmacotherapy? 
3) What are the similarities and differences between traditional knowledge and 
contemporary evidence regarding the use of CHM for insomnia? 
4) Considering coexisting TCM and EBPs, what are practitioners’ attitudes, knowledge 
and behaviours related to CHM for insomnia? 
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The full chapter has been published as Ni X, Shergis JL, Guo X, Zhang AL, Li Y, Lu C, et al. 
Updated clinical evidence of Chinese herbal medicine for insomnia: A systematic review and 
meta-analysis of randomized controlled trials. Sleep Med. 2015 Dec; 16(12):1462–81. 
Chapter 3. Clinical Evidence of Chinese Herbal Medicine for 
Insomnia: A Systematic Review and Meta-Analysis 
3.1. Introduction 
Insomnia is a common sleep disorder. Around one-third of adults experience the symptoms of 
insomnia and approximately 6 per cent meet the diagnosis of insomnia worldwide (2). 
Insomnia can result in functional impairment as well as increase the risk of severe conditions, 
such as depression and cardiovascular disease, in the long term (35, 138). Growing evidence 
suggests CBT-i is effective to improve subjective sleep outcomes (139). However, it is under-
utilised in clinical practice because of difficulty in successful patient compliance (140) and 
high requirements of well-trained psychotherapists (141). Pharmacotherapy such as BZRAs 
is considered beneficial to improving sleep as well (5). However, it is not without risks, 
including tolerance and addiction from long-term use (83, 87). Therefore, new treatments 
with low risk-to-benefit ratio are needed for insomnia. 
CHM, originating from ancient China, has been used to treat insomnia for more than 2000 
years in China (142). In modern China, both traditional herbal formulae and patent herbal 
products coexist in the treatment of insomnia (143). Also, conventional medicine and CHM 
are co-administered frequently in clinical practice for sleep disorders (8, 9, 144-146). In 
recent years, CHM is increasingly used as a form of CAM in the Western world such as in 
the US, Europe and Australia (10). Although the mechanism by which CHM improves sleep 
is not fully elucidated, preclinical studies have showed some Chinese herbal formulae or 
single herbal ingredients have sedative-hypnotic functions that are mediated by the gamma-
aminobutyric acid-ergic (GABAergic) system (11). For example, sour jujube seed (scientific 
name: Ziziphus spinosa Hu, pharmaceutical name: Semen Zizyphi Spinosae, Chinese pinyin: 
suan zao ren) has been shown to enhance the activity of GABA, ainhibitory neurotransmitter 
as a single herb (147), or as a main ingredient in a multi-herb formulation (known as sour 
jujube seed decoction) has modulated specific sedative effects in selective binding to the 
GABAA receptors (148). 
 47 
The public perception of the benefit of CHM to improving overall sleep and the potential 
hypnotic effects in animal studies need to be supported through critical evaluation of the 
clinical evidence. Two previous SRs concluded that there was insufficient evidence to 
support the efficacy of CHM for insomnia (12, 109). However, the latest Chinese evidence-
based guidelines for insomnia acknowledge the importance of CHM (11) without specific 
data on the role of CHM in clinical management for insomnia. Considering the growing 
number of clinical trials for CHM in recent years, it is important to update the search and 
evaluation to provide the best available evidence for insomnia. This SR and meta-analysis of 
RCTs aims to answer four clinical questions for insomnia: (1) whether CHM is more 
effective than placebo, (2) whether CHM is more effective than conventional therapies such 
as BZRAs and psychotherapies, (3) whether the adjunct use of CHM provides better 
outcomes than conventional medicine alone and (4) whether CHM is safe when it is used 
alone or in combination with conventional therapies. 
3.2. Methods 
3.2.1. Eligibility 
3.2.1.1. Inclusion Criteria 
Study Designs 
RCTs were eligible. 
Participants 
Participants of any age, gender or ethnic background with main complaint of insomnia were 
included. Insomnia needed to be defined by standard diagnostic instruments, including 
International Classification of Sleep Disorders (58, 61), Diagnostic and Statistical Manual of 
Mental Disorders (DSM) (1), Chinese Classification and Diagnosis of Mental Disease (60), 
International Classification of Diseases (59) and other current guidelines (88, 144, 145, 149). 
Interventions and Controls 
Intervention included oral CHM treatment prepared in any form, such as decoction, granule, 
capsule and tablet. Studies that evaluated CHM combined with conventional therapies were 
also eligible. The comparators included placebo, pharmacotherapy routinely used such as 
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BZDs and NBZDs and psychotherapy such as CBT-i and sleep hygiene education. When 
another treatment was combined with CHM, the adjunct needed to be the same as control. 
Outcomes 
The primary outcome was overall sleep quality measured by the PSQI. The PSQI is a well 
validated and commonly used instrument for sleep quality assessment. The global scores 
(value range: 0–21 points) were calculated by its seven domains reported by patients, 
including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, 
sleep disturbances, use of sleeping medications and daytime dysfunction (55). Higher scores 
indicated poorer sleep quality. It was translated into 56 additional languages, including 
mandarin Chinese (150). In the Chinese population, its minimal clinical important difference 
(MCID) for CM therapy was estimated to be 1.75 points by standard error of measurement 
method or 1.54 by distribution-based method (151). Therefore, it was used as the threshold to 
assess generalisation of results to clinical practice. 
Secondary outcomes included: 1) the total scores of Athens Insomnia Scale (AIS) (152), 2) 
the total scores of ISI (56), 3) the patient-rated sleep parameters, such as sleep-onset latency, 
total sleep duration, sleep efficiency (ratio of time asleep to time on bed) and frequency of 
early awakenings, 4) objective sleep parameters measured by PSG, such as sleep-onset 
latency, total sleep duration, sleep efficiency and times or duration of awakening after sleep 
onset, 5) clinical global impression (CGI), including Clinical Global Impression-Severity 
scale (CGI-S) and Clinical Global Impression-Improvement scale (CGI-I) (153) and 6) 
frequency and nature of adverse events. 
3.2.1.2. Exclusion Criteria 
Exclusion criteria included: 
• quasi-randomised controlled trials 
• insomnia defined as a symptom or a complaint only 
• insomnia induced by substance, such as alcohol and drugs 
• participants with other sleep disorders, such as breathing-related sleep disorders, 
restless leg syndrome, narcolepsy, delayed sleep phase type of circadian rhythm sleep-
wake disorders and parasomnias 
• participants diagnosed with other mental disease and physical conditions 
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• the CHM and the control were not standardised for all participants but were 
individualised 
• control was another CM therapy, such as acupuncture 
• control was pharmacotherapies not routinely recommended for insomnia, such as anti-
histamine drugs 
• no relevant outcomes. 
3.2.2. Database Search and Study Selection 
Five English databases (Cochrane Library, PubMed, EMBASE, CINAHL and AMED), four 
Chinese databases (CBM, CNKI, CQVIP and Wanfang) and five clinical trial registration 
databases (ClinicalTrials.gov, ICTRP, ChiCTR, EU-CTR and ANZCTR) were 
comprehensively searched in May 2014. The search terms were specified in the Appendix 
3.1. 
Two researchers (XN and JS) searched and screened the studies by finding duplications, 
excluding irrelevant titles and abstracts and then selecting eligible studies by reviewing full 
texts. 
3.2.3. Data Extraction and Management 
Two researchers (XN and FL) extracted data in the manner of double entry and checking 
using EpiData Software, version 3.1 (EpiData Association, Odense, Denmark). Basic 
characteristics and outcome data were extracted, including authors, year of publication, 
diagnostic instrument, disease duration, stage, sample size, age, gender, details of 
intervention and control, information of follow-up, outcomes and adverse events. The data 
were exported from EpidData to Microsoft Excel 2010 to facilitate sorting. Emails were sent 
to the authors for clarification if the important data were unavailable, duplication was 
suspected or when more than one article reported the same trial. Another researcher (JS) 
validated the final dataset and the translation into English. 
3.2.4. Assessment of Risk of Bias in Included Studies 
The risk of bias was appraised by two independent reviewers (XN and LZ) according to the 
Cochrane Collaboration’s tool for assessing risk of bias (154). Seven domains were 
evaluated, including random sequence generation, allocation concealment, blinding of 
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participants and personnel, blinding of outcome assessment, incomplete outcome data, 
selective reporting and other bias. The assessment for blinding was made based on patient-
reported outcomes (PROs) and clinician-reported outcomes (CROs). The objective sleep 
parameters rated by PSG were grouped as CROs because results can be affected by the 
assessors and assessment environments. Study protocols or registration information were 
used to help assess the risk of bias for selective reporting. Risk of other bias was judged by 
assessing baseline balance and funding source. Judgements were categorised as ‘low risk of 
bias’, ‘high risk of biases’ or ‘unclear risk of bias’. Disagreement was resolved by discussion 
and consultation with a senior researcher (XG) when necessary. 
3.2.5. Measures of Treatment Effect 
3.2.5.1. Main Meta-Analysis 
Continuous outcomes were presented as MD with 95% CI between two groups while 
dichotomous data were presented as relative risk (RR) with 95% CI. RevMan software 
(version 5.2.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2012) was used for data analysis. 
For trials with more than one CHM intervention group, such as CHM formula A versus CHM 
formula B versus pharmacotherapy, all relevant CHM groups were combined. For trials with 
more than one type of control, such as CHM versus pharmacotherapy versus placebo, pair-
wise comparison results were reported based on different class of comparators. When 
different outcomes for the same trial were reported in separate publications, the data were 
merged into one trial. 
The predefined main comparisons in the meta-analysis were: 1) CHM versus placebo, 2) 
CHM versus BZDs, 3) CHM versus NBZDs, 4) CHM versus psychotherapy, 5) CHM plus 
BZDs versus placebo plus BZDs, 6) CHM plus NBZDs versus placebo plus NBZDs, 7) CHM 
plus psychotherapy versus placebo plus psychotherapy, 8) CHM plus BZDs versus BZDs, 9) 
CHM plus NBZDs versus NBZDs and 10) CHM plus psychotherapy versus psychotherapy. 
3.2.5.2. Subgroup Analysis and Solutions to Heterogeneity 
Clinical heterogeneity between trials for the primary outcome was addressed by further 
subgroup analysis noting important factors, including treatment duration (≤4 week and >4 
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week), history of insomnia (<1 year and ≥1 year) and different preparations of CHM (i.e., 
decoction and non-decoction). Statistical heterogeneity was detected using a chi-square test. 
The fixed effect model was used to estimate the typical effect for studies with low 
heterogeneity (I
2
 < 50%) while the random effects model was used to estimate the average 
distribution for studies with substantial unexplained heterogeneity (I
2
 ≥ 50%). 
3.2.5.3. Sensitivity Analysis 
Blinding of participants and allocation concealment are important for the PRO results. The 
primary outcome (PSQI) was a PRO and sensitivity analysis was performed by only 
including trials with low risk of bias for blinding of participants and allocation concealment. 
In studies comparing CHM to pharmacotherapies, sensitivity analysis of PSQI scores was 
performed by including studies that removed the sixth domain (use of medication) because 
participants in the pharmacotherapy group would score higher on this domain. 
Imbalance baseline can suggest failure of randomisation (155). Another sensitivity analysis 
was conducted by excluding the studies with imbalance baseline of PSQI scores. 
3.2.6. Publication Bias 
Publication bias was assessed when the subgroup included more than 10  studies. 
3.3. Results 
3.3.1. Description of Included Studies 
3.3.1.1. Search Results 
The primary search identified 47,391 articles in literature databases and seven records in 
registries. Seventy-nine RCTs with 7, 886 participants published in 81 articles were finally 
included in the SR (156–236). A total of 76 were also included in the meta-analyses (156–
232, 235). The screening process is shown in Figure 3.1. 
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Figure 3.1. Flowchart of study screening 
3.3.1.2. Basic Characteristics of the Included Studies 
All included studies were randomised, parallel-group, controlled trials conducted in China 
between 2003 and 2014. Seven were multi-arm studies (165, 173, 194, 195, 200, 209, 227) 
and the rest were two-arm studies. The treatment duration ranged from one week to three 
months (mean: 29 days, median: 29 days, mode: 28 days). Thirteen conducted follow-up 
ranging from one week to six months after the end of the treatment (160, 162, 180, 182, 197, 
198, 204, 206, 217, 218, 220, 225, 233, 234). Participants aged from 15 to 84 years and 
insomnia was diagnosed by CCMD-3 in 64 studies (156, 157, 159–165, 167–173, 175, 188–
191, 194, 197, 199, 201, 202, 204, 206–209, 211, 213, 215–217, 219, 221–227, 229, 234, 
236), ICSD-2 in six studies (158, 193, 210, 214, 220, 228), ICD-10 in seven studies ((166, 
174, 189, 192, 198, 200, 218, 235), DSM-4 in one study (205) and Chinese national guideline 
in one study (203). The duration of insomnia history ranged from one month to 30 years. The 
PSQI was reported in 59 studies (156–160, 163–168, 170–172, 174, 175, 177–182, 184, 185, 
189–201, 203–205, 207–213, 215–221, 223, 225, 226, 228, 231, 236), the AIS in eight 
studies (169, 173, 176, 183, 202, 214, 227, 232), patient-rated sleep parameters in 13 studies 
(158, 161, 162, 167, 185, 186, 188, 197, 212, 220, 222, 229), PSG-reported sleep parameters 
in two studies (193, 211) and the CGI-S in four studies (187, 206, 224, 230). The ISI and the 
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CGI-I were not reported in any study. Twenty-six studies used Chinese patent herbal products 
(158, 165, 171, 175, 177, 181, 184, 188, 191, 192, 197–200, 208, 210–213, 216–218, 220, 
221, 225, 228, 236) and other studies used decoctions, the traditional form and combination 
method. Sixty-six herbal formulae were investigated in the included studies. The most 
frequent formulae were Xue Fu Zhu YuTang (traditional decoction) and Zao Ren An Shen 
Capsule (patent product). The herb most commonly used was sour jujube seed. The full 
characteristics of the included studies are shown in Table 3.1 and Table 3.2. 
3.3.2. Risk of Bias in the Included Studies 
Only one study registered the protocol in ChiCTR (193). Risk of bias for other studies was 
assessed based on their publications. Twenty-seven studies (34.18%) reported adequate 
methods of random sequence generation, including computer software (185, 193, 197, 198, 
212, 218, 221), random number table (157, 160, 165, 167, 170, 171, 174, 182, 186, 190, 194, 
195, 199–201, 204, 205, 207, 210, 223, 225) and drawing of lots (228). Sequence allocation 
was concealed in five studies (6.33%) (185, 194, 197, 198, 212, 218). Blinding of participants 
and personnel were performed in 10  studies (12.66%) (158, 180, 185, 193, 197, 198, 211, 
212, 218, 221, 225). Only one study (1.27%) used an independent outcome assessor (76). 
Two studies (2.53%) had high drop-out rate with unreported reasons and they did not 
appropriately treat missing data (193, 204). One study (1.27%) did not report its predefined 
primary outcome (PSQI scores) with unreported reason (230). Three studies showed 
imbalance baseline (3.80%) (167, 199, 226). Sixteen studies (20.25%) were supported by 
non-profit institutions such as by national scientific funding (192, 193, 212) or local scientific 
grant (160, 163–165, 181, 190, 194, 195, 201, 202, 204, 210, 228, 232) and the rest did not 
declare the presence or absence of a conflict of interest and the funding sources. The risk of 
bias is summarised in Figure 3.2. 
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Figure 3.2. Risk of bias in included studies. 
Note. CRO: clinician-reported outcome; PRO: patient-reported outcome. 
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Table 3.1. Basic Characteristics of the Included Studies 
Study Arm 
Randomised 
sample size: 
I/C 
Age:  
mean (SD) years, I/C 
Gender
: M/F 
Diagnostic 
instrument 
Duration of insomnia 
history: mean (SD), I/C 
Outcomes 
Follow-
up 
Niu ZZ 2014 (204) 2 48/48 
41.32 (7.46)/40.12 
(8.66) 
38/58 CCMD-3 
28.36 (11.51) m/26.89 
(13.65) m 
PSQI 10 d 
Li ZJ 2014 (196) 2 50/50 
43.32 (11.31)/42.13 
(12.41) 
47/54 CCMD-3 
28.36 (8.38) m/27.62 (7.68) 
m 
PSQI No 
Cai TR 2013 (160) 2 98/49 46.2 (6.5)/47 (6.2) 56/91 CCMD-3 5.6 (1.2) y/5.9 (1) y PSQI 3 m 
Hou N 2013 (160) 2 54/54 42.3 (5.3)/43.5 (4.3) NS CCMD-3 NS PSQI No 
Wang SM 2013 
(211) 
2 48/48 
45.12 (11.51)/44.58 
(12.17) 
34/62 CCMD-3 
27.16 (35.05) m/25.99 
(32.17) m 
PSQI and PSG No 
A M 2013 (156) 2 41/41 
44.45 (8.33)/45.12 
(7.76) 
55/27 CCMD-3 6.32 (2.43) y/6.76 (2.01) y PSQI No 
Gan JG 2013 (171) 2 60/60 67.2 (5)/66.5 (9.2) 46/74 CCMD-3 19.4 (6.1) m/20.6 (8.7) m PSQI No 
Zhang XZ 2013 
(229) 
2 110/55 40.5 (8.6)/41.3 (9.2) 65/100 CCMD-3 16.5 (2.7) m/15.5 (2.8) m 
Patient-rated 
sleep parameters 
No 
Huang HB 2013 
(180) 
2 33/33 28 (2.14)/30 (2.21) 32/34 CCMD-3 1.6 (0.61) y/1.4 (0.47) y PSQI 30 d 
Huang WM 2013 
(214) 
2 39/35 41.7 (10.5)/40.8 (9.8) 31/43 ICSD-2 19.2 (5.5) m/17.7 (4.7) m AIS No 
Li GX 2013 (192) 2 35/35 
49.93 (11.54)/52.7 
(10.54) 
27/34 
WHO ICD-
10 
10.13 (13.42) y/11.94 
(10.31) y 
PSQI No 
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Study Arm 
Randomised 
sample size: 
I/C 
Age:  
mean (SD) years, I/C 
Gender
: M/F 
Diagnostic 
instrument 
Duration of insomnia 
history: mean (SD), I/C 
Outcomes 
Follow-
up 
Sun XA 2013 
(208) 
2 50/50 
40.34 (12.6)/41.15 
(12.7) 
51/49 CCMD-3 2.64 (5.11) y/2.15 (4.18) y PSQI No 
Yuan CX 2013 
(225) 
2 30/30 
39.57 (12.38)/34.53 
(11.73) 
11/49 CCMD-3 2.18 (2.08) y/2.18 (1.98) y PSQI 7 d 
Lin YY 2013 (199) 2 30/30 
70.85 (3.06)/71.14 
(3.24) 
27/33 CCMD-3 6.43 (3.88) y/6.55 (3.12) y PSQI No 
Han YC 2013 
(174) 
2 32/32 45.2 (19.3)/40.7 (16) 26/38 
WHO ICD-
10 
7.8 (3.4) m/8.3 (3.9) m PSQI No 
Pan BX 2013 (205) 2 40/40 
40.25 (11.71)/41.25 
(15.3) 
36/44 DSM-4 3.30 (5.29) y/3.22 (4.14) y PSQI No 
Qian C 2012 (158) 2 158/52 
44.97 (13.55)/42.75 
(13.81) 
74/136 ICSD-2 
108.32 (44.12) d/111.79 
(44.96) d 
PSQI and patient-
rated sleep 
parameters 
No 
Chen WM 2012b 
(163) 
2 60/30 
39.8 (12.77)/37.3 
(12.39) 
53/37 CCMD-3 28.2 (11.9) m/24.9 (12.3) m PSQI No 
Zhang CL 2012 
(168) 
2 48/30 50/49 49/29 CCMD-3 1.9 y/1.8 y PSQI No 
Sheng CJ 2012 
(167) 
2 25/21 56.1 (6.5)/57.3 (7.1) 18/28 CCMD-3 NS 
PSQI and patient-
rated sleep 
parameters 
No 
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Study Arm 
Randomised 
sample size: 
I/C 
Age:  
mean (SD) years, I/C 
Gender
: M/F 
Diagnostic 
instrument 
Duration of insomnia 
history: mean (SD), I/C 
Outcomes 
Follow-
up 
Yang YL 2012 
(234) 
2 60/60 
73.15 (10.19)/73.18 
(10.15) 
81/39 CCMD-3 4.97 (2.11) y/4.95 (2.15)y PSQI 6 m 
Yang XC 2012 
(216) 
2 30/30 41 (12)/43 (13) 28/32 CCMD-3 7 m to 1 y/6 m to 21 y PSQI No 
Chen WM 2012a 
(164) 
2 50/30 
38.95 (10.57)/38.35 
(11.58) 
43/37 CCMD-3 26.5 (10.8) m/25.9 (11.2)m PSQI No 
Wang LH 2012 
(210) 
2 38/38 61 (12.4)/61 (12.8) 34/36 ICSD-2 NS PSQI No 
Lou YY 2012 
(109) 
2 30/30 
72.83 (6.18)/74.1 
(7.33) 
31/29 CCMD-3 4.13 (2.11) y/5.34 (4.2)y PSQI No 
Li Y 2012 & Li Y 
2013 (194, 195) 
3 30/30/30 NS NS CCMD-3 NS PSQI No 
Li GR 2012 (191) 2 30/30 37.8/37.4 28/32 CCMD-3 NS PSQI No 
Zhang HM 2012 
(176) 
2 32/34 
34.32 (1.45)/32.34 
(1.67) 
27/39 CCMD-3 7.34 (0.65) m/9.13 (0.15)m AIS No 
Li XL 2012 (2192) 2 96/90 43 (2)/43.5 (1) 73/113 CCMD-3 1.5 (0.5) y/1.8 (0.2)y PSQI No 
Miao WH 2012 
(213) 
2 30/29 
44.46 (12.34)/43.51 
(12.81) 
18/41 CCMD-3 
24.70 (29.74) m/17.48 
(15.63)m 
PSQI No 
Kuang JG 2012 
(186) 
2 40/40 73.8/74.1 43/37 CCMD-3 3.7 y/4.1 y 
Patient-rated 
sleep parameters 
No 
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Study Arm 
Randomised 
sample size: 
I/C 
Age:  
mean (SD) years, I/C 
Gender
: M/F 
Diagnostic 
instrument 
Duration of insomnia 
history: mean (SD), I/C 
Outcomes 
Follow-
up 
Li DY 2012 (190) 2 52/52 
45.9 (11.3)/44.54 
(10.6) 
41/63 CCMD-3 9.3 (4.7) m/10.7 (5.3)m PSQI No 
Luo HO 2012 
(201) 
2 60/59 NS 46/71 CCMD-3 NS PSQI No 
Zhu GQ 2012 
(231) 
2 34/34 NS 32/36 CCMD-3 NS PSQI No 
Cai Y 2011 (161) 2 21/21 
40.17 (11.26)/41.36 
(11.48) 
19/23 CCMD-3 
15.92 (11.55) m/16.39 
(12.21)m 
Patient-rated 
sleep parameters 
No 
Qi GF 2011 (172) 2 40/40 
51.2 (10.3)/53.5 
(12.42) 
36/44 CCMD-3 5.62 (2.35) y/6.30 (3.12)y PSQI No 
Sun P 2011 (207) 2 40/40 66.7 (5.8)/67.1 (6.2) 25/55 CCMD-3 12.8 (6.4) m/13.28 (6.9)m PSQI No 
Zhu WH 2011 
(232) 
2 31/30 NS 20/40 CCMD-3 NS AIS No 
Huang XY 2011 
(181) 
2 50/50 
44.58 (10.25)/44.2 
(7.83) 
40/60 CCMD-3 5.3 (1.5) y/5.1 (1.8)y PSQI No 
Jia B 2011 (157) 2 39/39 
50.63 (10.56)/47.76 
(10.58) 
37/41 CCMD-3 18 m/16 m PSQI No 
Wang C 2011 
(159) 
2 60/60 39.3/37.6 54/66 CCMD-3 2.9 y/3.1 y PSQI No 
Yang XH 2011 2 50/50 46.1/45 50/50 CCMD-3 9.78 m/9.44 m Patient-rated No 
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Study Arm 
Randomised 
sample size: 
I/C 
Age:  
mean (SD) years, I/C 
Gender
: M/F 
Diagnostic 
instrument 
Duration of insomnia 
history: mean (SD), I/C 
Outcomes 
Follow-
up 
(222) sleep parameters 
Jing XW 2011 
(221) 
2 21/27 
41.82 (12.88)/42.37 
(11.64) 
12/35 CCMD-3 7.9 (3.84) y/5.7 (2.53)y PSQI No 
Chen YY 2011 
(166) 
2 32/20 46.6 (1.5)/59.2 (0.9) 20/32 
WHO ICD-
10 
3.2 (0.3) y/3.3 (0.4)y PSQI No 
Xiao LG 2010 
(189) 
2 33/32 68.2 (18.3)/67.5 (19) 38/27 
WHO ICD-
10 
38 (18.5) m/45 (16.2)m PSQI No 
Jiang HQ 2010 
(178) 
2 183/183 71.9/70.8 176/188 CCMD-3 33.1(5.7) m/31.4 (7.1)m PSQI No 
Wang ZT 2010 
(212) 
2 41/39 NS NS CCMD-3 NS 
Patient-rated 
sleep parameters 
No 
Liao RD 2010 
(2336) 
2 22/18 
48.95 (1.468)/50.6 
(1.911) 
31/9 CCMD-3 NS PSQI 3 m 
Huang D 2010 
(179) 
2 42/38 50.2 (9.2)/53.6 (8.7) 47/33 CCMD-3 9.56 (5.42) y/10.37 (6.63) y PSQI No 
Wang F 2010 (170) 2 59/60 
40.23 (10.79)/39.92 
(11.47) 
36/83 CCMD-3 
37.49 (7.36) m/35.81 (9.92) 
m 
PSQI No 
Tian J 2010 (183) 2 30/30 70 (7)/67 (5) 26/34 CCMD-3 NS AIS No 
Huang Y 2010 
(182) 
2 62/62 47 (9)/48 (10) 60/64 CCMD-3 4.8 (1.2) y/4.16 (1.6) y PSQI 4 w 
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Study Arm 
Randomised 
sample size: 
I/C 
Age:  
mean (SD) years, I/C 
Gender
: M/F 
Diagnostic 
instrument 
Duration of insomnia 
history: mean (SD), I/C 
Outcomes 
Follow-
up 
Song XH 2010 
(198, 218) 
2 106/106 NS 54/147 
WHO ICD-
10 
NS CGI-S 2 w 
Lian FM 2009 
(197) 
2 71/36 
43.14 (13.91)/44.73 
(13.92) 
39/68 CCMD-3 
19.83 (27.13) m/20.92 
(45.12) m 
Patient-rated 
sleep parameters 
1 w 
Xia CY 2009 (169) 2 60/60 
42.18 (9.82)/42.75 
(10.72) 
33/87 CCMD-3 
11.09 (14.27) m/11.84 
(14.29) m 
AIS No 
Zhang XP 2009 
(228) 
2 82/80 
71.14 (3.24)/70.85 
(3.07) 
89/73 ICSD-2 6.51 (3.27) y/6.02 (3.45) y PSQI No 
Xu HK 2009 (175) 2 42/40 56 (7)/58 (7) 36/46 CCMD-3 56 (7) m/92 (8) m PSQI No 
Nie ZH 2009 (203) 2 50/45 
37.81 (10.42)/41.24 
(9.14) 
39/53 
Chinese 
guideline 
NS PSQI No 
She YQ 2009 (223) 2 60/59 
36.68 (8.53)/35.32 
(9.13) 
0/119 CCMD-3 3.22 (3.37) y/3.51 (3.67) y PSQI No 
Li X 2008 (215) 2 68/52 
36.64 (4.51)/37.26 
(4.79) 
60/60 CCMD-3 9 (4.85) m/8.89 (4.52)m PSQI No 
Jiang LP 2008 
(187) 
2 34/34 
44.8 (14.1)/39.26 
(12.38) 
31/37 CCMD-3 6.27 (4.18) m/5.91 (4.31) m CGI-S No 
Feng XD 2008 
(217) 
2 25/23 NS 20/28 CCMD-3 NS PSQI Unclear 
Zhang XM 2008 2 43/41 NS 38/46 ICSD-2 NS PSQI and patient- 3 m 
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Study Arm 
Randomised 
sample size: 
I/C 
Age:  
mean (SD) years, I/C 
Gender
: M/F 
Diagnostic 
instrument 
Duration of insomnia 
history: mean (SD), I/C 
Outcomes 
Follow-
up 
(220) rated sleep 
parameters 
Zhang JP 2008 
(188) 
2 30/30 
41.26 (10.25)/40.3 
(13.62) 
36/24 CCMD-3 2.35 (5.22) y/2.25 (4.27) y 
PSQI and patient-
rated sleep 
parameters 
No 
Sun Y 2008 (235) 2 52/50 3836 44/58 
WHO ICD-
10 
1.56 (1.04) y/1.61 (1.03)y PSQI No 
Ren YJ 2007 (206) 2 50/50 NS 48/62 CCMD-3 NS CGI-S 7 d 
Chang C 2006 
(236) 
2 19/18 18–65 12/25 CCMD-3 
51.32 (73.32) m/60.14 
(92.3) m 
PSQI No 
Chen JF 2006 
(184) 
2 30/30 NS 28/32 CCMD-3 NS PSQI No 
Zheng SY 2006 
(230) 
2 34/34 
38.67 (15.42)/39.26 
(12.38) 
28/40 CCMD-3 6.27 (4.18) m/5.92 (4.33) m CGI-S No 
Luo LC 2006 (202) 2 52/30 51.2/50.5 32/50 CCMD-3 2.6 y/2.5 y AIS No 
Chen FQ 2005 
(162) 
2 180/90 42 (15.4)/41 (14.9) 100/170 CCMD-3 NS 
Patient-rated 
sleep parameters 
3 m 
Yu HT 2005 (224) 2 48/45 32.6 (8.9)/30.6 (8.4) 45/48 CCMD-3 2.2 (0.6) y/2.8 (4.6) y CGI-S No 
Zhang JF 2003 
(185) 
2 113/114 
44.09 (13.29)/44.97 
(13.11) 
68/159 CCMD-3 
79.64 (102.66) m/71.89 
(93.5) m 
PSQI and patient-
rated sleep 
No 
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Study Arm 
Randomised 
sample size: 
I/C 
Age:  
mean (SD) years, I/C 
Gender
: M/F 
Diagnostic 
instrument 
Duration of insomnia 
history: mean (SD), I/C 
Outcomes 
Follow-
up 
parameters 
Zhu T 2013 (209) 3 60/60/60 NS 71/109 CCMD-3 NS PSQI No 
Chen H 2012 (173) 3 30/30/30 NS 75/15 CCMD-3 NS AIS No 
Liu Y 2009 (200) 3 30/30/30 
36.9 (11.48)/37.2 
(11.36)/37.8 (11.38) 
38/52 
WHO ICD-
10 
8.9 (2.89) m/9.3 (2.18) 
m/9.8 (2.28) m 
PSQI No 
Chen WQ 2008 
(165) 
3 68/72/76 
62.19 (6.09)/64.32 
(6.71)/66.19 (5.81) 
108/108 CCMD-3 NS PSQI No 
Zhan SQ 2008 
(227) 
3 39/21/40 
43.8 (12.8)/47.1 
(10.8)/44.6 (14.4) 
35/65 CCMD-3 NS AIS No 
Li Y 2009 (193) 4 NS 
32.7 (9.2)/37.6 
(10.3)/38.4 (13.8)/30 
(9.7) 
8/25 ICSD-2 
56.1 (36.4) d/39 (37.7) 
d/51.1 (32.9) d/ 47.7 (33.2) 
d 
PSQI and PSG No 
Note. AIS: Athens Insomnia Scale; BZDs: benzodiazepine drugs; C: control; CBT-i: Cognitive and behavioural therapy for insomnia; CHM: Chinese herbal medicine; CGI-
S: Clinician Global Impression-Severity; CCMD-3: Chinese Classification and Diagnosis of Mental Disease, Third Edition; DSM-4: Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition; d: day/days; F: female; M: male; m: month/months; I: intervention; ISCD-2: International Classification of Sleep Disorders, Second 
Edition; NS: not stated; PSQI: Pittsburgh Sleep Quality Index; PSG: polysomnography; WHO ICD-10: World Health Organization International Classification of Diseases, 
10th Version ; w: week/weeks; y: year/years 
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Table 3.2. Details of the Treatment in the Included Studies 
Study Formula 
†
Herbal ingredients 
$
I
M 
Preparation Dosage Frequency Comparator 
Treatment 
duration 
Niu ZZ 
2014 (204) 
Bu Shen Shu 
Gan Tang 
shu di, gou qi zi,sheng di, xuan shen, mai dong, 
dang gui, chuan xiong, chai hu, zhi ke, huang qin, 
huang lian, gan cao, ye jiao teng, bai he, zhen zhu 
mu 
N decoction 
1 pack 
decocted 
twice 
bid 
clonazepam 
tablet, 2–4 
mg, qn 
30 d 
Li ZJ 2014 
(196) 
Jia Wei 
Chang Pu Yu 
Jin Tang 
shi chang pu, yu jin, huang lian, rou gui, yun fu 
shen, yuan zhi,bai zi ren 
Y decoction 
1 pack 
decocted 3 
times 
tid 
estazolam 
tablet, 2 
mg,qn 
30 d 
Cai TR 
2013 (160) 
Tiao Zhong 
Hua Tan An 
Shen He Ji 
suan zao ren, fu ling, chai hu, huang qin, zhi mu, 
fa ban xia, chuan xiong, chen pi, zhu ru, shou wu 
teng, zhen zhu mu, zhi shi,zhi gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 1–2 
mg qn 
2 w 
Hou N 
2013 (177) 
Mian An 
Ning Ke Li 
dan shen, shu di huang, shou wu teng, bai zhu, 
chen pi, yuan zhi,da zao 
N granule 1 bag bid 
alprazolam 
tablet,0.4 mg 
qn 
3 w 
Wang SM 
2013 (211) 
Zao Ren An 
Shen Pian 
he shou wu, suan zao ren, sang shen,he huan hua, 
bai zi ren, dang gui, shu di huang, yuan zhi,chai 
hu 
N tablet 4 tablets tid Placebo 4 w 
A M 2013 
(156) 
Zi Ni Yang 
Xin An Shen 
Tang 
sheng di huang, mai men dong, dang gui, dan 
shen, ren shen, fu shen, bai zi ren, suan zao ren,ye 
jiao teng,zhi gan cao 
N decoction 
1 pack 
decocted 3 
times 
tid 
zolpidem 
tablet, 5 mg, 
qn 
4 w 
Gan JG Zao Ren An suan zao ren, dan shen,wu wei zi N capsule 5 tablets qn alprazolam 4 w 
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Study Formula 
†
Herbal ingredients 
$
I
M 
Preparation Dosage Frequency Comparator 
Treatment 
duration 
2013 (171) Shen Jiao 
Nang 
tablet, 0.8 
mg, qn 
Zhang XZ 
2013 (229) 
Yang Yin An 
Shen Jiao 
Nang 
suan zao ren, wu wei zi, ye jiao teng, zhi mu, fu 
shen, he huan hua, dan shen, hu po,ling ci shi 
N capsule 3 mg bid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
4 w 
Huang HB 
2013 (180) 
Xie Cao xie cao  N powder 3 g tid Placebo 150 d 
Huang 
WM 2013 
(214) 
Wen Dan 
Tang plus 
Xue Fu Zhu 
Yu Tang Jia 
Jian  
fa ban xia, chen pi, zhu ru, zhi shi, fu ling, tao 
ren, hong hua, chi shao, chuan xiong, niu xi, 
sheng di huang,dang gui,, jie geng,gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 2 mg, 
qn 
30 d 
Li GX 
2013 (192) 
Wen Dan 
Ning Xin Ke 
Li 
suan zao ren, dang shen, ban xia, chen pi, zhu ru, 
zhi shi, fu ling,shi chang pu, yuan zhi, shu di 
huang, long gu, mu li,zhi gan cao 
N granule 6 g tid 
estazolam 
tablet, 1–2 
mg, qn 
4 w 
Sun XA 
2013 (208) 
Shui Mian 
Ling 
ren shen, huang qi, wu wei zi, bai he, zhi yu 
cao,chao suan zao ren, ye jiao teng, dan shen, 
yuan zhi,fu ling, sheng di,nv zhen zi, chai hu, yu 
jin, he huan pi, shen qu, shan zha, you dong, bai 
zhu, zhi ke,ban xia 
Y pill 10 g tid 
zopiclone 
tablet, 3.75 
mg qn 
4 w 
Yuan CX Mei An Ke suan zao ren, ren shen, ci wu jia, fu ling, dang Y granule 4 g qn placebo + 2 w 
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Study Formula 
†
Herbal ingredients 
$
I
M 
Preparation Dosage Frequency Comparator 
Treatment 
duration 
2013 (225) Li  gui, chuan xiong estazolam, 1 
mg, qn 
Lin YY 
2013 (199) 
Jian Nao 
Ning Shen 
Ke Li 
suan zao ren, bai zi ren, huang lian, zhi zi, bai 
shao, mai dong, dan shen, long gu, zhen zhu mu, 
yuan zhi, bai he, shou wu teng 
N granule 1 bag bid 
estazolam 
tablet, 1 mg, 
qn 
4 w 
Han YC 
2013 (174) 
Tian Wang 
Bu Xin Dan 
bai shao, dan shen, chao zao ren, bai zi ren, bai 
he, shou wu teng, chao bai zhu, fu ling, sha ren, ji 
nei jin, zhen zhu mu, duan long chi, rou gui, bai 
dou kou, zhi gan cao, zhi zi 
N decoction 
1 pack 
decocted 4 
times 
qid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
4 w 
Pan BX 
2013 (205) 
Jian Pi Shu 
Gan Tang 
plus Fu Fang 
Zao Ren Jiao 
Nang 
tang ji :dang shen, fu chao bai zhu, fu ling, chen 
pi, fa ban xia, chao chai hu, bai shao, dang gui, 
bo he, yi yi ren, shan yao, zhi yuan zhi, shou wu, 
shen qu, sha ren, chao gu ya, gan cao 
Y 
Decoction + 
capsule 
1 bag 
decocted 
twice; 0.4 
g 
bid; qn 
estazolam 
tablet, 0.5–1 
mg, qn 
2 w 
Qian C 
2012 (158) 
Nan Wu Wei 
Zi Jiao Nang 
nan wu wei zi Y capsule 2 capsules qn Placebo  4 w 
Chen WM 
2012b 
(163) 
Tian Wang 
Bu Xin Dan 
suan zao ren, bai zi ren, dang gui, tian men dong, 
mai men dong, sheng di huang, dang shen, dan 
shen, xuan shen, fu ling, wu wei zi, yuan zhi, ju 
geng 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 1 mg 
qn 
8 w 
Zhang CL Zi Ni Yi shu di huang, yin yang huo, huang jing, nv zhen N decoction 1 pack bid diazepam 1 m 
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2012 (168) Shen An Mei 
Tang 
zi, wu wei zi, bai shao, suan zao ren, sheng long 
gu,sheng mu li, fo shou, gan song 
decocted 
twice 
tablet, 5 mg 
qn 
Sheng CJ 
2012 (167) 
Jian Pi He 
Wei Zhong 
Yao 
yi yi ren, huai shan yao, fu ling, ze xie, zhu ling, 
chen pi, jiao san xian, pu gong ying, suan zao ren, 
gan cao 
N decoction NS NS 
diazepam 
tablet, 5–10 
mg, qn 
10d 
Yang YL 
2012 (234) 
Suan Zao 
Ren Shui 
suan zao ren N decoction 
1 pack 
decocted 
once 
qn 
BZDs without 
details 
1w 
Yang XC 
2012 (216) 
Jie Yu Wan 
zi shao, chai hu, dang gui, fu ling, gan cao, xiao 
mai, da zao, yu jin, he huan pi 
N pill 4g bid 
estazolam 
tablet, 1–2 
mg, qn 
4w 
Chen WM 
2012a 
(164) 
Gui Pi Tang 
huang qi, dang shen, bai zhu, dang gui, fu shen, 
suan zao ren, yuan zhi, mu xiang, gan cao, long 
yan rou 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 1 mg, 
qn 
8w 
Wang LH 
2012 (210) 
Er Dong 
Yang Xin 
Kou Fu Ye 
di huang,tian dong,mai dong,huang qi,dang 
shen,bai zhu 
N oral solution 20ml bid 
estazolam 
tablet, 1 mg 
qn 
4w 
Lou YY 
2012 (226) 
Wen Yang 
Huo Xue 
Ning Xin 
Fang 
dang gui, zhi fu pian, tao ren, hong hua, chuan 
xiong, gua lou ke, chi shao, sheng di, shi chang 
pu, jiu yuan zhi, suan zao ren, ye jiao teng, zhen 
zhu mu 
Y decoction 
1 pack 
decocted 
once 
qd 
estazolam 
tablet, 1 mg, 
qn 
4 w 
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Li Y 2012 
& Li Y 
2013 (194, 
195) 
1.Qing Zhen 
Tang; 2.Jia 
Wei Wen 
Dan Tang 
1. huang lian, sha shen, bai he, dan shen, yuan 
zhi, niu xi, shi ju pu, gan cao, rou gui, fu ling, zhu 
ru, yan huang bai, long gu, mu li, zhu ye,ge gen, 
yu jin; 2. chen pi, fa ban xia, fu ling, zhi shi, zhu 
ru, shi chang pu, dan nan xing, zhi mu, yuan zhi, 
zhen zhu mu, ye jiao teng, chuan xiong, bai he, 
chao zao ren, gan cao 
Y decoction 
1 pack 
decocted 
once 
qd CBT 8 w 
Li GR 
2012 (176) 
Zao Ren An 
Shen Jiao 
Nang 
chao suan zao ren, dan shen, cu zhi wu wei zi N capsule 5 capsules   
estazolam 
tablet, 1 mg, 
qn 
2 w 
Zhang HM 
2012 (219) 
Xue Fu Zhu 
Yu Tang 
chai hu, zhi ke, chi shao, tao ren, chuan hong hua, 
dang gui, chuan xiong, sheng di, niu xi, ju geng 
N decoction 
1 pack 
decocted 3 
times 
tid 
estazolam 
tablet, 1 mg, 
qn 
4w 
Li XL 
2012 (219) 
Xue Fu Zhu 
Yu Tang 
tao ren, hong hua, dang gui, sheng di huang, 
chuan xiong, chi shao, niu xi, ju geng, chai hu, zhi 
ke, gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 1 mg, 
qn 
4 w 
Miao WH 
2012 (213) 
Xin Ren 
Shen An Jiao 
Nang 
sheng di huang,suan zao ren,lian zi xin,yuan 
zhi,chen pi,gan cao 
N capsule 1.35 g tid Placebo 4 w 
Kuang JG 
2012 (186) 
Tian Ma Gou 
Teng Yin 
tian ma, gou teng, shi jue ming, du zhong, niu xi, 
shan zhi, huang qin, ye jiao teng, fu shen 
N decoction 
1 pack 
decocted 
bid 
diazepam 
tablet, 2.5 
4 w 
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twice mg, qn 
Li DY 
2012 (190) 
He Wei An 
Shen Fang 
ban xia, yi yi ren, shi chang pu, fu ling, bai zhu, 
he huan pi, ye jiao teng, chao zao ren,  
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 1 mg, 
qn 
4 w 
Luo HO 
2012 (201) 
He Wei An 
Shen Fang 
ban xia, sheng yi ren, chen pi, fu ling, bai zhu, 
chai hu, chao huang qin, ye jiao teng, zhi gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
zolpidem 
tablet, 10 mg, 
qn 
4 w 
Zhu GQ 
2012 (231) 
Gan Cao Xie 
Xin Tang 
gan cao, dang shen, huang qin, huang lian, gan 
jiang, ban xia, da zao 
N decoction 
1 pack 
decocted 
twice 
bid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
12 w 
Cai Y 2011 
(163) 
Zi Ni Shu 
Gan Qing 
Xin Tang 
chai hu, yu jin, fo shou, zhi zi, he huan pi, ye jiao 
teng, suan zao ren, bai shao, chuan lian zi, fu 
shen, an mu xiang, zhi mu, gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
diazepam 
tablet, 2.5–5 
mg, qn 
2 w 
Qi GF 
2011 (172) 
Zi Ni Qing 
Hua Zi Yin 
Fang 
ban xia, xia ku cao, jiang can, yu jin, huang lian, 
bai he, zhi mu, fu ling, yuan zhi, chao zao ren, 
sheng di huang, dang gui, dan shen, ye jiao teng, 
sheng long chi 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 1 mg, 
qn 
28 d 
Sun P 2011 
(207) 
Zi Ni Jie Yu 
Hua Tan An 
Shen Tang 
huang lian, dan nan xing, chai hu, bai shao, zhi 
ke, xiang fu, zhu ru, ban xia, chang pu, yu jin, fu 
ling, ye jiao teng, yuan zhi, sheng gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 2 mg, 
qn 
30 d 
Zhu WH Wu Ling Jiao wu ling ju, suan zao ren, dan shen,wu wei zi  N capsule 3 capsules tid, qn estazolam 30 d 
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2011 (232) Nang + Zao 
Ren An Shen 
Jiao Nang 
tablet, 1 mg, 
qn 
Huang XY 
2011 (181) 
Wu Ling Jiao 
Nang 
wu ling jun N capsule 3 capsules tid 
diazepam 
tablet, 5 mg, 
qn 
4 w 
Jia B 2011 
(157) 
Wen Bu 
Zhen She 
Fang 
zhi fu zi, rou gui, yin yang huo, ling ci shi, long 
chi, zhen zhu mu, wu wei zi, chang pu, yuan zhi, 
zhi gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
diazepam 
tablet, 5 mg, 
qn 
30 d 
Wang C 
2011 (159) 
Qing Xin 
Ning Shen 
Fang 
lian zi xin, jiu huang lian, shui niu jiao, lian qiao, 
shan zhi, zhu ye, wu wei zi, mai dong, yuan zhi, 
chang pu, yu jin, suan zao ren, bai zi ren 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 1 mg, 
qn 
4 w 
Yang XH 
2011 (222) 
Gui Pi Tang 
huang qi, fu ling, bai zhu, dang shen, suan zao 
ren, mu xiang, yuan zhi, zhi gan cao, long yan 
rou, dang gui, bai zi ren, ye jiao teng, he huan pi 
N decoction 
1 pack 
decocted 3 
times 
tid 
estazolam 
tablet, 1 mg, 
qn 
4 w 
Jing XW 
2011 (221) 
Xin Shen 
Ning Pian 
suan zao ren, fu ling, shou wu teng, shen qu, wei 
zi 
Y tablet 6 tablets tid 
placebo + 
estazolam 
tablet, 1 mg, 
qn 
3 w 
Chen YY 
2011 (166) 
Chai Hu Jia 
Long Mu 
chai hu, huang qin, huang lian, ban xia, dang 
shen, gui zhi, bai shao, gan jiang, sheng long gu, 
N decoction 
1 pack 
decocted 
bid 
estazolam 
tablet, 2 mg, 
8 w 
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Tang plus 
Ban Xia Xie 
Xin Tang 
sheng mu li, ye jiao teng, gan cao, da zao twice qn 
Xiao LG 
2010 (189) 
Bu Xin An 
Shen Hua 
Tan Fang 
shu di huang, bai shao yao, e jiao, suan zao ren, 
fu shen, bai zi ren, chen pi, fa ban xia, zhu ru, he 
huan pi 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 1.3 
mg, qn 
6 w 
Jiang HQ 
2010 (178) 
Fu Zha Zao 
Ren Tang 
fu ling, shan zha, suan zao ren N decoction 
1 pack 
decocted 
twice 
bid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
3 w 
Wang ZT 
2010 (212) 
San Qi Ke Li suan zao ren, ji xue teng, san qi, xiao ji N granule 1 bag qd Placebo 4 w 
Liao RD 
2010 (233) 
No Name 
Formula 
sang ye, ju hua, tian ma, gou teng, chai hu, long 
gu, mu li, yu jin, shi chang pu, chi bai shao, dan 
shen, he huan pi 
N decoction 
1 pack 
decocted 
once 
qd 
estazolam 
tablet, 1–2 
mg, qn 
2 w 
Huang D 
2010 (179) 
Xue Fu Zhu 
Yu Tang 
tao ren, hong hua, dang gui, chuan xiong, sheng 
di huang, chi shao, chai hu, zhi ke, niu xi, ju geng, 
gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
alprazolam 
tablet, 0.8 
mg, qn 
4 w 
Wang F 
2010 (170) 
Jie Yu Ning 
Shen Fang 
chai hu, yu jin, bai zi ren, dang shen, bai zhu, 
shan yao, suan zao ren, shan yu rou, yuan zhi, fu 
shen, bai he, sheng long mu, zhen zhu mu, hu po, 
tao ren 
N decoction 
1 pack 
decocted 
twice 
bid 
diazepam 
tablet, 5 mg 
qn 
28 d 
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Tian J 
2010 (183) 
Shen Qi Wu 
Wei Zi Pian 
wu wei zi, dang shen, huang qi, suan zao ren N tablet 3 tablets tid 
estazolam 
tablet, 1 mg, 
qn 
8 w 
Huang Y 
2010 (182) 
An Shen Gao 
lian zi, qian shi, fu ling, hei zhi ma, mi zao ren, 
bai zi ren, ye jiao teng, yuan zhi, e jiao 
N soft extracts 15 ml qn 
zopiclone 
tablet, 7.5 
mg, qn 
6 w 
Song XH 
2010 (198, 
218) 
Wu Ling Jiao 
Nang 
wu ling jun N capsule 0.99 g tid Placebo 4 w 
Lian FM 
2009 (197) 
Chan Ye An 
Shen Jiao 
Nang 
tian zhu huang, can tui, shou wu teng, jiang can, 
di long, bai shao, gou teng, fa ban xia, suan zao 
ren, yuan zhi 
N capsule 2 g qd Placebo 3 w 
Xia CY 
2009 (169) 
Xia’s No.1 
Sleeping 
Prescription 
huang qi, bai zhu, suan zao ren,ye jiao teng, he 
huang pi, dan shen, huai xiao mai, fu ling, zhi 
yuan zhi, long gu, e jiao  
N decoction 
1 pack 
decocted 
twice 
bid 
Estazolam, 1 
mg, qn 
6 w 
Zhang XP 
2009 (228) 
Shen Song 
Yang Xin 
Jiao Nang 
ren shen, mai dong, wu wei zi, sang ji sheng, shan 
zhu yu,suan zao ren, dan shen, chi shao, tu bie 
chong, gan song, huang lian, long gu 
Y capsule 1.6 g qn to tid CBT 12 w 
Xu HK 
2009 (175) 
Yin Dan Xin 
Nao Tong 
Ruan Jiao 
yin xing ye, deng zhan xi xin, dan shen, jiao gu 
lan, san qi, bing pian, shan zha, da suan 
Y capsule 0.8 g bid 
estazolam 
tablet, 2 mg, 
qn 
4 w 
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Nang 
Nie ZH 
2009 (203) 
Rou Gan 
Ning Shen 
Tang 
suan zao ren, long chi, bai shao, ye jiao teng, he 
huan pi, yu jin, dan pi, chao zhi zi, gua lou pi, fu 
ling,  
N decoction 
1 pack 
decocted 
twice 
bid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
2 w 
She YQ 
2009 (223) 
No Name 
Formula 
suan zao ren, chuan xiong, fu ling, zhi mu, gan 
cao 
N decoction 
1 pack 
decocted 
twice 
bid 
diazepam 
tablet, 5 mg, 
qn 
4 w 
Li X 2008 
(215) 
Zhu Mian 
Tang 
ye jiao teng, chao zao ren, wu wei zi, lian zi rou, 
bai zi ren, shi chang pu, yuan zhi, fu ling, zhi mu, 
zhu ru, ban xia, gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
20 d 
Jiang LP 
2008 (187) 
Jie Yu Wan 
bai shao, chai hu, dang gui, yu jin, fu ling, bai he, 
he huan pi, gan cao, xiao mai, da zao  
N pill 12 g tid 
estazolam 
tablet, 2–12 
mg, bid 
6 w 
Feng XD 
2008 (217) 
Wu Ling Jiao 
Nang 
wu ling jun N capsule 3 capsules tid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
60 d 
Zhang XM 
2008 (220) 
An Shen Jiao 
Nang 
suan zao ren, zhi mu, dan shen, fu ling, chuan 
xiong, mai dong, zhi shou wu, wu wei zi 
N capsule 4 capsules tid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
8 w 
Zhang JP 
2008 (188) 
Ye He Jian 
Nao Pian 
ye jiao xi, he huan pi, wu wei zi, yuan zhi Y tablet 5 capsules tid 
zopiclone 
tablet, 7.5 
4 w 
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mg, qn 
Sun Y 
2008 (235) 
Zi Ni Wu 
Hua Shu Gan 
Tang 
fo shou hua, dai dai hua, lv e mei, chuan piao 
hua, mei gui hua, shou di, dang gui, bai shao, 
chao bai zhu, zhi gan cao 
N decoction 
1 pack 
decocted 
twice 
bid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
4 w 
Ren YJ 
2007 (206) 
Zao Ren An 
Shen Jiao 
Nang 
suan zao ren, dan shen, wu wei zi N capsule 5 capsules qn 
estazolam 
tablet, 1 mg, 
qn 
16 d 
Chang C 
2006 (236) 
Xin Ren 
Shen An Jiao 
Nang 
sheng di huang, suan zao ren, lian zi xin, yuan 
zhi, chen pi, gan cao 
Y capsule 3 capsules tid 
Placebo + 
sleep hygiene 
education 
4 w 
Chen JF 
2006 (184) 
Tian Meng 
Jiao Nang 
huang jing, huang qi, dang shen, ci wu jia, yin 
yang huo (zhi ),shan yao, ze xie, fu ling, gou qi zi, 
shu di huang, ma qian zi (zhi ) 
N capsule 3 capsules bid 
alprazolam 
tablet, 0.4–
0.8 mg, qn 
1 m 
Zheng SY 
2006 (230) 
Bai Lian 
Tang 
bai he, lian zi xin, chao zao ren, shan yu rou, 
sheng mu li, fu shen, mai dong, wu wei zi, shi 
chang pu, chuan bei mu, he huan pi 
N decoction 
1 pack 
decocted 
twice 
bid 
estazolam 
tablet, 2–12 
mg, bid 
6 w 
Luo LC 
2006 (202) 
Yi Shen 
Qiang Shen 
Yin 
rou cong rong, huang jing, huang qi, shan zha, 
jue ming zi 
N granule 4.5 g qd 
diazepam 
tablet, 5 mg, 
qn 
1 m 
Chen FQ 
2005 (162) 
An Shui 
Chong Ji         
chai hu, dang gui, xia ku cao, gou teng, dan shen, 
sheng di, long yan rou, bai he, zhen zhu mu, ye 
N granule 9–18 g tid 
diazepam 
tablet, 2.5–5 
1 m 
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jiao teng mg, qn 
Yu HT 
2005 (224) 
Jia Wei Suan 
Zao Ren 
Tang 
suan zao ren, zhi mu, chuan xiong, fu ling, long 
gu, chi shao, wu wei zi, yuan zhi, gan cao 
Y decoction 
1 pack 
decocted 
once 
qd 
lorazepam 
tablet, 0.5–
1.5 mg, qn 
4 w 
Zhang JF 
2003 (185) 
Suan Zao 
Ren Gao 
suan zao ren, zhi mu, fu ling, chuan xiong N soft extracts 20 g bid Placebo 4 w 
Zhu T 
2013 (209) 
Yang Xin An 
Shen Tang 
bai zi ren, ye jiao teng, he huan pi hua,fu shen, 
chao zao ren, dang gui, bai shao, hu po mo, wu 
wei zi, chen pi, zhi ke 
N
+
Y 
decoction 
1 pack 
decocted 
twice 
bid CBT 4 w 
Chen H 
2012 (173) 
Bai Le Mian 
Jiao Nang 
bai he, ci wu jia, shou wu teng, suan zao ren, he 
huan hua, zhen zhu mu, shi gao, fu ling, yuan zhi, 
dang can, sheng di huang, mai dong, wu wei zi, 
deng xin cao, dan can 
N
+
Y 
capsule 4 capsules bid 
zolpidem, 10 
mg, qn 
8 w 
Liu Y 2009 
(200) 
Zao Ren An 
Shen Jiao 
Nang 
zao ren, dan can, wu mei zi N capsule 5 capsules qn 
*
1: estazolam 
tablet, 1 mg, 
qn; 2: 
placebo, 5 
capsule, bid 
3 w 
Chen WQ 
2008 (165) 
Nao Kang II zhi shou wu, shou di, san qi, chang pu 
N
+
Y 
oral solution 50 ml bid 
diazepam 
tablet, 2.5 
mg, qn 
4 w 
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Zhan SQ 
2008 (227) 
Huo Li Su 
Kou Fu Ye 
zhi shou nia, gou qi zi, zhi huang jing, huang qi, 
yin yang huo, dan can 
N
+
Y 
oral solution 10 ml bid 
zolpidem, 5–
10 mg, qn 
4 w 
Li Y 2009 
(193) 
Jia Wei Xiao 
Yao San 
suan zao ren, fu shen, chai hu, dang gui,bai shao, 
bai shu, gan cao,bao he, wei sheng jiang 
N
+
Y 
decoction 
1 pack 
decocted 
twice 
bid 
1. Estazolam 
1 mg, qn + 
placebo of 
CHM; 2. 
placebo of 
CHM + 
placebo of 
estazolam 
6 w 
Notes. CBT-i: cognitive behaviour therapy for insomnia; CHM: Chinese herbal medicine; IM: integrative medicine; N: no, stating CM is used alone; Y: yes, stating CM is 
used as adjunct to conventional medicine; N+Y: stating there are two intervention groups, one for CM and the other for IM; d: day/days; m: month/months; w:week/weeks; 
y:year/years. *There are two groups of control: pharmacotherapy and placebo. #This is a study including four groups: CHM plus placebo of pharmacotherapy, CHM plus 
pharmacotherapy, pharmacotherapy plus placebo of CHM and placebo of CHM plus placebo of pharmacotherapy. $When CHM is used as an adjunct to conventional 
medicine, the control is the same as the conventional medicine in intervention group. †The herbal ingredients are presented as Chinese pinyin. A single formula is usually 
prepared in one pack. The correspondent scientific names are specified in the book ‘Dan Bensky, editor.Chinese Herbal Medicine: Materia Medica, Third Edition. Seattle, 
WA: Eastland Press, Inc; 2004’. 
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3.3.3. Estimated Effect of CHM on Insomnia 
3.3.3.1. PSQI 
CHM Alone Versus Control 
In terms of sleep quality assessed by PSQI, CHM was more effective than the placebo (MD: 
–3.06, 95% CI: –5.14 to –0.98, I2 = 97%; n = 8 RCTs, 853 participants) (180, 185, 197, 200, 
211–213, 218) and BZDs (MD: –1.94, 95% CI: –2.45 to –1.43, I2 = 96%; n = 35 RCTs, 3361 
participants) (157, 159, 160, 163–168, 170–172, 174, 177–179, 181, 184, 191, 192, 199, 200, 
203, 204, 208, 210, 215–217, 219, 220, 223, 231). However, CHM was not superior to 
NBZDs (MD: –0.16, 95% CI: –0.65 to 0.33, I2 = 57%; n = 3 RCTs, 323 participants) (156, 
182, 201) or psychotherapy (MD: –1.23, 95% CI: –2.48 to 0.01, n = 1 RCT, 120 participants) 
(209). A four-arm, double-blinding, double-dummy RCT (33 participants) reported CHM 
plus placebo of BZDs was not superior to BZDs plus placebo of CHM (MD: –2.10, 95% CI: 
–6.00 to 1.80) or placebo of BZDs plus placebo of CHM (MD: –1.60, 95% CI: –4.45to 1.25) 
(193). The results are shown in Figure 3.3. 
At the end of follow-up ranging from one week to three months, CHM group had a 
significantly better effect on the PSQI scores than placebo (MD: –6.30, 95% CI: –2.58 to –
0.02, I
2 
= 97%; n = 2 RCTs, 158 participants) (180, 197), BZDs (MD: –3.61, 95% CI: –5.81 
to –1.40, I2 = 97%; n = 3 RCTs, 228 participants) (204, 217, 220) and NBZDs (MD: –2.70, 
95% CI: –3.33 to –2.07; n = 1 RCT, 124 participants) (182). The results are showed in 
Appendix 3.2. 
CHM Plus Conventional Medicine Versus Control 
In terms of sleep quality assessed by the PSQI scores, the effect of CHM plus BZDs was 
significantly better than that of placebo plus BZDs (MD: –1.88, 95% CI: –2.78 to –0.97, 
I
2 
= 0; n = 3 RCTs, 121 participants) (193, 221, 225) and BZDs alone (MD: – 3.19, 95% CI: –
4.40 to –1.99, I2 = 89%; n = 5 RCTs, 462 participants) (165, 175, 196, 205, 226). CHM plus 
psychotherapy was more effective than psychotherapy alone (MD: –3.80, 95% CI: –4.91 to –
2.68, I
2 
= 68%; n = 3 RCTs, 372 participants) (194, 195, 209, 228). However, CHM plus 
NBZDs was not superior to NBZDs alone (MD: –1.15, 95% CI: –2.49 to 0.19; n = 1 RCT, 96 
participants) (208). One RCT (193 participants) reported CHM plus sleep hygiene education 
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was not superior to placebo plus sleep hygiene education (MD: –0.81, 95% CI: –2.26 to 0.64) 
(158). The results are shown in Figure 3.4. 
At the end of a 7-day follow-up, the effect of CHM plus BZDs on PSQI scores was not 
superior to placebo plus BZDs (MD: –1.43, 95% CI: –3.04 to 0.18; n = 1 RCT, 60 
participants) (225). The results are shown in Appendix 3.3. 
3.3.3.2. AIS 
CHM Alone Versus Control 
In terms of global sleep quality evaluated by the AIS, CHM was more effective than BZDs 
(MD: –1.42, 95% CI: –2.21 to –0.64, I2 = 63%; n = 6 RCTs, 463 participants) (169, 176, 183, 
202, 214, 232) but not more effective than NBZDs (MD: 0.14, 95% CI: – 0.26 to 0.54, 
I
2 
= 0%; n = 2 RCTs, 121 participants) (173, 227) .The results are shown in Appendix 3.4. 
CHM Plus Conventional Medicine Versus Control 
The effect of CHM plus NBZDs on the AIS scores was similar to that of NBZDs alone (MD: 
–0.57, 95% CI: –0.95 to –0.19, I2 = 0%; n = 2 RCTs, 120 participants) (173, 227). The results 
were shown in Appendix 3.5. 
3.3.3.3. Patient-Rated Sleep Parameters 
Sleep-Onset Latency 
In terms of sleep-onset latency reported by patients, CHM was more effective than placebo 
(MD: –19.87 minutes, 95% CI: –26.93 to –12.82 minutes, I2 = 0%; n = 3 RCTs, 395 
participants) (185, 197, 212) but not more effective than BZDs (MD: – 13.81 minutes, 95% 
CI: –31.27 to 3.65 minutes, I2 = 92%; n = 3 RCTs, 329 participants) (186, 220, 229). There 
was no significant difference between the effect of CHM plus NBZDs and NBZDs alone 
(MD: –1.93 minutes, 95% CI: –11.30 to 7.44 minutes; n = 1 RCT, 60 participants) (71) or 
CHM plus sleep hygiene and BZDs plus sleep hygiene (MD: –2.81 minutes, 95% CI: –8.17 
to 2.55 minutes; n = 1 RCT, 193 participants) (158).The results are shown in Appendix 3.6 
and Appendix 3.7. At the end of a 3-month follow-up period, participants who received CHM 
reported shorter sleep-onset latency than who received BZDs (MD: –32.00 minutes, 95% CI: 
–45.84 to –18.16 minutes; n = 1 RCT, 84 participants) (220). 
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Total Sleep Duration 
In terms of total sleep duration reported by patients, CHM was more effective than placebo 
(MD: 0.78 hour, 95% CI: 0.55 to 1.01 hour, I
2 
= 0%; n = 3 RCTs, 395 participants) (185, 197, 
212) and BZDs (MD: 1.12 hour, 95% CI: 0.36 to 1.87, I
2 
= 95%; n = 7 RCTs, 783 
participants) (161, 162, 167, 186, 220, 222, 229). The results are shown in Appendix 3.8. At 
the end of 3-month follow-up period, participants received CHM reported longer total sleep 
duration than those who received BZDs (MD: 1.60 hours, 95% CI: 1.08 to 2.12 hours; n = 1 
RCT, 84 participants) (220). 
Sleep Efficiency 
In terms of sleep efficiency calculated from patient-reporting sleep parameters, CHM was 
superior to placebo (MD: 9.72%, 95% CI: 6.49% to 12.96%, I
2 
= 0; n = 2 RCTs, 294 
participants) (185, 212) and BZDs (MD: 19.02%, 95% CI: 18.137% to 19.92%, I
2
 = 0; n = 2 
RCTs, 249 participants) (185, 220, 229). The results are shown in Appendix 3.9. At the end 
of a 3-month follow-up period, participants received CHM reported improved sleep 
efficiency than those who received BZDs (MD: 20%, 95% CI: 11.23% to 28.77%; n = 1 
RCT, 84 participants) (220). 
3.3.3.4. Sleep Parameters Measured by Polysomnography 
Sleep parameters measured by PSG were only reported in two RCTs. Data synthesis was not 
possible because the study design of these two studies varied. According to the only one RCT 
(96 participants) (211), CHM was not superior to placebo for sleep-onset latency (MD: –1.12 
minutes, 95% CI: –10.31 to 8.07), total sleep duration (MD: 20.33 minutes, 95% CI: –11.78 
to 52.44 minutes), sleep efficiency (MD: 3.00%, 95% CI: –2.80% to 8.80%) or times of 
awakenings (MD: –0.74 times, 95% CI: –2.88 to 1.40 times). The four-arm, double-blind and 
double-dummy RCT (n = 33 participants) (193) reported no significant difference in sleep-
onset latency, total sleep duration, sleep efficiency or times of awakenings between CHM 
plus placebo BZDs, BZDs plus placebo CHM, CHM plus BZDs and placebo CHM plus 
placebo BZDs. 
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3.3.3.5. Clinician Global Impression 
There was no significant difference in the severity of CGI assessed by CGI-S between CHM 
and BZDs (MD: 0.10, 95% CI: –0.20, 0.41, I2 = 0%; n = 3 RCTs, 236 participants) (187, 206, 
230) or between CHM plus BZDs and BZDs alone (MD: –0.47, 95% CI: –1.09 to 0.15; n = 1 
RCT, 86 participants) (224).The results are shown in Appendix 3.10. At the end of a 1-week 
follow-up period, the CGI-S score was lower in participants who received CHM than those 
who received BZDs (MD: –0.89, 95% CI: –1.41 to –0.37; n = 1 RCT, 100 participants) (206). 
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Figure 3.3. PSQI of CHM versus control  
Note. PSQI: Pittsburgh Sleep Quality Index; CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs; 
NBZDs: non-benzodiazepine drugs 
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Figure 3.4. PSQI of CHM plus conventional medicine versus control 
Note. PSQI: Pittsburgh Sleep Quality Index; CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs; 
NBZDs: non-benzodiazepine drugs 
3.3.4. Adverse Events 
Adverse events were monitored in 43 studies. Eleven of them found no adverse events for the 
whole study (159, 170, 176, 182, 183, 197, 205, 211, 212, 221, 225). Data of 23 studies were 
available for meta-analysis of frequency. There was no significant difference in the frequency 
of adverse events between CHM and placebo (RR: 1.65, 95% CI: 0.67 to 4.10, I
2 
= 0; n = 2 
RCTs, 400 participants) (185, 218). The CHM group had fewer adverse events than the BZDs 
group (RR: 0.15, 95% CI: 0.07 to 0.28, I
2 
= 76%; n = 16 RCTs, 1802 participants) (157, 160–
162, 167, 169, 171, 172, 178, 191, 206, 207, 210, 216, 232, 235) and the NBZDs group (RR: 
0.11, 95% CI: 0.02 to 0.58, I
2 
= 0; n = 2 RCTs, 199 participants) (156, 201). The adjunct 
CHM treatment did not significantly increase the frequency of adverse events associated with 
NBZDs (RR: 0.36, 95% CI: 0.10 to 1.27; n = 1 RCT, 96 participants; n = 1 RCT, 96 
participants) (208) or psychotherapy group (RR: 1.58, 95% CI: 0.08 to 30.90, I
2 
= 73%; n = 2 
RCTs, 372 participants) (158, 228). These results are shown in Figure 3.5 and Figure 3.6. The 
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most frequent types of adverse events in CHM groups were digestive dysfunction such as 
indigestion and mild increased defecation, dizziness, fatigue, drowsiness and dry mouth. But 
none of the studies assessed whether the reported adverse events were CHM associated. 
3.3.5. Other Analysis 
3.3.5.1. Subgroup Analysis of the Primary Outcome 
The subgroup analysis based on treatment duration (≤4 weeks or >4 weeks), insomnia history 
(<1 year or ≥1 year) and preparation of CHM (decoction or non-decoction) could not address 
the heterogeneity of meta-analysis for the PSQI scores. The results were shown in Table 3.3. 
 
Figure 3.5. Frequency of adverse events of CHM versus control 
Note. CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs; NBZDs: non-benzodiazepine drugs 
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Figure 3.6. Frequency of adverse events of CHM plus conventional medicine versus 
control 
Note. CHM: Chinese herbal medicine; NBZDs: non-benzodiazepine drugs. 
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Table 3.3. Subgroup Analysis of PSQI Scores Based on Treatment Duration, Insomnia History and Preparation of CHM 
Subgroup 
No. 
Study 
No. Participants 
Estimated Effect 
(MD, 95% CI) 
I
2
 Analysis Model 
CHM versus BZDs 
Treatment duration 
≤4 weeks 28 2874 –1.67 [–2.27, –1.08] 94% Random 
>4 weeks 7 487 –2.95 [–3.84, –2.07] 86% Random 
Duration of insomnia history 
<1 year 4 340 –0.55 [–2.62, 1.51] 96% Random 
≥1 year 20 2144 –1.98 [–2.61, –1.34] 96% Random 
Preparation of CHM 
Decoction 21 2175 –2.26 [–3.02, –1.50] 94% Random 
Non-decoction 14 1186 –1.47 [–2.25, –0.70] 97% Random 
CHM versus placebo 
Treatment duration 
≤4 weeks 7 796 –2.40 [–3.61,–1.19] 88% Random 
>4 weeks 1 57 –7.22 [–7.86, –6.58] NA Fixed 
Duration of insomnia history 
<1 year 1 60 –0.90 [–1.56, –0.24] NA Fixed 
≥1 year 5 527 –4.21 [–6.28, –2.15] 95% Random 
CHM versus NBZDs 
Duration of insomnia history 
≥1 year 2 206 0.12 [–0.24, 0.48] 24% Fixed 
<1 year 0 NA NA NA NA 
CHM plus BZDs versus BZDs 
Preparation of CHM 
Decoction 2 160 –4.21 [–5.75, –2.68] 82% Random 
Non-decoction 2 222 –3.11 [–3.50, –2.72] 7% Fixed 
Combination 1 80 –0.53 [–1.67, 0.61] NA Fixed 
Duration of insomnia history ≥1 year 4 322 –3.23 [–5.16, –1.31] 92% Random 
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Subgroup 
No. 
Study 
No. Participants 
Estimated Effect 
(MD, 95% CI) 
I
2
 Analysis Model 
<1 year 0 NA NA NA NA 
CHM plus BZDs versus BZDs plus placebo 
Duration of insomnia history 
<1 year 1 14 0.60 [–3.48, 4.68] NA Fixed 
≥1 year 2 107 –2.00 [–2.93, –1.07] 0% Fixed 
CHM plus psychotherapy versus psychotherapy 
Treatment duration 
≤4 weeks 1 120 –3.45[–4.54, –2.36] NA Fixed 
>4 weeks 2 252 –3.77[–5.77, –1.77] 71% Random 
Preparation of CHM 
Decoction 2 210 –3.25 [–4.22, –2.27] 0% Fixed 
Non-decoction 1 152 –4.55 [–5.02, –4.08] NA Fixed 
Note. PSQI: Pittsburgh Sleep Quality Index; CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs; NBZDs: non-benzodiazepine drugs; NA: not applicable; MD: 
mean difference; CI: confidential intervals. For some comparison, the subgroup analysis could not be achieved because of insufficient information related to treatment 
duration, duration of insomnia history or preparation of CHM. 
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3.3.5.2. Sensitivity Analysis 
Only four studies (582 participants) had low risk of bias relating to allocation concealment 
and blinding of participants (185, 197, 212, 218). All four studies compared non-decoction 
CHM treatment (≤1 month) to placebo. At the end of the treatment, the PSQI score was lower 
in participants who received CHM treatment than those who received placebo (MD: –2.13, 
95% CI: –3.92 to –0.35, I2 = 87%). 
Eleven studies comparing CHM to BZDs clarified they excluded the sixth domain (use of 
sleeping medications) when they calculated the total scores of PSQI (163, 164, 170, 172, 179, 
184, 189, 204, 210, 215, 219). The PSQI scores were significantly lower in the participants 
treated with CHM than those with BZDs (MD: –1.46, 95% CI: –2.10 to –0.81, I2 = 80%; 
n = 11 RCTs, 1046 participants). 
Imbalance baseline of PSQI scores was found in three studies in two heterogeneous meta-
analyses (167, 199, 226). After excluding them, greater reduction of PSQI scores was 
observed in the participants treated with CHM (MD: –1.93, 95% CI: –2.46 to –1.39, 
I
2 
= 96%; n = 33 RCTs, 3255 participants) and CHM combined with BZDs (MD: –2.72, 95% 
CI: –3.91 to –1.53, I2 = 85%; n = 4 RCTs, 402 participants) than those with BZDs alone. 
3.3.5.3. Post-Hoc Analysis 
The post-hoc subgroup analysis on primary outcome was made to explore the estimated 
effect of individual formula. Four formulae were investigated more than twice in the included 
RCTs with PSQI scores. The PSQI scores were lower in the participants treated with Zao Ren 
An Shen capsule (MD: 0.47, 95% CI: –0.43 to –1.36, I2 = 85%; n = 3 RCTs, 240 participants) 
(171, 191, 200), Xue Fu Zhu Yu decoction (MD: –1.29, 95% CI: –2.09 to –0.49, I2 = 0; n = 2 
RCTs, 266 participants) (179, 219) and Wuling capsule (MD: –2.34, 95% CI: –3.45 to –1.23, 
I
2 
= 96%; n = 2 RCTs, 148 participants) than those with BZDs (181, 217).There was no 
significant difference of PSQI scores after the treatment with Tian Wang Bu Xin pill and 
BZDs (MD: –0.73, 95 % CI: –2.87 to 1.42; I2 = 88%; n = 2 RCTs, 146 participants) (163, 
174). 
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3.3.5.4. Publication Bias 
Only the comparison between CHM and BZDs in the meta-analysis of PSQI scores included 
more than 10 studies. The publication bias was not detected in either visual funnel plot (see 
Appendix 3.11), Egger’s test (p = 0.708) or Begg’s test (p = 0.122). 
3.4. Discussion 
3.4.1. Evidence Summary and Applicability 
In this study, we systematically reviewed 79 RCTs investigating a variety of CHM treatments 
for participants with insomnia. We also performed meta-analyses to estimate the efficacy of 
CHM on subjective sleep quality assessed by validated instruments, patient-rated sleep 
parameters and clinician-reported severity and PSG results and to determine the safety of 
CHM. This SR provides up-to-date and comprehensive evidence of the efficacy and safety of 
CHM for insomnia. We also investigated the effect of different treatment strategies, subtypes 
of participants, various comparators and methodological designs on the effect, which makes 
our results clinically meaningful. Overall, this SR and meta-analysis showed that CHM used 
as a monotherapy was superior to placebo and BZDs and as an adjunct therapy was superior 
to BZDs and psychotherapy alone in terms of subjective sleep quality and quantity and 
safety. CHM was not associated with more benefit than NBZDs although the risks were less. 
These results suggest CHM could be a promising alternative therapy with a good benefit-risk 
ratio. 
In this SR, the most homogeneous meta-analysis of primary outcome came from the 
comparison of CHM plus BZDs with placebo CHM plus BZDs. It showed adjunct use of 
CHM resulted in larger reduction of PSQI scores by 1.88 points, which was greater than the 
MCID of PSQI scores (152). This result suggests that the estimated effect of CHM as a co-
intervention to BZDs is relevant and potentially important to the insomnia patients in real 
clinical practice. 
As this SR only included participants primarily diagnosed with insomnia, the evidence on 
CHM generated from this SR cannot be generalised to the population with comorbid 
insomnia or medication/substance induced insomnia. In addition, the longest follow-up 
duration of the CHM treatment was six months; thus, the evidence of safety related to CHM 
could not be generalised to a longer therapy. 
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3.4.2. Overall Completeness of Evidence and Clinical Implications 
A placebo effect is commonly observed for self-reported outcomes related to insomnia where 
placebo treatment significantly improved the total scores of PSQI by 2.0 points, increased 
total sleep duration by 23.0 minutes and decreases sleep-onset latency by 15.1 minutes, 
compared with no treatment (237). In this SR, our primary finding was that CHM was 
superior to placebo in terms of the improvement of PSQI scores, sleep-onset latency, total 
sleep duration and sleep efficiency in participants with insomnia. In the sensitivity analysis, 
the positive trend of CHM was robust after the studies with inadequate randomisation, 
allocation concealment or insufficient blinding were removed. This study provides new 
evidence of the effect of CHM on subjective insomnia. This result also suggests that CHM 
could be an alternative treatment for individuals with insomnia when CBT-i or 
pharmacotherapies are unavailable in clinical settings. 
Previous studies showed that short-term use of BZDs was effective for insomnia (83). 
However, the risks and side effects associated with BZDs, such as daytime drowsiness and 
drug dependency, have been noted in both research and clinical practice (86, 87, 238, 239). 
Another striking finding of our SR was CHM was associated with more benefit to subjective 
sleep quality, total sleep duration and sleep efficiency than BZDs and these results remained 
robust in sensitivity analysis. Also, the meta-analysis indicated that the frequency of adverse 
events in participants treated with short-to-medium CHM was significantly less than that of 
participants treated with BZDs and no serious adverse events were reported in any study. 
These results suggest CHM might be an alternative to BZDs for individuals whose 
predominant complaint is dissatisfaction with overall sleep quality and total sleep quantity. 
To what extent CHM was better than BZDs remains uncertain. However, CHM did not have 
a better effect than NBZDs on subjective outcomes of insomnia although it was associated 
with less adverse events. 
Insomnia management is complex where a sequential or integrative approach is used, 
particularly for persistent and chronic insomnia (134, 135). In this SR, we also investigated 
the add-on effect of CHM to conventional medicine. The meta-analysis showed adjunct use 
of CHM to conventional medicine resulted in greater improvement of subjective sleep quality 
compared with BZDs, NBZDs and CBT-i. The highest level of evidence was attained from 
the homogeneous meta-analysis comparing CHM plus BZDs to BZDs plus placebo. In 
addition, adjunct use of CHM to CBT or NBZDs did not increase the adverse events in 
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participants with insomnia. These results provide new knowledge that CHM could be used as 
a complementary therapy for insomnia patients with a predominant complain of 
dissatisfaction with overall sleep quality. 
Drug tolerance is commonly encountered in pharmacotherapies for insomnia (240). Our SR 
showed the effect of CHM was well sustained in the medium-to-long term follow-up and this 
effect was significantly better than placebo, BZDs and NBZDs in terms of PSQI scores. This 
result also adds new knowledge to the field. 
This SR showed there was no significant difference between CHM and BZRAs for increasing 
sleep-onset latency or reducing clinician-rated severity. This indicates the conscientious and 
judicious implementation of the CHM evidence is required in clinical practice because the 
effect of CHM on insomnia varies according to the outcome measurement. 
There was insufficient evidence addressing two important clinical questions: 1) whether 
CHM was more beneficial than CBT-i for participants with insomnia and 2) whether CHM 
changed the insomnia electrophysiology detected by PSG. 
3.4.3. Limitations and Implications for Research 
Proper randomisation and allocation to reduce the selection bias are necessary for an RCT. 
We noted that appropriate randomisation methods were only used in 34.18 per cent of studies 
and adequate allocation concealment in 6.33 per cent. The poor status of randomisation may 
be due to low methodological quality or low report quality. However, both are likely to 
exaggerate the estimate of efficacy (241, 242). Therefore, prospective registration of clinical 
trials and improvement of reporting quality according to CONSORT statement for herbal 
interventions are required in the future to present full transparency for the study design, 
implementation and data analysis (243–245). 
Insufficient blinding can also lead to overestimation of the effect size (242). Although 
double-blinding is encouraged in RCTs, it is difficult to practice it for herbal intervention 
because of the different shape, smell, taste and administration of CHM products from 
pharmacotherapy. Considering this challenge, the efficacy of any CHM product should be 
assessed in the comparison with placebo before its effectiveness is evaluated by using 
pharmacotherapy as its comparator. Sixty-six different CHM treatments found in the pool of 
RCTs but only 13 of them used placebo as comparators and only 10 used blinding. This 
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indicates more RCTs using placebo and blinding are needed. In addition, only two RCTs used 
placebo to CHM decoction, which suggests the research and development of a placebo to 
CHM decoction is needed. 
PROs, such as PSQI and patient-rated sleep parameters, directly measure the core treatment 
benefits from patients’ perspectives in a natural setting (246), which have been 
comprehensive analysed in this meta-analysis. However, the treatment effect on PROs is 
easily affected by insufficient allocation concealment and blinding (247). In light of the 
difficulty in blinding RCTs for Chinese herbal intervention, increasing use of CROs such as 
CGI-s and CGI-I performed by blinded assessors is needed to provide the overall assessment 
of insomnia progression. Sleep laboratory studies such as PSG and actigraphy should also be 
encouraged to explore the mechanism of CHM’s action in sleep structures. 
Heterogeneity across studies often results in unsuccessful meta-analysis (248). In this SR, we 
included RCTs of various interventions to have a broad perspective on the evidence regarding 
the use of CHM for insomnia and this caused heterogeneity in some meta-analyses. Clinical 
and methodological heterogeneity could not be well-addressed by subgroup or sensitivity 
analysis. Therefore, most results presented in this SR were the average effects of CHM on 
insomnia estimated by a random-effect model, rather than the typical effect. This solution to 
heterogeneity was based on the assumption that effect being estimated in different CHM 
treatments may not be identical but follows some distribution (249, 250). We noted the effect 
size of formulae varied in the post-hoc analysis, which agreed with our assumption. 
Therefore, further comprehensive searches and appraisals of the evidence for each CHM 
formula for insomnia are needed in the future. 
3.4.4. Agreements and Disagreements with Other Reviews 
A previous high-quality SR with meta-analysis on standardised CHM for insomnia also 
suggested that CHM was superior to placebo and safe for individuals with insomnia (12). 
However, our study is different from it in four main areas. First, the previous study used 
Jadad scale (251) to examine the study quality and concluded the poor methodological 
quality of the studies limited their ability to draw definitive conclusions. However, the use of 
Jadad scale is increasingly discouraged because the total scores is an unreliable assessment of 
validity (252–254). We used Cochrane risk and bias instrument to assess the domain-specific 
methodological quality, thus avoiding this problem. Second, we conducted the search up to 
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May 2014 and collected more up-to-date evidence. Third, we only included the participants 
diagnosed by standard instruments of insomnia, while the previous review treated insomnia 
as a complaint, which results in a different generalised population. Fourth, we used a 
comprehensive list of sleep measurements as outcomes, which provides more information for 
clinical practice and research. 
3.5. Conclusion 
Overall, CHM alone or combined with routine care can safely improve subjective sleep in 
people with insomnia. However, the typical effect of CHM cannot be determined when 
compared with BZRAs and CBT-i due to heterogeneity. Further SRs focusing on individual 
formula for insomnia is needed. The development of a comparable placebo to traditional 
decoction is encouraged as well to ensure the successful blinding in clinical trials. 
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Chapter 4. Traditional Use of Chinese Herbal Medicine for 
Insomnia: A Systematic Analysis of the Historical Literature 
4.1. Introduction 
Though Chapter 3 has demonstrated the benefits of CHM for insomnia by pooling clinical 
trials, a few research questions are to be resolved: ‘What has led to the varied effect sizes of 
CHM formulae?’ and ‘Which individual formula should be further researched as a priority?’ 
The historical literature of CM is a classical document about case reports or commentary 
from TCM practitioners in the pre-contemporary period (255). It forms the foundation of 
TCM clinical practice. The historical literature of CM also provides traditional knowledge of 
CHM, a promising source for new drug discovery, such as the successful story of artemisinin 
(256). Therefore, a systematic analysis of the historical literature of CM may identify the gap 
between the traditional use of Chinese Materia Medica and the available research evidence as 
well as reveal a promising herbal recipe for further research. 
In the past few years, the international collaboration between Guangdong Provincial 
Academy of Chinese Medical Sciences, China, and RMIT University, Australia, has been 
developing a methodology on the systematic evaluation of the historical literature of CM 
(257). This methodology has been applied to several conditions, such as dementia, diabetic 
nephropathy and chronic cough (258–260). Based on the established methodology, we 
systematically collected, appraised and analysed the pre-contemporary Chinese texts on 
CHM for insomnia. 
4.2. Methods 
4.2.1. Historical Textual Sources 
To obtain a representative sample of the ancient and pre-modern medical literature, we 
conducted a search of Zhong Hua Yi Cian CD 5.0 (ZHYDH, 5th edition; translation: The 
Encyclopaedia of Traditional Chinese Medicine Database; Chinese: 中华医典第 5版). It is 
the most comprehensive electronic collection of TCM, containing 1,158 medical books on a 
wide range of topics spanning 206 AD to 1949. It includes clinical monographs, Materia 
Medica, collections of herbal formulae and acupuncture books. 
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4.2.2. Insomnia Terms 
In ancient China, five Chinese words are commonly used to describe sleep, including Mei (in 
Chinese: 寐), Mian (in Chinese: 眠), Ming (in Chinese: 瞑), Wo (in Chinese: 卧) and Shui (in 
Chinese: 睡 ) (95–972). To select TCM disease nomenclatures potentially relevant to 
insomnia, we consulted dictionaries, monographs, medical nomenclatures and textbooks 
specific to insomnia in CM (6, 7, 95–99, 101–103, 261–267). To balance sensitivity and 
specificity, seven search terms were identified, consisting of bumei (in Chinese: 不寐), 
bumian (in Chinese: 不眠), bushui (in Chinese: 不睡), wumei (in Chinese: 无寐), wumian (in 
Chinese: 无眠), shimian (in Chinese: 失眠) and shimei (in Chinese: 失寐). 
4.2.3. Text Categorisation 
A citation—a distinct passage of text—was defined as the unit of text. Each term was entered 
into the ZHYD search fields to identify the relevant text. Then the texts were sorted by 
citations. A duplicate was defined as the same citation in the same book. After removing 
duplicates, the text was coded according to authors, book titles, publishing years and type of 
citations. Exclusion criteria were then applied to remove citations that were considered 
irrelevant to insomnia, contained no treatment information, books written after 1949 or 
translated from other languages. 
4.2.4. Coding Tree 
4.2.4.1. Codes on Clinical Characteristics of Insomnia 
The DSM-5 was consulted to identify the essential clinical characteristics of insomnia (1). 
The texts were coded on importance of insomnia complaints in clinical scenarios, duration, 
impairment, types of insomnia and differentiation of predefined disorders. Demographics, 
such as gender and age, were also coded. The coding system is specified in Table 4.1. 
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Table 4.1. Codes on Clinical Characteristics of Insomnia 
Domain  Code Description 
Domain 1 
Is insomnia the main complaint? 
1.1  Insufficient information to decide 
1.2 Insomnia as the main complaint 
1.3 Insomnia as the accompanied symptom 
Domain 2 
Duration of insomnia history 
2.1 Insufficient information to decide 
2.2 Acute 
2.3 Chronic 
Domain 3 
Impairment of insomnia  
3.1 Insufficient information to decide 
3.2 Daytime tiredness 
3.3 Impairment in life, work or social 
activity 
Domain 4 
Is insomnia diagnosed alone or 
concurrently? 
4.1 Insufficient information to decide 
4.2 Insomnia alone 
4.3 Comorbid insomnia 
Domain 5 
Does a possible differential diagnosis 
exist? 
5.1 No  
5.2 Insufficient information to decide 
5.3 Nightmare 
5.4 Abnormal behaviour during sleep 
5.5 Breathing disorder 
5.6 Other mental disorders 
5.7 Induced by previous treatment, wine, tea 
or other substance 
Domain 6 
Special group of insomnia patients 
6.1 Insufficient information to decide 
6.2 Children 
6.3 Women 
6.4 Elderly people 
4.2.4.2. Codes on Treatment Information and Outcomes 
A coding tree of treatment including two levels was also developed. The first level of codes 
comprised the type of treatment, including CHM, acupuncture and other therapies (e.g., 
dietary therapy, meditation and combination therapies). Only the citations related to CHM 
were included for further coding. The second level of codes consisted of specific categories 
of CHM treatment, including a multi-herb formula, single herb and several formulae used 
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together for one case. Codes on treatment outcomes included insufficient information to 
decide and effective and ineffective treatment outcomes. 
4.2.5. Development of Datasets 
Two datasets were derived in line with two levels of insomnia definition. The primary dataset 
included all citations in the coding procedure. Insomnia in this dataset was considered a 
complaint, in which insomnia could be the main focus or a concurrent symptom. 
The secondary dataset aimed to include information about treatments specific to insomnia 
and only citations with insomnia as the primary diagnosis (Code 1.2, Table 4.1) were 
included. Then codes on differential diagnosis were reviewed and citations with codes 5.2–
5.7 (i.e., insufficient information to decide, nightmare, abnormal behaviour during sleep, 
breathing disorder, other mental disorders and insomnia considered to be induced by previous 
treatment and wine, tea or other substance) were excluded. Insomnia in this dataset was 
considered a diagnosis and main clinical focus and the treatment was specific to insomnia. 
Information about formula names, herb ingredients, preparation methods, administration 
routes and treatment frequency and duration was collected where available. The citation 
without a formula name was replaced by a substituted name whose ingredients were the 
same. For the formula without herbal ingredients, other texts in the same book or texts 
written by the same author were searched. To ensure precision of the data, no further 
imputations of the missing data were undertaken. 
4.2.6. Data Analysis Procedure 
The primary dataset was used to gain an overview of citations, including treatment 
information and insomnia descriptions. The secondary dataset was used to investigate clinical 
characteristics of insomnia diagnosis in pre-contemporary times, such as which population 
was more likely to experience insomnia, which type of impairment is commonly derived 
from insomnia and which herbal formulae was the most popular. Descriptive statistics such as 
frequency calculation was applied. To further evaluate the relationship between treatment 
popularity and demographics, cross-tabulation and association analysis were used. The 
statistical analysis was performed in the IBM SPSS Statistics version 20.0.0. 
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4.2.7. Overall Flowchart for the Systematic Analysis of Pre-contemporary Texts  
The overall procedure included seven steps. Figure 4.1 details the procedure. 
 
Figure 4.1. Overall flowchart  
Note. ZHYD: Zhong Hua Yi Cian CD 5.0; English translation: The Encyclopaedia of Traditional Chinese 
Medicine Database; CHM: Chinese herbal medicine. 
4.3. Results 
4.3.1. Search Results 
The initial search hit 5,204 citations. Citations found by bumian accounted for the largest 
proportion and citations identified by bumei were the second largest. The number of citations 
in the primary dataset, which defined insomnia as a complaint, was 3,694 while the count in 
the secondary dataset decreased to 940 when insomnia was referred to as a clinical diagnosis. 
Table 4.2 details the search results in reference to different insomnia terms. 
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Table 4.2. Citations Per Insomnia Terms 
Terms 
All Data 
Insomnia at Complaint 
Level 
Insomnia at Diagnosis 
Level 
No. Citations 
(%) 
No. Citations (%) No. Citations (%) 
bumei 2,084 (40.1) 1285 (34.8) 316(33.6) 
bumian 2,222 (42.7) 1770 (47.9) 528(56.2) 
bushui 545 (10.5) 345 (9.3) 67(7.1) 
wumei 235 (4.5) 199 (5.4) 16 (1.7) 
wumian 100 (1.9) 84 (2.3) 12(1.3) 
shimian 11 (0.2) 7 (0.2) 0 (0) 
shimei 7 (0.1) 4 (0.1) 1 (0.1) 
Total 5,204 (100) 3694 (100) 940(100) 
Note. Insomnia at complaint level: insomnia could be the main focus or a concurrent symptom. Insomnia at 
diagnosis level: insomnia is the primary diagnosis. 
4.3.2. Insomnia Citations 
4.3.2.1. Books 
These citations came from 540 distinct books. The books published between the Chinese 
Ming and Qing dynasties accounted for the largest proportion (90.4%), followed by the 
Chinese Minguo dynasty (6.0%), Chinese Song, Jing and Yuan dynasties (3.3%) and the 
times before the Song dynasty (0.3%). The books with the most information on insomnia 
included Indispensable Tools for Pattern Treatment (in Chinese: 证治准绳 ) (n = 110 
citations), Continuation of Classified Case Histories by Renowned Physician (in Chinese: 续
名医类案) (n = 110), Formulae of Universal Benefits (in Chinese: 普济方) (n = 94), Direct 
Interpretations to Cold Damages (in Chinese: 伤寒直指) (n = 91), Collected Treatises of 
Jing-Yue (in Chinese: 景岳全书) (n = 84), Treatment Decisions Categorised According to 
Pattern (in Chinese: 类证治裁) (n = 83), Case Histories of Wang Meng-Ying (in Chinese: 王
孟英医案) (n = 69), Wondrous Lantern for Peering into the Origin and Development of 
Miscellaneous Disease (in Chinese: 杂病源流犀烛) (n = 66), Introduction to Medicine (in 
Chinese: 医学入门 ) (n = 64) and Systematic Great Compendium of Medicine Past and 
Present (in Chinese: 古今医统大全) (n = 48). 
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4.3.2.2. Insomnia Diagnosis 
Among the citations by insomnia diagnosis level, some were from a book chapter specific to 
insomnia such as the Wondrous Lantern for Peering into the Origin and Development of 
Miscellaneous Disease and some were quoted from case reports on insomnia therapy. 
Original Chinese texts of all quotations are specified in Appendix 4.1. 
The frequency of insomnia onset was seldom reported. Insomnia duration was observed in a 
few citations only. Acute insomnia was described in 44 citations. For instance, ‘being 
physically and mentally tired, the complaint of difficulty initiating sleep continues for ten 
days’. Chronic insomnia in 52 citations was mentioned; for example, ‘overthinking induced 
insomnia lasts for two year’. Only 31 citations clearly described impairments associated with 
insomnia, such as ‘inability to fall into sleep at all night which leads to fatigue and being 
emaciated’. 
Six-hundred and six treatment citations reported insomnia alone and 334 citations described 
comorbid insomnia described. Comorbidities included  
 Concurrent pain, such as ‘eye conditions with painful and swelling eyes and blurred 
vision may cause inability to fall asleep day and night’; 
 Concurrent arrhythmia, such as ‘insomnia accompanied by palpitation is due to the 
disorders of heart meridians’; and  
 Concurrent digestive disorders, such as ‘adverse rising of stomach qi resulting in 
disturbance of Qi-Blood and dysfunctions of viscera, and consequent insomnia’. 
Several special groups of people with insomnia were mentioned, including  
 Women and particularly those in postpartum, such as ‘the syndrome of postpartum 
insomnia referring to sleeplessness the whole night initially, followed by being 
irritable, sweating, thirsty and red face’; 
 Children with ‘poor appetite and insomnia due to diarrhoea or insomnia caused by 
itchiness after chicken pox’; and 
 Elderly people ‘being susceptible to insomnia’. 
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4.3.3. Chinese Herbal Therapy for Insomnia 
4.3.3.1. Therapeutic Principle 
CHM for insomnia was described in 840 citations. Insomniacs sharing the same 
characteristics were often grouped to guide treatment selection. As the Indispensable Tools 
for Pattern Treatment stated: 
Generally, there were two causes of insomnia. One was weakness right after 
recovering from an illness or deficient Blood in the elderly; the other was phlegm 
blocking the Gallbladder meridian. Liu Jun Zi plus zaoren was commonly used for the 
deficient scenario while Ban Xia Tang originated from Ling Shu for those identified 
as phlegm pattern. 
In addition, the book Treatment Decisions Categorised According to Pattern detailed 25 
Patterns and their corresponding treatments. Pattern encompassed a broad range of factors 
relevant to insomnia, including  
 Causes, such as ‘insomnia commonly caused by overthinking affecting mind, being 
frightened, annoyed and angry, depressed Qi producing phlegm, where Ban Xia Tang 
should be used’; 
 Pathogenesis, such as ‘stomach disharmony causes insomnia and restlessness. 
Because phlegm-fire blocks the downwards of stomach Qi, which results in irritability 
and then insomnia. Juhong, fuling, shihu, banxia, zhicao, zhishi, zharou and shenqu 
can be used for this condition’; 
 Phases, such as ‘when insomnia is induced by inexplicable anxiety right after 
recovering from a disease, Zhu ye shi gao tang or Fu ling bu xin tang can be applied’; 
 Phenotypes, such as ‘for frequently wakening up after sleep, Bie jia qiang huo wan 
can be used and for no sleep for the whole night, An wo ru shen tang’; 
 Demographics, such as ‘the elderly with insomnia is caused by deficient blood when 
Sheng yu tang could be used. Obese women commonly suffer from depression when 
emetic therapy could be used for insomnia by removing the phlegm-fire’; and  
 Concurrent medical conditions, such as ‘menopausal insomnia with deficiency of 
spleen-blood, was caused by overthinking and worry which can be relieved by Gui 
shao liu jun zi tang or Yi qi an shen tang’. 
4.3.3.2. Multi-Herb Formulae for Insomnia 
A multi-herb formula, the most common prescription of CHM, is not only a quantitative 
collection of herbs but a complex recipe of interrelated substances. The essence of TCM 
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formula is that each component has its own role that is believed to be more effective and less 
harmful together.  Insomnia treated with multi-herb formulae was described in 729 citations. 
The most common formula was Wen dan tang (in Chinese: 温胆汤). One citation stated that 
‘insomnia referred to a restless sleep. When it is caused by phlegm blocking Heart meridian 
and the deficiency of gallbladder Qi, Wen dan tang should be used to generate the Heart 
blood and then to regain a sound sleep’. The second most popular formula was Suanzaoren 
tang (in Chinese: 酸枣仁汤). For instance, ‘for those being difficult in falling asleep induced 
by unexplained irritability, Suan zao ren tang can be utilised’. The third most common 
formula was Gui pi tang (in Chinese: 归脾汤). For example, ‘Gui pi tang is for those who 
cannot return to sleep after wakening up, which is caused by overthinking induced Spleen 
impairment’. The fourth formulae was Ban xiashu mi tang (in Chinese: 半夏秫米汤), also 
called Ban xia tang (in Chinese: 半夏汤) or Ling shu ban xia tang (in Chinese: 灵枢半夏汤), 
which had the longest history of use for insomnia. Their ingredients are listed in Table 4.3. 
Others included in the top 10 formulae were Liu wei di huang wan (in Chinese: 六味地黄丸), 
Huan lian e jiao tang (in Chinese: 黄连阿胶汤), Xiao chai hu tang (in Chinese: 小柴胡汤), 
Liu jun zi tang (in Chinese: 六君子汤), Yang xin tang (in Chinese: 养心安神汤) and ZhI zi 
chi tang (in Chinese: 栀子豉汤). 
Excluding citations of comorbid insomnia, the top four formulae in the subgroup were the 
same as those in the overall insomnia diagnosis citations. In the citations on comorbid 
insomnia, Wen dan tang continued to rank first.  
4.3.3.3. Single-Herb Formulae for Insomnia 
There were 101 citations that described insomnia treated with 24 single-herb formulae. For 
instance, ‘If someone cannot fall asleep at night, fried Suan zao ren can be added’. SZR was 
the most common herb specific to insomnia (n = 71 citations) and was cited far more 
frequently than other herbs. Preparation techniques were considered critical to maintain herb 
property. For example, raw SZR was used for sleepiness and for insomnia when fried. 
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4.3.3.4. Multiple Formulae for an Insomnia Case 
Ten citations explained a more complicated approach, such as different formulae for different 
periods over a long-term follow up or multiple formulae taken for one day. There were 13 
clinical cases of successfully treated insomnia. For example: 
A 14-year-old boy, studying extremely hard, could not fall asleep at all at night, and 
then had poor appetite. He took Bu zhong qi yi tang in the morning and Yi gong san 
in the afternoon, which improved his appetite and sleep gradually. After continuing 
using this therapy, all symptoms completely disappeared. 
This case depicted the therapeutic strategy that treated insomnia in line with its dynamic 
nature and considered the timing of therapeutic administration important to achieve 
satisfactory outcomes. 
4.3.3.5. Other Factors Contributing to Formula Selection 
Among the 42 citations on CHM for women with insomnia, Gui pi tang was the most widely 
used (n = 10). As for the elderly with insomnia (n = 15 citations), Liu wei di huang wan 
(n = 3) and Liu jun zi tang (n = 3) were most frequently used. 
Twenty-three citations explained various formulae for children with insomnia and their 
therapeutic mechanism from the perspective of CM theory, such as: 
There are always predisposing factors to insomnia. Liu wei wan is indicated for the 
deficiency of kidney meridian with heat, Zhen zhu mu wan for deficiency of heart 
blood and Yang rong tang for lack of Qi or Spirit. Suan zao ren tang issued for 
insomnia after recovering from a disease, Ren shen zhu ye tang for insomnia due to 
deficient gallbladder with bitter mouth, modified Xiao chai hu tang for liver-fire 
induced insomnia followed by anxiousness, and Si jun zi tang adding sheng jiang 
and zao ren for palpitation induced insomnia.  
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Table 4.3. Multi-Herb Formulae for Insomnia 
Formula Name Frequency  Ingredients 
Special Preparation 
Techniques 
Administration 
Wen dan tang 61 
ban xia (Pinelliae Rihizoma), zhu ru (Bambusae Caulis in 
Taenias), zhi shi (Auranti Fructus Immaturus), chen pi (Citri 
Reticulatae Pericarpium), sheng jiang (Zingiberis Rhizoma 
Recens), gan cao (Glycyrrhizae Radix et Rhizoma) 
Ban xia was commonly 
processed to reduce its 
toxicity. 
Oral  
Suan za oren tang 43 
SZR (Ziziphi Spinosae Semen), chuan xiong (Chuanxiong 
Rhizoma), fu ling (Poria), zhi mu (Anemarrhenae Rhizoma), gan 
cao (Glycyrrhizae Radix et Rhizoma) 
SZR was commonly fried to 
present its sedative 
prosperity. 
Oral  
Gui pi tang 36 
Ren shen (Ginseng Radix et Rhizoma), huang qi (Astragali 
Radix), bai zhu (Atractylodis Macrocephalae Rhizoma), fu ling 
(Poria), SZR (Ziziphi Spinosae Semen), long yan rou (Longan 
Arillus), dang gui (Angelicae Sinensis Radix), yuan zhi 
(Polygalae Radix), mu xiang (Aucklandiae Radix), gan cao 
(Glycyrrhizae Radix et Rhizoma) 
NS Oral 
Ban xia shu mi tang 26 ban xia (Pinelliae Rihizoma), shu mi(Husked Sorghum) 
Ban xia was washed by water 
again and again to reduce its 
toxicity. 
Oral 
Note. The herbal ingredients are presented as Chinese pinyin followed by its English name. The English name was in reference with Chinese pharmacopoeia 2015. The use of 
some herbs such as mu xiang may be restricted in some countries. Readers are advised to comply with relevant regulations. 
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4.4. Discussion 
The analysis of historical literature suggested that TCM defined insomnia as the persistent 
dissatisfaction with sleep quantity or quality, which is similar to the modern understanding of 
insomnia. However, its diagnosis does not quantify the frequency and duration of insomnia 
complaints. People who are weak, such as suffering from chronic disease and the elderly, are 
more likely to suffer from insomnia, which is supported by contemporary epidemiological 
studies (24). 
As the analysis of historical literature showed, TCM categorises people with insomnia into 
several groups for which the therapeutic formulae were different. Generally, the principle 
therapeutic approach of TCM is to tonify deficiency and reduce excess. Specifically to 
insomnia, the strategies for reducing excess include resolving phlegm and clearing heat using 
Wen dan tang. For deficiency, strategies include tonifying and replenishing Qi and nourishing 
blood, such as the use of Gui pi tang, while herbs that sedate and calm the mind were always 
used alongside other methods such as SZR. In modern CM, ‘Zheng’, also translated to 
‘Syndrome’ or ‘Pattern’ was applied to this situation (268). Though the statements of 
Syndrome in CM differ from biomedical terms, systems biology has bridged them for some 
conditions, such as rheumatologic arthritis and coronary heart disease (269). A cross-
sectional survey also found a correlation between CM Syndrome and intracranial 
neurotransmitter levels such as 5-hydroxytryptamine and γ-aminobutyric acid (GABA) in 
patients with primary insomnia (270). These results suggest that the Syndrome that is mostly 
identified by patients’ subjective complaints, symptoms or signs is probably an indicator of 
changes in their intracranial neurotransmitters. 
The analysis of historical literature suggested that the traditional use of CHM is centred on 
the individual and include consultation, physical examination, disease diagnosis, syndrome 
differentiation, formula selection and follow-up therapies. To be specific, managing people 
with insomnia by CHM might also include sleep hygiene education, identification and 
resolution of the cause of insomnia as well as relieving the accompanied symptoms of 
sleeplessness. Therefore, the statement that the selection of Chinese herbal formulae is guided 
by Syndrome in TCM theory could be translated into CHM therapy should be tailored to 
different purposes of insomnia course management or different phenotypes of insomnia. 
However, there is a gap in the knowledge between CM Syndrome and modern sleep medicine 
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that requires more epidemiologic studies to elucidate the correlations. In addition, the belief 
that individualised Syndrome differentiation and CHM treatment performs better than non-
syndrome therapy is supported by contemporary evidence (122). Therefore, more clinical 
evidence exploring target phenotypes and stages of insomnia are increasingly required to 
ensure the precise use of CHM formulae in clinical settings. 
The most common formula for insomnia in the historical literature was Wen dan tang. Its 
earliest use for insomnia was traced back to 1174 to the book entitled Unification of the Three 
Aetiologies (120). It was more likely to be used for the Syndrome ‘disharmony between the 
Stomach and Gallbladder with phlegm-heat obstructing the Qi dynamic’ in people with 
insomnia. Pinelliae Rhizom apraeparatum is the chief ingredient to transform phlegm and 
regulate Stomach Qi according to TCM theory (120). It showed a synergic effect on 
pentobarbital-induced sleeping by increasing the numbers of mice falling asleep and reducing 
sleep latency and prolonged sleeping time, possibly via the GABAergic system from the 
perspective of ethnopharmacology (271). Additional laboratory experiments explained how 
the whole formula benefited people with insomnia. In a sleep-deprived rat model, Wendan 
tang could reduce insomnia-related anxiety in terms of open-field text via preventing a 
decrease in grehlin levels and increasing microRNA expression of ghrelin receptors, one of 
the brain-gut peptides associated with mood disorder (271). It also improved sleep-deprived, 
induced negative emotions by upregulating orexin-A and leptin, one of the key regulators of 
the sleep-wake cycle (271). Traditionally, CM clinicians used to make modifications 
according to individual patient complaints. Huang lian wen dan tang, one of its variations, is 
currently recommended for insomnia with severe phlegm-heat in Chinese evidence-based 
clinical guidelines (7). Shi wei wen dan tang was prescribed for insomnia accompanied by 
dreams attributed to excess phlegm (110), Wen dan ning xin granule, its modern preparation, 
presented greater improvements to subjective sleep quality and daytime functioning in people 
with primary insomnia compared to estazolamin in an RCT (192). Shen hu wen dan tang and 
Jia wei wen dan tang were considered more suitable for insomnia triggered by unexplained 
anxiety (274). However, further clinical evidence comparing the effectiveness of Wen dan 
tang with its variations for insomnia is required. 
Suan zao ren tang, the second most popular formula for insomnia, originated from the book 
Essentials from the Golden Cabinet in 220 AD (274). According to the traditional rules of 
herbal theory, SZR is the King in the formula, referring to the herb with the largest dosage 
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and an essential role in sedation and hypnosis (274). Spinosin from SZR is considered one of 
the main active ingredients in Suanzaoren tang by the reversed-phase high-performance 
chromatography (RP-HPLC) method (275). Jujubogenin from SZR is also found effective to 
interact with GABAA receptors through hydrolysis of Jujuboside A (276). Interestingly, 
another RP-HPLC study found that other herbs in Suan zao ren tang promote the significant 
absorption and pharmacokinetic action of spinosin (277). As for preclinical evidence, animal 
experiments showed that high doses of Suan zao ren tang increased NREM sleep rather than 
altering REM sleep, which may be mediated through serotonergic activation (278) and 
GABAA receptors (148). For the clinical evidence, an earlier trial found Suan zao ren tang 
improved overall sleep quality and wellbeing in 60 participants with sleep disorders, an effect 
greater than the placebo (279). A SR of 12 RCTs suggested it appears safe and shows some 
potential benefit although the methodological quality is poor (280). A recent randomised, 
double-blinded and placebo-controlled trial showed that a four-week treatment of Suan zao 
ren tang significantly improved subjective sleep during methadone maintenance in terms of 
the PSQI, improved average sleep efficiency in sleep disturbance and resulted in mild adverse 
events (281). Also, Suan zao ren tang safely improved daytime function of climacteric 
women with poor sleep quality in a prospective observational study (282). In addition, there 
are a few ongoing clinical trials investigating the variations of Suan zao ren tang for primary 
insomnia (283–284). In summary, preclinical and clinical evidence suggest that Suan zao 
reng tang improved sleep but further clinical trials are needed to confirm its efficacy on the 
target insomnia phenotype. 
Gui pi tang has been developed to Gui pi pill, an over-the-counter product popular among the 
public with insomnia (109). It is recommended to treat the people with insomnia using 
evidence-based clinical guidelines, as clinical trials suggest its potential in overall 
improvement for insomnia (7). Though Ban xia shu mi tang has a long history in the 
treatment of insomnia, it has been seldom investigated in modern experiments. Only one 
laboratory experiment found it protected against irritability and memory impairment in sleep-
deprived rats (285).  It may be due to a lack of knowledge translation to the research. 
The results of this research may be limited by only searching one source. The ZHYD is the 
largest electronically searchable resource, but it does not contain every historical Chinese 
medicine text and some classical books may have been missed.  
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4.5. Conclusion 
The analysis of historical literature found various CHM formulae for insomnia that might be 
used for different phenotypes or stages of insomnia. The empirical use of CHM for insomnia 
and their experimental evidence highlight that the most promising natural product candidates 
include Suan zao ren tang and Wen dan tang. More clinical evidence evaluating these 
formulae for subgroup of insomnia patients is required to support the evidence-based 
decision-making. 
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Chapter 5. Methodology of a Mixed-Method Design 
5.1. Introduction 
CHM has a long history of use for disease prevention and treatment (286). Traditionally, 
CHM practice was guided by classical literature authored by eminent doctors of CM and 
byapprenticeship (287). 
In the last two decades, EBM has emerged as a new paradigm, being motivated by improved 
outcomes of diagnosis and treatment as well as a reduction in unnecessary interventions 
(288). EBM is widely accepted by researchers and clinicians. However, the implementation 
of EBM takes a different view regarding the evidence hierarchy compared to the traditional 
use of CHM. For example, experts’ experience and case studies are the lowest level of 
evidence on the hierarchy. On the contrary, CM theory and practice cherishes the value of 
clinical experience and successful cases from eminent doctors. Thus, a research question 
generated from this distinction is whether CHM is ready to move towards EBP. 
As the literature review on insomnia (see Chapter 2) shows, CHM presents hypnotic and 
sedative functions in pharmacological studies. The SR of RCTs shows CHM is superior to a 
placebo in improving subjective sleep quality and quantity among people with insomnia (see 
Chapter 3). Analyses of the historical literature also suggest that the classical CHM formulae 
and herbs traditionally prescribed for insomnia demonstrated their benefits in clinical trials 
and exerted psychopharmacological functions for sleep enhancement (see Chapter 4). 
Recently, Chinese (EBP) guidelines for insomnia have been developed to assist CM 
practitioners’ clinical decision-making (47). Thus, it is possible that EBP will be one of the 
practice models of CHM for insomnia. 
To prepare for EBP in this field, it is significant to know how CM practitioners behave, 
determine how they view and understand EBM and the extent of their knowledge and skills. 
Hence, this study aims to address the research question, ‘What are the attitudes, 
understanding, knowledge, skills, behaviours and barriers to practising EBM among CM 
practitioners who specialise in insomnia treated by CHM?’ To resolve this question, a mixed-
method design is selected. This chapter discusses the study design from the perspective of 
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methodology. The methods and results of the development of the survey questionnaire and 
pilot study are also described. 
5.2. Methodological Paradigm 
5.2.1. Knowledge Claims 
A paradigm is simply a belief model that guides the way we do things and was first brought 
to the philosophy of the sciences by Thomas Kuhn (1970) (289). It is composed of ontology 
(i.e., how to view knowledge), epistemology (i.e., how to connect knowledge) and 
methodology (i.e., how to discover knowledge) (290). That is, how research is planned and 
conducted can be affected and guided by the paradigm that is believed. There are four 
paradigms, consisting of positivism, post-positivism, critical theory and constructivism. 
Positivism is defined as information obtained by a scientific and quantitative approach in 
which sensory observation is the only source of authoritative knowledge; thus, the truth of 
knowledge is derived in this way (291). Previously, positivism dominated health and medical 
sciences research, such as experimental design and hypothesis testing (292). 
Post-positivism is a critique of positivism. Like positivists, post-positivists believe that a truth 
exists, though they argue that it can be known only imperfectly and probabilistically (293). 
Constructivism and interpretivism also fall into the broad definition of post-positivism. In 
respect to research, post-positivism prefers the use of natural settings, allows more 
possibilities of ‘truth’ and emphasises ‘problem solving’, which is used more in social 
sciences, rather than ‘truth seeking’, such as ethnography and open-ended interviews (292). 
5.2.2. Why a Quantitative Study? 
Following positivism, quantitative research methods are defined as ‘explaining phenomena 
by collecting numerical data that were analysed using mathematically based methods, in 
particular statistics’ (294). By developing reliable measurement instruments, the physical 
world can be objectively studied.  
The most common quantitative studies for EBM are RCTs and SRs with meta-analysis. An 
RCT in which participants are randomly allocated to a treatment or control group after an 
eligibility assessment, is considered the golden standard for health intervention valuation 
because it reduces spurious causality and bias (295). A SR with meta-analysis, respondent to 
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the overwhelming number of RCTs, is used to appraise the existent evidence, pool the results 
to increase test power, improve the estimation precision of the effect size and resolve 
inconsistencies among different studies (154). Currently, the homogeneous SR of RCTs is 
recommended as the best evidence (296). The quantitative results from RCTs and meta-
analyses tell whether health care is possibly effective for a particular group of participants as 
well as how much it improves in ideal settings—they are powerful tools to provide the best 
available evidence. 
Sufficient emphasis has been placed on RCTs and SRs to provide the best available evidence. 
Currently, the research body of CHM for insomnia is in a similar situation (see Chapter 3). 
The classical RCT is an experiment on the human in an ideal situation. Its results only inform 
clinicians about the optimal effect of some therapy but its external validity is limited (297). 
For example, a homogenous meta-analysis indicated a Chinese herbal formula was effective 
for insomnia. However, there was little information about how this evidence was transferred 
to EBP of insomnia. EBP relies more on how practitioners form the clinical question, seek 
evidence and interpret and incorporate the evidence into practice with consideration of their 
expertise, patients’ preferences and accessibility to treatment (298). Once the best existent 
evidence has been found and evaluated, the next step of knowledge transformation is to apply 
the research to clinical decision-making. Hence, the clinician is the significant connector 
from evidence to patient management in a typical process of EBP. Even though the best 
evidence existed, a previous study reported that medical practice might not improve as 
expected (299). It is necessary to identify an appropriate research method to understand the 
gap between evidence and practice in real clinical settings. Further, the key processes of 
evidence transformation include comparing patients’ characteristics with the trials’ inclusion 
criteria, balancing the benefit and risk of the intervention, considering real settings and 
sharing decision-making with patients (300). Each of them cannot go through without 
clinicians’ thoughts and actions. Therefore, the collection of clinicians’ responses is essential 
to preparing for good EBP. 
Surveying a sample is a typical method to quantitatively collect clinicians’ responses. 
Although the definition of a survey varies, the most precise one is ‘a survey is a systematic 
method for gathering information from (a sample of) entities for the purpose of constructing 
quantitative descriptors of the attributes of the large population of which the entities are 
members’ (301). In terms of a research purpose, a quantitative survey could be used to 
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determine respondees’ attitudes, behaviour, knowledge and skills by a reliable measurement 
(302). Its design is usually driven by a predefined theoretical framework or empirical 
findings. Specifically, EBP surveys of health professionals have been published and the 
theoretical framework to explain the behaviours related to EBP has been established. It is 
possible to gain generic information of EBP among CM practitioners in breadth by surveying 
a representative sample as the first stage of a sequential approach. 
5.2.3. Why a Qualitative Study? 
Qualitative research is a method of inquiry traditionally employed in the social sciences that 
focuses on studying human beings and society (303). Qualitative research answers very 
different questions from those that are addressed in quantitative research (304). It is a process 
to collect and analyse information in reality to form a theoretical opinion that describes or 
explains a social phenomenon (305). 
As discussed in Section 5.2.2, the clinician is essential to EBP. A quantitative survey 
developed from pre-existing findings is a valuable way to gain an overview of CM 
practitioners’ attitudes, behaviours, knowledge and skills related to EBP. However, it may not 
be able to identify the specific issue of CHM for insomniacs well as discover new knowledge. 
Further, an in-depth understanding related to various scenarios is required, as it is insufficient 
to interpret only quantitatively the process of clinicians’ decision-making. 
Therefore, from the perspective of evidence transformation to clinical practice, a qualitative 
method is superior to a quantitative approach for its naturalism, interaction as well as the 
function of interpretation, process identification and explanation of attitudes and adherence 
(306). Qualitative research could be a powerful way to identify the gap between evidence and 
real clinical practice and a useful instrument to explain complex situations. 
Qualitative research is an umbrella term that includes a broad list of research techniques, such 
as interviews, case studies and ethnography. A qualitative interview, one of the most popular 
research techniques of qualitative studies, is an extension of a conventional dialogue. 
Interviewers ask predefined questions to capture the answers and also to explore some further 
information and unexpected thoughts from their interaction with interviewees (307). Most 
qualitative researchers favour semi-structured interviews that are organised in advance 
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around a list of predefined, open-ended questions, along with some additional potential 
questions depending on the interaction between the interviewer and interviewee(s) (308).  
The process for practitioners to make a medical decision could be very complicated. A great 
deal of information may come to mind, and then they process the material and produce an 
outcome. It is not easy to analyse the underlying meaning of an action and assume the 
potential incentive of a treatment from an observation and documentary source. A well-
designed semi-structured interview can lead to answer these complex questions and find new 
information. Further, an interactive interview could also delve into some important personal 
thoughts. 
5.2.4. Why a Mixed-Method Design? 
In mixed-method research that acknowledges the insights from both methods, there is no pre-
determined epistemological stance, and qualitative or quantitative components can have an 
equal status (309). There is no superiority or inferiority of either the quantitative or 
qualitative method in this study. The quantitative survey is better at providing information in 
breadth while the qualitative interview is better at exploring a problem in depth (310). In this 
project, what to know is not only how many clinicians agree or disagree with EBM for 
insomnia treated with CHM but also why and how they do so, which requires both breadth 
and depth. Further, the current state of CHM practice is complicated and conflicted because 
of the coexisting traditional model and evidence-based approach. A qualitative study is 
valuable to have additional explanations to the quantitative results, as it is better at explaining 
complex questions (310). Therefore, it is possible to have quantitative and qualitative 
research methods together to elaborate and enhance the findings of either method. This is 
termed ‘complementarity’. In addition, it may improve the credibility of self-rated attitudes, 
knowledge and behaviours if multiple sources of data are used for cross-validations, termed 
‘triangulation’. To answer the overarching research question, ‘What are the attitudes, 
understanding, knowledge, skills, behaviours and barriers to practise EBM of CM 
practitioners who specialise in insomnia treated by CHM?’, a mixed-method design is utilised 
to provide the most comprehensive findings, as complementarity and triangulation are two 
essential rationales for using both quantitative and qualitative studies (311). 
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5.3. Overall Design 
The quantitative and qualitative methods can be conducted concurrently or sequentially to 
address the research question. In light of the existing theory explaining the behaviours related 
to EBP and the empirical evidence of EBP, a sequential explanatory design (288) was 
considered more suitable. Specifically for the thesis, it was a two-phase design in which the 
quantitative data are first collected by a questionnaire survey, followed by a qualitative 
interview of a group of the sample. The purpose was to determine the numerical overview of 
CM practitioners’ attitudes, knowledge and behavioural of EBP by a survey, and then to 
further elaborate and validate the quantitative results by using the qualitative findings. These 
provided a thorough answer to the research question. 
5.4. Strategy of Inquiry 
Induction, deduction and also abduction are forms of logical reasoning that are used in 
qualitative and quantitative studies; together with observation, they create the basis of all 
research (312). They are the ways of connecting and generating ideas. 
5.4.1. Induction 
Induction is the logical process of moving from particular information to a general conclusion 
(313). This would include using statistical methods to form generalisations by finding 
similarities among a large number of cases. A quantitative survey is most likely to apply 
inductive reasoning. The generalisations derived in this way are probabilistic (313). 
Following inductive reasoning, the typical method of data analysis refers to statistical 
inference, which includes the parameters of estimation and hypothesis testing (314). 
Statistical inference is strong at quantitatively estimating the true effect and its probability, 
but assessing its meaningfulness and interpretations of health issues is always needed. 
5.4.2. Deduction 
Deduction is the logical process of reasoning that moves from general principles to 
conclusions about particular instances (315). Deductive arguments are evaluated in terms of 
their validity and soundness. 
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5.4.3. Abduction 
Abduction refers to the process of transitioning from everyday descriptions of the social 
world to social scientific descriptions and its analyses. It is a kind of reasoning developed by 
Charles Sanders Peirce (1839–1914) for the discovery of hypotheses or theories that differs 
from inductive and deductive inference (316). Abduction is a way of relating an observation 
or case to a theory (or vice versa) that results in a plausible interpretation. It aims to discover 
or generate a new theory. Grounded theory methodology used in qualitative inquiry is a 
typical example of abductive reasoning. 
Grounded theory was first presented by Glaser and Strauss in their book The Discovery of 
Grounded Theory (317). It was developed as a methodology for generating a theory that is 
grounded in data that are systematically gathered and analysed. It recognises that enquiry is 
always based on context and facts should be viewed as both theory- and value-laden. 
Knowledge is observed as actively constructed with meanings of existence only relevant to 
an experiential world. Essentially, this methodology is most commonly used to generate 
theory in which little is already known or to provide a fresh slant on existing knowledge 
(318). There is little knowledge of how CM clinicians understand, evaluate and incorporate 
evidence into their clinical practice or decision-making when they use CHM for insomnia 
patients. This is the gap to be filled in the EBM. 
A study using grounded theory is likely to begin with a question or even just with a collection 
of qualitative data (319). It is different from the traditional way in which a researcher 
predetermines an existing theoretical framework and then collects data only to demonstrate 
how the theory does or does not apply to the phenomenon under study. Guided by grounded 
theory, more categories and conceptualisations will appear as more data are collected and 
revisited. As previously stated, there is little evidence about how CM clinicians react to EBP 
of CHM for insomnia, which limits the predefined interview questions and possible patterns. 
A dynamic process that integrates data collection and analysis could find additional new 
knowledge and undefined questions that should be thoroughly explored through a qualitative 
interview. 
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5.5. Framework of Data Analysis 
The primary aim of data analysis corresponding to an sequential explanatory design in which 
quantitative analysis takes precedence over qualitative analysis is the provision of a 
numerical explanation to CM practitioners’ attitudes, knowledge and behaviours related to 
EBP of CHM for insomnia and the qualitative findings that supplement the quantitative 
results. The results of the first phase will inform the data analysis in the second phase. For 
example, additional barriers to EBP will be explored from the qualitative interview, though 
the main distribution was identified in the quantitative survey. 
The secondary aim of integrating the quantitative and qualitative results is to take advantage 
of their methodological superiority. Parallel analysis is also used here and refers to ongoing 
data collection and information exploration in the qualitative interview without limitations 
from the predefined theoretical framework or preliminary findings from the survey. The data 
can then be complementarily used to draw a more comprehensive conclusion of both breadth 
and depth. For example, why and how CM practitioners implement EBP of CHM for 
insomnia is mainly addressed in the qualitative interview and may not be identified from the 
survey. The exploration of themes may be driven by the issues raised by the interviewees. 
The third aim of combining the quantitative and qualitative results is to enhance the 
credibility through cross validation of the data. For example, self-rated attitudes, knowledge 
and behaviours could be debated if an external assessment is not applied. CM practitioners 
state they know about EBM in the survey. Interviewing CM practitioners for their 
descriptions of EBP may reveal the validity of their responses. 
The final aim of triangulating the quantitative and qualitative findings is to support a better 
understanding of the links between the general theoretical assumptions explaining the 
behaviours related to EBP and the empirical evidence as well as to aid the development of a 
new theory specific to CM. 
5.6. Ethical Considerations 
Since the whole project is to address one overarching research question by a mixed-method 
design, the primary application for ethics approval included the process of developing the 
questionnaire, pilot survey, main survey and interview. Revisions to the questionnaire and 
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implementation of the survey after the pilot study and revised interview proposal were 
submitted as an amendment to the primary approval. 
The critical ethics issue related to the two-phase design was the privacy protection of the 
participants who agreed to a follow-up interview and to leave their personal contact 
information when returning their questionnaire. The solution was to state clearly in the 
invitation letter that participation in the survey or interview, including leaving personal 
identifying information to the research team, was completely voluntary and answers would 
not be individually identified by any publication. Other ethics considerations are specified in 
the methods section of each phase. 
5.7. Development of the Survey Instrument and Pilot Survey 
For the quantitative survey, a questionnaire was developed. A pilot study was also performed 
that assessed the reliability, validity and feasibility of the survey instrument. Sections 5.7.1 
and 5.7.2 present the theoretical and empirical foundations of the questionnaire’s 
development, methods, results of the pilot survey and how the preliminary findings informed 
the implementation of the main survey (see Chapter 6). 
5.7.1. Development of the Survey Questionnaire 
Attitude has been an indispensable domain of inquiry within social psychology to understand 
people’s thoughts, feelings and behaviour (320). In the past, it was assumed that attitudes 
could predict subsequent behaviours (321). However, an argument emerged that knowledge 
could affect attitude–behaviour consistency (322). In public health, a knowledge, attitude and 
practice (KAP) survey was widely used to collect quantitative information for the 
investigation of health behaviour and health program planning (323). Therefore, the initial 
framework of the questionnaire included the three basic domains of KAP. 
A certain number of KAP surveys were implemented to investigate the EBP of physicians 
and nurses (324–328). The attitude domain commonly included the simplest affection, such 
as like or dislike of EBM, specific beliefs about evidence, clinical expertise and patients’ 
preferences. Motivations for EBP and beliefs about the perceived benefits were also nested in 
the attitude domain, as they were considered to affect the attitude–behaviour relation (329). 
Specific to this questionnaire, general attitudes towards EBM and specific attitudes towards 
evidence-based CHM for insomnia were both investigated. The practice domain mainly 
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investigated the practice guided by clinical guidelines. A typical process of EBP, such as 
asking a clinical question, literature searching and appraisal and decision-making using 
evidence, was also surveyed. The knowledge domain included the global rating of 
knowledge, experience of basic training, knowledge about the hierarchy of evidence, 
literature databases and terms and skills or capacity. 
As previous studies revealed, potential barriers to EBP included limited time, unavailable 
literature databases, lack of ability to understand the literature or to apply research to patients 
and negative organisational or peer factors (330–333). In this study’s questionnaire, specific 
barriers were included that related to the distinct nature of CHM, as a Chinese national survey 
suggested that the unique characteristics of CM such as the highlight of individual-centred 
therapy and low-quality research literature were the main barriers to evidence-based CM 
(15). 
In summary, the questionnaire used in the pilot study included: 
• participant’s consent form and instructions on completing the questionnaire, 
• demographic and socio-economic information (part one), 
• personal attitudes and perceived benefits of EBM (attitude domains) (part two), 
• personal use, understanding and limitation of EBM (practice domain) (part three), 
• knowledge of EBM (knowledge domain) (part four), and 
• open comments and invitation to a follow-up interview. 
The questionnaire circulated in the survey was in Chinese and it was designed to be 
completed in 10–20 minutes. The full Chinese questionnaire used in the pilot study can be 
found in Appendix 5.1 and its English translation is attached in Appendix 5.2. 
5.7.2. The Pilot Survey 
5.7.2.1. Methods 
As the questionnaire was newly developed, a pilot survey was conducted to test the validity 
and reliability of the questionnaire and the feasibility of the survey as well as inform 
refinement of question items. 
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The pilot survey was conducted in Guangdong Provincial Hospital of Chinese Medicine 
(GPHCM). GPHCM, located in Guangdong Province, is a tier three general hospital 
renowned for serving inpatients or outpatients with CM therapies as well as functioning as a 
teaching hospital affiliated with the Guangzhou University of Chinese Medicine 
(http://www.gdhtcm.com). 
To survey 10 practitioners, an invitation email with a link to a web-based questionnaire was 
sent to CM practitioners who worked in the departments that people with insomnia 
commonly visited. Twenty practitioners were invited based on the assumption that 50 per 
cent would respond to an internal online survey (234). Reliability of the questionnaire was 
measured in terms of Cronbach’s alpha (335). The decision to remove redundant items was 
made by considering the statistical results of inter-item correlation analysis and expert 
consensus. Facet validity was assessed by the research team, including the author of the thesis 
and supervisors. Feasibility of the survey was indicated by the respondent rate, duration of 
completing a questionnaire and participants’ open comments. As a result of the pilot survey, 
changes were made to the questionnaire and survey procedure. The protocol of the pilot study 
was fully approved by the Institutional Ethics Committee of GPHCM, China, who was 
responsible for oversight of the project and responsible for the primary ethical duty of care 
over the research participants (No. B2015-025-01). The ethics approval letters are attached in 
Appendix 5.3. The ethics approval was accepted by The College of Science Engineering and 
Health Human Ethics Advisory Network (CHEAN) of RMIT University with registration 
number ASEHAPP 11-15/RM No: 19252 (see Appendix 5.4). 
5.7.2.2. Results 
5.7.2.2.1. Respondent Information 
Invitation emails were sent to 20 CM practitioners from GPHCM in March 2015. Sixteen 
invitees (80%) completed the questionnaires and two (10%) agreed to a follow-up interview. 
The time to complete the questionnaire was 10.85 minutes on average, ranging from 4.00 
minutes to 28.27 minutes. The responses suggested that an online survey via email invitation 
was feasible in the CM practitioner group. Table 5.1 details the demographics of the 
participants.  
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Table 5.1. Demographics of the Participants in the Pilot Study 
Characteristics 
Number of 
Participants 
(%) 
Age Range (Years) 20–29  6 (37.5) 
30–39  9 (56.25) 
≥40 1 (6.25) 
Gender Male  10 (62.5) 
Female  6 (37.5) 
Highest Degree  Master 12 (75) 
Doctorate 4 (25) 
Licence Division  TCM 10 (62.5) 
Integrative Traditional and Western 
Medicine 
6 (37.5) 
Practice History ≤3 years 7 (43.75) 
4–6 years 6 (37.5) 
≥7 years 3 (18.75) 
Professional Title Intern 3 (18.75) 
Resident 3 (18.75) 
Attending 9 (56.25) 
Chief 1 (6.25) 
Clinical Specialty CM Psychology  3 (18.75) 
CM Neurology 6 (37.5) 
Chinese internal medicine 6 (37.5) 
Acupuncture and massage 1 (6.25) 
Major Work Clinical 12 (75) 
Research 3 (18.75) 
Clinical practice and research 1 (6.25) 
Number of Daily Patients* 0–20 5 (31.25) 
21–30 3 (18.75) 
31–40 3 (18.75) 
≥41 4 (24.5) 
Note. * One participant did not answer this question. 
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5.7.2.2.2. Reliability of Questionnaire 
Overall, the questionnaire was reliable in terms of Cronbach’s alpha. Table 5.2 details the 
reliability of the questionnaire. 
Table 5.2. Cronbach’s Alpha of the Questionnaire 
Items No. of Items Cronbach's α 
Section 1. Attitude towards EBM 15 0.795 
Section 2. Self-rated behaviour related to EBP 16 0.856 
Section 3. Knowledge of EBM 23 0.854 
Total items 54 0.904 
Note. Two items were removed from the analysed dataset because of zero variance; EBM: 
evidence-based medicine; EBP: evidence-based practice 
5.7.2.2.3. Main Findings and the Procedure of Revising the Survey Questionnaire 
Generally, two-thirds of participants (12 out of 16) showed positive attitudes towards EBM 
and agreed that they understood what was meant by EBM. However, their attitudes towards 
the necessity of applying EBM in CHM were different from the attitudes towards Western 
medicine (11 participants for CHM v. 15 participants for Western medicine). In terms of self-
rated behaviour related to clinical practice, four participants (25%) thought that their clinical 
practice was evidence-based and six participants (37.5%) thought that clinical evidence 
supported most of the interventions they used for their patients. As for overall knowledge of 
EBM, most participants rated their level of knowledge as moderate (n = 12).  
Sixteen responses to the open question, ‘What do you think are the major barriers to 
practising EBM?’ were collected. Eight responses referred to a lack of environmental context 
and resources, such as ‘a lack of convenient information resource’, ‘inadequate promotion’, 
‘being too busy in clinical practice to keep up to date of research outcomes’ and ‘being short 
of collective environment, particularly having difficulty finding colleagues to have an EBM 
discussion’. Five highlighted an inadequate understanding and knowledge towards EBM. 
Three responses considered the distinct nature of CM therapy, such as ‘the outcome 
measurement in EBM was always single, however, CM may benefit the conditions by multiple 
pathways’. One response was related to both the professional role of CM practitioners and the 
nature of CM therapy, stating that ‘insufficient high-quality evidence and uncertain 
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comparative effectiveness would result in no intervention of Chinese medicine to use when an 
evidence-based decision process was applied’. 
Although the data from the pilot survey could not be generalised because of the sampling 
method and the small sample size, they were valuable to assist the design of the main survey. 
As illustrated in the main findings of the pilot survey, the overall attitude and practice of 
EBM might be inconsistent from those who were specifically related to evidence-based CHM 
in terms of descriptive analysis. In addition, two participants considered their major barrier to 
EBM was the difference between Western medicine and CM. These results suggest that 
practitioners might agree with EBM but disagree with EBP of CHM. Therefore, some items 
were rephrased to ensure they answered the specific research question, ‘Did CM practitioners 
use EBM when they treated insomnia patients with CHM?’ Regarding barriers to practising 
EBM, two additional possibilities that related to the nature of CM therapy were collected by 
open questions. Hence, the answer options, ‘There is insufficient high-quality evidence of 
CHM for insomnia’ and ‘CM theory contradicts EBM’ were added to the barrier question 
item. 
Four participants provided suggestions to the questionnaire design in the open comment item, 
such as ‘the survey was lengthy’ and ‘the setting of the answer options should be improved’. 
Therefore, the questionnaire was re-examined to remove redundant items and the online 
survey system was reviewed to ensure its friendly interface. In addition, the answer options 
and wording were refined by using the information collected by open-ended questions. The 
full decision log of the questionnaire revision is specified in Appendix 5.5. 
5.7.2.2.4. Overview of the Questionnaire Used for the Main Survey 
After revisions and additions to the participant’s consent form and instructions on completing 
the questionnaire, the questionnaire distributed in the main survey included six parts with 41 
question items: 
• part one—demographic and socio-economic characteristics (n = 12 question items), 
• part two—general attitudes towards EBM and specific attitudes towards EBM of 
CHM for insomnia (n = 13 question items, attitude domain), 
• part three—EBP of CHM for insomnia and barriers to EBP (n = 6 question items, 
behaviour domain), 
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• part four—knowledge, skills and capacity of EBM (n = 8 question items, knowledge 
domain), and 
• part five—open comments and invitation to a follow-up interview (n = 2 question 
items). 
The full questionnaire is provided in Appendix 5.6 (original Chinese version) and Appendix 
5.7 (English translation version). 
5.8. Discussion 
5.8.1. Summary 
The methodological considerations for answering the research question, ‘What are CM 
practitioners’ attitudes, understanding, knowledge, skills, behaviours and barriers to practice 
EBM of CM practitioners who specialise in insomnia treated by CHM?’ were described in 
this chapter. A mixed-method design, including a quantitative survey and qualitative 
interview was selected to guide the research. The two-phase sequential explanatory approach 
was used to primarily determine the numerical overview of CM practitioners’ attitudes, 
knowledge and behavioural of EBP by a survey, and to further elaborate and validate the 
quantitative results by using the qualitative findings that will provide a thorough conclusion. 
Further, the framework of data analysis was discussed in this chapter. To provide a 
conclusion with breadth and depth, the data analysis strategies from the perspective of 
complementarity, triangulation and theorisation were integrated. Last, the development of a 
survey instrument and a discussion on how the pilot study informed the design of the main 
survey were presented. Managing confidentiality was considered the principle ethics issue. 
The methodological design outlined in this chapter provided rich explanations to CM 
practitioners’ attitudes, knowledge and behaviour related to EBP of CHM for insomnia, 
including answers to ‘what’, ‘how many’, ‘why’ and ‘how’ questions. In addition, a better 
understanding of the links between the general theoretical assumptions explaining the 
behaviours related to EBP and the empirical evidence were added as well as the development 
of a new theory specific to the CM discipline. 
5.8.2. Challenges and Possible Solutions 
The mixed-method design is recently popular in health service research because it 
appropriately deals with various and complex health care questions in a pragmatic rather than 
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ideological world (336). However, there are a few significant challenges. As Section 5.2.2 
states, implementing research evidence into clinical practice largely depends on CM 
practitioners’ behaviours. However, the pathway of implementation is complex and affected 
by multiple factors, such as practice setting, regulation body and patients and individual CM 
practitioner’s attitude and knowledge (337). Therefore, the quantitative results should be 
cautiously interpreted because pragmatic problems are always weaving in non-linear fashions 
at multiple levels and the qualitative findings may not apply to another practitioner group due 
to distinct external environments. Also, the findings from the quantitative and qualitative 
studies may present discrepancies due to different epistemological stances. Several solutions 
may address this challenge, including exploring the methodological rigour of each component 
and ongoing comparisons between each dataset (338). 
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Chapter 6. A Quantitative Survey of Chinese Medicine 
Practitioners Assessing Evidence-Based Practice of Chinese 
Herbal Medicine for Insomnia 
6.1. Introduction 
EBM is ‘the conscientious, explicit, and judicious use of current best evidence in making 
decisions about the care of individual patients’ (339). It de-emphasises the use of non-human 
study findings as the foundation for making clinical decisions and encourages the importance 
of clinical evidence in formulating individual treatment strategies (340). The major 
components in this paradigm include clinical question forming, evidence searching, critical 
appraisal and incorporating the best available evidence into clinical practice with 
consideration of practitioners’ personal expertise, patients’ preferences and accessibility to 
facilities (298). EBP is to provide health care guided by an effective integration of the best 
available evidence with clinical expertise (341). 
Over the last two decades, CM scholars and practitioners have increasingly incorporated the 
theory and practice of EBM into CM practice (342). A national survey conducted in China 
indicated that most CM practitioners had heard of EBM and supported its use but admitted 
they had insufficient knowledge of EBM and seldom incorporated it to their daily practice 
(15). An interview of CM practitioners in Europe examining at their understanding of EBM 
concluded that the application of the complete EBM process in CM practice was clearly 
absent (16). These studies evaluated a broad range of clinicians from different speciality areas 
but the use of EBM in a single area was not undertaken.  
Evidence of moderate quality detailed in the SR (see Chapter 3) showed that CHM safely 
improved subjective sleep in people with insomnia compared to a placebo. However, the 
comparative effectiveness between CHM and pharmacotherapy or psychotherapy remained 
inconclusive due to methodological shortfalls. This may complicate decision-making in an 
environment in which psychotherapy, pharmacotherapy and CM are all covered under a 
national health care system, such as that in mainland China. CM practitioners may interpret 
and implement evidence differently because of distinct attitudes, knowledge and skills of 
EBM as well as considerations of various clinical settings and patients’ preferences. To 
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prepare for EBP of CHM for insomnia, it is significant to know how CM practitioners 
behave, view and understand EBM and to what extent are their knowledge and skills. 
In the methodology chapter (see Chapter 5), the questionnaire survey of a representative 
group of CM practitioners was discussed as an appropriate method to achieve the research 
aim. The survey questionnaire was found to be reliable and valid in the pilot study. This 
chapter presents the methods and results of the main survey and discusses the main findings. 
6.2. Methods 
6.2.1. Sample Selection of the Main Survey 
6.2.1.1. The Population 
The target population was CM practitioners who specialised in the treatment of CM for 
insomnia in Guangdong Province, China. 
Guangdong is located in Southern China with a population of 108.49 million and a GDP of 
7.28 trillion yuan (RMB) (343). There are 2,670 CM institutes (including CM hospitals, 
outpatient divisions and clinics) and 419,000 licensed CM practitioners who served clients 
96.251 million times (344). 
6.2.1.2. The Sample 
Purposive sampling, one of the non-probability sampling methods, was applied as a sampling 
strategy because the total number of CM practitioners specialised in treating people with 
insomnia was unknown. Purposive samples are based on criteria that the investigator 
establishes at the outset that describe participant characteristics (345). 
To identify a representative sample for the population, the Guangdong Provincial Association 
of Traditional Chinese Medicine (GPATCM) and Guangdong Provincial Association of 
Integrative Medicine (GPAIM) were contacted, as they are the biggest not-for-profit 
academic organisations of CM in Guangdong. GPATCM was established in 1956 and 
includes 16,342 individual members and 57 specialties (346) while GPAIM was established 
in 1981 and includes 8, 540 individual members and 68 specialties (347).  
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Three criteria were applied to examine participants’ eligibility, including giving consent to 
participating in the survey, being a licensed CM practitioner (including the subclass of TCM 
and the subclass of integrative Chinese and Western Medicine) and often treating people with 
insomnia in clinical practice. The survey aimed to recruit 100 participants. 
6.2.2. Procedure of the Main Survey 
Wenjuanxing (https://www.sojump.com/), one of the most popular Chinese online survey 
systems, was used to collect the data. To recruit participants, the research team prepared an 
invitation email linking to the online questionnaire. The administrative departments of 
GPATCM and GPAIM forwarded the email to their member practitioners. The list of eligible 
participants was generated by the online system after member practitioners completed the 
eligibility questions. They were then able to complete the whole questionnaire and the survey 
results returned without inputting any identifiable personal information. In addition, 
participants were recruited by distributing paper-based invitation letters and questionnaires at 
annual conferences chaired by GPATCM and GPAITWM. Identifiable ‘personal’ data were 
not collected. 
6.2.3. Data Analysis of the Main Survey 
6.2.3.1. Dataset Development 
Data from the online survey system were exported directly into a SPSS (.sav) file. Responses 
from participants who completed the paper-based questionnaire were extracted and checked 
by using the EpiData Entry software and then transferred to a SPSS file. In addition to multi-
choice questions and open-ended questions, there were 41 five-point Likert scale questions, 
six three-point Likert scale questions and 10 yes or no binary questions. 
To facilitate further cross-tabulation analysis, the questions with a five-point Likert scale 
were transferred into a three-point Likert. To be specific, the ‘strongly agree’ was combined 
with ‘agree’, ‘strongly disagree’ was combined with ‘disagree’ and ‘neutral’ was kept. 
6.2.3.2. Descriptive Analysis 
Responses from the survey were analysed in IBM SPSS Statistics version 23 for Microsoft 
Windows. Descriptive analysis was undertaken to identify the data distribution. For 
categorical data collected by close-ended questions, frequency and proportion were 
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calculated and presented in tabular or graphic format. For ‘text’ data collected by open-ended 
questions, content analysis was applied. 
6.2.3.3. Inferential Analyses 
The inferential tests were selected to answer four research questions: 
• Were demographic and socio-economic characteristics significantly associated with 
the attitudes towards EBM or the practice or knowledge of EBM? 
• Were the attitudes towards EBM significantly associated with the practice of EBM? 
• Was the knowledge of EBM significantly associated with the practice of EBM? 
• Were the barriers to EBM significantly associated with the practice of EBM? 
Specifically, cross-tabulation analyses followed by a chi-square test or Fisher exact test were 
initially performed to explore the relationship between categorical variables. Other non-
parametric tests such as the Mann–Whitney U test and Kruskal-Wallis H test were conducted 
to further examine the relationship between ordinal and nominal variables such as the 
associations between the attitude towards EBM (i.e., ordinal dependent variables) and the 
source of CM education (i.e., nominal independent variable). Bivariate correlation analysis 
such as Spearman's rank correlation test was performed to further investigate the monotonic 
relationship between two ordinal variables such as whether the attitude towards EBM was 
negatively or positively correlated with the practice of EBM. A p value less than 0.05 was 
considered statistically significant. 
6.2.3.4. Logistic Regression Analysis 
Binary logistic regression analysis was selected to answer the research question, ‘What 
factors explain CM practitioners’ use of EBM to guide their practice relating to CHM for 
insomnia?’ 
A univariate logistic regression was initially conducted to predict the likelihood of 
implementing EBP of CHM for insomnia in terms of individual factors selected from the 
cross-tabular analysis. To group the independent variables, an exploratory factor analysis was 
performed by including the variables with statistical significance in the univariate logistic 
regression. In this context, p < 0.1 was considered statistically significant and the precision 
level of the estimation was presented as an Odd Ratio (OR) with 90% CI. 
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A diagnosis of multicollinearity between independent variables and an outlier examination 
was then performed to test the assumption of multivariate logistic regression. If appropriate, a 
multivariate logistic regression analysis was conducted using a stepwise method of entering 
blocks in SPSS. A final model was developed by including those independent variables with 
significant contributions to the model (p < 0.1) with theoretical meaningfulness. The OR in 
the multivariate logistic regression model explained the likelihood of implementing EBP of 
CHM for insomnia compared to the reference group when controlling for the effect of other 
independent variables. In this context, a p < 0.05 was considered statistically significant. The 
precision level of the estimation was presented as an OR with 95% CI. 
The percentage accurate in classification (PAC), -2 Log likelihood, Nagelkerke R
2
, Omnibus 
Tests of Model Coefficients and Hosmer and Lemeshow test were used as indicators to 
evaluate the fitness of the model (348). The full process is summarised in Figure 6.1. 
 
Figure 6.1. Process of developing a multivariate logistic regression model 
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6.2.4. Ethical Considerations 
The participants were informed in writing about the research purpose, dissemination and 
voluntary nature of the study. Considering privacy protection, the administrative departments 
of the associations rather than the research team contacted the member physicians. The 
original data were kept confidential and any results of the survey were not individually 
identified in publications. 
The protocols of the survey were fully approved by the Institutional Ethics Committee of 
GPHCM, China, who was responsible for oversight of the project and primary ethical duty of 
care over the research participants (No. B2015-025-02). The ethics approval letters are 
attached in Appendix 6.1. The ethics approval was accepted by the Science, Engineering and 
Health College Human Ethics Advisory Network (CHEAN) of RMIT University with a 
registration number of ASEHAPP 11-15/ RM No: 19252 (see Appendix 6.2). 
6.3. Results 
6.3.1. Survey Respondents 
Invitation letters were sent to 1328 practitioners between September 2015 and August 2016, 
including 891 from GPATCM and 437 from GPAIM (see Table 6.1). 
Table 6.1. Clinical Background of the Recruited Practitioners 
Association Specialty Field 
Number of 
Practitioners Invited 
GPATCM Psychology 107 
Neurology 169 
Gynaecology 55 
Gastroenterology  63 
Endocrinology  125 
Circulation 182 
Respiratory Medicine 137 
Otorhinolaryngology 53 
GPAIM Psychology and sleep 
medicine 
71 
Endocrinology 88 
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Gynaecology 59 
Gastroenterology 90 
Neurology 129 
Total  1328  
Among 1328 practitioners were invited, of which 124 consented to enter the procedure 
examining their eligibility. Eighty-two practitioners were considered eligible and had 
different fields of expertise (see Figure 6.2). All practitioners provided written consent to 
participate in the survey and complete the questionnaire. The flowchart of participant 
recruitment is specified in Figure 6.3.  
 
Figure 6.2. Fields of expertise of the participants 
 130 
 
 
Figure 6.3. Flowchart of participant recruitment 
6.3.2. Demographic and Socio-Economic Characteristics of Participants 
Eligible participants were all of adult age and their CM practice history ranged from less than 
three years to more than 25 years. Almost all the participants received CM education by 
attending university except three learned CM by short-term training and one by self-learning. 
The majority of participants (97.6%) had a bachelor's degree or higher and most (96.3%) 
were employed in hospitals. Approximately half of participants (58.5%) practised CM in 
Guangzhou, the capital city of Guangdong, while the others worked in other cities across 
Guangdong Province. Most practitioners (41.5%) saw 21–40 patients per day. The full 
demographic and socio-economic data are shown in Table 6.2. 
Being recruited 
(n=1328) 
Under eligibility 
examination 
(n=124) 
Participating in 
the survey (n=82) 
Completing the 
survey (n=82) 
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Table 6.2. Demographic and Socio-Economic Characteristics of the Participants (n = 82) 
Characteristics Number of Participants (%) 
Age (year)  
 20–29 6 (7.3) 
 30–39 31 (37.8) 
 40–49 29 (35.4) 
 50–59 14 (17.1) 
 ≥60 2 (2.4) 
History of being licensed CM practitioners (year)  
 ≤3  7 (8.5) 
 4–10  18 (22.0) 
 11–24 36 (43.9) 
 ≥25 21 (25.6) 
Gender   
 Male 48 (58.5) 
 Female 34 (41.5) 
Source to gain education  
 University/college 78 (95.1) 
 Non-university/college* 4 (4.9) 
Highest level of education  
 Diploma 2 (2.4)  
 Bachelor 23 (28.0) 
 Master 27 (32.9) 
 Doctor 30 (36.6) 
City of practising CM  
 Guangzhou (capital city of Guangdong) 48 (58.5) 
 Other cities# 34 (41.5) 
Setting of practising CM  
 Hospital-based 79 (96.3) 
 Community clinic-based 3 (3.7)  
Patients per day  
 0–20 25 (30.5) 
 21–40 34 (41.5) 
 ≥41 23 (28.0) 
Daily major work  
 Clinical practice 68 (82.9) 
 Research 6 (7.3) 
 Teaching 6 (7.3) 
 Clinical practice with teaching 2 (2.4) 
Note. *Non-university education included learning by short-term training (n = 3) and self-learning (n = 1). 
#Other cities included Heshan, Lianzhou, Maoming, Qingyuan, Shantou, Shaoguan, Shunde, Taishan, Yangjiang, 
Yunfu, Zhaoqing and unspecified (n =1 for each city); Huizhou, Zhanjiang and Zhongshan (n = 2 for each city); 
Dongguan and Zhuhai (n = 3 for each city); Foshan (n = 4) and Shenzhen (n = 6). 
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6.3.3. Measurements of Attitudes Towards EBM and Practice and Knowledge of EBM 
Sections 6.3.3.1 to 6.3.3.4 present the key findings of the descriptive statistics about the 
attitudes towards EBM, the practice and knowledge of EBM and barriers to EBP. The results 
of inferential statistics examining these relationships and the demographic and socio-
economic characteristics are also presented. 
6.3.3.1. General Attitudes Towards EBM  
Nearly three-quarters of participants (71.0%) generally showed positive attitudes towards 
EBM. One practitioner disagreed with EBM and approximately one-quarter (28.0%) showed 
neutral attitudes. Most participants (91.5%) stated they generally understood what was meant 
by EBM and the majority (84.1%) were interested in learning or improving their skills about 
incorporating EBM into their clinical practice. A minority (7.3%) disagreed that EBM took 
patients’ preferences into consideration and nearly one-quarter (24.4%) were uncertain about 
EBM. Around one-quarter of participants (24.4%) agreed with the difficulty in incorporating 
EBM into their practice setting while others (75.6%) disagreed or showed neutral attitudes 
regarding the difficulty. Figure 6.4 shows the attitudes towards EBM among participants in 
terms of a five-point Likert scale. 
 
Figure 6.4. General attitudes towards EBM among participants (n = 82) 
The Kruskal-Wallis H test showed that there was no significant statistical difference in 
participants’ self-rated overall attitudes towards EBM between participants with different age 
ranges (χ2 = 4.6, df = 4, p = 0.33), genders (χ2 = 0.9, df = 1, p = 0.34), education sources 
3 
7 
16 
25 
17 
49 
53 
50 
28 
20 
11 
7 
25 
6 
1 
9 
1 
EBM is difficult to incorporate in my practice
setting.
EBM takes into consideration patient preferences.
I am interested in learning or improving the skills
necessary to incorporate EBM into my practice.
I understand what is meant by EBM.
strongly agree agree neutral disagree strongly disagree
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(χ2  .04, df = 1, p = 0.85), highest degrees (χ2  1.1, df = 3, p = 0.77), years as a licensed CM 
practitioner (χ2  .9, df = 4, p = -.10), institutions for the practice of CM (χ2 = 2.1, df = 1, 
p = 0.15) and numbers of patients per day (χ2 = 5.4, df = 4, p = 0.25). 
6.3.3.2. Specific Attitudes Towards EBM for Insomnia Treated with CHM 
Around three-quarters of participants (76.8%) believed the application of EBM was necessary 
for insomnia treated with CHM, three out of 82 disagreed with the necessity while others 
showed neutral attitudes. Nearly all participants (96.3%) agreed with the necessity of 
applying EBM for the treatment of insomnia with conventional medicine; however, three 
were uncertain (see Figure 6.5). 
Kruskal-Wallis H tests suggested that there was no statistical difference in the rating of 
‘Application of EBM is necessary for the treatment of insomnia with CHM’ among 
participants with different demographic and socio-economic characteristics, including 
different age ranges (χ2 = 2.8, df = 4, p = 0.60), genders (χ2 = 1.2, df = 1, p = 0.27), education 
sources (χ2 = 1.2, df = 1, p = 0.27), highest degrees (χ2 = 1.7, df = 3, p = 0.64), years as a 
licensed CM practitioner (χ2 = 4.8, df = 4, p = 0.31.), institutions for the practice of CM 
(χ2 = 0.14, df = 1, p = 0.71) and numbers of patients per day (χ2 = 3.3, df = 4, p = 0.51). 
 
Figure 6.5. Attitudes towards necessity of EBM for insomnia per CHM or conventional 
medicine (n=82) 
14 
25 
49 
54 
16 
3 3 
Application of EBM is necessary
for the treatment of insomnia with
Chinese herbal medicine.
Application of EBM is necessary
for the treatment of insomnia with
conventional medicine.
strongly agree agree neutral disagree
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Slightly more than two-thirds of participants (69.5%) believed that EBM could help them 
make decisions about insomnia patient care using CHM while others disagreed or showed 
neutral attitudes regarding the benefits of EBM in decision-making. The proportion of 
participants who agreed they valued scientific studies more than clinical experience in 
making decisions related to CHM for insomnia (23.2%) was the same as those who 
disagreed, while 53.7 per cent of participants showed neutral attitudes. Nearly three-quarters 
(70.7%) stated they needed to increase the use of evidence related to CHM practice for 
insomnia. Most participants (81.7%) considered new research findings on CHM for insomnia 
useful for their clinical practice while half (51.2%) believed they were aware of the latest 
research in CHM for insomnia. Table 6.3 details the attitudes towards EBM in the practice of 
CHM for insomnia. 
Table 6.3. Attitudes Towards Applying EBM in the Practice of CHM for Insomnia 
(n = 82) 
Items 
Strongly 
Agree 
n (%) 
Agree 
n (%) 
Neutral 
n (%) 
Disagree 
n (%) 
Strongly 
Disagree 
n (%) 
EBM can help me make decisions 
about insomnia patient care using 
CHM. 
8 (9.8) 49 (59.8) 20 (24.4) 5 (6.1) 0 (0) 
In making decisions related to CHM 
for insomnia, I value scientific 
studies more than clinical experience. 
3 (3.7) 16 (19.5) 44 (53.7) 16 (19.5) 3 (3.7) 
I need to increase the use of evidence 
in my daily practice related to CHM 
for insomnia. 
11 (13.4) 47 (57.3) 20 (24.4) 4 (4.9) 0 (0) 
New research findings of CHM for 
insomnia are useful in my day-to-day 
practice. 
17 (20.7) 50 (61.0) 9 (11.0) 6 (7.3) 0 (0) 
I am aware of the latest research in 
CHM for insomnia. 
3 (3.7) 39 (47.6) 27 (32.9) 12 (14.6) 1 (1.2) 
Around one-third of the 82 participants (32.9%) considered reading classical literature as the 
most common way to update their knowledge of CHM for insomnia. Reading modern 
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research (25.6%) was the second most applied method, followed by attending conferences or 
training courses (14.6%) and learning from senior practitioners (12.2%). A minority of 
participants (4.9%) sought help from the latest guidelines and 9.8 per cent of people tended to 
use a combination approach. One of the participants considered exploration in their own 
clinical practice as an additional method to update their knowledge. 
The chi-square test showed that there was a significant statistical difference in the most 
common way to update participants’ knowledge of CHM for insomnia among highest degrees 
(χ2 = 32.3, df = 15, p = 0.006), years as a licensed CM practitioner (χ2 = 32.9, df = 20, 
p = 0.034) and the number of the patients per day (χ2 = 34.7, df = 20, p = 0.022). 
In terms of rating the highest level of evidence, the RCT was most selected (49.4%), followed 
by meta-analysis with homogeneity (30.9%). A minority of participants considered case 
reports, classical literature and experience from eminent practitioners as the highest evidence 
(8.6%, 6.2% and 4.9%, respectively). 
The Kruskal-Wallis H test showed that there was a significant statistical difference in the 
rating of the highest level of evidence related to CHM for insomnia among participants with 
the demographic and socio-economic factors of age range (χ2 = 12.8, df = 4, p = 0.013), 
gender (χ2 = 8.3, df = 1, p = 0.004) and institutions for the practice of CM (χ2 = 5.2, df = 1, 
p = 0.023). 
6.3.3.3. Knowledge and Skills About EBM 
Forty-eight participants (56.0%) rated their overall knowledge of EBM as moderate, 22 
(26.8%) rated it as poor and 12 (14.6%) rated it as good. Fifty-seven out of 82 participants 
(69.5%) stated they were trained in the foundations of EBM and 42 (51.2%) received formal 
training in the critical appraisal of research. More than half of participants (57.3%) were 
confident in their ability to find relevant research to answer their clinical questions, 28 
(34.1%) were uncertain about their confidence and seven (8.5%) disagreed with their 
confidence. 
The Kruskal-Wallis H test showed there was a significant statistical difference in the overall 
knowledge of EBM among participants receiving CM education from different sources 
(χ2 = 4.3, df = 1, p = 0.038) and there was a significant statistical difference in participants’ 
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confidence to find relevant research to answer clinical questions among those with different 
highest degrees (χ2 = 9.1, df = 3, p = 0.028). 
Most participants (86.5%) were aware of as well as used the China National Knowledge 
Infrastructure (CNKI), one of the biggest Chinese literature databases. Compared to the 
CNKI, fewer participants (70.7%) used Chinese Biomedical Literature Database (CBM). A 
smaller number of participants were aware of or used English literature databases. For 
example, around half of participants (51.2%) were aware of and used PubMed. Cochrane 
Library, an essential evidence database, was known to slightly less than half of participants 
(48.8%) and used by a minority (22.0%). Table 6.4 details participants’ awareness of and use 
of medical literature databases. 
Table 6.4. Participants’ Awareness of and Use of Medical Literature Databases (n = 82) 
Items 
Unaware 
n (%) 
Aware But Do Not 
Use 
n (%) 
Aware and Use 
n (%) 
Cochrane Library 24 (29.2) 40 (48.8) 18 (22.0) 
PubMed 16 (19.5) 24 (29.3) 42 (51.2) 
CNKI 3 (3.7) 8 (9.8) 71 (86.5) 
CBM 6 (7.3) 18 (22.0) 58 (70.7) 
Note. CNKI: China National Knowledge Infrastructure; CBM: Chinese Biomedical Literature Database 
Awareness, understanding and application of the terms commonly used to understand the 
research literature are detailed in Table 6.5. Almost all participants had heard of RCT, SR, 
meta-analysis and CI (95.1%). Among these participants, RCT was well understood and used 
by most participants (48.8%). The terms of least awareness included OR, heterogeneity and 
publication bias (5 out of 82). 
Table 6.5. Awareness, Understanding and Applications of Terms on Research 
Literature (n = 82) 
Terms 
Never 
Heard 
n (%) 
Heard But Do 
Not 
Understand 
n (%) 
Somewhat 
Understand 
n (%) 
Understand 
Well 
n (%) 
Understand 
Well and 
Use 
n (%) 
RCT 2 (2.4)  2 (2.4)  14 (17.1)  24 (29.3) 40 (48.8) 
SR 2 (2.4)  8 (9.8)  30 (36.6)  20 (24.4)  22 (26.8) 
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Meta-analysis 2 (2.4)  8 (9.8)  24 (29.3)  24 (29.3)  24 (29.3) 
RR 4 (4.9)  15 (18.3)  29 (35.4)  22 (26.8)  12 (14.6) 
Absolute risk 4 (4.9)  16 (19.5) 31 (37.8)  20 (24.4) 11 (13.4) 
OR 5 (6.1)  18 (22.0)  30 (36.6)  14 (17.1)  15 (18.3) 
MD 4 (4.9)  12 (14.6)  19 (23.2)  28 (34.1)  19 (23.2) 
CI 2 (2.4)  7 (8.5) 26 (31.7)  24 (29.3)  23 (28.0) 
Heterogeneity 5 (6.1)  16 (19.5)  29 (35.4) 20 (24.4)  12 (14.6) 
Publication bias 5 (6.1) 14 (17.1) 26 (31.7) 21 (25.6) 16 (19.5) 
6.3.3.4. Evidence-Based Practice of CHM for Insomnia 
Less than half of participants agreed they used EBM to guide their practice related to CHM 
for insomnia (36 agreements v. 46 disagreements). Chi-square tests showed that there was no 
significant statistical difference in whether participants used EBM to guide their practice 
among different demographic and socio-economic characteristics, including age range 
(χ2 = 7.4, df = 4, p = 0.117), gender (χ2 = 0.9, df = 1, p = 0.349), education source (χ2 = 0.063, 
df = 1, p = 0.802), highest degree (χ2 = 2.9, df = 3, p = 0.412), years as a licensed CM 
practitioner (χ2 = 1.0, df = 4 , p = 0.912), institutions for the practice of CM (χ2 = 0.1, df = 1, 
p = 0.704) and numbers of patients per day (χ2 = 2.5, df = 4, p = 0.640). 
The most common frequency for a participant to apply a typical EBP process in their clinical 
practice was two to five times per month, including formulating a research question (51.2%), 
searching electronic databases (42.7%), critically reading a research paper (47.6%) and using 
research results to assist decision-making (50.0%). Table 6.6 details the frequency within the 
last month. 
Table 6.6. Frequency of Applying a Typical EBP Process in Clinical Practice in the Last 
Month (n = 82) 
Items 
Frequency in the Last Month 
≤1  2–5  6–10  11–15  ≥16  
 n (%) n (%) n (%) n (%) n (%) 
Formulated a clearly answerable 
question that defines the client or 
problem, the intervention and 
outcomes of interest 
27 (32.9) 42 (51.2)  11 (13.4)  1 (1.2)  1 (1.2) 
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In practice, around half of participants (56.1%) believed they were confident in their 
understanding of EBM and half (51.2%) agreed they were aware of the latest research into 
CHM for insomnia. Less than half of participants (40.2%) actively sought guidelines 
pertaining to insomnia treated with CM. More than three-quarters (82.9%) believed they were 
able to incorporate patient preferences with practice guidelines. Table 6.7 specifies the 
behaviours related to EBP for insomnia treated with CHM among participants. 
Table 6.7. Specific Behaviours Related to EBP for Insomnia Treated with CHM (n = 82) 
The Kruskal-Wallis H test indicated that the participants’ confidence in their understanding 
of EBM was significantly different across various age ranges (χ2 = 15.1, df = 4, p = 0.005) 
and years as a licensed CM practitioner (χ2 = 13.0, df = 4, p = 0.011). The test also showed 
Searched an electronic database 20 (24.4) 35 (42.7)  15 (18.3)  3 (3.7)  9 (11.0) 
Critically read a published research 
report 
30 (36.6) 39 (47.6)  10 (12.2)  1 (1.2)  2 (2.4) 
Used research findings to make a 
clinical decision 
27 (32.9) 41 (50.0)  12 (14.6)  0 (0)  2 (2.4) 
Items 
Strongly 
Agree 
n (%) 
Agree 
n (%) 
Neutral 
n (%) 
Disagree 
n (%) 
Strongly 
Disagree 
n (%) 
I am confident in my understanding 
of EBM. 
12 (14.6) 34 (41.5) 30 (36.6) 6 (7.3) 0 (0) 
I am aware of the latest research in 
CHM for insomnia. 
3 (3.7) 39 (47.6) 27 (32.9) 12 (14.6) 1 (1.2) 
I actively seek practice guidelines 
pertaining to CHM for insomnia. 
8 (9.8) 25 (30.5) 36 (43.9) 10 (12.2) 3 (3.7) 
I am able to incorporate patient 
preferences with practice guidelines. 
14 (17.1) 54 (65.9) 13 (15.9) 1 (1.2) 0 (0) 
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that participants’ awareness of the latest research on CHM for insomnia was significantly 
different across various age ranges (χ2 = 12.0, df = 4, p = 0.018).  
Among 36 practitioners who stated they used EBP of CHM for insomnia, the most common 
EBM source they used was research findings from academic journals (n = 30), followed by 
Chinese insomnia guidelines. Not many practitioners used EBM databases such as Up-To-
Date and Best Practice (n = 13). One practitioner considered classical literature as their 
evidence source of CHM for insomnia. Over 33 participants selected guidelines as their 
evidence sources. The ‘Chinese Guideline for Diagnosis and Treatment of Adult Insomnia’ 
was the most widely used (n = 23), followed by ‘Insomnia Chapter, Chinese Evidence-Based 
Guidelines for Clinical Medicine of Chinese Medicine: Internal Medicine’ (n = 21), the 
‘China Guidelines for Prevention and Treatment of Insomnia’ (n = 19) and ‘An Expert 
Consensus on Insomnia Definition, Diagnosis and Pharmacotherapy’ (n = 17).  
6.3.3.5. Barriers to Evidence-Based Practice of CHM for Insomnia 
Around 66 per cent of participants stated that a major barrier to EBP related to CHM for 
insomnia was insufficient high-quality evidence of CHM for insomnia, followed by a lack of 
resources to find evidence (54.9%), incapacity of research skills to understand EBM (47.6%) 
and a lack of generalisability of the literature’s findings to the patient population (43.9%). 
Further barriers included a workload too great to keep up to date with the new evidence 
(42.7%), inability to critically appraise the literature (41.5%), lack of collective support 
among colleagues at their facility (37.8%), insufficient time to practise EBM (35.4%), a lack 
of understanding of statistical analysis (34.1%), inability to apply research findings to 
individual patients with unique characteristics (30.5%) and the belief ‘CM theory contradicts 
EBM’ (26.8%). Table 6.8 details the barriers to EBM related to CHM for insomnia. 
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Table 6.8. Barriers to EBM Related to CHM for Insomnia 
Items 
Strongly 
Agree 
n (%) 
Agree 
n (%) 
Neutral 
n (%) 
Disagree 
n (%) 
Strongly 
Disagree 
n (%) 
I have insufficient time 
to practise EBM. 
3 (3.7)  26 (31.7)  23 (28.0) 27 (32.9) 3 (3.7) 
My workload is too 
great for me to keep up 
to date with the new 
evidence. 
5 (6.1)  30 (36.6) 26 (31.7) 19 (23.2) 2 (2.4) 
I have a lack of 
resources to find 
evidence. 
6 (7.3) 39 (47.6) 18 (22.0) 18 (22.0) 1 (1.2) 
I have a lack of research 
skills to understand 
EBM. 
6 (7.3) 33 (40.2) 19 (23.2) 19 (23.2) 5 (6.1) 
I have a poor ability to 
critically appraise the 
literature. 
3 (3.7) 31 (37.8) 17 (20.7) 24 (29.3) 7 (8.5) 
I lack understanding of 
statistical analysis. 
4 (4.9) 24 (29.3) 24 (29.3) 23 (28.0) 7 (8.5) 
I lack collective support 
among my colleagues at 
my facility. 
5 (6.1) 26 (31.7) 20 (24.4) 23 (28.0) 8 (9.8) 
There is a lack of 
generalisability of the 
literature’s findings to 
my patient population. 
6 (7.3) 30 (36.6) 33 (40.2) 11 (13.4) 2 (2.4) 
I am unable to apply 
research findings to 
individual patients with 
unique characteristics. 
5 (6.1) 20 (24.4) 26 (31.7) 27 (32.9) 4 (4.9) 
There is insufficient 
high-quality evidence 
on CHM for insomnia. 
9 (11.0) 45 (54.9) 16 (19.5) 10 (12.2) 2 (2.4) 
CM theory contradicts 9 (11.0) 13 (15.9) 27 (32.9) 26 (31.7) 7 (8.5) 
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EBM. 
Nine participants provided additional comments on barriers to EBM. Generalisability of 
the research findings was highlighted by two participants. For example, ‘The available 
research evidence was far less than the clinical situations and patients with various 
characteristics’. Unique characteristics of CM were commented by three participants. For 
instance, ‘The unique approach of Chinese medicine that syndrome differentiation guided the 
treatment selection, had to be incorporated to evidence-based medicine’ and ‘Chinese 
medicine highlighted individualised treatment and syndrome differentiation’. Two 
participants commented on their understanding of the evidence, such as ‘being unable to 
understand the clinical value of the evidence’ and ‘preferring to read historical literature of 
Chinese medicine’. One participant commented on the resources to learn about EBM and the 
other worried about the clinical outcome of applying EBM, such as ‘the outcome when EBM 
was applied to a clinical practice was unsatisfactory’. 
6.3.4. Additional Analysis 
Sections 6.3.4.1 to 6.3.4.3 present key findings of the inferential analysis about the 
associations between the attitudes, knowledge and barriers to EBM and EBP of CHM for 
insomnia. Additional results of the logistic regression and factor analysis to develop a model 
explaining the factors leading to EBP of CHM for insomnia are presented in Section 6.3.4.4. 
6.3.4.1. Association Between Attitudes Towards EBM and EBP of CHM for Insomnia 
The chi-square test found no statistical association between the following items and the use of 
EBM to guide practice related to CHM for insomnia: 
• ‘I understand what is meant by EBM’ (χ2 = 3.1, df = 1, p= 0.080). 
• ‘Application of EBM is necessary for the treatment of insomnia with conventional 
medicine’ (χ2 = 3.6, df = 1, p = 0.059). 
• ‘EBM is difficult to incorporate in my practice setting’ (χ2 = 5.9, df =2, p = 0.053). 
• ‘The clinical evidence of CHM for insomnia does not support most of the 
interventions I use for my patients’ (χ2 = 3.5, df = 2, p = 0.172). 
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The Spearman's correlation analysis showed there was a significant positive correlation 
between whether to use EBM to guide practice related to CHM for insomnia and the 
following items: 
• ‘Please rate your overall attitude towards EBM’(rs = 0.299, p = 0.006). 
• ‘Application of EBM is necessary for the treatment of insomnia with CHM’ 
(rs = 0.372, p = 0.001). 
• ‘New research findings of CHM for insomnia are useful in my day-to-day practice’ 
(rs = 0.299, p = 0.006). 
• ‘In making decisions related to CHM for insomnia, I value scientific studies more 
than clinical experience’ (rs = 0.433, p < 0.0001). 
• ‘I need to increase the use of evidence in my daily practice related to CHM for 
insomnia’ (rs = 0.411, p < 0.0001). 
6.3.4.2. Association Between the Knowledge or Skills of EBM and EBP of CHM for 
Insomnia 
The Spearman's correlation analysis showed there was a statistically positive correlation 
between whether to use EBM to guide practice related to CHM for insomnia and the 
following items: 
• ‘Have you received formal training in critical research appraisal?’ (rs = 0.273, 
p = 0.013). 
• ‘Have you been trained in the foundations of EBM?’ (rs = 0.319, p = 0.003). 
• ‘Are you confident in your ability to find relevant research to answer your clinical 
questions?’ (rs = 0.414, p < 0.001). 
• ‘Please rate your overall knowledge of EBM’ (rs = 0.289, p = 0.009). 
The specific items about awareness of the Cochrane Library, PubMed, CNKI and CBM were 
combined to a domain called ‘awareness of literature databases’. Specific items about 
awareness of EBM terms (i.e., RCT, SR, meta-analysis, RR, absolute risk, OR, MD, CI, 
heterogeneity and publication bias) were also combined for further analysis of their 
association with the practice of EBM. The Shapiro-Wilk test showed that the scores about 
awareness of EBM terms (SW = 1.0, df = 82, p = 0.067) were within a normal distribution 
while the scores of database awareness deviated from a normal distribution (SW = 0.9, 
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df = 82, p < 0.0001). The independent samples t-test suggested that there was a difference in 
the scores for awareness of EBM terms in participants who used EBM to guide their practice 
of CHM for insomnia (mean = 37.4 points, standard deviation = 10.0) and those who did not 
(mean = 33.3 points, standard deviation = 8.3), which was statistically significant (t = –2.1, 
df = 80, p < 0.043). The Mann–Whitney U test suggested that the difference in awareness of 
the medical literature databases was statistically significant between participants using EBM 
to guide their practice of CHM for insomnia and those who did not (U = 572.5, p = 0.015).  
6.3.4.3. Associations Between Barriers to EBP and EBP of CHM for Insomnia 
As for the barriers to EBP of CHM for insomnia, the chi-square test suggested that 
behaviours to using EBM to guide practice of CHM for insomnia was statistically different 
between participants with the barrier ‘CM theory contradicts EBM’ and those without it 
(χ2 = 6.514, df = 2, p = 0.039). 
6.3.4.4. Factors Related to Evidence-Based Practice of Chinese Herbal Medicine for 
Insomnia 
6.3.4.4.1. A Summary of Potential Factors 
The inferential statistical tests above (Sections 6.3.4.1 to 6.3.4.3) suggested a significant 
association between five question items about attitudes towards EBM, seven about the 
knowledge and skills of EBM and one about the barriers towards EBP with EBP of CHM for 
insomnia (see Table 6.9). 
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Table 6.9. Potential Factors Related to EBP of CHM for Insomnia 
Questionnaire 
Domain 
Factor Questionnaire Item 
Attitudes 
Towards EBM 
A1 Q25: Please rate your overall attitude towards EBM. 
A2 
Q15: Application of EBM is necessary for the treatment of insomnia 
with CHM.  
A3 
Q17: New research findings of CHM for insomnia are useful in my day-
to-day practice. 
A4 
Q18: In making decisions related to CHM for insomnia, I value 
scientific studies more than clinical experience. 
A5 
Q19: I need to increase the use of evidence in my daily practice related 
to CHM for insomnia. 
Knowledge 
and Skills 
 
KS1 Q32: Have you received formal training in critical research appraisal? 
KS2 Q33: Have you been trained in the foundations of EBM? 
KS3 
Q35: Are you confident in your ability to find relevant research to 
answer your clinical questions? 
KS4 Q39: Please rate your overall knowledge of EBM. 
KS5 Q34.1: Are you aware of the Cochrane Library? 
KS6 
Q34: Are you aware of the following databases (i.e., Cochrane Library, 
PubMed, CNKI and CBM)? 
KS7 
Q37: What is your understanding of the following terms (i.e., RCT, SR, 
meta-analysis, RR, absolute risk, OR, MD, CI, heterogeneity and 
publication bias)? 
Barriers to 
EBP 
B1 Q31.11: CM theory contradicts EBM. 
6.3.4.4.2. Univariate Logistic Regression 
After examining the response frequencies of the potential factors to EBP of CHM for 
insomnia, the variables with more than two categories were transferred into binary data to 
allow further analysis of logistic regression. Two items, including ‘Please rate your overall 
attitude towards EBM.’ and ‘Please rate your overall knowledge of EBM.’ were removed 
from the univariate logistic regression as they were too general to be meaningful in practice. 
‘Are you aware of the Cochrane Library?’ was not included in the univariate logistic 
regression as it was tightly correlated to the item ‘Are you aware of the following databases 
(i.e., Cochrane Library, PubMed, CNKI and CBM)?’ The univariate logistic regression 
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suggested that without taking potential covariates into consideration, participants who agreed 
with A2-5, KS1-3 or disagreed with B1 were more likely to use EBM to guide their practice 
of CHM for insomnia than the referencing group. Participants who were more aware of the 
literature databases or the EBM terms probably practised more EBP of CHM for insomnia. 
Table 6.10 shows the univariate logistic regression about factors associated with EBP of 
CHM for insomnia.  
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Table 6.10. Factors Associated with EBP of CHM for Insomnia: A Univariate Logistic 
Regression 
Variable OR (90% CI) P value n 
A2. Application of EBM is necessary for the treatment of insomnia with 
CHM. 
  82 
 Disagree or neutral (referencing) - -  
Agree 10.0 (2.7 to 36.5) 0.04*  
A3. New research findings of CHM for insomnia are useful in my day-to-
day practice. 
  82 
 Disagree or neutral (referencing) - -  
Agree 6.7 (1.8 to 24.9) 0.017*  
A4. In making decisions related to CHM for insomnia, I value scientific 
studies more than clinical experience. 
  82 
 Disagree or neutral (referencing) - -  
Agree 5.2 (2.0 to 13.6) 0.005*  
A5. I need to increase the use of evidence in my daily practice related to 
CHM for insomnia. 
  82 
 Disagree or neutral (referencing) - -  
Agree 9.2 (3.1 to 27.9) 0.001*  
KS1. Have you received formal training in critical research appraisal?   82 
 No (referencing) - -  
Yes 3.1 (1.4 to 6.7) 0.015*  
KS2. Have you been trained in the foundations of EBM?   82 
 No (referencing) - -  
Yes 4.8 (1.9 to 12.1) 0.006*  
KS3. Are you confident in your ability to find relevant research to answer 
your clinical questions? 
  82 
 Disagree or neutral (referencing) - -  
Agree 6.4(2.7 to 15.1) <0.0001*  
KS6. Are you aware of the following databases (i.e., Cochrane Library, 
PubMed, CNKI and CBM)?a 
1.3 (1.0 to 1.6) .058* 82 
KS7. What is your understanding of the following terms (i.e., RCT, SR, 
meta-analysis, RR, absolute risk, OR, MD, CI, heterogeneity and 
publication bias)?b 
1.1 (1.0 to 1.1) 0.047* 82 
B1. CM theory contradicts EBM.   82 
 Agree (referencing) - -  
Neutral and disagree 2.6 (1.2 to 5.5) 0.043*  
Note. All independent variables are binary data except variablesa&b, which are continuous data. *P value less 
than 0.1 was considered statistically significant. The precision level of the estimation was presented as OR with 
90% CI. The full statistical results are specified in Appendix 6.3. 
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6.3.4.4.3. Exploratory Factor Analysis 
To group the independent variables with statistical significance in univariate logistic 
regression analysis, an exploratory factor analysis was conducted to extract the essential 
factors to implementing EBP of CHM for insomnia. The subjective-to-variable (STV) ratio of 
the dataset met the rule that the STV should be no lower than five in terms of minimum 
sample size for factor analysis (349). The inter-item correlation analysis and the Bartlett's 
Test of Sphericity (p < 0.0001) suggested there was a patterned relationship among the items 
but multicollinearity was not found (determinant = 0.023). Also, the Kaiser-Meyer-Olkin 
(KMO) Measure of Sampling Adequacy suggested the dataset was suitable for exploratory 
factor analysis (KMO = 0.729). The full results of the assumption evaluation are specified in 
Appendix 6.4. 
By taking the theoretical domains of EBP implementation (350) into consideration, a strategy 
consisting of a fixed number of factors was used for exploratory factor analysis. This resulted 
in five factors for EBP of CHM for insomnia that accounted for 80.8 per cent of total 
variance. Table 6.11 shows the factor loadings of the exploratory factor analysis using the 
principle components method and orthogonal varimax rotation. There were 13 (28.0%) non-
redundant residuals with absolute values greater than 0.05 and the communalities were all 
above 0.6 with a mean of 0.8, suggesting that the model was a good fit. The full results of the 
model evaluation are specified in Appendix 6.4. 
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Table 6.11. Exploratory Factor Loadings for EBP of CHM for Insomnia 
Items  Factor 
One 
Factor 
Two 
Factor 
Three 
Factor 
Four 
Factor 
Five 
I need to increase the use of evidence in my daily 
practice related to CHM for insomnia. 
0.848     
New research findings of CHM for insomnia are 
useful in my day-to-day practice. 
0.798     
In making decisions related to CHM for 
insomnia, I value scientific studies more than 
clinical experience. 
0.766     
Application of EBM is necessary for the 
treatment of insomnia with CHM. 
0.679     
Have you received formal training in critical 
research appraisal? 
 0.884    
Have you been trained in the foundations of 
EBM? 
 0.833    
Are you aware of the following databases (i.e., 
Cochrane Library, PubMed, CNKI and CBM)? 
  0.932   
What is your understanding of the following 
terms (i.e., RCT, SR, meta-analysis, RR, absolute 
risk, OR, MD, CI, heterogeneity and publication 
bias)? 
  0.708   
Are you confident in your ability to find relevant 
research to answer your clinical questions? 
   0.842  
CM theory contradicts EBM.     0.911 
Eigenvalues 2.5 1.8 1.5 1.1 1.1 
% of variance 24.9 17.9 15.3 11.4 11.2 
To summarise, the independent variables were categorised into five factors, consisting of 
motivation and goals (four variables), basic knowledge and skills of EBM (two variables), 
specific knowledge and skills of EBM (two variables), beliefs about capacity (one variable) 
and nature of the intervention (one variable). This suggested that five blocks could be applied 
when developing the multivariate logistic regression model. 
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6.3.4.4.4. Multivariate Logistic Regression Analysis 
The multicollinearity was not a concern in terms of the tolerance and variance inflation factor 
(see Appendix 6.5). Table 6.12 highlights the process of developing the multivariate logistic 
regression model using a stepwise method of entering by blocks. In this context, the ‘blocks’ 
were equivalent to the ‘factors’ derived from the exploratory factor analysis in Section 
6.3.4.4.3. 
When controlling for other variables, three items—‘I need to increase the use of evidence in 
my daily practice related to CHM for insomnia’, ‘Have you been trained in the foundations of 
EBM?’ and ‘Are you confident in your ability to find relevant research to answer your 
clinical questions?’, continuously showed significant associations to implementing EBP of 
CHM for insomnia (p < 0.05). The item ‘Application of EBM is necessary for the treatment 
of insomnia with CHM’ showed a significant contribution to the model only when controlling 
for motivation and goals and knowledge and skills of EBM (p < 0.1). The full statistical 
results are specified in Appendix 6.5. 
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Table 6.12. Factors Associated with EBP of CHM for Insomnia: A Multivariate Logistic Regression Analysis (n = 82) 
Independent Variable 
Block One Block Two Block Three Block Four Block Five 
OR (90% CI) OR (90% CI) OR (90% CI) OR (90% CI) OR (90% CI) 
Application of EBM is necessary for the treatment of 
insomnia with CHM. 
     
 Disagree or neutral (referencing) - - - - - 
Agree 4.0 (0.9 to 17.7) 4.7 (1.0 to 21.6)
*
 5.0 (1.1 to 23.8)
*
 4.2 (0.8 to 20.8) 4.1 (0.8 to 20.4) 
New research findings of CHM for insomnia are 
useful in my day-to-day practice. 
     
 Disagree or neutral (referencing) - - - - - 
Agree 1.5 (0.3 to 7.4) 2.1 (0.4 to 10.9) 2.1 (0.4 to 11.2) 1.5 (0.3 to 8.7) 1.6 (0.3 to 9.0) 
In making decisions related to CHM for insomnia, I 
value scientific studies more than clinical experience. 
     
 Disagree or neutral (referencing) - - - - - 
Agree 2.5 (0.9 to 7.1) 2.6 (0.8 to 8.2) 3.2 (1.0 to 10.6) 2.3 (0.6 to 8.4) 2.3 (0.6 to 8.4) 
I need to increase the use of evidence in my daily 
practice related to CHM for insomnia. 
     
 Disagree or neutral (referencing) - - - - - 
Agree 4.9 (1.5 to 16.1)
**
 7.0 (1.9 to 25.8)
**
 6.5 (1.7 to 24.5)
**
 8.4 (2.2 to 32.8)
**
 8.0 (2.0 to 32.3)
**
 
Have you received formal training in critical research 
appraisal? 
     
 No (referencing)  - - - - 
Yes  0.9 (0.3 to 3.1) 1.0 (0.3 to 3.5) 0.6 (0.1 to 2.5) 0.6 (0.1 to 2.4) 
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Independent Variable 
Block One Block Two Block Three Block Four Block Five 
OR (90% CI) OR (90% CI) OR (90% CI) OR (90% CI) OR (90% CI) 
Have you been trained in the foundations of EBM?      
 No (referencing)  - - - - 
Yes  7.0 (2.1 to 37.6)
**
 8.5 (1.9 to 37.2)
**
 9.9 (2.0 to 48.4)
**
 10.0 (2.0 to 
48.8)
**
 
Are you aware of the following databases (i.e., 
Cochrane Library, PubMed, CNKI and CBM)?
a
 
  1.3 (0.9 to 1.7) 1.3 (0.9 to 1.9) 1.3 (0.9 to 1.9) 
What is your understanding of the following terms 
(i.e., RCT, SR, meta-analysis, RR, absolute risk, OR, 
MD, CI, heterogeneity and publication bias)?
b
 
  
1.0 (0.9 to 1.0) 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.0) 
Are you confident in your ability to find relevant 
research to answer your clinical questions? 
     
 Disagree or neutral (referencing)    - - 
Agree    5.8 (1.5 to 23.0)
**
 5.9 (1.5 to 23.2)
**
 
CM theory contradicts EBM.      
 Agree (referencing)     - 
Neutral and disagree     0.8 (0.3 to 2.5) 
-2 Log Likelihood 88.9 76.9 75.5 70.5 70.5 
PAC (%) 69.5 78.0 76.8 80.5 79.3 
Note. All independent variables are binary data except variablesa&b, which are continuous data. EBM: evidence-based medicine; EBP: evidence-based practice; CHM: 
Chinese herbal medicine; CI: confidence interval; *p < 0.1, **p < 0.05 
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After examining the practical meaningfulness of the variables with statistical significance, 
four independent variables were included in the final multivariate logistic regression model. 
Table 6.13 shows the ORs and their 95% CI. 
Table 6.13. Multivariate Logistic Regression Model on Implementing EBM of CHM for 
Insomnia 
Variable OR (95% CI) n 
Application of EBM is necessary for the treatment of insomnia with 
CHM.  
 82 
 Disagree or neutral (referencing) -  
Agree 4.8 (0.8 to 27.6)  
I need to increase the use of evidence in my daily practice related to 
CHM for insomnia. 
 82 
 Disagree or neutral (referencing) -  
Agree 8.5 (1.9 to 37.8)
**
  
Have you been trained in the foundations of EBM?  82 
 No (referencing) -  
Yes 4.6 (1.2 to 17.8)
*
  
Are you confident in your ability to find relevant research to answer 
your clinical questions? 
 82 
 Disagree or neutral (referencing) -  
Agree 3.8 (1.1 to 13.1)
*
  
Model evaluation  
 Omnibus tests of model coefficients (p value) p < 0.0001 
Hosmer and Lemeshow Test  p > 0.05 
Nagelkerke R Square 0.5 
PAC (%) 79.3 
Note. *p < 0.05; **p < 0.01.The full results of model development and evaluation are found in Appendix 6.6. 
After controlling for the items ‘I need to increase the use of evidence in my daily practice 
related to CHM for insomnia’, ‘Have you been trained in the foundations of EBM?’ and ‘Are 
you confident in your ability to find relevant research to answer your clinical questions?’ the 
variable related to motivation and goals, ‘Application of EBM is necessary for the treatment 
of insomnia with CHM’, was not significantly associated with the implementation of EBM of 
CHM for insomnia.  
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After controlling for other variables about motivation and goals, basic knowledge and skills 
of EBM and beliefs about capacity, participants who agreed they needed to increase the use 
of evidence in their daily practice related to CHM for insomnia were 8.5 times more likely to 
implement EBP of CHM for insomnia than those who disagreed or were neutral. Participants 
who had trained in the foundations of EBM were 4.6 times more likely to implement EBP 
than those had not undertaken any training. Those who were confident in their ability to find 
relevant research to answer their clinical questions were 3.8 times more likely to implement 
EBP than those who showed neutral attitudes or disagreed. 
The model was a good fit and of a moderate accuracy in its rate of prediction in terms of the 
Omnibus tests of model coefficients, Hosmer and Lemeshow Test, Nagelkerke R Square and 
PAC. 
6.4. Discussion 
6.4.1. Strength and Significance 
Debates and strategies of applying EBM to CM have been discussed in much of the literature. 
However, to our knowledge, none of the previous surveys in China investigated CM 
practitioners’ attitudes, behaviour and knowledge towards EBM relating to their practice of 
CHM for insomnia. The survey detailed in this chapter is significant as it fills this knowledge 
gap. In addition, this survey found two major barriers to EBP in the field of CM, including 
potentially beneficial CM therapies would need more high-quality RCTs, and training in 
EBM knowledge was needed. These findings would assist with improving the 
implementation of evidenced-based CM. Also, as stated in the overview of insomnia (see 
Chapter 2), it is possible that EBM was implemented for the practice of CHM for insomnia in 
light of the best available evidence and their recommendation strength in EBP guidelines. 
Discovering the essential contributing factors to EBP would be helpful for translating the 
evidence and guidelines to a day-to-day clinical practice of CHM for insomnia as well as 
providing implications for evidence-based CHM practice in other conditions. 
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6.4.2. Explanation of the Main Findings and Implications 
6.4.2.1. Attitudes, Knowledge and Practice of EBM Related to CHM for Insomnia 
The survey found that most participants generally showed positive attitudes to EBM, 
understood what was meant by EBM and were interested in learning and improving their 
EBM skills. Specifically, most participants acknowledged the necessity of applying EBM in 
the field of CHM for insomnia as well as its value for clinical decision-making. However, 
around half of participants were unsure about the comparative superiority between scientific 
research and clinical experience. The most common pathway for them to update their 
knowledge of CHM for insomnia was through reading classical literature followed by reading 
modern research. Instead of selecting homogeneous meta-analysis as the highest level of 
evidence, participants most valued RCTs. 
The survey also found most participants were conservative about their overall knowledge of 
EBM. Only around half of participants were trained in the critical appraisal of research and 
were confident in finding relevant research to answer their clinical questions, a skill essential 
to the evidence-based decision procedure. The participants preferred to use Chinese literature 
databases to English ones. Their use of the Cochrane Library, an essential evidence database, 
was totally lacking. Among a collection of terms relevant to EBM, participants appeared 
most familiar with RCT. 
The positive attitudes towards EBM and inadequate knowledge of EBM revealed by the 
survey are consistent with a national survey of CM academics and practitioners in China; 
however, this survey was not specific to a particular condition (15). 
The survey suggested that around half of participants believed they implemented EBP of 
CHM for insomnia. The moderate lack of EBP is also supported by another cross-sectional 
survey of multiple CM hospitals in China although the sample is different (351). In the 
survey of the thesis, the CM practitioners with EBP appeared not be active in seeking a 
clinical practice guideline (CPG)—an indispensable procedure of EBP to guide the relevant 
practices. The low utility of CPG is consistent with other studies, such as a national survey of 
CM practitioners on the use of the CPGs for CM (352). In this reference, the lack of strong 
evidence and heterogeneous CM diagnosis and treatment were discussed as potential barriers 
to poor compliance with CPG. Another possible barrier to low utility may be the inadequate 
quality of CPG. This is supported by a SR of the First Batch of Evidence-Based CPG for CM 
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(353). In this SR, the results of the Appraisal of Guidelines for Research and Evaluation 
(AGREE) suggested that applicability, including consideration of the costs and the variations 
in organisation was of low quality. Though CHM therapy was recommended in the CPG of 
insomnia for all health professionals (354), the comparative evidence between conventional 
medicine and CHM was not reviewed and presented specifically for CHM for insomnia. This 
may result in poor applicability of the CPG when clinical settings allowed for the practice of 
pharmacotherapy, psychotherapy, CHM and acupuncture. 
6.4.2.2. Barriers to EBP Related to CHM for Insomnia 
The top barriers to EBP revealed by the survey included insufficient high-quality evidence, 
incapacity of research skills to understand EBM and a lack of generalisability of the 
literature’s findings to the patient population. These obstacles related to EBP of CM have 
been previously discussed as expert opinions. However, this survey was the first to provide 
empirical evidence and raise the issue specific to the field of CHM for insomnia. 
As the SR (see Chapter 3) showed, poor reporting of randomisation methods, a lack of 
allocation concealment, insufficient blinding and inappropriate use of outcome measurements 
were noted as the methodological shortfalls of RCTs specific to CHM for insomnia. These 
are common limitations for RCTs of CM that are supported by methodological reviews of 
CM RCTs across different time ranges (355, 356). As these reviews showed, the RCTs 
improved over time but the current quality judged by publications remains poor, particularly 
those published in Chinese journals. The SR of CM published in Chinese journals was also 
found to be of high quantity in terms of production but of low quality such as through poor 
compliance with reporting guidelines and development handbooks (357). Though the 
Cochrane SRs of CHM were considered of a higher quality, an overview suggested they 
should be improved in several areas, such as the involvement of CM practitioners, searching 
Chinese databases and method pooling of different CHM treatments (358). 
As stated in the methodology (see Chapter 5), knowledge was the dominant factor affecting 
the relationship between attitudes and practice. Improving CM practitioners’ knowledge of 
EBM would be a key measure to advance the implementation of EBP of CHM for insomnia. 
The survey also showed that the incapacity of research skills to understand EBM, a key 
component of EBM knowledge, was one of the top barriers to EBP. It is noted that Chinese 
organisations of EBM such as the Chinese Cochrane Centre and Chinese EBM Centre (in 
 156 
 
Chinese: 中国循证医学中心) have for many years run workshops and short-term courses on 
the knowledge of EBM (359, 360) as have CM academic bodies such as the EBM board of 
the Chinese Association of Integrative Medicine (in Chinese: 中国中西医结合学会循证医
学专业委员会) (361. However, most of their training target researchers who are motivated 
by conducting clinical trials or SRs instead of clinicians who would like to apply clinical 
evidence in their practice. These might explain why CM practitioners considered the 
incapacity of research skills to understand EBM as the major obstacle to EBP. It is 
noteworthy that the McMaster University, the birthplace of evidence-based health care, 
started a TCM session in the EBCP 2017 Workshop aimed at clinicians who wish to improve 
their clinical practice through enhancing their skills in reading, interpreting and applying the 
medical literature of CM (362). In addition to the training of a typical EBP procedure, also 
included are assessing the risk of bias, interpreting the effect, determining applicability in 
individual patients and evaluating the trade-offs between the benefits and harms of the 
intervention. It would be beneficial to train CM practitioners in China for better utility of the 
clinical evidence. 
Another top barrier revealed by the survey was a lack of generalisability of the literature’s 
findings to the patient population. It may be explained by the inadequate consideration of the 
unique characteristics of CM practice compared to the biomedical model, which had been 
collected from CM practitioners’ open comments. Another possibility was that the available 
clinical evidence of CM could not resolve CM practitioners’ clinical questions in day-to-day 
practice. However, the survey did not investigate it further due to the limitation of its 
quantitative design. 
6.4.2.3. Contributing Factors to EBP of CHM for Insomnia 
In the survey, the logistic regression explored the association between relevant factors and 
whether to implement EBP of CHM for insomnia. The results suggest that the motivation and 
goals for EBM (the specific components of attitudes) as well as the knowledge and skills 
associated with EBM mainly explained whether participants implemented EBP of CHM for 
insomnia. The following diagram summarises the contributing factors to EBP of CHM for 
insomnia (see Figure 6.6). 
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Figure 6.6. Contributing factors to EBP of CHM for insomnia  
Note. EBM: evidence-based medicine; EBP: evidence-based practice 
Previously an expert consensus approach aimed at changing health care professionals’ 
behaviour produced 12 theoretical domains of an integrative framework of EBP (350). The 
contributing factors found by this survey are consistent with the theory in the domains of 
motivation and goals and knowledge and skills. It suggests that these domains are important 
for improving health care professionals’ behaviour in EBP either in the field of biomedicine 
or CM. However, some domains, such as environmental context and resources, social 
influences and behavioural regulation, were not identified by the survey. This may be 
explained by the common context of the surveyed participants, who were almost all 
university trained, worked in the hospitals of Guangdong and were regulated by the same 
governing body. It has been argued that the effectiveness of this strategy is related to 
behaviour changes and is sensitive to context (363). Confirmation of the external validity of 
the findings from the survey requires further research. 
6.4.3. Limitations and Implication for Future Research 
This survey only included CM practitioners who specialised in CHM for insomnia in 
Guangdong. The result may not be generalised to other areas of China. As the introduction 
stated, evidence-based clinical practice guidelines aimed at CM practitioners and general 
health professionals have been developed to guide CHM therapy for insomnia, which may 
differ from other health conditions. The factors to improve EBP from the perspective of CM 
practitioners’ attitudes, knowledge and behaviour could be typical but need further 
consideration of specific condition when it is applied in other areas. 
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This survey approached the research questions by using quantitative methods, which are 
valuable to provide an overview. ‘Why’ questions were not addressed by this survey. For 
example, why some CM practitioners preferred to update their knowledge by reading the 
historical literature rather than reviewing recent research and why there was a lack of 
generalisability of the literature’s findings to the patient population. ‘How’ questions were 
also difficult to be explained by this survey, such as how a clinical decision and action of 
EBP was made when practitioners treated patients using CHM. The qualitative method is 
superior to a quantitative approach for its function of interpretation, process identification and 
explanation (307). Therefore, a qualitative interview of the same population was needed to 
further investigate these questions. 
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Chapter 7. A Qualitative Interview of Chinese Medicine 
Practitioners for Their Perspectives on Evidence-Based Medicine 
and Evidence-Based Practice of Chinese Herbal Medicine for 
Insomnia 
7.1. Introduction 
As stated in the methodology (see Chapter 5), the quantitative study was good at providing 
information in breadth while the qualitative interview was better at exploring a problem in 
depth and explaining complex questions. The two types of methodological design 
complement each other and combined provide a thorough investigation of the research 
question. Also, the methodological triangulation from the quantitative and qualitative studies 
validated the data through cross verification of two sources. 
In Chapter 6, the quantitative survey demonstrated the overall measurements of CM 
practitioners’ attitudes, knowledge, behaviour and barriers to EBP related to CHM for 
insomnia as well as the essential factors contributing to EBP. Though the survey was good at 
providing the information in breadth, a few ‘why’ questions were not able to be explored in 
depth. For example, why CM practitioners preferred to update their knowledge by reading the 
historical literature rather than reviewing recent research and why there was a lack of 
generalisability of the literature’s findings to the patient population. The qualitative method is 
further needed due to its superiority in interpretation, process and explanation (306). 
As Chapter 6 showed, almost all the CM practitioners surveyed were optimistic about EBM 
and the application of EBP in CHM for insomnia. However, according to the self-
administrated questionnaire, only some of them implemented EBP in their clinical practice. 
Potential factors were thoroughly investigated in the survey (see Table 6.9) and four essential 
factors explaining whether CM practitioners implemented EBP were identified by a 
multivariate logistic regression model with a good fit (see Table 6.13). However, the findings 
were limited because of the empirical knowledge of EBP and the hypothesis-driven design. 
To explore other issues explaining the behaviour of EBP, a qualitative approach was chosen 
because of its post-positivism nature (292). 
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In addition, the findings of the survey were based on a self-administrated questionnaire that 
requires further validation by checking the understanding of participants. Methodological 
triangulation from the quantitative and qualitative studies is able to improve validity, as it 
could validate the data through cross verification of two sources. 
In light of the unresolved questions in the survey and the conflicts between the attitudes, 
knowledge and practice of EBP, the key issues to be explored in the follow-up qualitative 
research include CM practitioners’ perspectives on the definition of EBM, understanding of 
evidence and traditional knowledge of CM as well as the application of EBP in the practice 
CHM for insomnia. 
A qualitative interview, one of the most popular research techniques of qualitative studies, is 
an extension of a conventional dialogue. Interviewers ask questions to capture answers and 
explore further information and unexpected thoughts from the interaction with interviewees 
(307). Considering the overall research aim of the mixed-method design and the existent 
findings of the survey, a semi-structured interview was used and pre-organised around a list 
of predefined open-ended questions, along with some potential questions that depended on 
the interaction between the interviewer and interviewee(s) (308). This chapter presents the 
methods and analyses of the semi-structured interviews of CM practitioners for their 
perspectives on EBM and EBP of CHM for insomnia as well as discussions of the main 
findings. 
7.2. Methods 
7.2.1. Overall Design 
The qualitative interview was semi-structured. As a component of a mixed-method study, its 
primary aim was to obtain the CM practitioners’ in-depth perceptions on EBM and to explain 
their behaviours associated with EBP. Its secondary aim was to develop a theory useful for 
EBCMP. The overall design, implementation and reporting followed the Consolidated 
Criteria for Reporting Qualitative Research (COREQ) (364). 
7.2.2. Methodological Orientation and Theory 
Though the survey (see Chapter 6) validated the contribution of attitudes and knowledge of 
EBM to behaviours related to EBP from the perspective of KAP theory (322), a 
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psychological theory (350) suggested there were other potential factors to behavioural 
changes in EBP. In addition, according to our best knowledge, there was not an existing 
specific theory that was useful for behavioural changes related to EBCMP. Therefore, 
grounded theory (317)—‘a qualitative research method that uses a systematic set of 
procedures to develop an inductively derived grounded substantive theory about a 
phenomenon’—was applied to gain in-depth explanations and to craft a theory tailored to 
EBCMP. 
7.2.3. Participant Selection 
Purposive sampling (also called theoretical sampling) was applied to identify the 
interviewees regarding their qualifications and experience. Eligibility included being 
qualified in TCM or IM practice, frequently treating insomnia and willing to participate in the 
interview. The inclusion criteria of interviewees were the same as those of the survey 
participants to ensure that both studies represented the same population. People with severe 
visual, listening and speaking impairments were excluded. 
Interviewees were initially recruited from the responders of the survey (see Chapter 6). At the 
end of the survey, participants were asked whether to participate in the following interview. 
The candidates who showed interest in the interview could leave information on how to 
contact them. Oral informed consent to the interview and appointment were confirmed by 
emails or telephone. The reasons why interviewees did not participate were recorded. Finally, 
a detailed face-to-face explanation of the benefits and risks of the interviews and a review 
and signing of the paper-based documents of informed consent were processed before the 
interview commenced. 
The recruitment was moved to a snowball method via the interviewee network when the 
interviewees did not meet the diversity of characteristics or the saturation of themes had not 
occurred. The interviewees recruited by this method also underwent an examination of 
eligibility as described above. According to experience, approximately 20 interviewees were 
recruited until the saturation of themes was reached. However, the sample size was not fixed 
as the nature of theoretical sampling allows for flexibility. 
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7.2.4. Setting 
The interview occurred in the workplace of the interviewees, such as clinics, hospitals or 
universities. Only the interviewer and interviewee were involved in the interview 
conversation. 
7.2.5. Data Collection 
7.2.5.1. Method of Approaching the Interviewee 
The interviewees were approached for one-to-one and face-to-face interviews. The interviews 
were conducted in Chinese and audio recorded following written consent. Brief field notes 
were taken during the interview as a supplement. The total duration of each interview was 
estimated to be approximately half an hour, but flexibility was allowed. 
7.2.5.2. Interview Guide 
The interview guide was semi-structured as outlined in Table 7.1. The interview guide was 
not fixed. It could be modified with concurrent analysis of the interview data, subsequent 
questions modified and new questions added. Interviewees could also introduce relevant 
topics during the interview and discuss it freely.  
The interview guide was developed to complement the survey, mainly to explain and validate 
the findings from the survey. The survey identified the agreement and disagreement with 
EBM among CM practitioners; however, little was known about how they perceived the term 
‘EBM’, ‘evidence’ and ‘EBP’, particularly whether their understandings were in line with the 
conventions. Without interviewing the responders of the survey for their in-depth 
understandings, the underlying meaning of the overall positive attitudes towards EBM but 
moderate lack of EBP could not be elucidated. Hence, a couple of main questions were 
developed to achieve this aim, including ‘Could you tell me what first comes into your mind 
regarding EBM?’,  ‘Could you explain how you understand ‘evidence’?’, and ‘In what way 
do you perceive that the paradigm of EBM is used to guide the clinical practice of CM for 
insomnia?’. In addition, the current paradigm of EBM approached evidence using a different 
hierarchy from traditional CM. RCT and SR studies were located in the highest level of the 
evidence while traditional CM preferred to follow the knowledge with a long history.  Hence 
two more specific questions were developed to explain the meachanism why two systems 
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embraced distinct evidence hierarchy, including ‘How do you perceive the evidence from a 
SR and RCTs?’ and ‘How do you perceive the knowledge on CM for insomnia gained from 
classical literature or traditional textbook?’.  Other sections in the interview guide include 
the lead-in and the wrap-up questions. The lead-in question was designed to approach the 
practitioners easily by sharing their clinical experience, which was related to their day-to-day 
practice. The wrap-up questions were for open comments if the interviewees were happy to 
offer additional relevant information. 
Table 7.1. Primary Interview Guide 
Function Interview Questions 
Lead-In Question 
How many years have you practised CM for insomnia? 
[in Chinese: 您从事失眠的临床工作有多久了？] 
What subgroup of insomniacs do you meet most in your clinic? 
[in Chinese: 您经常遇到哪一类型的失眠病人？] 
When do you use CM to treat the people with insomnia?  
[in Chinese: 在哪种情况下，您会选择用中药治疗失眠？] 
Main Questions 
Could you tell me what first comes into your mind regarding EBM?  
[in Chinese: 提到循证医学，您最先会想到什么？] 
Could you explain how you understand ‘evidence’? 
[in Chinese: 您是怎么理解“证据”的？] 
How do you perceive the evidence from a SR and RCTs? 
[in Chinese: 您对来源于系统评价和随机对照试验的证据怎么看？] 
How do you perceive the knowledge on CM for insomnia gained from classical 
literature or traditional textbook? 
[in Chinese: 您怎么看在古籍和传统教科书上关于中药治疗失眠的知识呢？] 
In what way do you perceive that the paradigm of EBM is used to guide the 
clinical practice of CM for insomnia?  
[in Chinese: 您怎么看用循证医学的理念来指导中药治疗失眠的临床实践？] 
Wrap-Up 
Question 
Do you come up with anything else? 
[in Chinese: 您还有其他的想法或者建议吗？] 
7.2.6.  The Pilot Interview 
One pilot interview was conducted by using the interview guide.  It was used for testing the 
validity of the interview guide and preparing the ‘probes’ questions. It was also used for 
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technique developments, including familiarity with the interview guide, building trust 
between the interviewer and interviewee, speaking with an appropriate tone and language, 
handling the order of questions, and responding to the interviewee naturally and flexibly. 
The pilot interview suggested that the interview guide was relevant to the research aim, and 
the responses were informative. However, it also revealed that two additional issues might 
affect the interview. First, it seemed that the interviewee might consider the interviewer as the 
examiner for a test of EBM knowledge, and the response was similar to reciting the texts 
from EBM textbooks. Secondly, a fixed sequence of questions with pre-defined probes 
questions was infeasible as the interviewee usually introduce many additional comments. 
To improve the quality of the main interview, the research team decided to keep the main 
research questions fixed only. The sequence of the questions and probes were open to collect 
as much relevant information as possible. It was also not necessary for the interviewer to 
include a background of EBM training and research in their self-introduction when meeting 
with the interviewees. 
7.2.7. Data Analysis 
Grounded theory (317) guided the process of data analysis. One of its key features was the 
iterative design, entailing cycles of simultaneous data collection and analysis in which the 
analysis informed the next cycle of data collection. In brief, the steps of data analysis 
included: 
• Transcription: Full transcription was applied. The interviewer transcribed the audio 
recording and written notes to text on the same day of the interview. 
• Open coding: Open coding was initially applied. The coding was more inductive and 
not oriented by any pre-determined theoretical framework. Two main questions 
guided the coding including ‘What were the data for?’ and ‘What actually happened 
in the data?’ The interviewer conducted the initial coding of an interview before the 
next interview.  
• Constant comparison and ongoing data collection: Whereas issues of interest were 
noted in the data, they were constantly compared with other interviews for similarities 
and differences, refined the theoretical constructs and informed the ongoing data 
collection. 
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• Categorisation and conceptualisation: The codes were grouped and then 
conceptualised. They were then moved to the higher level called categories. In further 
categorisation, the highest level of evidence was called a theme. Another research 
member with training in qualitative research and the capacity to read Chinese 
performed the member check. 
• Reflexive memo writing: Keeping a reflective memo was the key to review of the 
data and the ongoing process to make conceptual leaps from the raw data to the 
abstractions that gave a deep explanation of the phenomenon.  
• Axial coding: Axial coding (365) was further applied, aiming to elevate the data to a 
higher level of abstraction. 
• Data saturation: Data collection was saturated when no more new themes appeared. 
Discrepancy and timing of the data saturation were confirmed by a team decision. 
• Theorisation: Theory was derived from the grounded data by iterative data collection 
and analysis.  
• Triangulation analysis: Triangulation (366) was used to combine several research 
methods of the same phenomenon in the study. To be specific, the data was further 
crossed verified from the findings of the survey and the interview after the theory was 
drafted. 
• Theory finalisation: The theory was finalised by taking together all the findings from 
the data analysis. 
NVivo qualitative data analysis software (QSR International Pty Ltd. Version 9, 2010) was 
used to assist in data analysis. An audit trail was made to keep decision-making transparent. 
7.2.8. Credentials and Occupational Training of the Interviewer 
The author of the thesis, a PhD candidate with broad training in qualitative research from 
RMIT, Monash University and Peking University (China), conducted the interview. She was 
also a sixth-year licensed CM practitioner with a bachelor degree in TCM and a master 
degree in IM who underwent advanced clinical training at a tertiary hospital in Guangdong, 
China. Chinese was her first language and she was also an accredited Chinese–English 
translator for the China Accreditation Test for Translators and Interpreters (CATTI). 
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7.2.9. Ethical Considerations 
7.2.9.1. Informed Consent 
The interviewees were fully informed about the research purpose and benefits or risks 
brought by the interview. The interviewees confirmed that they had a full understanding of 
the provided information, voluntary and free characteristics of the participants, right to 
withdraw from the interview as well as agreeing to participate in the interview. Permission to 
be audio recorded was requested as well. Written informed consent was made by face-to-face 
and signing of documents was required. 
7.2.9.2. Confidentiality 
The confidentiality of the interviewees was protected as follows: 
• Identified information of the interviewees was removed from the original data, 
including audio files, filed notes and transcripts. 
• All the data with a label number only were kept to ensure transparent decision-
making. 
• Only the research team, research sponsor and ethics committee could access the 
interview data. 
• The publications related to the interview identified no personal information. 
7.2.9.3. Approval from the Ethics Committee 
The research proposal of the interview, as a component of the mixed-design study, was 
approved by the Institutional Ethics Committee of GPHCM, China, who was responsible for 
the oversight of the project and for primary ethical duty of care over the research participants 
(No. B2015-025-04). The ethics approval was accepted by the Science, Engineering and 
Health College Human Ethics Advisory Network (CHEAN) of RMIT University with a 
registration number ASEHAPP 11-15/ RM No: 19252. 
The approval letter issued by the Institutional Ethics Committee of GPHCM, China, and the 
registration letter of external approval in RMIT are specified in Appendix 7.1 and 7.2. The 
approved participant information and consent form can be found in Appendix 7.3 and its 
translation is in Appendix 7.4. 
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7.3. Results 
7.3.1. Interview Participants 
7.3.1.1. Recruitment Results 
Of the 98 participants who completed the questionnaire in the pilot survey or main survey 
(see Chapter 6), 12 indicated their interest in a follow-up interview. Of these, eight completed 
the interview, two did not respond to the confirmation and two were not able to participate 
due to time restrictions. Although qualitative research does not aim to recruit a large sample, 
participants with a wider variety of clinical specialities, practice history, settings, education 
background and research experience were required. A snowball sampling method via the 
interviewee network was used to recruit another seven participants. In addition, the success of 
the sampling was also indicated when the saturation of themes was reached. In total, 15 
participants completed the semi-structured interview. The duration of interviews ranged from 
29 to 83 minutes, with an average of 56.6 minutes. Figure 7.1 shows the flowchart of the 
interviewee recruitment. 
 
Figure 7.1. The flowchart of interviewee recruitment 
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7.3.1.2. Demographic and Socio-economic Characteristics of the Interviewees 
All the interviewees had an equivalent master degree in medicine or higher. Two of them 
were primarily trained in conventional clinical medicine (called Western medicine in the 
Chinese health care system) and underwent CM training afterwards. One participant was 
primarily trained in CM and then underwent education in conventional clinical medicine. 
Another 12 interviewees had a background in CM (including IM) education only. The ratio of 
male and female or experience with or without insomnia research was around fifty-fifty. 
There was a wide variation on participants’ age, practice history and professional position. As 
for clinical settings, interviewees working in the community, general hospitals and CM 
hospitals were all included. In terms of the fields of expertise, that most interviewees 
specialised in mental health and neurological conditions, was in line with the survey response 
(see Chapter 6). Interviewees with other fields of expertise such as gastroenterology, 
gynaecology, CM prevention and acupuncture and massage were also included to ensure a 
diverse and representative sample. The success of the sampling strategy was indicated by the 
distribution of the demographic and socio-economic characteristics. Though half of the 
interviewees (7/15) were not recruited from the survey participants, the overview of the 
demographic and socio-economic characteristics was in line with those of the survey, except 
that the interview did not include CM practitioners with a degree equivalent or lower than a 
bachelor. Table 7.2 specifies the demographic and socio-economic characteristics of the 
interviewees.  
Table 7.2. Demographic and Socio-Economic Characteristics of the Interviewees (n=15) 
Characteristics 
Number of 
Responses/Interviewees 
Age Range (Years) 20–29  2/15 
30–39  9/15 
40–49 2/15 
≥50 2/15 
Gender Male  7/15 
Female  8/15 
Highest Degree  Master 10/15 
Doctor 5/15 
Practice Division  TCM 8/15 
IM 7/15 
Practice History (Years) ≤3 3/15 
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4–6 3/15 
7–10 3/15 
11–24 4/15 
≥25 2/15 
Treating Insomnia (Years)
1
 ≤3 2/13 
4–6 3/13 
7–10 3/13 
11–24 4/13 
≥25 1/13 
Professional Position Resident doctor 3/15 
Attending doctor 5/15  
Associate chief doctor 4/15 
Chief doctor 3/15 
Clinical Specialty Mental health
2
 5/15 
Neurology
3
 4/15 
CM gastroenterology 1/15 
CM gynaecology 1/15 
CM prevention 2/15 
Acupuncture and massage
4
 2/15 
Insomnia Research Experience Yes 7/15 
No 8/15 
Clinical Setting CM hospital 11 
General hospital  3 
Community clinic  1 
Note. 1. Two of the interviewees were not certain about how long they treated people with insomnia. 2. The 
practitioners who specialised in mental health included CM practitioners holding a psychotherapy qualification 
(n = 4) and a physician practising clinical psychology and CM (n = 1). 3. The practitioners who specialised in 
neurology included CM practitioners who specialised in the treatment of neurology conditions (n = 3) and a 
physician practising clinical neurology and CM (n = 1). 4. The practitioners who specialised in acupuncture and 
massage referred to acupuncturists who practise acupuncture therapies and CM specific for insomnia. 
7.3.2. Findings of the Data Analysis 
The findings of data analysis are presented as the themes that emerged from open coding of 
the interviews (see Section 7.3.2.1), the relationship between themes that emerged from axial 
coding and theorisation (see Section 7.3.2.2) and triangulation analysis and theory finalisation 
(see Section 7.3.2.3). Representative quotes are provided to illustrate the themes. Instead of 
identifying personal information, interviewee numbers (e.g. P-001 for Participant 001) were 
used to protect interviewees’ privacy. The original quotes in Chinese and their English 
translation are detailed in Appendix 7.5. 
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7.3.2.1. The Themes that Emerged from Open Coding 
The following sections show the themes that emerged from the open coding and 
categorisation. 
Theme One: CM practitioners generally showed positive attitudes towards EBM as they 
thought EBM was beneficial. 
Theme one that emerged from the data coding revealed interviewees’ positive attitudes 
towards EBM. As detailed below, there were two sub-themes. Sub-theme 1A: generally 
perceived benefits of EBM more likely associated with improving individual clinical practice. 
Sub-theme 1B: perceived benefits of EBM specific to CM more associated with improving 
the whole discipline. 
Sub-Theme 1A: Generally Perceived Benefits of Evidence-Based Medicine More 
Associated with Improving Individual Clinical Practice. 
Almost all interviewees acknowledged the benefit of EBM. The most common response to 
the interview question was ‘good’. There were various reasons to comply with EBM 
generally.  
Interviewees commented that EBM could assist with evaluating the outcome of individual 
clinical practice: ‘I think evidence-based medicine is generally good because sometimes you 
are uncertain about the therapeutic effectiveness. Specific for insomnia, standard scales and 
objective measurements from devices are the minimal [to confirm effectiveness]. When you 
ask the patient ‘Do you feel better?’ and the patient says, ‘It seems better’. You can’t write 
‘improved’ on the medical chart, particularly in the resident department because it 
[insomnia] may improve naturally as time passes. ‘Improved’ can’t be stated so rashly, 
rather, an objective evaluation should be accounted for’. (P-001) 
Interviewees thought EBM was an efficient way to train clinical doctors: ‘It [EBM] can train 
our doctors in a standardised way and they [doctors] can master the conventional 
[procedures of] diagnosis and therapy for the common disease in a short term. When patients 
come, at least I have these [knowledge or skills of the conventional procedure] at hand with 
the evidence of 70–80% improvement rates. Therefore, it [this training] is a very good thing. 
(P-011)’ 
 171 
 
Interviewees acknowledged that EBM corrected wrong clinical practice by giving the 
example of steroid use for stroke: ‘It [EBM] changes the clinical practice of western 
medicine after its appearance. As far as I know, steroid was injected to the patients with 
stroke, either cerebral haemorrhage or ischaemic stroke before its [EBM’s] appearance. 
Why? It was considered to relieve the cerebral oedema, right? After evidence-based medicine 
appears, the endpoint measurement finds that mortality is not reduced and the survival goes 
down although the temporary state of condition improves rapidly when steroid is injected. 
Nowadays, the patients with stroke are not commonly injected with steroid as you see’. (P-
007) 
Sub-Theme 1B: Perceived Benefits of EBM Specific to CM More Associated With 
Improving the Whole Discipline. 
Most interviewees believed that EBM was also beneficial to CM because it was a powerful 
tool for improving the whole discipline.  
Interviewees thought EBM explained the clinical phenomenon and guided the practice to a 
higher level: ‘Each study is a tiny part [of the great whole]. Everyone tries to explore it from 
every side, like [the blind people] touching the elephant, some touch on the ear, some on the 
trunk, some on the tail and some on the ivory. Finally, when we synthesise them [the different 
components], things turn to a level with more scientific and broader data for explaining the 
clinical phenomena and effectiveness as well as for guiding the clinical practice. Its 
reproducibility is not as simple as the apprentice repeating the master, but refers to a more 
intelligent process for either a person or the Chinese medicine education’. (P-007) To be 
specific, it was a sign of progress for CM to develop from being based on experience to being 
evidence-based: ‘It would be difficult to demonstrate the disciplinary development of Chinese 
medicine, if personal experience [of CM practitioners] was displayed only. So it is nothing 
wrong to head towards the evidence-based approach or the standardisation [of CM]’. (P-
010) 
Interviewees also believed that high-quality evidence by substantially validating CM 
benefited the development of CM: ‘Significant contribution to the whole discipline derives 
from a large collection of high-quality evidence. Only after the validation [of CM], the whole 
Chinese medicine discipline can be developed’. (P-006) Vice versa, the implementation of 
the EBM was a motivation to improve the quality of the original study: ‘Being evidence-
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based can probably advance the raw material [original studies] of Chinese medicine, which 
is to improve the clinical trials’. (P-006) 
Moreover, interviewees believed the overall therapeutic effectiveness of CM would improve 
when scientific facts were accounted for: ‘Nowadays, Chinese medicine may be on the wrong 
track when there is a lack of awareness of the modern scientific method and western 
medicine. Actually, over the past thousands of years, things might easily go wrong and in 
mysterious directions when it was just based on sensation [and emotion], rather than the 
evidence of facts. So, I think the therapeutic effectiveness could be much better with the 
training of scientific thinking’. (P-003) To be specific, a clinical trial could reduce subjective 
perception of therapeutic effectiveness: ‘Most of the time, we conduct clinical trials by a 
scientific approach to confirm the effectiveness of the therapy which we previously thought 
effective. This can avoid our subjective perception. For those with real effectiveness, it 
[clinical trial] can further investigate which component of the whole therapy is essential. 
Afterwards [after the effectiveness is confirmed and the essential component is identified], it 
is possible to simplify the therapy and to conduct pharmacological study to explain the 
mechanism. I think it is an ongoing process of deepening and further validation [of Chinese 
medicine therapy]’. (P-015)  
Some interviewees thought that senior practitioners’ experience required further validation 
for a better inheritance of CM: ‘The experts’ experience needs support from evidence. At the 
Rescue Stage [to preserve the wisdom and knowledge of the old generation of Chinese 
medicine practitioners in mainland China], all patient cases were cherished equally no 
matter whether they were good or bad, effective or ineffective. This [preservation strategy] 
could a problem because the therapeutic experience of same bad cases could be included and 
passed down to the next generation [with equal importance as the good cases]. To be honest, 
I witness the practice of some eminent Chinese medicine practitioners and the feedback [from 
patients] is not always good. It is not difficult to have 100 successful cases when the practice 
has lasted for the whole life [of a practitioner]. Following it is simple to publish a book, isn’t 
it? I think experts need evidence-based [thinking]. If so, the experience of these experts is 
pretty objective. Sometimes, the summary of experts’ experience is not done well or someone 
might be good at practice but bad at explanations. Misconception of the mechanism [of the 
treatment] is also possible’. (P-001) 
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Theme Two: The Primary Concern for Understanding EBM More related to Evidence 
Theme two emerged from the data coding and revealed that the primary concern for 
understanding EBM was more related to the ‘evidence’. As detailed below, there were three 
sub-themes: evidence being fundamental to EBM (Sub-theme 2A), the main measurements of 
evidence including reliability and validity (Sub-theme 2B), and evidence has a hierarchy 
where RCTs and SRs are usually at the top (Sub-theme 2C). 
Sub-Theme 2A: Evidence being Fundamental to EBM  
With respect to the first impression of EBM, the most common word from the interviewees 
was ‘evidence’. Most interviewees’ primary understanding of EBM was that the evidence 
was the foundation and a necessary component, such as ‘external evidence is the necessary 
foundation of evidence-based medicine and the experience of using it is followed’. 
Sub-theme 2B: The Main Measurement of Evidence including Reliability and Validity 
In regard to the simplest understanding of ‘evidence’, most interviewees thought evidence 
was something supported by data. Furthermore, the inerviewees thought ‘evidence is 
something real, objective, tangible and replicable’ that was to mean reliability, and validity 
was main measurements for evidence: ‘I personally think there are two layers of meaning 
about evidence. On the one hand, evidence refers to patients’ responses to the medication, 
which is objective evidence. On the other hand, it is the reliability after the therapy is 
repeated many times. So, it [evidence] is about the reliability and validity, from my 
understanding’. (P-008) 
Sub-theme 2C: Evidence has a hierarchy where RCTs and SRs are usually at the top. 
Most interviewees agreed that ‘evidence has levels’. Some interviewees detailed their 
personal criteria to determine the level of evidence, that evidence was more research-based: 
‘as for evidence, I would say it is the finding of scientific research. The findings included 
many research results. And those with many studies and ready for clinical practice, I think, 
are evidence’. Some interviewees thought evidence needed to be up to date:‘[Concerning 
evidence], the textbook is reliable [evidence] certainly because it [the textbook] is the dogma 
and passed down from generation to generation. Nowadays, it [evidence] probably refers to 
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large studies, particularly the latest ones. It is the most convincing because it is the latest and 
things are always progressing’. (P-004) 
Study quality was emphasised to judege evidence, such as ‘my initial awareness [of 
evidence] refers to the study quality; quality control is essential to a study’. The saying 
‘garbage in, garbage out’ was made widely aware by the interviewees concerning the value 
of a SR. Most interviewees believed the quality of the original studies contributed most to the 
value of a SR or meta-analysis. For example, ‘I think, for a meta-analysis, good original 
material, good evaluation outcome; bad original material, bad outcome’. 
Interviewees were aware that an RCT was at the higher level of an evidence hierarchy for 
biomedicine while experts’ consensus and experience were at a lower level. They believed 
that the results of high-quality RCTs were worth trusting, stating ‘from the perspective of 
research, a new drug compared with placebo, if its data are free of problems and the data 
clarify a question, it is worth trusting’. The interviewees also highlighted the critivcal value 
of an explanatory RCT, such as ‘according to my understanding, an RCT can help me further 
approach the formulae for the condition in a more standard and clearer way. In a 
circumstance with less confounding factors, the effect of the formula can be identified’. 
Most interviewees acknowledged that a SR with meta-analysis was superior to a single RCT 
because it often represented a broader view: ‘I like it because systematic review or meta-
analysis is a secondary analysis of RCTs. It is quite similar to our interview. I give you my 
comments. You also collect others’ comments. Then it [the whole interview] would be more 
objective and more comprehensive. That is to say, the conclusion [of a systematic review or 
meta-analysis] will be more comprehensive. [Because] more can be referenced than a single 
RCT. An RCT with positive results can be attributed to many things, such as the population 
characteristics in this area, or the experience or the samples. It is hard to identify to what 
extent these characteristics are similar to our patients. However, meta-analysis is a summary 
of much information. Its conclusion can be a better reference within reach’. (P-014) Other 
reasons why a SR with meta-analysis was more advanced included its systematic process of 
quality appraisal and quantitative synthesis, such as ‘it calculates the literature with and 
without effectiveness rather than just concluding the effectiveness according to subjective 
sensation’. 
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Interviewees commented that practitioners might be more familiar with clinical practice 
guidelines, though they saw that RCTs and SRs were the evidence in the higher level: ‘In the 
past, we thought evidence was what we read in the textbook. As there is more awareness of 
scientific research, we believe that a large multi-site randomised controlled trial is the 
evidence with the highest level, isn’t it? A meta-analysis in an approach of synthesis [of many 
trials] provides an overview further, right? Then clinical practice guidelines include the 
meta-analysis. We, as junior doctors, read clinical practice guidelines most’. (P-013) 
Theme Three: Behaviours in the practice of CHM for insomnia are more likely affected by 
the traditional CM education.  
Theme three emerged from the data coding and revealed that behaviours in the practice of 
CHM for insomnia were more likely affected by the traditional CM education. As detailed 
below, there were two sub-themes: the acquisition of CM clinical skills mainly including 
reading textbooks, classical literature and case reports (Sub-theme 3A), and the therapeutic 
decision-making of CM usually following textbooks, classical literatue and the supervisor’s 
practice in an apprenticeship (Sub-theme 3B). 
Sub-theme 3A: The Acquisition of CM Clinical Skills Mainly Including Reading 
Textbooks, Classical Literature and Case Reports 
Most of the interviewees stated that their acquisition of clinical skills about CHM for 
insomnia involved several stages, including undergraduate education, apprenticeship under 
senior CM practitioners and additional learning. However, textbooks and classical literature 
were the major source of knowledge and skills. 
Textbooks played an elementary role in delivering relevant knowledge during interviewees’ 
undergraduate education. For example, ‘our initial impression is in the textbook’. Post-
undergraduate apprenticeship often involved learning from the postgraduate supervisors or 
senior practitioners because they believed ‘the instruction from someone experienced in 
therapy is important’ and ‘[the experience of being an apprentice assists in] gaining 
intensive understandings of Chinese medicine pathogenesis for insomnia as well as having 
extensive selection of CHM prescriptions’. 
Additional learning included reading literature, attending conferences or training workshops 
and reflective practice. The most commonly mentioned was the reading of historical 
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literature, particularly classical literature of CM. Only one interviewee described his learning 
experience by conducting clinical studies on CM for insomnia. Most interviewees updated 
their knowledge through two separate learning systems for CM and modern medicine. For 
example: ‘To gain the knowledge of modern medicine, papers and guidelines are read while 
[gaining the knowledge of] Chinese medicine involves reading historical literature and 
learning from experienced practitioners’. (P-002) 
As the path to improving their clinical practice of CHM for insomnia, none of the 
interviewees considered reading recent clinical trials, SRs with meta-analyses or clinical 
practice guidelines. Instead, the interviewees considered reading case reports in journals or 
monographs useful for clinical practice because they wanted to enhance their clinical thinking 
by reading ‘something similar to a clinical scenario’. 
Sub-Theme 3B: The Therapeutic Decision-Making Usually Following Textbooks, 
Classical Literature and the Supervisor’s Practice in an Apprenticeship 
Most interviewees selected CHM formulae for insomnia according to the textbook ‘Chinese 
Internal Medicine’ because they thought the textbook provided ‘the fundamental therapeutic 
principle’ and ‘the most basic knowledge’. Some interviewees selected the formulae used by 
the teacher in the apprenticeship. The reason why they preferred to apply supervisors’ 
experience in personal practice, rather than research-based evidence was related to the precise 
diagnosis of the CM syndrome: ‘[The formulae] I use most are from the apprenticeship. I 
might try the formulae from the research. But I am a little worried about whether the 
syndrome I diagnose is the same as the one described in the research or not … In the 
apprenticeship, I am confident that my diagnostic criteria is exactly the same as my teacher 
because he/she teaches me to make a diagnosis;.(P-011) 
Interviewees also selected formulae recorded in the classical literature and amended them 
according to individual patients’ symptoms. One interviewee commented that she often 
selected the formula with more consensuses. None of the interviewees selected CHM 
formulae for insomnia primarily according to the latest scientific research or clinical practice 
guidelines. None of the interviewees selected formulae only by personal perception. 
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Theme Four: Unique Characteristics of Chinese Medicine Practice Referring to 
Individualised Treatments and the Emphaiss of Traditional Knowledge 
Theme four emerged from the data coding and revealed the unique characteristics of CM 
practice. As detailed below, there were three sub-themes: individualised treatment (Sub-
theme 4A), the emphasis of traditional knowledge (Sub-theme 4B), and the respect for the 
experience accumulated from a long-term practice (Sub-theme 4C). 
Sub-Theme 4A: Invididualised Treatment  
Individualised treatment, as an overall theurapeutic model, was an outstanding feature of CM 
compared to conventional medicine. Most interviewees commented that CM therapy took 
care of variations of individual patients more than the common characteristics: ‘The patient, 
to a certain extent, is the focus of the Chinese medicine practice. First, individualised therapy 
is provided because I don’t use the same formula for every patient. Although patients have 
something in common, everyone doesn’t feel exactly the same for the [same] disease and 
everyone presents distinct symptoms. So my prescriptions are not always the same. Patients 
also have their own decisions. For example, he thinks ‘I feel good about this formula and I 
don’t feel good about the next formula’. This is part of patients’ preferences, because he/she 
may not want to take the formula which he feels bad for. Sometimes the patient prefers 
Chinese medicine therapy [to Western medicine] because he is scared of the side effect of 
Western medication. In that scenario, I would have Chinese medicine play the greatest role in 
the therapeutic plan’. (P-002) 
An individual patient’s response to treatment was emphasised in CM practice. Most 
interviewees commented that CM practitioners were more likely to determine the clinical 
outcome of CM practice by collecting patient feedback following a clinical visit. In the case 
of CHM for insomnia, most interviewees were concerned about the improvement of ‘total 
sleep duration’ reported by the patients. The quote below depicted one interviewee’s strong 
belief in patient feedback: ‘I think Chinese medicine does benefit a large population although 
you can’t prove its efficacy now. Like my family, my kids and my mum, they don’t take 
Western medication. My relatives seek help from me [CM practitioner] when their problems 
can’t be solved by Western medicine hospitals. I can resolve most of them. So I still believe 
Chinese medicine is effective because of the [positive] feedback I collect from the real world 
even though there is a lack of support for high-level evidence’. (P-003) 
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Sub-Theme 4B: The Emphasis of Traditional Knowledge  
Most interviewees considered that traditional knowledge was a treasure for CM practice. 
With respect to CM knowledge, most interviewees selected classical literature of CM like 
‘Shang hanlun’ and ‘Huang di neijing’ as their favourite books because ‘it is equivalent to a 
guideline of Chinese medicine’ and ‘it is the fundamental guide’. Interviewees also 
considered that reading classical literature improved clinical thinking, as it was the origin of 
CM practice: ‘I think reading classical literature is an advancement of the thinking. We recite 
‘Shan hanlun’ [a classical monograph of Chinese medicine published in Donghan Dynasty of 
pre-modern China] and according to it we develop schools of thoughts. Following the 
experience in all schools of thoughts is added to it again. If one only reads the new and 
abandons the classical literature, he could treat disease generally but there is a lack of 
flexibility. For example, he uses the effective formula in the report [of the research]. Of 
course it works in practice. But if the formula ran out, how could he treat a patient? It is hard 
to say’. (P-007) 
Sub-Theme 4C: The Respect for the Experience Accumulated from a Long-term Practice 
Experience was valued in CM practice. Most interviewees acknowledged the importance of 
doctors’ experience, such as ‘a doctor who has more diagnostic and therapeutic experience 
and successful cases for a condition is capable of helping more patients’. Some also 
commented that ‘the experience of Chinese medicine with thousands of years can’t be 
ignored’.  
Theme Five: Barriers to Applying Modern Evidence in Chinese Medicine Practice 
Theme five emerged from the data coding and revealed interviewees’ barriers to applying 
modern evidence in CM practice. As detailed below, there were three sub-themes: 
indirectness of evidence for CM practice (Sub-theme 5A), low quality of evidence resulting 
in uncertainty (Sub-theme 5B) and evidence production requiring more considerations of 
CM’s unique characteristics (Sub-theme 5C). 
Sub-theme 5A: Indirectness of Evidence for CM Practice 
Most interviewees thought that the directness of the evidence—whether the evidence was 
able to solve specific clinical questions relevant to CM practice—was essential to CM 
 179 
 
practice. One interviewee gave a vivid example to illustrate his strong affection on this 
viewpoint: ‘High-level evidence is like a high-quality screw made of gold. The information 
[the high-quality screw is made of gold] is irrelevant to me. Because I am going [to find a 
suitable screwdriver] to loosen the screw but it [the information] doesn’t tell whether it is the 
hexagonal screw or not. I know it [the evidence] is good, but it is useless [for my practice]’. 
(P-001) 
However, the current evidence could not be used for guiding CM practice. One interviewee 
portrayed the gap between the solutions generated from a RCT and the clinical question of 
CM: ‘If fact, the randomised controlled trial sets lots of criteria and accordingly patients are 
screened because similar baseline is required. And then the patients included are extremely 
‘pure’ and a ‘simple’ intervention always results in a good result. I think it is true indeed. 
But, in fact, we can’t meet such a ‘pure’ patient in clinical practice or say not all the patients 
are as simple as it is. So the application will fall into a narrow scope’. (P-011) 
Ann ideal example of CHM evidence with high directness was illustrated as: ‘If there is 
[evidence that] a formula is specific for a pattern, that is, to mean it [the evidence] can tells 
what formula treats what pattern or syndrome and these things [the research questions] 
originate from clinical practice, it would be better’. (P-011) 
Sub-Theme 5B: Low Quality of Evidence Resulting in Uncertainty 
The CM practitioners’ evidence-based beliefs were greatly influenced by the quality of CM 
evidence. Most interviewees commented that the quality of CM studies was poor and the 
results unreliable: ‘Why someone is against evidence-based Chinese medicine? That’s 
because the [CM] evidence made of the raw material [original study] with poor quality differ 
greatly from the reality. A good meal cannot be made without rice even for a skilful 
housewife. Certainly its [CM evidence] value of guidance differs from the evidence of 
Western medicine. The quality of clinical trials for Western medicine is high and [the clinical 
trial] matches the clinical practice. So the value of guidance [of Western medicine evidence] 
is significant. People who find it [the evidence] is useful in practice will go for it, absolutely. 
But it [there is a lack of high-quality evidence of CM] is only a temporary phase. Gradually, 
when all the clinical trials turn to high quality, their results will match the clinical practice 
much more. More people will go for it naturally’. (P-006) 
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Sub-Theme 5C: Evidence Production Requiring More Considerations of CM’s unique 
Characteristics 
Most interviewees commented that the current RCTs were designed and tailored to the nature 
of conventional medicine but the individualised approach of CM practice required a new 
methodology of CM evidence production: ‘The design of an RCT is influenced by the 
therapeutic thinking of Western medicine. What Western medicine focuses on, such as the 
criteria of disease diagnosis, are presented comprehensively. But nothing is presented [in an 
RCT] about what Chinese medicine emphasises, such as specific symptoms, tongue and 
pulse. Even when the Chinese medicine evidence is of high quality, it can be applied in 
Western medicine practice only. It is useless for me because nothing of Chinese medicine 
interest is reported. And with respect to therapeutic effectiveness, for example, Suanzaoren 
decoction for insomnia, its effective rate is not 100% [in an RCT]. If the effective rate is 80%, 
then your confidence in successfully treating a patient is 80%. That also means you are not 
using Suanzaoren decoction well. Why is there another 20% [the ineffectiveness rate]? 
[When designing the next RCT], we may need to consider further stratification [of the 
participants], narrowing the inclusion criteria or including the Chinese medicine 
characteristics into the eligibility’. (P-001) 
Interviewees also pointed out that the practice of CM was complicated and many components 
were involved: ‘In Western medicine, dexamethasone injected by anyone, as long as it 
remains the same dose, has the same effect. Nothing differs. However, Chinese medicine is 
different. The same formula with the same dose prescribed by different people may have 
different effects. Then, patients may buy the herbs in different stores or hospitals after they 
receive the prescription. The herb quality decides part of the effect, right? [So the herbal 
source also contributes to effectiveness.] In addition, although placebo effect should be 
removed when conducting a research, placebo effect contributes to the effectiveness in 
clinical practice. We need to take great advantage of the placebo effect. For example, the 
formula prescribed by the senior practitioner has superior effectiveness to the same one 
prescribed by a young practitioner. That is because the patient has the strong trust [in the 
senior CM practitioner] during his initial visit and therapy’. (P-007) 
Interviewees further commented that the complexity of CM practice would make a classical 
RCT impractical: ‘RCT, I previously thought it was objective, being true and objective. But it 
may not fit the research into Chinese medicine, though it is objective because the variation of 
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Chinese medicine is huge. There are many factors leading to the therapeutic outcome of a 
Chinese medicine therapy. First, the medication is out of control because it is a formula of 
multi-herb and every single herb has many active ingredients. So it is hard to know their 
causal relationship to the therapeutic outcome. Secondly, the practice of Chinese herbal 
medicine involves lots of factors, such as psychological factors and Chinese population’s 
belief. Thirdly, for the implementation, the use of a multi-herb formula by the research 
personnel is of more variability than the use of a single drug, such as estazolam. The way 
research personnel provide the therapy to the patient is a big difference. So I don’t think it 
might be the most appropriate method’. (P-003) 
Interviewees were uncertain whether the modifications of Chinese herbal formulae for 
individual patients could be investigated in a RCT: ‘Concerning conducting an RCT, I have 
no idea whether the Chinese herbal medicine modified for individuals meets the criteria [of 
an RCT] nor not. Western medicine sets strict criteria for an RCT, right? The dose and the 
brand of the drugs are exactly the same. But Chinese herbal medicine is commonly modified 
according to individuals. You can’t use one formula for everyone. If you did it in an RCT like 
this, it would be odd’. (P-013) 
Interviewees emphasised that the importance of understanding patients’ experiences, stating 
‘I would like to know patients’ experience about taking the formula, not only the RCTs but 
also the studies about patient experience’. One interviewee preferred the long-term 
observational studies from a practical perspective: ‘For example, a patient visits you and you 
prescribe a formula, like Suanzaoren decoction. Then you add Dahuang, another herb to it 
because you think it fits his/her symptoms. The patient improves in his/her second visit. It is 
inappropriate to attribute the benefit to Dahuang only because the patient takes the whole 
formula. It is difficult to identify the contribution of each herb in every modification process. 
But when the data is accumulated to a big pool, the data analysis can reveal it. It is in low 
efficiency and not practical for having a study, like comparing Suanzaoren decoction to 
Suanzaoren decoction plus Dahuang. I would prefer to record the data that what herb and 
how many grams the patient takes as well as which symptom is improved [every time]. It may 
not work for only hundreds of records. Hundreds of thousands of records from a large group 
of doctors rather than a single doctor, big data, the data analysis could tell you their 
relationship’. (P-001) 
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7.3.2.2. The Relationship Between Themes Constructed from Axial Coding 
As Theme 3 revealed, most CM practitioners practised according to the knowledge or skills 
they gained from textbooks, apprenticeship, classical literature, expert consensus and case 
report/series, although they appreciated the benefits of EBM for CM. These practitioners 
updated their knowledge of modern medicine by reading the latest research and guidelines. In 
addition, their therapeutic decision-making was always consistent with their acquisition of 
clinical skills. 
As Theme 2 suggested, CM practitioners’ perceptions were consistent with the conventional 
definitions and rules related to EBM. However, CM practitioners highlighted the distinct 
characteristics of CM compared to modern medicine, particularly the individualised 
therapeutic principle that was described in ‘Theme 4 distinct characteristics of Chinese 
medicine practice’. 
The differences between CM and modern medicine are described in ‘Theme 5 barriers to 
applying modern evidence in Chinese medicine practice’. CM practitioners raised barriers 
and possible solutions by taking the basic nature of EBM and the unique feature of CM 
practice into consideration. 
In summary, although attitude and knowledge were commonly considered the principle to 
behaviour, they were not the outstanding issues in this interview. All the CM practitioners 
acknowledged the benefits of EBM for CM and their understanding of evidence was 
consistent with conventions. The actual behaviour in the practice described by the 
interviewees suggested that CM practitioners were commonly using the lowest levels of 
evidence such as expert opinions and case reports and series (296). Taking the unique 
characteristics of CM practice and the barriers of applying modern evidence into CM practice 
together, a lack of high-level evidence such as SRs or RCTs directed at CM practice and of a 
high methodological quality were possible explanations for why CM practitioners behaved 
inconsistently with their attitudes towards EBM. Unique characteristics of CM practice 
compared to biomedicine might be the most influential factor to evidence indirectness. The 
following diagram summarises the relationship between the themes constructed from the 
axial coding (see Figure 7.3). 
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Figure 7.2. The relationship between themes constructed from axial coding 
7.3.2.3. Methodological Triangulation and Theorisation 
To enhance the credibility of the findings from the interview, methodological triangulation 
was performed further by integrating the findings of the survey and the interview. 
As the quantitative survey (see Chapter 6) suggested, the motivation and goals for EBM (the 
specific components of attitudes), knowledge associated with EBM and capacity of EBP (the 
specific components of knowledge) mainly explained whether CM practitioners implemented 
EBP of CHM for insomnia (see Figure 7.4). 
.  
Figure 7.3. The contributing factors to EBP constructed from the survey  
Note. EBM: evidence-based medicine, EBP: evidence-based practice 
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By cross validating the findings from the interview and survey, CM practitioners’ positive 
attitudes towards EBM and the application of EBP in CM for insomnia were found to be 
generally consistent. The interview also found that positive attitudes may be attributed 
specifically to the belief about the promising consequences of EBM. Therefore, considering 
the mixed analyses of the survey and the interview, the leading components of the ‘attitude to 
EBM’ that are associated with CHM for insomnia include motivation and goals and the belief 
about the consequences of EBP. 
As the interview suggested, low-quality evidence was one of the leading barriers to EBP. 
Although the definition of quality varies, in the interview it probably refers to whether the 
study was rigorously designed, implemented, analysed and reported. This obstacle may be 
associated with the training of EBM and relevant research skills, the main contributor to the 
‘knowledge of EBM’ found by the survey. Since CM practitioners in mainland China could 
be evidence producers, the lack of training of EBM may lead to the production of low-quality 
evidence, which correlates with the diagrams constructed by the survey and interview. 
Although unique characteristics of CM practice were discussed as a factor associated with the 
survey’s findings of the lack of generalisability of the literature’s findings to individual 
patients, further investigations were not undertaken. The in-depth explanations from the 
interview found that the unique characteristic of CM referred to the principle of 
‘individualised treatment’ that was the focus of individual variations, rather than common 
characteristics of patients. Therefore, the evidence indirectness that the available evidence of 
CM was not linked with the unique characteristics of CM practice was another outstanding 
factor influencing CM practitioners’ utility of evidence. Figure 7.5 summaries the theoretical 
framework useful for EBCMP that was constructed from the survey and interview. 
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Figure 7.4. Theoretical framework useful for evidence-based Chinese medicine practice 
Note. EBM: evidence-based medicine, EBP: evidence-based practice, CM: Chinese medicine 
7.4. Discussion 
7.4.1. Explanation for the Main Findings and Implications 
The interviewees showed positive attitudes to EBM and acknowledged the benefit of EBM 
applied in the practice of CHM for insomnia. This was in line with the findings from the 
survey. 
The analysis of the interview further explained the benefits of EBM, including assisting with 
evaluating personal practice, being an efficient way to train clinical doctors and correcting 
wrong clinical practice. The interview also revealed the main justifications as to why EBM 
benefited CM, including explaining the clinical phenomenon and guiding the practice to a 
higher level, benefiting the development of the discipline of CM, improving the quality of the 
original study and CM therapeutic effectiveness. In addition, the interviews explored how 
CM practitioners perceived evidence from the perspectives of the role, basic nature and 
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hierarchy of evidence. It was the most striking finding that CM practitioners critically applied 
the experience of senior practitioners although they believed that apprenticeship benefited the 
improvement of clinical practice. The research into the clinical experience of eminent CM 
practitioners, particularly those accredited by the national or provincial administrations of 
TCM, has been conducted over decades. Currently, the majority of the studies aimed to 
preserve clinical thinking and therapeutical strategy of CM by documenting their clinical 
cases or scenarios of clinical practice (367–368). Most studies also sought to discover new 
knowledge, such as the rules of using CHM by quantitative analysis (369). Only a few studies 
evaluated their treatments by using an experimental design (370). CM practitioners’ 
behaviours found by the interview and the available relevant studies suggest that future 
studies are needed to critically evaluate the clinical experience of eminent CM practitioners 
to support their inheritance. 
The interview also explored the barriers to applying contemporary evidence in CM practice 
from the perspectives of the directness, quality and production of evidence. Moreover, 
investigation of the unique characteristics of CM practice from the aspects of the overall 
therapeutic model, roles of experience, patients and traditional knowledge revealed that the 
principle ‘individualised treatment’ was essential to CM practice. This feature influenced the 
decision-making and utility of CM evidence in EBP from the perspective of evidence 
directness. The finding here is significant as it reveals another essential barrier that 
supplemented the survey (see Chapter 6). To our best knowledge, the interview detailed in 
this chapter is the first to provide empirical evidence that CM practitioners acknowledge the 
superiority of RCTs and meta-analyses regarding validity and reliability. They expect the 
research community to take the unique characteristics of CM, such as the focus of individual 
variations, into consideration when designing a clinical trial or SR, rather than de-emphasise 
the value of experimental design. The CONSORT Extension for Chinese Herbal Medicine 
Formulas launched in 2017 and elaborated on the importance of considering the unique 
characteristics of CM for reporting clinical trials and acknowledged the necessity of pattern 
differentiation in participant eligibility (371). However, the discussion of evidence grading of 
CM evidence has not reached consensus. For example, an expert commentary suggested that 
the highest level of CM evidence referred to the homogeneous evidence boding, including 
two or more of the following studies: RCT, cohort study, case-control study or case series 
(126). The main argument is that the current evidence hierarchy of biomedicine de-
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emphasises individualised pattern differentiation of CM treatment and this feature may not be 
evaluated by a classical randomised, placebo-controlled clinical trial. 
Also, the interview examined CM practitioners’ behaviours in the practice of CHM for 
insomnia from the perspective of the acquisition of clinical skills and therapeutic decision-
making. As the interview suggested, CM practitioners updated their knowledge of modern 
medicine by reading the latest research and clinical practice guidelines. Their understanding 
of the evidence hierarchy was consistent with universal conventions. However, they updated 
their knowledge of CM by reading historical literature and learning from experienced 
practitioners. This enabled them to improve their clinical thinking because of the similarity to 
a clinical scenario. The phenomenon of updating knowledge may explain why less than half 
of CM practitioners stated they did not implement EBP related to CHM for insomnia. 
Although it is possible that some CM practitioners were unaware of the validity of 
experimental studies compared to observational studies and personal experience, it is more 
likely that the available high-level evidence of a SR or RCT about CHM for insomnia was 
not able to resolve the clinical questions of CM. As Chapter 4 shows, the traditional use of 
CHM for insomnia is guided by pattern differentiation. That is, CM categories people with 
insomnia into subgroups by clinical manifestations and an individual CHM formula is usually 
only used for a particular phenotype of insomnia .Therefore, the clinical questions driven by 
CM practice may not be the same as those motivated by biomedicine. This difference may 
explain why CM practitioners cannot find the evidence applied to their patient although the 
methodological quality of CM studies has improved over the years. 
7.4.2. Strength and Significance 
The qualitative interview detailed in this chapter functions well as a component of a mixed-
method design. In addition to providing empirical evidence about CM practitioners’ in-depth 
understandings of evidence and explanations for the unique characteristics of CM practice, it 
validated practitioners’ attitudes towards EBM, explained their behaviour related to EBP and 
supplemented the barrier to applying contemporary evidence in CM practice. 
Also, over the past 20 years of EBM development in China, many efforts have been made in 
the evaluation and production of CM evidence. However, only very few studies evaluated 
CM practitioners’ EBP and none of the studies were designed to determine what evidence is 
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needed to solve clinical questions from the perspective of CM practitioners. The interview is 
meaningful as it fills in this gap. 
Further, the interview is significant as the theoretical framework useful for EBCMP is 
constructed by grounded theory analysis and methodological triangulation. Four factors were 
identified to improve EBCMP, comprising of motivation and goals for EBM, belief about the 
consequence of EBM, fundamental training of EBM and capacity of EBP. These enhancers 
fall within the KAP model in public health. Also, two obstacles to EBCMP were determined, 
including evidence indirectness and low-quality evidence of CM, which are both CM 
specific. This theoretical framework may inform the future development of EBCMP in 
education and research. For example, more fundamental training of EBM and capacity of 
EBP targeting CM practitioners are needed to assist their evidence-based decision-making in 
the practice of CM. Clinical trials of both high methodological quality and clinical 
significance are also needed. 
7.4.3. Limitations and Future Directions 
Many efforts for reliability and credibility have been made to ensure rigour in the qualitative 
interview, including recording the interviews and then transcribing them into original Chinese 
for analysis and member checking, constant comparisons back and forth, writing a reflective 
memo and audit trail. Triangulation analysis was further applied to ensure the trustworthiness 
(372) of the mixed-method design, including the quantitative survey and qualitative 
interview. Theorisation was also used to improve transferability and to maximise potential of 
the work for the whole population (373). However, because of the following concerns, the 
findings are to be cautiously interpreted. First, as the interviewer was the main data collector 
and interpreter, the research can never be wholly replicable. Second, the transferability of the 
qualitative research findings to other scenarios is mainly decided by the potential users who 
will have to thoughtfully compare the similarity between the study and potential settings 
(374). Third, the interview did not include any CM practitioner with a degree equivalent or 
lower than a bachelor, which differed from the survey responses. These CM practitioners 
having been missed out may have additional explanations to EBM. Further research is 
required, including crafting the theory of EBCMP into another population and validating it by 
experimental intervention studies. 
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Chapter 8. General Discussion and Conclusions 
8.1. Summary of Main Findings 
8.1.1. Evidence of Chinese Herbal Medicine for Insomnia 
Chapter 3 provided an updated SR and meta-analysis of RCTs investigating the efficacy and 
safety of CHM for insomnia. Through a thorough search of the literature databases and trial 
registries as well as eligibility evaluation, 79 RCTs (7,886 participants) were finally included 
in the review and 76 in the meta-analysis. The risk of bias assessment identified 27 trials that 
reported methods of random sequence generation, five used allocation concealment and 
blinding of participants and personnel were used in 10 studies. The main meta-analysis 
showed CHM alone was more effective than the placebo by reducing scores of PSQI (MD: –
3.06, 95% CI: –5.14 to –0.98, I2 = 97%). The effect was also observed when CHM was 
combined with BZDs compared with the placebo plus BZDs (MD: –1.88, 95% CI: –2.78 to –
0.97, I
2 
= 0%) or CBT-i (MD: –3.80, 95% CI: –4.91 to –2.68, I2 = 68%) alone. There was no 
significant difference between CHM and the placebo regarding the frequency of adverse 
events (RR: 1.65, 95% CI: 0.67 to 4.10, I
2 
= 0). This study suggests that overall oral CHM 
used as a monotherapy or an adjunct to conventional therapies appears safe and may improve 
subjective sleep quality and quantity in the people with insomnia. However, the conclusion 
cannot be made on the comparative effectiveness between CM and BZDs or psychotherapy 
due to heterogeneity and high risks of bias. 
Chapter 4 provided a systematic search and analysis of the pre-contemporary CM literature. 
The historical literature is classical documents recording the traditional knowledge of CM. 
The Encyclopaedia of Traditional Chinese Medicine 5th edition was systematically searched 
for nine CM disease nomenclatures potentially relevant to insomnia. Texts were categorised 
by applying a coding tree developed from a modern insomnia diagnostic instrument. A total 
of 729 citations portrayed the treatment of multi-herb formulae from 940 citations that 
described an insomnia diagnosis. People with insomnia were often categorised into groups in 
which the herbal formulae were different. Gender, age and concurrent conditions affected the 
formulae selection. The frequency analysis found that the most common CHM formulae and 
herbs for insomnia continue to be used today. A comparison between traditional knowledge 
and the contemporary evidence suggested that various CHM formulae might be used 
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according to distinct phenotypes, stages and severity levels of insomnia, which was 
traditionally identified as ‘Syndrome’. After taking the empirical use and contemporary 
evidence together, Suan zao ren tang and Wen dan tang were identified as the most 
promising candidates for natural product development. 
8.1.2. Evidence-Based Practice Related to CHM for Insomnia 
Chapter 6 provided a quantitative survey of CM practitioners for their attitudes, knowledge 
and skills towards EBM as well as behaviours and barriers related to EBP of CHM for 
insomnia. Eighty-two CM practitioners from GPATCM and GPAIM completed the 
questionnaire. The descriptive analysis found that most participants showed positive attitudes 
to EBM and acknowledged the necessity of applying EBM in the field of CHM for insomnia. 
However, around half of participants were unsure about the comparative superiority between 
scientific research and clinical experience with respect to CHM for insomnia. More than half 
of participants remained conservative about their overall knowledge and skills related to 
EBM. Their use of the Cochrane Library, an essential evidence database, was completely 
lacking. Less than half of participants believed they implemented EBP of CHM for insomnia 
but appeared to not be active in seeking CPG for decision-making assistance. The top barriers 
to EBP included insufficient high-quality evidence, incapacity of research skills to understand 
EBM and a lack of generalisability of the literature’s findings to individual patients. 
Association analyses by inferential statistics identified 13 potential factors related to EBP of 
CHM for insomnia, including five related to the domain of attitudes, seven related to 
knowledge and skills and one related to the barrier. The logistic regression and factor analysis 
determined the essential factors explaining the behaviours related to EBP of CHM for 
insomnia, including the motivation and goals for EBM (the specific components of attitudes) 
and the knowledge and skills associated with EBM (the specific component of knowledge). 
8.1.3. Opinions on Evidence-Based Medicine and Evidence-Based Practice of CHM for 
Insomnia 
Chapter 7 provided a qualitative interview of CM practitioners on their perspectives on EBM 
and EBP of CHM for insomnia. There were 15 CM practitioners who specialised in CHM for 
insomnia that completed the interview, including eight who participated in the survey and 
seven who were recruited by snowball sampling. All the interviewees showed positive 
attitudes to EBM and acknowledged the benefit of EBP of CHM for insomnia. 
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Additional benefits of EBM were identified, including its value in evaluating personal 
practice and its efficiency in training clinical doctors and correcting wrong clinical practice. 
Specific benefits of EBM to CM discipline were also found, including explaining the clinical 
phenomenon and guiding the practice to a higher level, benefiting the development of CM 
discipline, improving the quality of the original study and therapeutic effectiveness of CM. 
Interviews about the role, basic nature and hierarchy of evidence revealed that the 
interviewees had conventional understandings of EBM. Specific to the practice of CM, while 
the interviewees believed that apprenticeship benefited the improvement of clinical practice, 
they critically applied the experience of senior practitioners instead of fully inheriting the 
experience. 
The interview also explored the barriers to applying contemporary evidence in CM practice 
from the perspectives of the directness, quality and production of evidence. Moreover, 
investigation of the unique characteristics of CM practice revealed that the principle 
‘individualised treatment’ was essential to CM practice. This feature influenced the decision-
making and utility of CM evidence in EBP. 
The examination of behaviours related to the practice of CHM for insomnia suggested that 
the interviewees updated their knowledge of conventional medicine by reading the latest 
research and clinical practice guidelines. However, to improve clinical thinking, the 
interviewees updated CM knowledge by reading historical literature and apprenticeship 
because of their similarity to a clinical scenario. 
8.1.4. Theoretical Framework for Evidence-Based CM Practice 
A theoretical framework useful for EBCMP was constructed by mixed analyses of the 
quantitative survey and qualitative interview. Four factors were identified to improve 
EBCMP, comprising motivation and goals for EBM, belief about the consequence of EBM, 
fundamental training of EBM and capacity of EBP. Two obstacles to EBCMP were also 
determined, consisting of evidence indirectness and low-quality evidence, which were CM 
specific. 
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8.2. Overall Strength of the Study 
By investigating the typical case ‘CHM for insomnia’, this study gained an overview of the 
contemporarily clinical evidence and traditional knowledge, CM practitioners’ attitudes, 
knowledge, skills and behaviours, barriers related to EBP and their perspectives of EBM in 
the field of CM. It also constructed a theoretical framework useful for EBCMP. The study not 
only filled in the specific knowledge gaps identified by the overview of insomnia diagnosis 
and treatment (see Chapter 2) but also answered common questions in the field of CM and 
EBM.  
A mixed-method design consisting of a quantitative survey and qualitative interview was 
used to answer the research question ‘What are CM practitioners’ attitudes, understanding, 
knowledge, skills, behaviours and barriers to practise EBM?’ Compared to a traditional 
design, this study provided a thorough explanation of CM practitioners’ attitudes, knowledge 
and behaviour related to EBP of CHM for insomnia. Further, the methodological 
triangulation used for data analysis improved the creditability of the conclusion. 
8.3. Implications for CM Practice 
First, it is necessary to incorporate the best available evidence, clinicians’ expertise and 
patients’ preference into the clinical decision-making of a therapeutic plan. As Chapter 3 
showed, CHM was superior to a placebo in improving subjective sleep quality and quantity. 
However, it remained uncertain about the comparative effectiveness between CHM and 
conventional medicine due to high heterogeneity and a notable risk of bias. This means that 
in the clinical setting where pharmacotherapy, psychotherapy and CHM are all available such 
as in mainland China, it is significant to discuss with patients about their preferences. The SR 
also suggested that CHM provided additional benefits to pharmacotherapy or psychotherapy 
without additional adverse events. Therefore, if the effect of conventional medicine is not 
optimal, CHM could be added to enhance the prognosis. The subgroup analysis revealed that 
treatments of longer than four weeks and oral decoctions of CHM resulted in a better sleep 
quality, which is helpful in prescribing a better recipe for people with insomnia. Further, 
since there was no clear conclusion on any individual CHM formula or different CHM 
formula with varied effect sizes that may target different insomniac subgroups, it was 
determined that clinicians’ expertise such as skills in insomnia assessment and CHM 
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knowledge were essential to formula selection. Insomniacs who would like to try CHM are 
recommended to visit CM practitioners who received formal clinical training. 
Second, CM practitioners have to critically appraise the traditional knowledge and experience 
from apprenticeship when they apply them in their CM practice. As Chapter 4 revealed, a 
certain amount of traditional knowledge of CHM was not evaluated by an experimental 
design or explained by the modern conception of insomnia. In addition, as Chapter 7 
suggested, experience from senior CM practitioners was usually preserved by documenting 
their successful cases, rather than investigating the effectiveness and safety by clinical trials. 
Therefore, there should be cautious application of traditional knowledge and experience in 
CM practice when higher level evidence is unavailable. A reflective model of CM practice 
needs to be considered. 
8.4. Implications for CM Evidence Production 
A lack of high-quality evidence is the common issue in the field of CM (355, 356). As is 
other CAM evidence. A systematic review of CAM for insomnia suggested that many RCTs 
were without methodological rigor, and they included small sample size only (375). There are 
a number of implications for evidence production in the future. First, considerable efforts 
should be made to improve the methodological quality of the evidence, including enhancing 
the appropriate use of randomisation, blinding and outcome measurements to ensure a precise 
estimation of effect size. Second, prospective registration of clinical trials and improvement 
of reporting quality are required in the future to present full transparency for the study design, 
implementation and data analysis. 
As Chapter 7 revealed, the indirectness of the CM evidence was one of the main barriers to 
EBP of CHM for insomnia. Therefore, the available evidence is without clinical significance 
of CM and the production of evidence with clinical significance should be encouraged to 
answer the essential research questions of CM. In addition, unique characteristics of CM such 
as the principle ‘individualised treatment’ for insomnia should be taken into consideration in 
the design of clinical trials. The methodology such as N-of-1 randomised trials addressing the 
research questions focusing on individual patients could be increasing applied in clinical 
studies of CM (376).   
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Further, regarding the valuable clinical experience of senior CM doctors and the traditional 
practice of CM, a critical appraisal, particularly through evaluation by experimental design, is 
further needed to improve the reliability and validity of traditional knowledge. 
8.5. Implications for CM Education 
In mainland China, a three-year standardised residency training in a tertiary hospital was 
recently made compulsory for a fully qualified CM practitioner, in which EBM was included 
in the theoretical curriculum (377). This means that the lack of fundamental training of 
EBM—one of the barriers to EBP—may be resolved in the future. However, more 
investigation into the duration, structure and content of the EBM course is needed to train 
CM practitioners. As Chapter 7 suggested, CM practitioners continue to practice TCM even 
though they had a conventional understanding of EBM and commonly approached 
biomedicine by EBP. Therefore, EBCMP should be emphasised and the explanations of CM 
evidence should be incorporated into conventional EBM training. However, initiating basic 
EBM training for CM practitioners is urgent in CM education programs outside China, such 
as Australia (378). EBM has recently developing new methodologies and tools for designing 
studies, evaluating evidence and translating evidence into practice (379), which may resolve 
challenges in implementing EBCM such as CM focusing on individual patients. These should 
be included in EBM training for CM researchers. 
In addition to the training of CM practitioners by using a modern medical education 
approach, China continues to encourage apprenticeship (380). As outlined in Chapter 4 and 7, 
though the benefits of apprenticeship in improving clinical thinking and skills were well 
acknowledged, the majority of traditional knowledge and as well as the clinical experience of 
senior CM practitioners were not critically evaluated. Therefore, it is necessary to select 
teachers through a rigorous procedure and a reflection upon clinical experience is required for 
apprentices. 
8.6. Limitations and Future Directions 
In the SR (see Chapter 3), RCTs of various interventions were included to ensure a broad 
perspective on the evidence regarding the use of CHM for insomnia. However, the meta-
analysis found that the varied effect of CHM formulae for insomnia might lead to unresolved 
heterogeneity. In addition, the systematic analysis of the pre-contemporary CM literature (see 
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Chapter 4) suggested that a particular CHM formula targeted a subgroup of insomniacs that 
may be characterised by distinct phenotypes, stages and severity levels of insomnia. 
Therefore, the estimation of a typical effect size of CHM for insomnia should be based on a 
search and analysis of a particular CHM formula. Hence, it is necessary to identify promising 
formulae for further study. 
In the quantitative survey (see Chapter 6), nearly all participants received CM training by 
university education and practised CHM in the hospital. It is common for CM universities in 
China to deliver the fundamental knowledge of biomedicine to CM students. It is compulsory 
for CM practitioners working in Chinese hospitals to gain residency training, including 
conventional therapeutic skills of biomedicine. It is unsurprising that they are more familiar 
with EBM because EBM is introduced to biomedicine at an earlier time. However, the results 
cannot be generalised to all CM practitioners, particularly those who learn CM through non-
university training and those who practise CM in non-hospital settings. In addition, the 
typical prevalence of attitudes, knowledge, skills and behaviours among the CM practitioners 
cannot be estimated because the survey introduced non-probability sampling and the 
representative sample only came from two academic organisations in Guangdong. Further, 
though a precise estimation of prevalence rate is beyond the scope of this thesis, a large 
number of invitation email non-respondents may reveal problems. Some CM practitioners 
may be missed out because of limited access to the internet or infrequency in checking emails 
even though emails are commonly used for academic communications. Also, it is possible 
that non-responding CM practitioners to the survey were those who disagreed with EBM. 
This possibility may greatly affect the result. However, due to the anonymous nature of the 
survey, a thorough analysis of the reasons is impossible. In addition, the current findings need 
further validation by a larger sample becuause moderate-to-moderate-sample-size studies 
employing logistic regression as an analytical tool to investigate the association of exposure 
variables may overestimate the effect (381). Considering all limitations mentioned above, a 
population-based survey by randomly sampling the CM practitioners in the whole province 
could be conducted to gain a precise estimation. This approach may be valuable for 
policymaking and resource allocation related to the implementation of evidence-based CM 
education and EBCMP.  
The survey suggests that fundamental training in EBM knowledge and the capacity of EBP 
are essential factors leading to EBP. However, what specific knowledge or skills of EBM 
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should be trained and how long the training would be effective remain unsolved. Further 
investigation specific to EBM training is needed and may be helpful for developing a well-
structured course or workshop of EBCMP for CM practitioners. 
In the qualitative interview (see Chapter 7), the unique characteristic of CM ‘individualised 
treatment’ was identified as an essential factor leading to evidence indirectness by 
investigating the case ‘CHM for insomnia’. Though it is a common therapeutic principle of 
CM practice, there may be some exceptions. In addition, the transferability of qualitative 
research findings to other scenarios is mainly decided by the potential users who need to 
thoroughly compare the similarity between the study and potential settings. Other works 
should be undertaken in the future, including crafting the theory of EBCMP to other 
populations and validating it by experimental intervention studies. 
8.7. General Conclusions 
This study gained an overview of the contemporary evidence and traditional knowledge, CM 
practitioners’ attitudes, knowledge, skills, behaviours and barriers related to EBP and their 
perspectives of EBM in the field of CHM for insomnia. The key Chinese herbal formulae and 
individual herbs for insomnia have been consistently used in both ancient and contemporary 
practice. Current clinical evidence has been identified that CHM can safely improve 
subjective sleep among people with insomnia. A group of CM practitioners in Guangdong, 
China have demonstrated their positive attitudes towards EBP of CHM for insomnia.  
Capacity building on EBM and the improvement of CM evidence were considered essential 
to developing EBP of CHM for insomnia. Based on these findings, a theoretical framework 
for enhancing EBCMP has been constructed. This study not only fills the specific knowledge 
gaps related to insomnia treatments, but contributes to the global development of CM as a 
form of EBP that meets the public expectation of evidence generation, evaluation and 
translation (eGET). The valuable experience of CM heading towards being evidence-based 
could be applied in other countries or areas where traditional medicine and modern medicine 
are both included into a national health system.  
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Appendices  
Appendix 3.1 Search strategy 
Comprehensive English search strategy: 
#1:Sleep Initiation and Maintenance Disorders OR Sleep Disorders OR DIMS OR Early 
Awakening  OR Nonorganic Insomnia  OR Primary Insomnia OR Secondary Insomnia OR 
Transient Insomnia OR Rebound Insomnia OR Sleep Initiation Dysfunction OR Sleep 
Initiation Dysfunctions OR Sleeplessness OR Insomnia Disorder OR Insomnia Disorders OR 
Insomnias OR  Chronic Insomnia OR Psychophysiological Insomnia OR Dyssomnia 
#2: Traditional Chinese Medicine OR Chinese Traditional Medicine OR Chinese Herbal 
Drugs OR Chinese Drugs, Plant OR Medicine, Traditional OR Ethnopharmacology OR 
Ethnomedicine OR Ethnobotany OR Medicine, Kampo OR Kanpo OR TCM OR OR 
Medicine, Ayurvedic OR Phytotherapy OR Herbology OR Plants, Medicinal OR Plant 
Preparation OR Plant Extract OR Plants, Medicine OR Materia Medica OR Single 
Prescription OR Herbs OR Chinese Medicine Herb OR Herbal Medicine 
#3:Acupuncture OR Meridians OR Electroacupuncture OR Moxibustion OR Auriculotherapy 
OR plum blossom OR acupressure OR ear acupuncture OR ear acupressure OR acupuncture, 
ear OR acupuncture therapy OR moxa OR laser acupuncture OR seven star needle OR 
acupuncture analgesia OR acupuncture points OR electro-acupuncture OR electro 
acupuncture OR TENS OR transcutaneous nerve stimulation OR transcutaneous electric 
nerve stimulation OR transcutaneous electrical nerve stimulation OR electro-stimulation OR 
electro stimulation OR pharmacopuncture OR point injection OR catgut embedding 
#4:Tai Ji OR Tai chi OR Breathing exercises OR Qi gong OR Qigong OR Chi Kung OR 
Tuina OR anmo Tuina OR Chinese massage OR cupping OR guasha OR blood letting OR 
bloodletting OR diet therapy OR therapy, diet OR therapies, diet OR phlebotomy 
#5: #2 OR #3 OR #4 
#6: #1 AND #5 
Comprehensive Chinese search strategy: 
#1: 入睡和睡眠障碍 OR失眠 OR 睡眠 OR 不寐;  
#2: 中医 OR 中西医 OR 中医疗法 OR 辨病论治 OR 辨证 OR 辨证论治 OR 辨症 OR 辩
证 OR 汉方 OR 祖国医学 OR 传统医学 OR 传统治疗 OR 传统疗法 OR 替代医学 OR 替
代治疗 OR 中国传统医学 OR 民族医药 OR 民族医学 OR 草药 OR 中草药 OR 中药 OR 
中药疗法 OR 中西药 OR 传统医药 OR 中成药 OR 植物药 OR 中医治法 OR 治则 OR 中
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医疗法 OR 熏洗 OR 薰洗 OR 药浴 OR 外洗 OR 沐足 OR 足浴 OR 浴足 OR 灌肠 OR 药
熨 OR热熨 OR热敷 OR 敷脐 OR 药枕 OR 足疗 OR外敷 
#3: 针刺 OR 针灸 OR 针灸疗法 OR 针灸治疗 OR 灸 OR 针法 OR 刺法 OR 体针 OR 腹
针 OR 温针 OR 火针 OR 电针 OR 梅花针 OR 水针 OR 穴位注射 OR 经络注射 OR 穴位
按压 OR 穴位按摩 OR 穴位疗法 OR 指压 OR 耳压 OR 耳针 OR 耳穴 OR 耳豆 OR 压豆 
OR 点穴 OR 埋线 OR 埋针 OR 头针 OR 眼针 OR 蜂针 OR穴位贴敷 OR 小针刀 OR 皮
肤针 
#4: 外治 OR 外治法 OR 推拿 OR 按摩 OR 拔罐 OR 药罐 OR 推罐 OR 闪罐 OR 火罐 OR 
针罐 OR 砭石 OR 刮痧 OR 挑治 OR 发泡 OR 导引 OR 吐纳 OR 气功 OR 太极 OR 八段
锦 OR 刺络 OR 刺血 OR 刺血疗法 OR 放血 OR 三棱针 OR 离子导入 OR 理疗 OR 情志
疗法 OR 中医音乐 OR 五行音乐 
#5: #2 OR #3 OR #4 
#6: #1 AND #5  
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Appendix 3.2 Meta-analysis:PSQI of CHM versus conventional medicine in follow-up. 
 
PSQI: Pittsburgh Sleep Quality Index; CHM: Chinese herbal medicine; BZDs: 
benzodiazepine drugs; Non-BZDs: non-benzodiazepine drugs. 
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Appendix 3.3 Meta-analysis: PSQI of CHM plus conventional medicine versus 
conventional medicine in follow-up. 
 
PSQI: Pittsburgh Sleep Quality Index; CHM: Chinese herbal medicine; BZDs: 
benzodiazepine drugs. 
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Appendix 3.4 Meta-analysis: AIS of CHM versus conventional medicine. 
 
AIS: Athens Insomnia Scale; CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs; 
Non-BZDs: non-benzodiazepine drugs. 
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Appendix 3.5 Meta-analysis: AIS of CHM plus conventional medicine versus 
conventional medicine. 
 
AIS: Athens Insomnia Scale; CHM: Chinese herbal medicine; Non-BZDs: non-
benzodiazepine drugs. 
 232 
 
Appendix 3.6 Meta-analysis: Sleep onset latency (minutes) of CHM versus conventional 
medicine. 
 
CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs. 
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Appendix 3.7 Meta-analysis: Sleep onset latency (minutes) of CHM plus conventional 
medicine versus conventional medicine. 
 
CHM: Chinese herbal medicine; Non-BZDs: non-benzodiazepine drugs. 
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Appendix 3.8 Meta-analysis: Total sleep duration (hours) of CHM versus conventional 
medicine. 
 
CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs.  
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Appendix 3.9 Meta-analysi: Sleep efficiency (%) of CHM versus conventional medicine. 
 
CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs. 
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Appendix 3.10 Meta-analysi: CGI-S of CHM versus conventional medicine. 
 
CGI-S: Clinician Global Impression-Severity; CHM: Chinese herbal medicine; BZDs: 
benzodiazepine drugs
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Appendix 3.11 Funnel plot of PSQI scores in the comparison between CHM and BZDs. 
 
PSQI: Pittsburgh Sleep Quality Index; CHM: Chinese herbal medicine; BZDs: 
benzodiazepine drugs. 
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Appendix 4.1 Chinese characters for quotations in text 
English translation Original Chinese  
Being physically and mentally tired, the complaint of 
difficulty initiating sleep continues for ten days. 
形神俱劳，十昼夜目不得
瞑。 
Overthinking induced insomnia lasts for two year.  思虑过甚，二年不得寐。 
Inability to fall into sleep at all night which leads to fatigue 
and being emaciated. 
通宵不寐，精神渐疲，形容
枯槁。 
Eye conditions with painful and swelling eyes and blurred 
vision may cause inability to fall asleep day and night. 
目疾肿痛赤瘴，昼夜不寐。 
Insomnia accompanied by palpitation is due to the 
disorders of heart meridians. 
心经之病，怔忡不寐。 
Adverse rising of stomach qi resulting in disturbance of 
Qi-Blood and dysfunctions of viscera, and consequent 
insomnia. 
若胃气一逆，则气血不得其
宜，脏腑不得其所，不寐之
症，由此生焉。 
The syndrome of postpartum insomnia referring to 
sleeplessness the whole night initially, followed by being 
irritable, sweating, thirsty and red face. 
产后不寐一证，达旦不寐，
烦躁出汗，面赤口渴等证叠
见。 
Poor appetite and insomnia due to diarrhoea or insomnia 
caused by itchiness after chicken pox. 
一小儿痢后，不食少寐; 一小
儿痘后作痒，夜甚不寐。 
The elderly people being susceptible to insomnia. 年高之人多不寐。 
Generally, there were two causes of insomnia. One was 
weakness right after recovering from an illness or deficient 
Blood in the elderly; the other was phlegm blocking the 
Gallbladder meridian. Liu Jun Zi plus zaoren was 
commonly used for the deficient scenario while Ban Xia 
Tang originated from Ling Shu for those identified as 
phlegm pattern. 
不寐有二。有病后虚弱。有
年高人血衰不寐。有痰在胆
经。神不归舍。亦令人不
寐。虚者。六君子加枣仁。
痰者。灵枢半夏汤。 
Insomnia commonly caused by overthinking affecting 
mind, being frightened, annoyed and angry, depressed Qi 
producing phlegm, where Ban Xia Tang should be used. 
盖不寐多由思虑劳神，惊忧
怒火，气郁生涎，用半夏
汤。 
Stomach disharmony causes insomnia and restlessness. 
Because phlegm-fire blocks the downwards of stomach Qi, 
which results in irritability and then insomnia. Juhong, 
fuling, shihu, banxia, zhicao, zhishi, zharou and shenqu 
can be used for this condition. 
胃不和则卧不安，盖胃气主
降，若痰火阻痹，则烦扰不
寐也。宜橘红、茯苓、石
斛、半夏、炙草、枳实、楂
肉、神曲之属。 
When insomnia is induced by inexplicable anxiety right 
after recovering from a disease, Zhu ye shi gao tang or Fu 
ling bu xin tang can be applied. 
由病后虚烦不眠，竹叶石膏
汤，茯苓补心汤。 
For frequently wakening up after sleep, Bie jia qiang huo 
wan can be used and for no sleep for the whole night, An 
wo ru shen tang. 
有卧易惊醒者，鳖甲羌活
丸。有通宵不寐者，安卧如
神汤。 
The elderly with insomnia is caused by deficient blood 
when Sheng yu tang could be used. Obese women 
commonly suffer from depression when emetic therapy 
由高年血衰不寐，圣愈汤。
凡妇人肥盛，多郁，不得眠
者吐之，从郁结痰火治。 
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could be used for insomnia by removing the phlegm-fire. 
Menopausal insomnia with deficiency of spleen-blood, was 
caused by overthinking and worry which can be relieved 
by Gui shao liu jun zi tang or Yi qi an shen tang. 
由思虑伤脾，脾血亏损，经
年不寐，归芍六君子汤，或
益气安神汤。 
Insomnia referred to a restless sleep. When it is caused by 
phlegm blocking Heart meridian and the deficiency of 
gallbladder Qi, Wen dan tang should be used to generate 
the Heart blood and then to regain a sound sleep. 
不寐, 原来睡不宁，胆虚痰气
沃心经，治当温胆生心血，
一枕黄粱梦不惊。 
For those being difficult in falling asleep induced by 
unexplained irritability, Suan zao ren tang can be utilised. 
虚烦不得眠, 酸枣仁汤主之。 
Gui pi tang is for those who cannot return to sleep after 
wakening up, which is caused by overthinking induced 
Spleen impairment. 
归脾汤治思虑伤脾，寤而不
寐。 
A 14-year-old boy, studying extremely hard, could not fall 
asleep at all at night, and then had poor appetite. He took 
Bu zhong qi yi tang in the morning and Yi gong san in the 
afternoon, which improved his appetite and sleep 
gradually. After continuing using this therapy, all 
symptoms completely disappeared. 
一小儿十四岁，勤于功课，
彻夜不寐，饮食无味，早间
用补中益气汤，午后用异功
散，饮食渐有味，夜稍得
寐，仍用补中益气汤、八味
汤而愈。 
There are always predisposing factors to insomnia. Liu wei 
wan is indicated for the deficiency of kidney meridian with 
heat, Zhen zhu mu wan for deficiency of heart blood and 
Yang rong tang for lack of Qi or Spirit. Suan zao ren tang 
issued for insomnia after recovering from a disease, Ren 
shen zhu ye tang for insomnia due to deficient gallbladder 
with bitter mouth, modified Xiao chai hu tang for liver-fire 
induced insomnia followed by anxiousness, and Si jun zi 
tang adding sheng jiang and zao ren for palpitation induced 
insomnia. 
然其不寐，岂尽无故而然？
有因肾经虚热者，宜六味
丸。有心血不足者，宜珍珠
母丸。或精神短少，宜养荣
汤。若因病后不寐，宜酸枣
仁汤。而有胆虚不寐者，其
口必苦，宜人参竹叶汤。有
肝火不宁不寐者，其心必
烦，宜加味小柴胡汤。有振
悸不寐者，其心必怔，宜四
君子汤，但宜加生姜、枣
仁。 
Note. The quotations are listed following the sequence of their appearance in the main texts.
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Appendix 5.1 Questionnaire used in the pilot study (original Chinese version) 
中医师应用中药治疗失眠的循证医学调查 
 
请您先在以下方框内打勾： 
 我已经阅读与理解有关本调查的介绍。是 不是 
 我已经充分理解本调查可能产生的风险与受益。是 不是 
 我知晓参加调查是自愿的。是 不是 
 我同意参加本调查。是 不是 
 我持有中医或中西医结合医师执照。是 不是 
 我经常治疗失眠的患者。是 不是 
指导语 
本调查均为单选题，请在最符合您情况的答案方框内打勾。如果选择“其他”，请在横线上填
写具体内容。 
第一部分：个人信息 
1. 您的年龄范围是： 
20-29 岁30-39 岁40-49 岁50-59 岁60 岁以上 
2. 您的性别是： 
男 女 
3. 您接受中医教育的主要途径是： 
大学教育 短期培训 师承 其他_________________ 
4. 您的最高学历是： 
专科 本科 硕士 博士 其他_________________ 
5.您的执业范围是： 
中医 中西医结合 其他_________________ 
6. 您执业的时间是： 
≤3 年 4-6 年 7-10 年 11-24 年 ≥25 年 
7. 您的职称是： 
实习生 住院医师 主治医师 副主任医师 主任医师  
8.您的执业地点是： 
医院 社区 私人诊所 其他_________________ 
9.您工作的主要城市是： 
_________________ 
10.您的临床专科方向是： 
心理科 精神科 神经科 全科 针灸推拿 其他_________________ 
11.您的主要工作内容是： 
临床 科研 教学 行政 其他_________________ 
12.您出诊当天的平均门诊量是： 
0-20 人 21-30 人 31-40 人 41-50 人 ≥51 人 
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第二部分：对循证医学的态度与获益 
13. 您接收最新的中药治疗失眠的知识主要是通过： 
途径 是 不是 
1) 跟随高年资医师学习。   
2) 阅读最新研究进展的文献。   
3) 学习古籍。   
4) 参加会议或培训课程。   
5) 其他___________________________   
 
问题 
1 2 3 4 5 
完全同意 同意 中立 不同意 完全不同意 
14.您理解什么是循证医
学。 
     
15.在中药治疗失眠的过程
中应用循证医学有必要。 
     
16.在用西医治疗失眠的过
程中应用循证医学有必
要。 
     
17.最新的研究进展对您的
临床工作有帮助。 
     
18.您觉得自己绝大部分的
临床工作都是以按循证的
方法进行实践的。 
     
19.做医疗决策时，您重视
临床经验多于医学研究。 
     
20.您需要增加循证医学在
临床中的应用。 
     
21.您有兴趣学习将循证医
学与临床实践结合的技
术。 
     
22.循证医学对您管理病人
有用。 
     
23.在您的执业环境中难以
应用循证医学。 
     
24.目前中药治疗失眠的证
据匮乏。 
     
25.目前的临床研究证据和      
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您常用的治疗方法不一
致。 
26.循证医学对您制定医疗
决策有帮助。 
     
27.循证医学会考虑病人的
需求。 
     
 
28.您对循证医学的总体态度是： 
支持 反对 观望 
第三部分：对循证医学的理解与应用 
29. 您在临床中应用循证医学的理念。 
是 不是 
如果您回答“是”，请继续选择您使用的循证医学资源。 
如果您回答“不是”，则请跳至 30 题。 
循证医学相关资源 是 不是 
1) 中国成人失眠诊断与治疗指南（中华神经科杂志）   
2) 中医循证临床实践指南-失眠症（中国中医药出版社）   
3) 中国失眠防治指南（人民卫生出版社）   
4) 失眠定义、诊断及药物治疗专家共识草案（中华神经科
杂志） 
  
5) 期刊论文   
6) 循证实践数据库，例如 Up-to-date，Best Practice   
7) 其他_____________________________________   
 
问题 
1 2 3 4 5 
完全同意 同意 中立 不同意 完全不同意 
30.您了解中药治疗失眠的
最新研究进展。 
     
31.您对循证医学的理解充
分。 
     
32.您主动应用中医药治疗
失眠的指南。 
     
33.您能够在应用指南时考
虑病人的意愿。 
     
 
34.阻碍您应用循证医学的
问题是： 
1 2 3 4 5 
完全同意 同意 中立 不同意 完全不同意 
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1) 没有时间。      
2) 没有足够的资源。      
3) 欠缺科研技能去理解。      
4) 评价研究文献的能力不
足。 
     
5) 研究结果的推论归纳性
不够。 
     
6) 缺乏将研究结果应用到
具体病人的能力。 
     
7) 欠缺统计知识。      
8) 欠缺单位集体的支持。      
9) 对循证医学没有兴趣。      
10) 工作太忙以致没有时间
更新证据。 
     
11) 无法接触到足够的资源
去使用循证医学。 
     
 
35.您认为阻碍循证医学在临床中应用的最主要问题是： 
 
 
 
第四部分：循证医学的知识 
问题 是 不是 
36.您接受过关于评价研究结果，证据评价或文献评价等的正式培训
吗？ 
  
37.在您的执业地点能查阅最新的科研进展吗？   
38.在非工作地点您能查阅到最新的科研进展吗？   
39.您的工作单位支持在临床中应用循证医学吗？   
40.您接受过循证医学的基本培训吗？   
 
41. 您对以下文献库的了解程度是： 不知道 知道但没用过 知道并使用 
1) Cochrane library    
2) PubMed    
3) 中国知网（CNKI）    
4) 中 国 生 物 医 学 文 献 数 据 库
（CBM） 
   
 
42.您对自己找到相关研究结果回答临床问题的能力很自信。 
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完全同意 同意 中立不同意 完全不同意 
43. 最近一月，您进行以下活动的次数是： 
1 2 3 4 5 
≤1 2-5 6-10 11-15 ≥16 
1) 提出一个清晰具体的临床问题。      
2) 检索电子文献数据库。      
3) 阅读已发表的研究报告。      
4) 应用研究结果进行临床决策。      
 
44.您对以下概念的理解是： 
1 2 3 4 
从未听过 听过但不理解 有点理解 充分理解 
1) 随机对照试验（RCT）     
2) 系统评价（SR）     
3) 荟萃分析（meta 分析）     
4) 相对风险度（RR）     
5) 绝对风险度（AR）     
6) 比值比（OR）     
7) 均数差（MD）     
8) 可信区间（CI）     
9) 异质性     
10) 发表偏倚     
 
45.您认为在中药治疗失眠的证据中，哪一类是最高级别的证据： 
病案报道 古籍 随机对照试验 低异质性的荟萃分析 名医经验  
46.您认为自己在循证医学方面的知识掌握程度是： 
好 一般 欠缺 
 
如果您对我们的调查有任何意见或建议，请您不吝笔墨地写下： 
 
 
您有兴趣参加一项约半小时的面对面访谈吗？ 
有 无 
 
感兴趣的医师请留下您的联系方式，我们将在调查结束后联系您。 
姓名  
单位  
科室  
电子邮箱  
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联系电话  
感谢您的配合与支持！ 
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Appendix 5.2 Questionnaire use in the pilot survey (English translation version) 
 
Chinese Herbal Medicine for Insomnia:  
An Evidence-Based Medicine Survey of Chinese Medicine Practitioners 
 
Please tick the boxes indicating your response: 
 I have read and understood the participant information statement. □ Yes □ No 
 I have understood the risk and benefit brought by the survey. □ Yes □ No 
 I understand being in this study is completely voluntary. □ Yes □ No 
 I agree to participate in the survey. □ Yes □ No 
 I am a licensed Chinese medicine or Integrative medicine practitioner. □ Yes □ No 
 I often treat people with insomnia in my clinical practice. □ Yes □ No 
 
Part 1: The following section inquires about personal demographics.  
For the following items, tick the appropriate box indicating your response. 
1. What is your age? 
20-29 years  30-39 years  40-49 years  50-59 years  60 + years  
2. What is your gender? 
Male  Female     
3. Where did you receive your education/ training in Chinese medicine? 
University  Short-term course  Apprentice  Other  
Specify:_________________ 
4. What is your highest level of education? 
Diploma  Bachelor  Master  Doctorate  Other  
Specify:_________________ 
5. What division of Chinese medicine are you licensed? 
Traditional Chinese medicine  Integrative medicine  
6. How many years have you been a licenced Chinese medicine practitioner? 
≤ 3 years  4-6 years  7-10 years  11-24years  ≥25years  
7. What is your professional title? 
Intern  Resident  Attending  Vice-chief  Chief  
8. Where do you practice Chinese medicine? 
Hospital  Community  Private clinic  Other , Specify:________________ 
9. In which city do you practice Chinese medicine? 
_____________________City  
10. What is your clinical speciality? 
Psychology Psychiatry
 
Neurology General 
physician 
Acupuncture or 
massage 
Others, Specify: 
___________ 
11. In what area is the majority of your work undertaken? 
Clinical  Research  Teaching  Administration  Other  
Specify:_______________ 
12. On a typical day, how many patients do you see in clinic? 
0-20  21-30  31-40  41-50  ≥51  
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Part 2: The following section inquires about your personal attitudes and perceived benefits 
of evidence-based medicine (EBM).  
For the following items, tick the appropriate box indicating your response. 
 
13. I update my knowledge on CHM for insomnia by: Yes No 
a) Learning from senior physicians   
b) Reading new research    
c) Reading classical literature   
d) Attending conferences or training courses   
e) Other, Specify ___________________________   
 
 1 2 3 4 5 
Strongly 
disagree 
Disagree Neutral Agree Strongly 
agree 
14. I understand what is meant by EBM      
15. Application of EBM is necessary in 
the treatment of insomnia with Chinese 
herbal medicine 
     
16. Application of EBM is necessary in 
the treatment of insomnia with Western 
medicine 
     
17. New research findings are useful in 
my day-to-day practice 
     
18. I feel the majority of my clinical 
practice is evidence-based 
     
19. In making decisions, I value clinical 
experience more than scientific studies. 
     
20. I need to increase the use of 
evidence in my daily practice. 
     
21. I am interested in learning or 
improving the skills necessary to 
incorporate EBM into my practice 
     
22. EBM is useful in the management 
of patients 
     
23. EBM is difficult to incorporate in 
my practice setting 
     
24. Current evidence on CHM for 
insomnia is lacking. 
     
25. The clinical evidence does not 
support most of the interventions I use 
for my patients. 
     
26. EBM helps me make decisions 
about patient care. 
     
27. EBM takes into consideration 
patient preferences. 
     
28. Please rate your overall attitude towards EBM.      For   Against   Neutral 
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Part 3: The following section inquires about your personal use, understanding and 
limitations of evidence-based medicine. 
For the following items, tick the appropriate box indicating your response. 
 
29. I use EBM to guide my practice.  Yes  No 
If yes, what resources have you used? Yes No 
a) Guideline for adult insomnia management   
b) Evidence-based guidelines on CHM for insomnia   
c) Guideline for insomnia treatment and prevention   
d) Expert consensus guideline   
e) Journal articles of new research findings   
f) Evidence based database, such as, UpToDate, and Best Practice   
g) Other, specify _____________________________________   
 
 1 2 3 4 5 
Strongly 
disagree 
Disagree Neutral Agree Strongly 
agree 
30. I am aware of the latest research in 
CHM for insomnia. 
     
31. I am confident in my understanding 
of EBM 
     
32. I actively seek practice guidelines 
pertaining to CHM for insomnia.   
     
33. I am able to incorporate patient 
preferences with practice guidelines. 
     
 
34. Please rate your barriers to EBM in 
the following statements. 
1 2 3 4 5 
Strongly 
disagree 
Disagree Neutral Agree Strongly 
agree 
a) I have insufficient time to practice 
EBM 
     
b) I have a lack of information 
resources to find EBM 
     
c) I have a lack of research skills to 
understand EBM 
     
d) I have a poor ability to critically 
appraise the literature 
     
e) There is a lack of generalizability of 
the literature findings to my patient 
population 
     
f) I am unable to apply research 
findings to individual patients with 
unique characteristics 
     
g) I lack understanding of statistical 
analysis 
     
h) I lack collective support among my 
colleagues in my facility 
     
i) I lack interest in EBM      
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j) My workload is too great for me to 
keep up to date with the new evidence. 
     
k) Access to resources to me is 
inadequate to undertake EBM 
     
35. What do you think are the major barriers to practicing EBM?  
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Part 4: The following section inquires about your knowledge of evidence-based medicine (EBM). 
For the following items, tick the appropriate box indicating your response. 
 
 Yes No 
36. Have you received formal training in critical research appraisal?   
37. Do you have access to current research at your place of work?   
38. Can you access current research at home or locations other than your place of 
work? 
  
39. Does your work place support the use of EBM in practice?   
40. Have you been trained in the foundations of EBM?   
 
41. Are you aware of the 
following databases? 
Unaware Aware but not use Aware and use 
a) Cochrane    
b) PubMed    
c) CNKI    
d) CBM    
 
42. I am confident in my ability to find relevant research to answer your clinical questions? 
Strongly disagree  Disagree  Neutral  Agree   Strongly agree  
 
43. In the last month how many 
times have you… 
1 2 3 4 5 
≤1times 2-5 times 6-10 times 11-15 times ≥16times 
a) Formulated a clearly 
answerable question that defines 
the client or problem, the 
intervention and outcomes of 
interest? 
     
b) Searched an electronic 
database? 
     
c) Read a published research 
report? 
     
d) Used research findings to 
make a clinical decision? 
     
 
44. What is your understanding of 
the following terms: 
1 2 3 4 
Never heard Heard but do not 
understand 
Somewhat 
understand 
Understand 
well 
a) Randomised controlled trial     
b) Systematic review     
c) Meta-analysis     
d) Relative risk     
e) Absolute risk     
f) Odds ratio     
g) Mean difference     
h) Confidence interval     
i) Heterogeneity     
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j) Publication bias     
 
45. From the examples below, what do you think is the highest level of evidence? 
a) Case study   
b) Classical literature   
c) Randomised controlled trial   
d) Meta-analysis with homogeneity  
e) Experience from famous physician or teacher  
46. Please rate your overall knowledge of EBM. good  moderate  poor  
 
Feel free to make any comments about the survey below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Would you be interested to participate in a follow up face-to-face interview?  Yes  No 
If yes, please write down your contact information: 
Name: __________________________________________________________________ 
Affiliation: _______________________________________________________________ 
Department：_______________________________________________________________ 
Email: ___________________________________________________________________ 
Telephone: _____________________________________________________________ 
 
Thank you for your time in completing this questionnaire.
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Appendix 5.3 Approval letter issued by the Institutional Ethics Committee of Guangdong 
Provincial Hospital of Traditional Chinese Medicine, China 
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Appendix 5.4 Registration letter of external approval in RMIT 
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Appendix 5.5 The decision log of questionnaire revision 
Number Original item Revised item  Justification 
Q12 
CN:您出诊当天的平均门诊量是: 
Translation: On a typical day, how many patients do you 
see in clinic? 
CN:您平均每天接诊的病人是： 
Translation: How many patients do you see 
on average per day? 
Some practitioners only work in the 
inpatient department according to the pilot 
survey results. 
Q13 
CN:您接收最新的中药治疗失眠的知识主要是通过： 
Translation: I update my knowledge on CHM for 
insomnia by: …. 
CN:您最经常通过以下哪个途径更新您用
中药治疗失眠的知识： 
Translation: Which is the most common 
way to update your knowledge of CHM for 
insomnia? 
Some practitioners use multi-sources to 
update their knowledge of CHM for 
insomnia according to pilot survey results. 
The original question cannot measure the 
priority source of updating knowledge. So 
we change another way to ask the question. 
Q17 
CN: 最新的研究进展对您的临床工作有帮助。 
Translation: New research findings are useful in my day-
to-day practice 
CN: 最新的研究进展对您用中药治疗失
眠的临床工作有帮助。 
Translation: New research findings of CHM 
for insomnia are useful in my day-to-day 
practice. 
The pilot survey find the overall attitude to 
EBM is not completely consistent with 
specific attitude to CHM. We assume that 
practitioners may agree that western 
medicine should comply with EBM, but 
CHM may not have to do so. The revision is 
to ensure the attitudes and practice of EBM 
is CHM specified. 
Q20 
CN: 您需要增加循证医学在临床中的应用。 
Translation: I need to increase the use of evidence in my 
daily practice. 
CN: 您需要增加循证医学在中药治疗失
眠临床实践中的应用。 
Translation: I am interested in learning or 
improving the skills necessary to 
incorporate EBM into my practice. 
Q26 
CN: 循证医学对您制定医疗决策有帮助。 
Translation: EBM helps me make decisions about patient 
care. 
CN: 循证医学可协助您做中药治疗失眠
的医疗决策。 
Translation: EBM helps me make decisions 
about insomnia patient care using CHM. 
Q18 
CN: 您觉得自己绝大部分的临床工作都是以按循证的
方法进行实践的。 
Translation: I feel the majority of my clinical practice is 
evidence-based. 
Being removed. 
It asks the similar question as Q29. I use 
EBM to guide my practice. Panel discussion 
decides on removing Q18. 
Q19 
CN: 做医疗决策时，您重视临床经验多于医学研究。 
Translation: In making decisions, I value clinical 
experience more than scientific studies. 
CN: 做中药治疗失眠的医疗决策时，相
对于临床经验，您更重视科研结果。 
Translation: In making decision related to 
1. Adding ‘related to CHM for insomnia’ 
makes the question specific. 
2. Data analysis will be easier if all 
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CHM for insomnia, I value scientific studies 
more than experience. 
questions are asked in the same direction. 
Q22 
CN: 循证医学对您管理病人有用。 
Translation: EBM is useful in the management of 
patients. 
Being removed. 
It asks the similar question as Q26 EBM 
helps me make decisions about patient care 
(item-item correlation Q22/Q26: 0.55).Panel 
discussion decides on removing Q22. 
Q24 
CN: 目前中药治疗失眠的证据匮乏。 
Translation: Current evidence on CHM for insomnia is 
lacking. 
Being moved into the options of barriers to 
EBM. 
1. It cannot measure the attitude towards 
EBM. 
2. Insufficient evidence of CHM may be one 
of the key barriers to Evidence-based CM 
according to the open-ended question ‘What 
do you think are the major barriers to 
practicing EBM?’ 
Q25 
CN: 目前的临床研究证据和您常用的治疗方法不一
致。 
Translation: The clinical evidence does not support most 
of the interventions I use for my patients. 
CN: 目前的中药治疗失眠的临床研究证
据不支持您常用的治疗方法。 
Translation: The clinical evidence of CHM 
for insomnia does not support most of the 
interventions I use for my patients. 
Revising the Chinese to make the question 
more relevant to attitudes towards evidence. 
Q28 
CN:您对循证医学的总体态度是： 
支持反对观望 
Translation: Please rate your overall attitude towards 
EBM. For Against Neutral 
CN:您对循证医学的总体态度是： 
支持观望反对 
Translation: Please rate your overall attitude 
towards EBM. For Neutral Against    
The order of the answer options is changed 
to ensure consistency of answer direction 
with other items. 
Q34.2/ 
Q34.11 
CN: 阻碍您应用循证医学的问题是：2) 没有足够的资
源 11）无法接触到足够的资源去使用循证医学。 
Translation: Please rate your barriers to EBM in the 
following statements. b)I have a lack of information 
resources to find EBM.k) Access to resources to me is 
inadequate to undertake EBM. 
CN: 阻碍您应用循证医学的问题是：2) 
缺乏找到证据的资源。 
Translation: Please rate your barriers to 
EBM in the following statements. b) I have 
a lack of resources to find evidence. 
Q34.2 and Q34.11 asked the similar question 
(item-item correlation Q34.2/Q34.11: 0.85). 
Panel discussion decides on removing 
Q34.11. 
Q34.3 
CN: 阻碍您应用循证医学的问题是：3) 欠缺科研技能
去理解。 
Translation: Please rate your barriers to EBM in the 
following statements. c)I have a lack of research skills to 
understand EBM. 
CN: 阻碍您应用循证医学的问题是：3)
 欠缺科研技能去理解循证医学。 
Translation: Please rate your barriers to 
EBM in the following statements. c)I have a 
lack of research skills to understand EBM. 
Revising the Chinese to make the question 
more specific for evidence-based medicine. 
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Q34.5 
CN: 阻碍您应用循证医学的问题是：5) 研究结果的推
论归纳性不够。 
Translation: Please rate your barriers to EBM in the 
following statements. e) There is a lack of 
generalizability of the literature findings to my patient 
population. 
CN: 阻碍您应用循证医学的问题是：5)研
究结果难以推广到您的病人。 
Translation: Please rate your barriers to 
EBM in the following statements. e) There 
is a lack of generalisability of the literature 
findings to my patient population. 
Revising the Chinese to make the question 
easier to be understood. 
Q34.9 
CN: 阻碍您应用循证医学的问题是：9) 对循证医学没
有兴趣。 
Translation: Please rate your barriers to EBM in the 
following statements.i) I lack interest in EBM. 
Being removed. 
Only one participant select this answer 
according to the pilot study and the result is 
not meaningful in practice. Panel discussion 
decides on removing Q34.9. 
Q35 
CN: 您认为阻碍循证医学在临床中应用的最主要问题
是? 
Translation: What do you think are the major barriers to 
practicing EBM? (open-ended question) 
Removing this question and add ‘Other, 
specify’ as one of the answer options for 
question 34. 
Two answers collected in the pilot survey 
were added to Q34, including   
“There is insufficient high quality evidence 
of CHM for insomnia”, and “Chinese 
medicine theory contradicts EBM”. 
This question aimed to collect more 
possibilities of barriers to EBM in the pilot 
survey. So additional barriers are added to 
Q34 and it is unnecessary to have this 
question alone in the main survey. 
Q37 
CN: 在您的执业地点能查阅最新的科研进展吗？ 
Translation: Do you have access to current research at 
your place of work? 
Being removed. 
These questions are more relevant to the 
barriers to EBM. And similar questions have 
been asked in that section. 
Q38 
CN: 在非工作地点您能查阅到最新的科研进展吗？ 
Translation:Can you access current research at home or 
locations other than your place of work? 
Q39 
CN: 您的工作单位支持在临床中应用循证医学吗？ 
Translation:Does your work place support the use of 
EBM in practice? 
Q43.3 
CN: 最近一月，您进行以下活动“3) 阅读已发表的研
究报告”的次数是? 
Translation: In the last month how many times have you 
c) read a published research report? 
CN: 最近一月，您进行以下活动“3) 批
判性阅读已发表的研究报告”的次数是? 
Translation: In the last month how many 
times have you c) critically read a published 
research report? 
General reading is not the process in EBM. 
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Appendix 5.6 The invitation letter and questionnaire used in the main survey (original 
Chinese version) 
 
知情告知书 
 
尊敬的中医师： 
您好！我是广东省中医院的主治医师倪小佳，也是该院与澳洲皇家墨尔本理工大学联合培
养的博士生，现特邀请您在百忙之中抽出时间参加一项中医师应用中药治疗失眠的循证医
学调查。该项目是我博士课题的一部分，由广东省中医院的李艳主任医师、郭新峰研究员
与澳洲皇家墨尔本理工大学的 Prof Charlie Xue （薛长利教授）, Dr Tony Zhang （张林博
士） 与 Dr Johannah Shergis 带领我共同进行。 
  近十几年，中医界开始关注与应用循证医学的理念。然而，循证医学在中医师应用中
药治疗失眠中的地位如何仍未有清晰的定论。本研究旨在通过一项全面的调查了解中医师
在应用中草药治疗失眠的临床实践中对循证医学的态度、理解与应用情况。您的参与将对
这一领域的发展起到重要的促进作用。 
  本调查完全是匿名的，需要您耗时 10-20分钟。是否参与本调查完全取决于您的自
愿，在调查最后您将被邀请参与一项跟本调查相关的深度访谈，如果有意向请留下您的联
系方式。这项研究获得的所有信息都是保密的，并将保留 5 年，仅用于撰写科研论文和博
士学位论文。任何跟本调查有关的公开报告不会披露您的个人身份。我们将在法律允许的
范围内，尽一切努力保护您的个人隐私。 
本调查已获得广东省中医院和澳洲皇家墨尔本理工大学的伦理委员会批准。如果您还
有任何疑问可联系：倪小佳医师（邮箱：grace1984325@126.com）或李艳医师（邮箱：
janeliyan2002@163.com）；或致电：020-81887233-35839。 
如果您有意向参与本调查，请点击此处链接进入问卷。 
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中医师应用中药治疗失眠的循证医学调查 
 
请您先在以下方框内打勾： 
 我已经阅读与理解有关本调查的介绍。是 不是 
 我已经充分理解本调查可能产生的风险与受益。是 不是 
 我知晓参加调查是自愿的。是 不是 
 我同意参加本调查。是 不是 
 我持有中医或中西医结合医师执照。是 不是 
 我经常治疗失眠的患者。是 不是 
备注：如果以上方框有任何一个选项为‘不是’，将直接跳至最后一页‘感谢您的配合与支
持！’。 
指导语 
本调查均为单选题，请在最符合您情况的答案方框内打勾。如果选择“其他”，请在横线上
填写具体内容。 
第一部分：个人信息 
1. 您的年龄范围是： 
20-29岁  30-39岁  40-49岁  50-59岁  60岁以上 
2. 您的性别是： 
男 女 
3. 您接受中医教育的主要途径是： 
大学教育 短期培训 师承 其他_________________ 
4. 您的最高学历是： 
专科 本科 硕士 博士 其他_________________ 
5.您的执业范围是： 
中医 中西医结合 其他_________________ 
6. 您执业的时间是： 
≤3年 4-6年 7-10年 11-24年 ≥25年 
7. 您的职称是： 
实习医师 住院医师 主治医师 副主任医师 主任医师  
8.您的执业地点是： 
医院 社区 私人诊所 其他_________________ 
9.您工作的主要城市是： _________________ 
10.您的临床专科方向是： 
心理科 精神科 神经科 全科 针灸推拿 其他_________________ 
11.您的主要工作内容是： 
临床 科研 教学 行政 其他_________________ 
12.您平均每天接诊的病人是： 
0-20人 21-30人 31-40人 41-50人 ≥51人 
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第二部分：对循证医学的态度与获益 
13. 您最经常通过以下哪个途径更新您用中药治疗失眠的知识： 
跟随高年资医师学习 阅读现代研究进展 阅读最新的指南 
阅读古籍 参加会议或培训课程 其他_________ 
问题 
1 2 3 4 5 
完全同意 同意 中立 不同意 完全不同意 
14.您理解什么是循证医学。      
15.在中药治疗失眠的过程中应用
循证医学有必要。 
     
16.在用西医治疗失眠的过程中应
用循证医学有必要。 
     
17.最新的研究进展对您用中药治
疗失眠的临床工作有帮助。 
     
18. 做中药治疗失眠的医疗决策
时，相对于临床经验，您更重视
科研结果。 
     
19.您需要增加循证医学在中药治
疗失眠临床实践中的应用。 
     
20.您有兴趣学习将循证医学与临
床实践结合的技术。 
     
21.在您的执业环境中难以应用循
证医学。 
     
22.目前的中药治疗失眠的临床研
究证据不支持您常用的治疗方
法。 
     
23. 循证医学可协助您做中药治
疗失眠的医疗决策。 
     
24.循证医学会考虑病人的需求。      
25.您对循证医学的总体态度是： 
 支持  观望  反对 
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第三部分：对循证医学的理解与应用 
26. 您在中药治疗失眠的临床实践中应用循证医学。 
是    不是 
如果您回答“是”，请继续选择您使用的循证医学资源。 
如果您回答“不是”，则请跳至 27题。 
循证医学相关资源 是 不是 
中国成人失眠诊断与治疗指南（中华神经科杂志）   
中医循证临床实践指南-失眠症（中国中医药出版社）   
中国失眠防治指南（人民卫生出版社）   
失眠定义、诊断及药物治疗专家共识草案（中华神经科杂志）   
期刊论文   
循证实践数据库，例如 Up-to-date，Best Practice   
其他_____________________________________   
 
问题 
1 2 3 4 5 
完全同意 同意 中立 不同意 完全不同意 
27.您了解中药治疗失眠的最新研究
进展。 
     
28.您对循证医学的理解充分。      
29. 您主动应用中医药治疗失眠的指
南。 
     
30.您能够在应用指南时考虑病人的
意愿。 
     
 
31.阻碍您在中药治疗失眠中应用循
证医学的问题是： 
1 2 3 4 5 
完全同意 同意 中立 不同意 完全不同意 
1) 没有时间。      
2) 缺乏找到证据的资源。      
3) 欠缺科研技能去理解循证医学。      
4) 评判文献的能力不足。      
5) 研究结果难以推广到您的病人。      
6) 缺乏将研究结果应用到具体病人
的能力。 
     
7) 欠缺统计知识。      
8) 欠缺单位集体的支持。      
9) 工作太忙以致没有时间更新证
据。 
     
10) 中药治疗失眠缺乏高质量的证      
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据。 
11) 中医理论不认同循证医学。      
12) 其他_____________________________________ 
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第四部分：循证医学的知识 
问题 是 不是 
32. 您接受过关于评价研究结果，证据评价或文献评价的正式培训
吗？ 
  
33.您接受过循证医学的基本培训吗？   
 
34. 您对以下文献库的了解程度是： 不知道 知道但没用过 知道并使用 
1) Cochrane 图书馆 
   
2) PubMed    
3) 中国知网 （CNKI） 
   
4) 中国生物医学文献数据库（CBM） 
   
 
35.您对自己找到相关研究结果回答临床问题的能力很自信。 
完全同意 同意 中立 不同意 完全不同意 
 
36. 最近一月，您进行以下活动的次数是： 
1 2 3 4 5 
≤1 2-5 6-10 11-15 ≥16 
1) 提出一个清晰具体的临床问题。      
2) 检索电子文献数据库。      
3) 批判性阅读已发表的研究报告。      
4) 应用研究结果进行临床决策。      
  
37.您对以下概念的理解是： 
1 2 3 4 5 
从未
听过 
听过但
不理解 
有点理
解 
充分
理解 
充分理解
并能应用 
1) 随机对照试验（RCT）      
2) 系统评价（SR）      
3) 荟萃分析（meta 分析）      
4) 相对风险度（RR）      
5) 绝对风险度（AR）      
6) 比值比（OR）      
7) 均数差（MD）      
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8) 可信区间（CI）      
9) 异质性（Heterogeneity）      
10) 发表偏倚 （publication bias）      
 
38.您认为在中药治疗失眠的证据中，哪一类是最高级别的证据： 
病案报道 古籍 随机对照试验 低异质性的荟萃分析 名医经验  
39.您认为自己在循证医学方面的知识掌握程度是： 
好 一般 欠缺 
 
 
40.如果您对我们的调查有任何意见或建议，请您不吝笔墨地写下： 
 
 
 
41.您有兴趣参加一项约半小时的面对面访谈吗？ 
 有   无 
感兴趣的医师请留下您的联系方式，我们将在调查结束后联系您。 
姓名  
单位  
科室  
电子邮箱  
联系电话  
 
感谢您的配合与支持！
Chinese Herbal Medicine for Insomnia: An Evidence-Based Medicine Survey of Chinese Medicine Practitioners  
Edition No. 002/20150731                                                                                         
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Appendix 5.7 The invitation letter and questionnaire use in the main survey (English translation) 
 
Invitation letter 
 
Dear Chinese medicine practitioner, 
I am Xiaojia Ni, the attending physician in Guangdong Provincial Hospital of (Traditional) Chinese 
Medicine as well as the PhD candidate co-supervised by RMIT University, Australia and the hospital. You 
are invited to participate in a survey entitled “Chinese Herbal Medicine for Insomnia: An Evidence-Based 
Medicine Survey of Chinese Medicine Practitioners”, which is part of my PhD research. Dr Yan Li and Dr 
XinfengGuo from Guangdong Provincial Hospital of (Traditional) Chinese Medicine and Professor Charlie 
Xue (Chinese name: ChangliXue), Dr Tony Zhang (Chinese name: Lin Zhang) and Dr JohannahShergis 
will oversee and contribute to the conduct of the survey.  
Over the last decades, Evidence-based medicine has been noticed and introduced into Chinese medicine. 
However, its role remains unclear when Chinese medicine practitioners treat insomnia by Chinese herbal 
medicine. This research aims to survey the Chinese medicine practitioners who specialize in Chinese 
herbal medicine for insomnia, for their attitude, understanding and practice of Evidence-based medicine. 
Your answers will contribute to the improvement of clinical practice of CHM for insomnia. We would 
appreciate your time in completing this questionnaire. 
This is an anonymous survey, which will take you approximately 10 to 20 minutes to complete. Being in 
this study is completely voluntary. You will be asked whether to participate in a relevant in-depth interview 
at the end of the survey. If you are interested in the interview, you could write down the correspondence. 
All the information related to the survey will be kept confidential and saved for five years. The results of 
the survey will be used only for research articles and PhD thesis. Your answer will not be individually 
identified by any publication. We will try our best to protect your personal privacy.  
This survey has been approved by the Institutional Ethics Committee of Guangdong Provincial Hospital of 
Traditional Chinese Medicine and registered in RMIT Ethics Committee, Australia. If you have any 
question or concerns, please feel free to contact Dr.Xiaojia Ni by email: grace1984325@126.com and Dr. 
Yan Li by email: janeliyan2002@163.com; or phone: 020-81887233-35839. 
If you would like to participate online, please click here to enter the survey. 
 
Please tick the boxes indicating your response： 
 I have read and understood the participant information statement. □ Yes □ No 
 I have understood the risk and benefit brought by the survey. □ Yes □ No 
 I understand being in this study is completely voluntary. □ Yes □ No 
 I agree to participate in the survey. □ Yes □ No 
 I am a licensed Chinese medicine or Integrative medicine practitioner. □ Yes □ No 
 I often treat people with insomnia in my clinical practice. □ Yes □ No 
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Part 1: The following section inquiries about personal demographics.  
For the following items, tick the appropriate box indicating your response. 
 
1. What is your age? 
20-29 years  30-39 years  40-49 years  50-59 years  ≥60 years  
2. What is your gender? 
Male  Female     
3. Where did you receive your education/ training in Chinese medicine? 
University  Short-term course  Apprentice  Other  
Specify:_________________ 
4. What is your highest level of education? 
Diploma  Bachelor  Master  Doctorate  Other  
Specify:_________________ 
5. What division of Chinese medicine are you licensed? 
Traditional Chinese medicine  Integrative medicine  Other  
Specify:_________________ 
6. How many years have you been a licenced Chinese medicine practitioner? 
≤ 3 years  4-6 years  7-10 years  11-24years  ≥25years  
7. What is your professional title? 
Intern  Resident  Attending  Vice-chief  Chief  
8. Where do you practice Chinese medicine? 
Hospital  Community  Private clinic  Other  
Specify:________________ 
9. In which city do you practice Chinese medicine? 
_____________________City  
10. What is your clinical speciality? 
Psychology Psychiatry Neurology General 
physician 
Acupuncture or massage 
 
Others  Specify: ___________ 
11. In what area is the majority of your work undertaken? 
Clinical  Research  Teaching  Administration  Other  
Specify:_______________ 
12. How many patients do you see on average per day? 
0-20  21-30  31-40  41-50  ≥51  
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Part 2: The following section inquires about your personal attitudes and perceived benefits of 
evidence-based medicine (EBM).  
For the following items, tick the appropriate box indicating your response. 
 
13. Which is the most common way to update your knowledge of CHM for insomnia?   
a) Learning from senior physicians b) Reading modern research  
c) Reading the latest guidelines  d) Reading classical literature 
e) Attending conferences or training courses  f) Other  Specify _____________ 
 1 2 3 4 5 
Strongly 
disagree 
Disagree Neutral Agree 
Strongly 
agree 
14. I understand what is meant by EBM      
15. Application of EBM is necessary for the 
treatment of insomnia with Chinese herbal 
medicine. 
     
16. Application of EBM is necessary for the 
treatment of insomnia with conventional 
medicine. 
     
17. New research findings of CHM for 
insomnia are useful in my day-to-day 
practice. 
     
18. In making decisions related to CHM for 
insomnia, I value scientific studies more than 
clinical experience. 
     
19. I need to increase the use of evidence in 
my daily practice related to CHM for 
insomnia. 
     
20. I am interested in learning or improving 
the skills necessary to incorporate EBM into 
my practice. 
     
21. EBM is difficult to incorporate in my 
practice setting. 
     
22. The clinical evidence of CHM for 
insomnia does not support most of the 
interventions I use for my patients. 
     
23. EBM helps me make decisions about 
insomnia patient care using CHM. 
     
24. EBM takes into consideration patient 
preferences. 
     
25. Please rate your overall attitude towards EBM.      For   NeutralAgainst 
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Part 3: The following section inquires about your personal use, understanding and limitations of 
evidence-based medicine. 
For the following items, tick the appropriate box indicating your response. 
 
26. I use EBM to guide my practice related to CHM for insomnia.  Yes  No 
If yes, what resources have you used? 
If no, please move to question No.27. 
 Yes No 
a) Guideline for adult insomnia management   
b) Evidence-based guidelines on CHM for insomnia   
c) Guideline for insomnia treatment and prevention   
d) Expert consensus guideline   
e) Journal articles of research findings   
f) Evidence based database, such as, UpToDate, and Best Practice   
g) Other, specify _____________________________________   
 
Questions 
1 2 3 4 5 
Strongly 
disagree 
Disagree Neutral Agree 
Strongly 
agree 
27. I am aware of the latest research in 
CHM for insomnia. 
     
28. I am confident in my understanding of 
EBM. 
     
29. I actively seek practice guidelines 
pertaining to CHM for insomnia.   
     
30. I am able to incorporate patient 
preferences with practice guidelines. 
     
 
31. Please rate your barriers to EBM related 
to CHM for insomnia in the following 
statements. 
1 2 3 4 5 
Strongly 
disagree 
Disagree Neutral Agree 
Strongly 
agree 
a) I have insufficient time to practice EBM.      
b) I have a lack of resources to find 
evidence. 
     
c) I have a lack of research skills to 
understand EBM. 
     
d) I have a poor ability to critically appraise 
the literature. 
     
e) There is a lack of generalisability of the 
literature findings to my patient population. 
     
f) I am unable to apply research findings to      
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individual patients with unique 
characteristics. 
g) I lack understanding of statistical 
analysis. 
     
h) I lack collective support among my 
colleagues at my facility. 
     
i) My workload is too great for me to keep 
up to date with the new evidence. 
     
j) There is insufficient high quality evidence 
of CHM for insomnia 
     
k) Chinese medicine theory contradicts 
EBM. 
     
l) Other, specify_____________________________________ 
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Part 4: The following section inquires about your knowledge of evidence-based medicine 
(EBM). 
For the following items, tick the appropriate box indicating your response. 
 
 Yes No 
32. Have you received formal training in critical research appraisal?   
33. Have you been trained in the foundations of EBM?   
 
34. Are you aware of the following databases? Unaware Aware but do not use Aware and use 
a) Cochrane library    
b) PubMed    
c) CNKI    
d) CBM    
 
35. Are you confident in your ability to find relevant research to answer your clinical questions? 
Strongly disagree  Disagree  Neutral  Agree   Strongly agree  
 
36. In the last month how many 
times have you… 
1 2 3 4 5 
≤1time 2-5 times 6-10 times 11-15 times ≥16times 
a) Formulated a clearly 
answerable question that defines 
the client or problem, the 
intervention and outcomes of 
interest? 
     
b) Searched an electronic 
database? 
     
c) Critically read a published 
research report? 
     
d) Used research findings to 
make a clinical decision? 
     
 
37. What is your 
understanding of the following 
terms: 
1 2 3 
4 
 
5 
Never 
heard 
Heard but do 
not understand 
Somewhat 
understand 
Understand 
well 
Understand 
well and use 
a) Randomised controlled trial      
b) Systematic review      
c) Meta-analysis      
d) Relative risk      
e) Absolute risk      
f) Odds ratio      
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g) Mean difference      
h) Confidence interval      
i) Heterogeneity      
j) Publication bias      
 
38. From the examples below, what do you think is the highest level of evidence related to CHM for 
insomnia? 
a) Case study   
b) Classical literature   
c) Randomised controlled trial   
d) Meta-analysis with homogeneity  
e) Experience from famous physician or teacher  
39. Please rate your overall knowledge of EBM. poor  moderate good  
 
 
 
 
 
 
 
 
 
  
 271 
 
40. Feel free to make any comments about the survey below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41. Would you be interested to participate in a follow up face-to-face interview?  
 Yes  No 
If yes, please write down your contact information: 
Name: __________________________________________________________________ 
Affiliation: _______________________________________________________________ 
Department：_______________________________________________________________ 
Email: ___________________________________________________________________ 
Telephone: _____________________________________________________________ 
Thank you for your time in completing this questionnaire. 
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Appendix 6.1 Approval letter issued by the Institutional Ethics Committee of Guangdong 
Provincial Hospital of Traditional Chinese Medicine, China 
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Appendix 6.2 Registration letter of external approval in RMIT 
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Appendix 6.3 Detailed results of univariate logistic regression 
RRQ20.2: Application of EBM is necessary for the treatment of insomnia with Chinese 
herbal medicine. (Referencing group: disagree or neutral) 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
Step 1
a
 RRQ20.2(1) 2.299 .789 8.489 1 .004 9.966 2.721 36.493 
Constant -2.140 .748 8.196 1 .004 .118   
a. Variable(s) entered on step 1: RRQ20.2. 
 
RRQ20.4:New research findings of CHM for insomnia are useful in my day-to-day 
practice.(Referencing group: disagree or neutral) 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
Step 1
a
 RRQ20.4(1) 1.902 .798 5.680 1 .017 6.697 1.803 24.880 
Constant -1.872 .760 6.073 1 .014 .154   
a. Variable(s) entered on step 1: RRQ20.4. 
 
RRQ20.5: In making decisions related to CHM for insomnia, I value scientific studies more 
than clinical experience. (Referencing group: disagree or neutral) 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
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Step 1
a
 RRQ20.5(1) 1.652 .584 7.998 1 .005 5.218 1.996 13.641 
Constant -.623 .264 5.549 1 .018 .537   
a. Variable(s) entered on step 1: RRQ20.5. 
 
RRQ20.6: I need to increase the use of evidence in my daily practice related to CHM for 
insomnia. (Referencing group: disagree or neutral) 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
Step 1
a
 RRQ20.6(1) 2.224 .672 10.956 1 .001 9.240 3.061 27.896 
Constant -1.946 .617 9.940 1 .002 .143   
a. Variable(s) entered on step 1: RRQ20.6. 
 
RQ27:Have you received formal training in critical research appraisal? (Referencing group: 
no) 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
Step 1
a
 RQ27(1) 1.135 .465 5.956 1 .015 3.111 1.448 6.685 
Constant -.847 .345 6.030 1 .014 .429   
a. Variable(s) entered on step 1: RQ27. 
 
RQ28:Have you been trained in the foundations of EBM? (Referencing group: no) 
Variables in the Equation 
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B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
Step 1
a
 RQ28(1) 1.562 .566 7.609 1 .006 4.769 1.879 12.106 
Constant -1.386 .500 7.687 1 .006 .250   
a. Variable(s) entered on step 1: RQ28. 
 
RRQ30:Are you confident in your ability to find relevant research to answer your clinical 
questions? (Referencing group: disagree or neutral) 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
RRQ30(1) 1.863 .518 12.924 1 .000 6.444 2.748 15.115 
Constant -1.386 .423 10.762 1 .001 .250   
a. Variable(s) entered on step 1: RRQ30. 
 
RQ29:Are you aware of the following databases (Cochrane library, PubMed, CNKI and 
CBM)? 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
Step 1
a
 RQ29 .235 .124 3.594 1 .058 1.266 1.032 1.552 
Constant -2.551 1.251 4.162 1 .041 .078   
a. Variable(s) entered on step 1: RQ29. 
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RQ32: What is your understanding of the following terms (randomised controlled trial, 
systematic review, meta-analysis, relative risk, absolute risk, odds ratio, mean difference, 
confidential interval, heterogeneity, publication bias)? 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
Step 1
a
 RQ32 .052 .026 3.945 1 .047 1.053 1.009 1.099 
Constant -2.079 .959 4.702 1 .030 .125   
a. Variable(s) entered on step 1: RQ32. 
 
RRQ25.11: Chinese medicine theory contradicts EBM. (Referencing group: agree) 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
90% C.I.for 
EXP(B) 
Lower Upper 
Step 1
a
 RRQ25.11(1
) 
.938 .463 4.108 1 .043 2.555 1.193 5.469 
Constant -.633 .300 4.442 1 .035 .531   
a. Variable(s) entered on step 1: RRQ25.11. 
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Appendix 6.4 Detailed results of exploratory factor analysis 
A 6.4.1 Inter-item correlation analysis 
Correlation Matrix
a
 
Question item 1 2 3 4 5 6 7 8  9 10 
1. Application of EBM is necessary for the treatment of insomnia 
with Chinese herbal medicine. 
1.000 .541
***
 .414
***
 .558
***
 -.034 .015 .244
*
 -.029 .141 .406
***
 
2. New research findings of CHM for insomnia are useful in my 
day-to-day practice. 
.541
***
 1.000 .463
***
 .549
***
 .158 .073 .170 -.002 .046 .307
**
 
3. In making decisions related to CHM for insomnia, I value 
scientific studies more than clinical experience. 
.414
***
 .463
***
 1.000 .536
***
 .108 .039 .276
**
 -.045 .113 .266
**
 
4. I need to increase the use of evidence in my daily practice 
related to CHM for insomnia. 
.558
***
 .549
***
 .536
***
 1.000 .101 .022 .022 .019 .103 .392
***
 
5. Have you received formal training in critical research appraisal? -.034 .158 .108 .101 1.000 .626
***
 .433
***
 .345
**
 .467
***
 .011 
6. Have you been trained in the foundations of EBM? .015 .073 .039 .022 .626
***
 1.000 .457
***
 .406
***
 .468
***
 .012 
7. Are you confident in your ability to find relevant research to 
answer your clinical questions? 
.244
*
 .170 .276
**
 .022 .433
***
 .457
***
 1.000 .345
**
 .554
***
 .154 
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8. Are you aware of the following databases (Cochrane library, 
PubMed, CNKI and CBM)? 
-.029 -.002 -.045 .019 .345
**
 .406
***
 .345
**
 1.000 .622
***
 .069 
9. What is your understanding of the following terms (randomised 
controlled trial, systematic review, meta-analysis, relative risk, 
absolute risk, odds ratio, mean difference, confidential interval, 
heterogeneity, publication bias)? 
.141 .046 .113 .103 .467
***
 .468
***
 .554
***
 .622
***
 1.000 .280
**
 
10. Chinese medicine theory contradicts EBM. .406
***
 .307
**
 .266
**
 .392
***
 .011 .012 .154 .069 .280
**
 1.000 
Notes: Determinant = .023. ***p < 0.001 level (1-tailed).**p<0.01 level (1-tailed).*p<.05 level (1-tailed). 
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A 6.4.2 The Kaiser-Meyer-Olkin (KMO) and the Bartlett's Test  
KMO and Bartlett's Test 
Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy. 
.729 
Bartlett's Test of 
Sphericity 
Approx. Chi-Square 288.294 
df 45 
Sig. .000 
 
A 6.4.3 Communalities analysis 
Communalities 
 Initial Extraction 
1. Application of EBM is necessary for the treatment of insomnia 
with Chinese herbal medicine. 
1.000 .671 
2. New research findings of CHM for insomnia are useful in my day-
to-day practice. 
1.000 .688 
3. In making decisions related to CHM for insomnia, I value scientific 
studies more than clinical experience. 
1.000 .740 
4.I need to increase the use of evidence in my daily practice related to 
CHM for insomnia. 
1.000 .817 
5.Have you received formal training in critical research appraisal? 1.000 .834 
6.Have you been trained in the foundations of EBM? 1.000 .778 
7.Are you confident in your ability to find relevant research to answer 
your clinical questions? 
1.000 .901 
8.Are you aware of the following databases (Cochrane library, 
PubMed, CNKI and CBM)? 
1.000 .915 
9.What is your understanding of the following terms (randomised 
controlled trial, systematic review, meta-analysis, relative risk, 
absolute risk, odds ratio, mean difference, confidential interval, 
heterogeneity, publication bias)? 
1.000 .821 
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10.Chinese medicine theory contradicts EBM. 1.000 .912 
Notes: The communalities were all above 0.6 with a mean of 0.8. 
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A 6.4.4 Residualsbetween observed and reproduced correlations 
 
Residuals 
 1 2 3 4 5 6 7 8 9 10 
1. Application of EBM is necessary for the treatment of insomnia with 
Chinese herbal medicine. 
 -.026 -.170 -.037 -.011 .062 -.024 .021 -.019 -.133 
2. New research findings of CHM for insomnia are useful in my day-to-
day practice. 
-.026  -.125 -.155 -.049 -.046 .048 .051 -.003 -.013 
3. In making decisions related to CHM for insomnia, I value scientific 
studies more than clinical experience. 
-.170 -.125  -.011 .034 .021 -.096 -.012 .015 .119 
4.I need to increase the use of evidence in my daily practice related to 
CHM for insomnia. 
-.037 -.155 -.011  -.002 .007 .053 -.061 .017 -.017 
5.Have you received formal training in critical research appraisal? -.011 -.049 .034 -.002  -.167 -.007 -.008 .018 .022 
6.Have you been trained in the foundations of EBM? .062 -.046 .021 .007 -.167  -.035 .016 -.041 -.015 
7.Are you confident in your ability to find relevant research to answer 
your clinical questions? 
-.024 .048 -.096 .053 -.007 -.035  .026 -.061 -.007 
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8.Are you aware of the following databases (Cochrane library, PubMed, 
CNKI and CBM)? 
.021 .051 -.012 -.061 -.008 .016 .026  -.112 .030 
9.What is your understanding of the following terms (randomised 
controlled trial, systematic review, meta-analysis, relative risk, absolute 
risk, odds ratio, mean difference, confidential interval, heterogeneity, 
publication bias)? 
-.019 -.003 .015 .017 .018 -.041 -.061 -.112  -.044 
10.Chinese medicine theory contradicts EBM. -.133 -.013 .119 -.017 .022 -.015 -.007 .030 -.044  
Notes: Residuals are computed between observed and reproduced correlations. There are 13 (28.0%) nonredundant residuals with absolute values greater than 0.05. 
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Appendix 6.5 Detailed process of developing a multivariate logistic regression model 
A 6.5.1 Multicollinearity diagnosis for multivariate logistic regression  
Independent variables 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
Collinearity Statistics 
B Std. Error Beta Tolerance VIF 
1. Application of EBM is necessary for the treatment of insomnia 
with Chinese herbal medicine. 
-.286 .266  -1.075 .286   
.194 .147 .165 1.320 .191 .537 1.862 
2. New research findings of CHM for insomnia are useful in my 
day-to-day practice. 
-.001 .150 -.001 -.009 .992 .615 1.626 
3. In making decisions related to CHM for insomnia, I value 
scientific studies more than clinical experience. 
.148 .122 .126 1.214 .229 .778 1.285 
4. I need to increase the use of evidence in my daily practice 
related to CHM for insomnia. 
.308 .119 .283 2.589 .012 .704 1.420 
5. Have you received formal training in critical research appraisal? -.040 .130 -.040 -.308 .759 .487 2.055 
6. Have you been trained in the foundations of EBM? .279 .134 .259 2.079 .041 .542 1.845 
7. Are you confident in your ability to find relevant research to 
answer your clinical questions? 
.286 .123 .285 2.329 .023 .562 1.779 
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8.Are you aware of the following databases (Cochrane library, PubMed, 
CNKI and CBM)? 
.035 .030 .142 1.154 .252 .558 1.791 
9.What is your understanding of the following terms (randomised 
controlled trial, systematic review, meta-analysis, relative risk, absolute 
risk, odds ratio, mean difference, confidential interval, heterogeneity, 
publication bias)? 
-.011 .008 -.196 -1.376 .173 .413 2.420 
10. Chinese medicine theory contradicts EBM. .044 .105 .043 .420 .676 .784 1.276 
Notes: Multicollinearity is not a concern as tolerance is more than 0.1 and the variance inflation factor (VIF) is less than 10.
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A 6.5.2 The process of developing a multivariate logistic regression model  
 
Case Processing Summary 
Unweighted Cases
a
 N Percent 
Selected Cases Included in Analysis 82 100.0 
Missing Cases 0 .0 
Total 82 100.0 
Unselected Cases 0 .0 
Total 82 100.0 
a. If weight is in effect, see classification table for the total number of cases. 
 
Dependent Variable Encoding 
Original Value Internal Value 
No 0 
Yes 1 
 
Categorical Variables Codings 
 Frequency 
Parameter 
coding 
(1) 
Chinese medicine theory contradicts EBM. disagree+neutra
l 
49 1.000 
agree 33 .000 
New research findings of CHM for insomnia are 
useful in my day-to-day practice. 
disagree+neutra
l 
15 .000 
agree 67 1.000 
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In making decisions related to CHM for insomnia, I 
value scientific studies more than clinical 
experience. 
disagree+neutra
l 
63 .000 
agree 19 1.000 
I need to increase the use of evidence in my daily 
practice related to CHM for insomnia. 
disagree+neutra
l 
24 .000 
agree 58 1.000 
Have you received formal training in critical 
research appraisal? 
No 40 .000 
Yes 42 1.000 
Are you confident in your ability to find relevant 
research to answer your clinical questions? 
Disagree+Neutr
al 
35 .000 
Agree 47 1.000 
Have you been trained in the foundations of EBM? No 25 .000 
Yes 57 1.000 
Application of EBM is necessary for the treatment of 
insomnia with Chinese herbal medicine. 
diagree+neutral 19 .000 
agree 63 1.000 
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Block 0: Beginning Block 
 
Iteration History
a,b,c
 
Iteration -2 Log likelihood 
Coefficients 
Constant 
Step 0 1 112.454 -.244 
2 112.454 -.245 
3 112.454 -.245 
a. Constant is included in the model. 
b. Initial -2 Log Likelihood: 112.454 
c. Estimation terminated at iteration number 3 because parameter estimates changed by less than .001. 
 
Classification Table
a,b
 
 
Observed 
Predicted 
 I use EBM to guide my practice 
related to CHM for insomnia. 
Percentage 
Correct  No Yes 
Step 0 I use EBM to guide my practice 
related to CHM for insomnia. 
No 46 0 100.0 
Yes 36 0 .0 
Overall Percentage   56.1 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -.245 .223 1.213 1 .271 .783 
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Block 1: Method = Enter 
Iteration History
a,b,c,d
 
Iteration -2 Log likelihood 
Coefficients 
Constant 
Application of EBM is 
necessary for the 
treatment of insomnia 
with Chinese herbal 
medicine.(1) 
New research findings of 
CHM for insomnia are 
useful in my day-to-day 
practice.(1) 
In making decisions 
related to CHM for 
insomnia, I value 
scientific studies more 
than clinical experience. 
(1) 
I need to increase the use 
of evidence in my daily 
practice related to CHM 
for insomnia.(1) 
Step 1 1 90.429 -2.080 .868 .188 .886 1.147 
2 88.941 -2.919 1.253 .344 .940 1.506 
3 88.866 -3.170 1.370 .407 .934 1.593 
4 88.866 -3.189 1.378 .412 .933 1.598 
5 88.866 -3.189 1.378 .412 .933 1.598 
a. Method: Enter 
b. Constant is included in the model. 
c. Initial -2 Log Likelihood: 112.454 
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d. Estimation terminated at iteration number 5 because parameter estimates changed by less than .001. 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 23.588 4 .000 
Block 23.588 4 .000 
Model 23.588 4 .000 
 
Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 88.866
a
 .250 .335 
a. Estimation terminated at iteration number 5 because parameter estimates 
changed by less than .001. 
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Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 1.587 4 .811 
 
Classification Table
a
 
 
Observed 
Predicted 
 I use EBM to guide my practice related to CHM for insomnia. 
Percentage Correct  No Yes 
Step 1 I use EBM to guide my practice related to CHM for insomnia.  No 27 19 58.7 
Yes 6 30 83.3 
Overall Percentage   69.5 
a. The cut value is .500 
 
 
 
 292 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
90% C.I.for EXP(B) 
Lower Upper 
Step 1
a
 Application of EBM is necessary 
for the treatment of insomnia with 
Chinese herbal medicine.(1) 
1.378 .908 2.304 1 .129 3.969 .891 17.673 
New research findings of CHM for 
insomnia are useful in my day-to-
day practice.(1) 
.412 .966 .182 1 .670 1.510 .308 7.394 
In making decisions related to 
CHM for insomnia, I value 
scientific studies more than clinical 
experience. (1) 
.933 .626 2.219 1 .136 2.542 .907 7.123 
I need to increase the use of 
evidence in my daily practice 
related to CHM for insomnia.(1) 
1.598 .719 4.941 1 .026 4.945 1.515 16.138 
Constant -3.189 1.034 9.509 1 .002 .041   
a. Variable(s) entered on step 1: Application of EBM is necessary for the treatment of insomnia with Chinese herbal medicine; New research findings of CHM for insomnia 
are useful in my day-to-day practice; In making decisions related to CHM for insomnia, I value scientific studies more than clinical experience; I need to increase the use of 
evidence in my daily practice related to CHM for insomnia. 
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Block 2: Method = Enter 
 
Iteration History
a,b,c,d
 
Iteration -2 Log likelihood 
Coefficients 
Constant 
Application of 
EBM is necessary 
for the treatment 
of insomnia with 
Chinese herbal 
medicine.(1) 
New research 
findings of CHM 
for insomnia are 
useful in my day-
to-day practice.(1) 
In making 
decisions related 
to CHM for 
insomnia, I value 
scientific studies 
more than clinical 
experience. (1) 
I need to increase 
the use of 
evidence in my 
daily practice 
related to CHM 
for insomnia.(1) 
 
Have you received 
formal training in 
critical research 
appraisal? (1) 
Have you been 
trained in the 
foundations of 
EBM? (1) 
Step 1 1 80.892 -2.994 .904 .110 .790 1.187 .151 1.245 
2 77.221 -4.636 1.308 .513 .940 1.701 .031 1.917 
3 76.874 -5.333 1.514 .716 .970 1.911 -.078 2.162 
4 76.868 -5.434 1.551 .744 .971 1.943 -.098 2.192 
5 76.868 -5.436 1.552 .745 .971 1.943 -.098 2.193 
6 76.868 -5.436 1.552 .745 .971 1.943 -.098 2.193 
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a. Method: Enter 
b. Constant is included in the model. 
c. Initial -2 Log Likelihood: 88.866 
d. Estimation terminated at iteration number 6 because parameter estimates changed by less than .001. 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 11.997 2 .002 
Block 11.997 2 .002 
Model 35.585 6 .000 
 
Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 76.868
a
 .352 .472 
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a. Estimation terminated at iteration number 6 because parameter estimates 
changed by less than .001. 
 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 4.289 7 .746 
 
Classification Table
a
 
 
Observed 
Predicted 
 I use EBM to guide my practice related to CHM for insomnia. 
Percentage Correct  No Yes 
Step 1 I use EBM to guide my practice related to CHM for insomnia. No 37 9 80.4 
Yes 9 27 75.0 
Overall Percentage   78.0 
a. The cut value is .500 
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
90% C.I.for EXP(B) 
Lower Upper 
Applicat
ion of 
EBM is 
necessar
y for the 
treatmen
t of 
insomni
a with 
Chinese 
herbal 
medicin
e.(1) 
Application of EBM is 
necessary for the treatment of 
insomnia with Chinese herbal 
medicine.(1) 
1.552 .925 2.816 1 .093 4.722 1.031 21.618 
New research findings of CHM for 
insomnia are useful in my day-to-
day practice.(1) 
.745 1.001 .554 1 .457 2.106 .406 10.932 
In making decisions related to 
CHM for insomnia, I value 
scientific studies more than clinical 
experience. (1) 
.971 .693 1.964 1 .161 2.640 .845 8.249 
I need to increase the use of 
evidence in my daily practice 
related to CHM for insomnia.(1) 
1.943 .794 5.991 1 .014 6.981 1.892 25.765 
Have you received formal training 
in critical research appraisal? (1) 
-.098 .743 .017 1 .895 .907 .267 3.076 
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Have you been trained in the 
foundations of EBM? (1) 
2.193 .872 6.317 1 .012 8.961 2.134 37.640 
Constant -5.436 1.438 14.283 1 .000 .004   
a. Variable(s) entered on step 1: Have you received formal training in critical research appraisal? Have you been trained in the foundations of EBM?  
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Block 3: Method = Enter 
 
Iteration History
a,b,c,d
 
Iteration 
-2 Log 
likelihood 
Coefficients 
Constant 
Application of 
EBM is 
necessary for 
the treatment 
of insomnia 
with Chinese 
herbal 
medicine.(1) 
New research 
findings of 
CHM for 
insomnia are 
useful in my 
day-to-day 
practice.(1) 
In making 
decisions 
related to 
CHM for 
insomnia, I 
value scientific 
studies more 
than clinical 
experience. (1) 
I need to 
increase the 
use of 
evidence in my 
daily practice 
related to 
CHM for 
insomnia.(1) 
 
Have you 
received 
formal training 
in critical 
research 
appraisal? (1) 
Have you been 
trained in the 
foundations of 
EBM? (1) 
Are you aware 
of the 
following 
databases 
(Cochrane 
library, 
PubMed, 
CNKI and 
CBM)? (1) 
What is your 
understanding 
of the 
following 
terms 
(combing all 
terms)? (1) 
Step 1 1 79.794 -3.691 .995 .062 .884 1.129 .168 1.146 .142 -.018 
2 75.852 -5.579 1.404 .477 1.100 1.630 .077 1.849 .205 -.030 
3 75.482 -6.406 1.587 .707 1.159 1.837 -.023 2.109 .228 -.033 
4 75.477 -6.518 1.617 .739 1.163 1.868 -.042 2.140 .230 -.033 
5 75.477 -6.520 1.618 .739 1.163 1.869 -.042 2.140 .230 -.033 
6 75.477 -6.520 1.618 .739 1.163 1.869 -.042 2.140 .230 -.033 
a. Method: Enter 
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b. Constant is included in the model. 
c. Initial -2 Log Likelihood: 76.868 
d. Estimation terminated at iteration number 6 because parameter estimates changed by less than .001. 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 1.391 2 .499 
Block 1.391 2 .499 
Model 36.977 8 .000 
 
Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 75.477
a
 .363 .486 
a. Estimation terminated at iteration number 6 because parameter estimates 
changed by less than .001. 
 
Hosmer and Lemeshow Test 
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Step Chi-square df Sig. 
1 7.893 8 .444 
 
Classification Table
a
 
 
Observed 
Predicted 
 I use EBM to guide my practice related to CHM for insomnia. 
Percentage 
Correct  No Yes 
Step 1 I use EBM to guide my practice related to CHM for insomnia. No 36 10 78.3 
Yes 9 27 75.0 
Overall Percentage   76.8 
a. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
90% C.I.for EXP(B) 
Lower Upper 
Step 1
a
 Application of EBM is necessary for the treatment of 
insomnia with Chinese herbal medicine.(1) 
1.618 .944 2.939 1 .086 5.040 1.068 23.795 
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New research findings of CHM for insomnia are useful in my 
day-to-day practice.(1) 
.739 1.022 .523 1 .469 2.094 .390 11.246 
In making decisions related to CHM for insomnia, I value 
scientific studies more than clinical experience. (1) 
1.163 .730 2.535 1 .111 3.198 .962 10.629 
I need to increase the use of evidence in my daily practice 
related to CHM for insomnia.(1) 
1.869 .809 5.337 1 .021 6.480 1.713 24.517 
Have you received formal training in critical research 
appraisal? (1) 
-.042 .779 .003 1 .957 .959 .266 3.453 
Have you been trained in the foundations of EBM? (1) 2.140 .897 5.694 1 .017 8.503 1.944 37.180 
Are you aware of the following databases (Cochrane library, 
PubMed, CNKI and CBM)?(1) 
.230 .197 1.360 1 .244 1.258 .910 1.739 
What is your understanding of the following terms (combing 
all terms)? (1) 
-.033 .046 .536 1 .464 .967 .897 1.043 
Constant -6.520 2.083 9.801 1 .002 .001   
a. Variable(s) entered on step 1: Are you aware of the following databases (Cochrane library, PubMed, CNKI and CBM)?What is your understanding of the following terms 
(randomised controlled trial, systematic review, meta-analysis, relative risk, absolute risk, odds ratio, mean difference, confidential interval, heterogeneity, publication 
bias)? 
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Block 4: Method = Enter 
 
Iteration History
a,b,c,d
 
Iteration 
-2 Log 
likelihood 
Coefficients 
Constant 
Application 
of EBM is 
necessary for 
the treatment 
of insomnia 
with Chinese 
herbal 
medicine.(1) 
New 
research 
findings of 
CHM for 
insomnia are 
useful in my 
day-to-day 
practice.(1) 
In making 
decisions 
related to 
CHM for 
insomnia, I 
value 
scientific 
studies more 
than clinical 
experience. 
(1) 
I need to 
increase the 
use of 
evidence in 
my daily 
practice 
related to 
CHM for 
insomnia.(1) 
 
Have you 
received 
formal 
training in 
critical 
research 
appraisal? 
(1) 
Have you 
been trained 
in the 
foundations 
of EBM? (1) 
Are you 
aware of the 
following 
databases 
(Cochrane 
library, 
PubMed, 
CNKI and 
CBM)? (1) 
What is your 
understanding 
of the 
following 
terms 
(combing all 
terms)? (1) 
Are you 
confident in 
your ability 
to find 
relevant 
research to 
answer your 
clinical 
questions? 
(1) 
Step 
1 
1 75.563 -3.194 .822 -.005 .594 1.270 -.150 1.116 .136 -.039 1.128 
2 70.960 -4.815 1.225 .236 .759 1.874 -.350 1.912 .223 -.070 1.589 
3 70.546 -5.551 1.403 .391 .831 2.103 -.490 2.247 .262 -.082 1.747 
4 70.539 -5.662 1.431 .418 .839 2.133 -.515 2.289 .267 -.083 1.765 
5 70.539 -5.664 1.431 .419 .839 2.134 -.516 2.290 .267 -.083 1.765 
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6 70.539 -5.664 1.431 .419 .839 2.134 -.516 2.290 .267 -.083 1.765 
a. Method: Enter 
b. Constant is included in the model. 
c. Initial -2 Log Likelihood: 75.477 
d. Estimation terminated at iteration number 6 because parameter estimates changed by less than .001. 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 4.937 1 .026 
Block 4.937 1 .026 
Model 41.914 9 .000 
 
Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 70.539
a
 .400 .536 
a. Estimation terminated at iteration number 6 because parameter estimates 
changed by less than .001. 
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Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 4.729 8 .786 
 
Classification Table
a
 
 
Observed 
Predicted 
 I use EBM to guide my practice related to CHM 
for insomnia. 
Percentage Correct  No Yes 
Step 1 I use EBM to guide my practice related 
to CHM for insomnia. 
No 39 7 84.8 
Yes 9 27 75.0 
Overall Percentage   80.5 
a. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
90% C.I.for EXP(B) 
Lower Upper 
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Step 1
a
 Application of EBM is necessary for the 
treatment of insomnia with Chinese herbal 
medicine.(1) 
1.431 .974 2.157 1 .142 4.183 .842 20.779 
New research findings of CHM for insomnia are 
useful in my day-to-day practice.(1) 
.419 1.062 .155 1 .693 1.520 .265 8.712 
In making decisions related to CHM for insomnia, I 
value scientific studies more than clinical experience. 
(1) 
.839 .787 1.138 1 .286 2.315 .635 8.445 
I need to increase the use of evidence in my daily 
practice related to CHM for insomnia.(1) 
2.134 .825 6.683 1 .010 8.449 2.173 32.847 
Have you received formal training in critical research 
appraisal? (1) 
-.516 .861 .359 1 .549 .597 .145 2.461 
Have you been trained in the foundations of EBM? 
(1) 
2.290 .966 5.616 1 .018 9.875 2.015 48.392 
Are you aware of the following databases (Cochrane 
library, PubMed, CNKI and CBM)?(1) 
.267 .220 1.481 1 .224 1.306 .910 1.875 
What is your understanding of the following terms 
(combing all terms)? (1) 
-.083 .057 2.138 1 .144 .920 .837 1.010 
Are you confident in your ability to find relevant 
research to answer your clinical questions? (1) 
1.765 .833 4.487 1 .034 5.843 1.484 23.014 
Constant -5.664 2.172 6.800 1 .009 .003   
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a. Variable(s) entered on step 1: Are you confident in your ability to find relevant research to answer your clinical questions?  
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Block 5: Method = Enter 
Iteration History
a,b,c,d
 
Iteration 
-2 Log 
likelihood 
Coefficients 
Constant 
Application 
of EBM is 
necessary 
for the 
treatment of 
insomnia 
with 
Chinese 
herbal 
medicine.(1) 
New 
research 
findings of 
CHM for 
insomnia 
are useful 
in my day-
to-day 
practice.(1) 
In making 
decisions 
related to 
CHM for 
insomnia, I 
value 
scientific 
studies 
more than 
clinical 
experience. 
(1) 
I need to 
increase the 
use of 
evidence in 
my daily 
practice 
related to 
CHM for 
insomnia.(1) 
 
Have you 
received 
formal 
training in 
critical 
research 
appraisal? 
(1) 
Have you 
been 
trained in 
the 
foundations 
of EBM? 
(1) 
Are you 
aware of 
the 
following 
databases 
(Cochrane 
library, 
PubMed, 
CNKI and 
CBM)? (1) 
What is your 
understanding 
of the 
following 
terms 
(combing all 
terms)? (1) 
Are you 
confident 
in your 
ability to 
find 
relevant 
research to 
answer 
your 
clinical 
questions? 
(1) 
Chinese 
medicine 
theory 
contradicts 
EBM. (1) 
Step 
1 
1 75.477 -2.966 .776 -.006 .594 1.234 -.161 1.116 .140 -.042 1.143 -.176 
2 70.900 -4.624 1.195 .250 .753 1.824 -.376 1.917 .228 -.073 1.599 -.160 
3 70.482 -5.371 1.375 .410 .823 2.051 -.521 2.254 .268 -.085 1.755 -.165 
4 70.476 -5.481 1.402 .438 .831 2.081 -.547 2.297 .274 -.086 1.773 -.169 
5 70.476 -5.483 1.403 .438 .831 2.082 -.548 2.298 .274 -.086 1.773 -.169 
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6 70.476 -5.483 1.403 .438 .831 2.082 -.548 2.298 .274 -.086 1.773 -.169 
a. Method: Enter 
b. Constant is included in the model. 
c. Initial -2 Log Likelihood: 70.539 
d. Estimation terminated at iteration number 6 because parameter estimates changed by less than .001. 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step .064 1 .800 
Block .064 1 .800 
Model 41.978 10 .000 
 
Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 70.476
a
 .401 .537 
a. Estimation terminated at iteration number 6 because parameter estimates 
changed by less than .001. 
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Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 5.583 8 .694 
 
Classification Table
a
 
 
Observed 
Predicted 
 I use EBM to guide my practice related to CHM 
for insomnia. 
Percentage Correct  No Yes 
Step 1 I use EBM to guide my practice related 
to CHM for insomnia. 
No 38 8 82.6 
Yes 9 27 75.0 
Overall Percentage   79.3 
a. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
90% C.I.for EXP(B) 
Lower Upper 
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Step 1
a
 Application of EBM is necessary for the treatment 
of insomnia with Chinese herbal medicine.(1) 
1.403 .982 2.042 1 .153 4.067 .809 20.446 
New research findings of CHM for insomnia are useful in 
my day-to-day practice.(1) 
.438 1.068 .169 1 .681 1.550 .268 8.982 
In making decisions related to CHM for insomnia, I 
value scientific studies more than clinical experience. (1) 
.831 .787 1.114 1 .291 2.295 .629 8.377 
I need to increase the use of evidence in my daily 
practice related to CHM for insomnia.(1) 
2.082 .848 6.028 1 .014 8.017 1.988 32.331 
Have you received formal training in critical research 
appraisal? (1) 
-.548 .870 .396 1 .529 .578 .138 2.419 
Have you been trained in the foundations of EBM? (1) 2.298 .966 5.656 1 .017 9.955 2.031 48.785 
Are you aware of the following databases (Cochrane 
library, PubMed, CNKI and CBM)?(1) 
.274 .222 1.521 1 .218 1.315 .913 1.894 
What is your understanding of the following terms 
(combing all terms)? (1) 
-.086 .058 2.200 1 .138 .918 .834 1.009 
Are you confident in your ability to find relevant research 
to answer your clinical questions? (1) 
1.773 .834 4.519 1 .034 5.888 1.493 23.215 
Chinese medicine theory contradicts EBM. (1) -.169 .669 .064 1 .800 .844 .281 2.535 
Constant -5.483 2.290 5.730 1 .017 .004   
a. Variable(s) entered on step 1: Chinese medicine theory contradicts EBM.  
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Appendix 6.6 Final model of the multivariate logistic regression 
 
Case Processing Summary 
Unweighted Cases
a
 N Percent 
Selected Cases Included in Analysis 82 100.0 
Missing Cases 0 .0 
Total 82 100.0 
Unselected Cases 0 .0 
Total 82 100.0 
a. If weight is in effect, see classification table for the total number of cases. 
 
Dependent Variable Encoding 
Original Value Internal Value 
No 0 
Yes 1 
 
Categorical Variables Codings 
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 Frequency 
Parameter coding 
(1) 
Are you confident in your ability to find 
relevant research to answer your clinical 
questions?  
Disagree+Neutral 35 .000 
Agree 47 1.000 
I need to increase the use of evidence in 
my daily practice related to CHM for 
insomnia. 
disagree+neutral 24 .000 
agree 58 1.000 
Have you been trained in the foundations 
of EBM? 
No 25 .000 
Yes 57 1.000 
Application of EBM is necessary for the 
treatment of insomnia with Chinese herbal 
medicine 
diagree+neutral 19 .000 
agree 63 1.000 
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Block 0: Beginning Block 
 
Iteration History
a,b,c
 
Iteration -2 Log likelihood 
Coefficients 
Constant 
Step 0 1 112.454 -.244 
2 112.454 -.245 
3 112.454 -.245 
a. Constant is included in the model. 
b. Initial -2 Log Likelihood: 112.454 
c. Estimation terminated at iteration number 3 because 
parameter estimates changed by less than .001. 
 
Classification Table
a,b
 
 
Observed 
Predicted 
 I use EBM to guide my practice related to CHM for 
insomnia. 
Percentage Correct  No Yes 
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Step 0 I use EBM to guide my practice related 
to CHM for insomnia. 
No 46 0 100.0 
Yes 36 0 .0 
Overall Percentage   56.1 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -.245 .223 1.213 1 .271 .783 
 
Block 1: Method = Enter 
 
Iteration History
a,b,c,d
 
Iteration -2 Log likelihood 
Coefficients 
Constant 
Application of EBM is 
necessary for the 
treatment of insomnia 
with Chinese herbal 
medicine. (1) 
I need to increase the 
use of evidence in my 
daily practice related to 
CHM for insomnia.(1) 
Have you been trained 
in the foundations of 
EBM? (1) 
Are you confident in 
your ability to find 
relevant research to 
answer your clinical 
questions? (1) 
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Step 1 1 78.656 -3.116 .846 1.366 .953 1.036 
2 75.314 -4.560 1.338 1.946 1.401 1.290 
3 75.113 -5.024 1.538 2.121 1.518 1.339 
4 75.112 -5.066 1.560 2.136 1.525 1.341 
5 75.112 -5.066 1.560 2.136 1.525 1.341 
a. Method: Enter 
b. Constant is included in the model. 
c. Initial -2 Log Likelihood: 112.454 
d. Estimation terminated at iteration number 5 because parameter estimates changed by less than .001. 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 37.342 4 .000 
Block 37.342 4 .000 
Model 37.342 4 .000 
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Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 75.112
a
 .366 .490 
a. Estimation terminated at iteration number 5 because parameter estimates 
changed by less than .001. 
 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 5.632 5 .344 
 
Classification Table
a
 
 
Observed 
Predicted 
 I use EBM to guide my practice related to 
CHM for insomnia. 
Percentage Correct  No Yes 
Step 1 I use EBM to guide my practice related to CHM 
for insomnia. 
No 38 8 82.6 
Yes 9 27 75.0 
Overall Percentage   79.3 
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a. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Step 1
a
 Application of EBM is necessary 
for the treatment of insomnia with 
Chinese herbal medicine.(1) 
1.560 .897 3.029 1 .082 4.761 .821 27.597 
I need to increase the use of 
evidence in my daily practice 
related to CHM for insomnia .(1) 
2.136 .764 7.826 1 .005 8.466 1.896 37.814 
Have you been trained in the 
foundations of EBM? (1) 
1.525 .690 4.888 1 .027 4.596 1.189 17.769 
Are you confident in your ability to 
find relevant research to answer 
your clinical questions? (1) 
1.341 .627 4.573 1 .032 3.824 1.118 13.076 
Constant -5.066 1.172 18.677 1 .000 .006   
a. Variable(s) entered on step 1: Application of EBM is necessary for the treatment of insomnia with Chinese herbal medicine; I need to increase the use of evidence in my 
daily practice related to CHM for insomnia; Have you been trained in the foundations of EBM? ; Are you confident in your ability to find relevant research to answer your 
clinical questions? 
 318 
 
Appendix 7.1 The approval letter issued by the Institutional Ethics Committee of 
Guangdong Provincial Hospital of Traditional Chinese Medicine, China 
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Appendix 7.2 The registration letter of external approval in RMIT 
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Appendix 7.3 The approved participant information and consent form (original Chinese 
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Appendix 7.5 The quotes in original Chinese and their English translations 
Chapter 
source 
Participant 
No. 
Original quotes in Chinese English translation 
Sub-
Theme 
1A 
P-001 
我觉得循证还是挺好的。因为说实话，有时候
啊，有时候你也对自己的疗效没有底的。那起码
从失眠来讲的话，起码要有这种标准的量表啦、
起码有这种客观评价的仪器啦，起码有这种啦。
要不然你就问一下病人“点啊？好点没啊？”病人
说“嗯嗯，好像好点了”，那你就在病历上写上好
转；尤其是住院的病人，越往后的时间肯定是越
往后越改善的啦。起码不能这样随随便便地说“改
善”，还是实实在在客观地评价。 
I think evidence-based medicine is generally good because 
sometimes you are uncertain about the therapeutic 
effectiveness. Specific for insomnia, standard scales and 
objective measurements from devices are the minimal [to 
confirm the effectiveness]. When you ask the patient ‘do you 
feel better?’ and the patient says ‘it seems better’. Youcan’t 
write ‘improved’ on the medical chart, particularly in the 
resident department because it [insomnia] may improve 
naturally as the time goes. ‘Improved’ can’t be stated so 
rashly, rather, an objective evaluation should be accountedfor.  
P-011 
就是说它能标准化地培训我们的医生，然后在短
时间内就掌握对主要病种就是单病种主要病种主
要证型的一个常规的诊疗。就是说比如说这个人
来了，我起码用这个特别好上手，然后又有证据
可以改善它的 70%或者 80%，所以这是非常好的
事情。 
It [Evidence-based medicine] can train our doctors in a 
standardised way and they [doctors] can master the 
conventional [procedures of] diagnosis and therapy for the 
common disease in a short term. When patients come, at least 
I have these [knowledge or skills of the conventional 
procedure] at hand with the evidence of 70-80% improvement 
rates. Therefore, it [this training] is a very good thing.  
P-007 
它改变了西医的这个临床看病的方式。你说在它
出现之后的话，就我知道的，在这个出现之前包
括中风的人来是吧，脑出血也好，脑梗塞中风的
也好，就直接用激素，那个时候就直接打激素
了，为什么？缓解脑部的组织的水肿嘛对不对？
但是循证医学出现以后呢，它用一些终点指标来
It [Evidence-based medicine] changes the clinical practice of 
western medicine after its appearance. As far as I know, 
steroid was injectedto the patients with stroke, either cerebral 
haemorrhage or ischemic stroke before its [evidence-based 
medicine’s] appearance. Why? It was considered to relieve the 
cerebral edema, right? After evidence-based medicine appears, 
the endpoint measurement finds that mortality is not reduced 
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衡量了以后发现这个打了激素以后呢，这个病情
是缓解倒是快了，但是这个人啊死亡率没有什么
改善，活的人，存活率反正还少一些，那么就是
说最后呢，你看现在我们中风入院的病人是没有
常规去注射激素的。 
and the survival goes down although the temporary state of 
condition improves rapidly when steroidis injected. Nowadays 
the patients with stroke are not commonly injected with 
steroid as you see.  
Sub-
Theme 
1B 
P-007 
每一项研究可能还是一个点一个侧面，那么到最
后的话呢，可能我们从每个侧面去摸象嘛，先摸
到这个耳朵后面摸到身子，最后摸到尾巴是吧，
有的人摸到象牙，但是我们把它全部综合起来以
后呢，还是就是说从一个更加科学的数据量更大
的一个层面去阐释我们的整个临床现象和疗效，
指导临床了，它重复的意义可能就不是简单的一
个跟师这种简单的重复了，是吧。那可能就是上
升到一种可能是对人才也好，或者是对中医学习
啊，它可能就会达到一个更加智能的高度了。 
Each study is a tiny part [of the great whole]. Everyone tries to 
explore it from every side, like [the blind people] touching the 
elephant, some touch on the ear, some on the trunk, some on 
the tail and some on the ivory. Finally, when we synthesize 
them [the different components], things turn to a level with 
more scientific and broader data for explaining the clinical 
phenomena and effectiveness as well as for guiding the 
clinical practice. Its reproducibility is not as simple as the 
apprentice repeating the master, but refers to a more intelligent 
process for either a person or the Chinese medicine education.  
P-006 
你真正要对学科贡献大的还是要那些大批的那一
类的高质量的循证去验证以后，你才能推动中医
大学科的发展。 
Significant contribution to the whole discipline derives from a 
large collection of high-quality evidence. Only after the 
validation [of Chinese medicine], the whole Chinese medicine 
discipline can be developed.  
P-006 
就是循证也，肯定能够促进你中医那些原材料
吧，就是各个临床试验它的一个水平的提高。 
Being evidence-based can probably advance the raw material 
[original studies] of Chinese medicine, which is to improve the 
clinical trials.  
P-003 
像现在的中医，要是不了解现代的这种科研方
法，不了解西医学啊这些的呢，很容易走偏。其
实中医这么多年，几千年来它本身就是容易走偏
的，所以的话很多时候这个玄之又玄就跟它的这
Nowadays, Chinese medicine may be on the wrong track when 
there is a lack of awareness of the modern scientific method 
and western medicine. Actually, over the past thousands of 
years, things might easily go wrong and in mysterious 
directions when it was just based on sensation [and emotion], 
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个感觉有关，它感觉偏向这儿就认为事实就是这
样子感觉偏向那就，就没有一个事实依据，所以
我觉得是要有这种科学思维的训练的，这样呢，
你的有效性就会更高。 
rather than the evidence of facts. So I think the therapeutic 
effectiveness could be much better with the training of 
scientific thinking.  
P-015 
我们做的临床试验，其实更多的是把我们这边有
效的话去再去求证，到底从科学的角度或是用科
学的办法去看看我们所认为有效的方法是不是真
的有效，这样子也可以避免我们一些主观的一些
因素吧，而且如果说真的有效的话，它也可以再
进一步细化说到底哪一部分是最重要的，可以精
化一些药物，甚至你也可以可以再做一些药理研
究说看看这个方案到底是怎么样起作用的。我觉
得就是一个不断深化还有确认的这样一个过程。 
Most of the time, we conduct clinical trials by a scientific 
approach to confirm the effectiveness of the therapy which we 
previously thought effective. This can avoid our subjective 
perception. For those with real effectiveness, it [clinical trial] 
can further investigate which component of the whole therapy 
is essential. Afterwards [after the effectiveness is confirmed 
and the essential component is identified], it is possible to 
simplify the therapy and to conduct pharmacological study to 
explain the mechanism. I think it is an ongoing process of 
deepening and further validation [of Chinese medicine 
therapy].  
P-001 
专家经验也还是要基于证据。现在很多这种专
家，十五、十一五做很多老中医的传承，当时那
个会我也去了。有人提出，这些名老中医的经验
很宝贵，要抢救式地这种。他就真的不论好和
坏，不知道治疗这个病有没有效，他的病案都拿
来，如珍如宝，其实没有经过评价是否治好的，
万一治死了也不管，都拿过来。这样就麻烦了，
就会出现，一些差的案例治疗经验进去了。传给
后人，治疗越来越差的。这就麻烦了。其实说实
话，也跟过其他一些名老专家，你发现门诊的复
诊率很低，回来的反应也不是很好，只是你治疗
一辈子，怎么也能凑齐一百个有效的案例吧。也
挺简单的，出本书，对吧。我觉得不应该这样，
应该还是要以证据为基础的专家。如果是这种专
家得出来的话，那你专家经验就是一种客观的。
The experts’ experience needs support from evidence. At the 
Rescue Stage [to preserve the wisdom and knowledge of the 
old generation of Chinese medicine practitioners in Mainland 
China], all patient cases were cherished equally no matter 
whether they were good or bad, effective or ineffective. This 
[preservation strategy] could a problem because the 
therapeutic experience of same bad cases could be included 
and passed down to the next generation [with equal 
importance as the good cases]. To be honest, I witness the 
practice of some eminent Chinese medicine practitioners and 
the feedback [from patients] is not always good. It is not 
difficult to have one hundred successful cases when the 
practice has lasted for the whole life [of a practitioner]. 
Following it is simple to publish a book, isn’t it? I think 
experts need evidence-based [thinking]. If so, the experience 
of these experts is pretty objective. Sometimes the summary of 
experts’ experience is not done well or someone might be 
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有时候专家经验有可能他自己总结得不那么好，
有时候是能用但说不出自己为什么这样用，或者
是说错了误会是另一种机理，也是有可能的。 
good at practice but bad at explanations. Misconception of the 
mechanism [of the treatment] is also possible.  
Sub-
theme 
2A 
P-005 
循证医学一定是现有外部证据，再有怎么用的经
验。 
External evidence is the necessary foundation of evidence-
based medicine and the experience of using it is followed. 
Sub-
theme 
2B 
P-008 
那么证据来讲我觉得有两层含义，从我的个人角
度，一个第一个是，嗯，这个证据，就是说这个
药物给用到病人身上出现的反应，那么出现了一
些客观的依据，那么这是一个方面。再一个就是
另外一个，就是说，嗯，所谓的就是说，通过这
么多的这种治疗啊，可信度，它的一个信度的问
题，从这个角度，对，信度和效度。其实我觉得
我的层面了解就是这个。 
Ipersonally think, there are two layers of meaning about 
evidence. On the one hand, evidence refers to patients’ 
responses to the medication, which is objective evidence. On 
the other hand, it is the reliability after the therapy is repeated 
many times. So, it [evidence] is about the reliability and 
validity, from my understanding.  
Sub-
theme 
2C 
P-004 
教科书是教条嘛，也是一代一代传承下来的，教
科书也是很可信的。那这时候，可能就是往大型
的研究，特别最近的这方面倾向。因为它相对来
说毕竟是最新的，应该是最有说服力的，都是在
不断进步的。 
[Concerning evidence], the textbook is reliable [evidence] 
certainly because it [the textbook] is the dogma and passed 
down from generation to generation. Nowadays, it [evidence] 
probably refers to large studies, particularly the latest ones. It 
is the most convincing because it is the latest and things are 
always in progressing.  
P-014 
这个我倒是比较喜欢。因为 meta分析的话，确实
是把这些 RCT它二次去评价过。就相当于就这一
次做访谈一样，你去问我我会给你一套结论，但
是你去问不同的人之后他的那个怎么说客观性和
全面性就会比较稍微高一点吧。所以就是他可能
得出来的结论更加全面，就是让我们自己本人去
I like it because systematic review or meta-analysis is a 
secondary analysis of RCTs. It is quite similar to our 
interview. I give you my comments. You also collect others’ 
comments. Then it [the whole interview] would be more 
objective and more comprehensive. That is to say, the 
conclusion [of a systematic review or meta-analysis] will be 
more comprehensive. [Because] More can be referenced than 
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参考的时候就会有更加多的侧面去考虑吧，就不
会说单纯看一个 RCT，它说有用我就用。因为它
这个 RCT能出阳性结果有很多原因，我们说就是
一果多因嘛，所以就是它可能跟这个地域的人群
特征或者是它这个拥有的经验，它取得这些患者
的标本啊就都很有关系，它这些东西跟我自己病
人的同质性有多高，那就很难判断。但是你作为
meta分析的话，你是看了更多的东西再去总结的
话，它的结论可能对我们的参考价值是更接近一
些。 
a single RCT. An RCT with positive results can be attributed 
to many things, such as the population characteristics in this 
area, or the experience, or the samples. It is hard to identify to 
what extent these characteristics are similar to our patients. 
However, meta-analysis is a summary of much information. 
Its conclusion can be a better reference within reach. 
P-013 
以前我们觉得那些证据有可能就是书本我看到课
本上的那些，然后后面跟着慢慢的知道那些科研
的一些东西，那你就目前来说我们说他，嗯……
共同的事实上就肯定是一个大型的一个多中心的
一个 RCT，那肯定是证据是最高的，是吧。对
吧，然后的话慢慢他会上升一个，哎，一个一个
综合的一个一个 meta分析综合得出一个结果，是
吧。最后可能他们那些 META分析那些可以做指
南了可能那个，那我们就来做指南。反正目前像
我们这些医生，我们这些还属于低级的，比较低
级的医生，主要还是看指南多点。 
In the past, we thought evidence was what we read in the 
textbook. As there is more awareness of scientific research, we 
believe that a large multi-site randomised controlled trial is the 
evidence with the highest level, isn’t it? A meta-analysis in an 
approach of synthesis [of many trials] provides an overview 
further, right? Then clinical practice guidelines include the 
meta-analysis. We, as junior doctors, read clinical practice 
guidelines most.  
Sub-
theme 
3A 
P-002 
分两种，我觉得。一种是如果现代医学知识的话
还是会通过文献的阅读和指南的学习；如果说是
有涉及到中医一部分的话，还会涉及到一些古籍
的阅读啊，然后就是跟比较有经验的医生的一种
To gain the knowledge of modern medicine, papers and 
guidelines are read while [gaining the knowledge of] Chinese 
medicine involves reading historical literature and learning 
from experienced practitioners.  
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学习。 
Sub-
theme 
3B 
P-011 
最多的还是跟师吧，然后研究的我可能也会尝试
一下，但是我觉得对我来说就是会有一点惴惴不
安，有的时候不知道自己辨的证和这个研究上叙
述那个证是不是那个。因为我在师的时候，我会
非常相信我的诊断标准和老师两个人是一样的，
因为他教给我就是这几条就诊断成这个。 
[The formulae] I use most are from the apprenticeship. I might 
try the formulae from the research. But I am a little worried 
about whether the syndrome I diagnose is the same as the one 
described in the research or not…In the apprenticeship, I am 
confident that my diagnostic criteria is exactly the same as my 
teacher because he/she teaches me to make a diagnosis. 
Sub-
theme 
4A 
P-002 
首先病人来是一个个性化的治疗，因为不是每一
个我都是用的同一个方子，尽管有共性的东西，
但是每一个病人他感受他犯了这个疾病的感受不
一样，他表现出来的症状不一样，我可能给的药
物也不一样。那病人也有他自己的这种选择，他
觉得我吃这个药那我觉得好，我吃下一个方子又
觉得不好，其实在这个过程当中也存在这个一个
病人的选择，他可能告诉你我觉得这个方子不太
好可能就不太想吃上面的这个方子。包括病人的
价值观也一样，病人有时候可能会更倾向于中医
的治疗，因为害怕西药的一个副作用，那这种时
候，我会更希望，中医中药在他的这个治疗当中
发挥最大的功效。 
The patient, to a certain extent, is the focus of the Chinese 
medicine practice. First, individualised therapy is provided 
because I don’t use the same formula for every patient. 
Although patients have something in common, everyone 
doesn’t feel exactly the same for the [same] disease and 
everyone presents distinct symptoms. So my prescriptions are 
not always the same. Patients also have their own decisions. 
For example, he thinks ‘I feel good about this formula and I 
don’t feel good about the next formula’. This is part of 
patients’ preferences, because he/she may not want to take the 
formula which he feels bad for. Sometimes the patient prefers 
Chinese medicine therapy [to western medicine] because he is 
scared of the side effect of western medication. In that 
scenario, I would have Chinese medicine play the greatest role 
in the therapeutic plan.  
P-003 
像中医，你证明不到它有没有效，但是它在实际
上在这么一个大的人群里面，这么多人得到了获
益。就像是在我家里，我的小孩基本上不吃西
药，我妈基本上不吃西药，我的七姑妈八姨婆去
西医院不能解决的问题来找我，很多问题也都能
得到帮助，所以我就是即使没有这么高级别的证
据支持，但我还是依然相信中医是有效的。这是
I think, Chinese medicine does benefit a large population 
although you can’t prove its efficacy now. Like my family, my 
kids and my mum, they don’t take western medication. My 
relatives seek help from me [Chinese medicine practitioner] 
when their problems can’t be solved by western medicine 
hospitals. I can resolve most of them. So I still believe Chinese 
medicine is effective because of the [positive] feedback I 
collect from the real world even though there is a lack of 
 335 
 
你从实际的反馈得到的对吧。 support for high level evidence.  
Subm-
theme 
4B 
P-007 
我觉得啊看古籍呢，他是在原有思路上的添砖加
瓦，流程病症，我们就一直把伤寒论给他背书啊
是吧，然后各家各派的他是按照这个思路去的，
要把各家各派各系积累的经验往上面进行一个堆
积。如果是新的这种只看新的不看古代典籍这些
东西啊，那么他也能看病，但是他这种怎么说
呢，向其他方面的这种延展性就差了。比如说我
都是看报道这个药，对于这个失眠有效果，那么
我后面用这个药就行了，是吧，也有效果，我只
要用就有效果。但是如果让这个医生没有这个药
可用的话，他怎么去治疗又是一个问题了。 
I think, reading classical literature is an advancement of the 
thinking. We recite ‘Shan han lun’ [a classical monograph of 
Chinese medicine published in Donghan Dynasty of pre-
modern China] and according to it we develop schools of 
thoughts. Following, the experience in all schools of thoughts 
is added to it again. If one only reads the new and abandons 
the classical literature, he could treat disease generally but he 
is a lack of flexibility. For example, he uses the effective 
formula in the report [of the research]. Of course it works in 
practice. But if the formula ran out, how could he treat a 
patient? It is hard to say.  
Sub-
theme 
5A 
P-001 
证据很高很好，例如就告诉你螺丝这个质量好，
是金做的，但是没有告诉你是六角螺丝，我现在
是要开这个螺丝，不是要怎么怎么样，你要告诉
我一堆无关的东西，很好，我也觉得很好，可是
真的用不上。 
High level evidence is, like a high-quality screw made of gold. 
The information [the high-quality screw is made of gold]is 
irrelevant to me. Because I am going [to find a suitable 
screwdriver] to loosen the screw but it [the information] 
doesn’t tell whether it is the hexagonal screw or not. I know it 
[the evidence] is good, but it is useless [for my practice].  
P-011 
事实上我觉得是这样的，就是我觉得那些，就是
特别你刚才说的那个随机对照试验是吧，然后完
了之后它可能就会设好多好多的限制，然后去筛
选这个病人，因为它要求基线一致嘛是吧，最后
筛选出来是特别单纯的病人，然后用了一个特别
单纯的手段然后效果特别好，这个我觉得是确实
会可能出现了，但实际上在临床中我们不可能就
遇到如此单纯的病人，或者说不可能所有的病人
都是如此单纯，所以它在应用的时候就变成范围
If fact, the randomised controlled trial sets lots of criteria and 
accordingly patients are screened because similar baseline is 
required. And then the patients included are extremely ‘pure’ 
and a ‘simple’ intervention always results in a good result. I 
think it is true indeed. But in fact we can’t meet such a ‘pure’ 
patient in clinical practice or say not all the patients are as 
simple as it is. So the application will fall into a narrow scope.   
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是会比较窄，就是这一类的研究。 
P-011 
如果确实是有一个方子对于某一型的，就是他已
经分析得非常清晰了，就是说什么汤治疗某一体
质或者什么证型的哪一类的很明确的，还是从临
床中来的，然后再发展的指导大家，我觉得这是
非常好的。 
If there is [evidence that] a formula is specific for a pattern, 
that is to mean, it [the evidence]can tells what formula treats 
what pattern or syndrome and these things[the research 
questions] originate from clinical practice, it would be better.  
Sub-
theme 
5B 
P-006 
为什么现在反对呢，就是中医那些循证，那些原
材料质量不高出来的循证跟实际差别有点大。那
真的没办法嘛，巧妇难做无米之炊呀，你原材料
就是这样，你出来的循证的证据跟西医那些循证
出来的证据那个就是对临床的指导意义是不一样
的嘛。比如说西医它那个临床试验水平很高，它
循证出来那个对……水平也是很高，并且它跟临
床非常……切合临床的嘛，所以他指导意义就非
常大，人就，他用，临床意义大它用起来好用，
那他肯定是很认可的。你比如中医做了一个循
证，它出来了以后的结果，那真的可能跟临床的
实际情况差别会很大的嘛。那这肯定是一个阶
段，慢慢的，你所有的那些那些试验水平都高
了，它出来的跟临床的拟合度就非常大。慢慢慢
慢接受的人就很，就会，就会很多的。 
Why someone is against evidence-based Chinese medicine? 
That’s because the [Chinese medicine] evidence made of the 
raw material [original study] with poor quality differ greatly 
from the reality. A good meal cannot be made without rice 
even for a skilful housewife. Certainly its [Chinese medicine 
evidence’s] value of guidance differs from the evidence of 
western medicine. The quality of clinical trials for western 
medicine is high and [the clinical trial] matches the clinical 
practice. So the value of guidance [of western medicine 
evidence] is significant. People who find it [the evidence] is 
useful in practice will go for it absolutely. But it [there is a 
lack of high quality evidence of Chinese medicine] is only a 
temporary phase. Gradually, when all the clinical trials turn to 
high quality, their results will match the clinical practice much 
more. More people will go for it naturally.  
Sub-
theme 
5C 
P-001 
RCT这种设计啊，还是受到西医、西药这套用药
思维的影响，西医关注的点西医的 RCT都有，诊
断标准、排除标准，都是一套套的；但是我中医
关心的东西，症状、舌头、脉象，一个都没有。
The design of an RCT is influenced by the therapeutic 
thinking of western medicine. What western medicine focuses 
on, such as the criteria of disease diagnosis, are presented 
comprehensively. But nothing is presented [in an RCT] about 
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它质量很高，都是用中药治疗，但只能说这个中
药只适合在西医的方法或思维下用，OK没问
题，但是中医真心用不起来，因为我关心的点它
一个都没有报道出来，怎么用呢？而且实际上，
疗效，例如酸枣仁汤治疗失眠，这个疗效总不可
能百分百吧，总有治不好的吧。你疗效 80%，那
你治疗这个病人的把握也是 80%，其实也没能真
正用好酸枣仁汤。它为什么有 20%没有治好，要
不要再细分啊，纳入标准要不要再严，纳入标准
要不要加入一些中医的特征进去，这样子。 
what Chinese medicine emphasizes, such as specific 
symptoms, tongue and pulse. Even when the Chinese medicine 
evidence is of high quality, it can be applied in western 
medicine practice only. It is useless for me because nothing of 
Chinese medicine interest is reported...And with respect to 
therapeutic effectiveness, for example Suanzaoren decoction 
for insomnia, its effective rate is not 100% [in an RCT]. If the 
effective rate is 80%, then your confidence in successfully 
treating a patient is 80%. That also means you are not using 
Suanzaoren decoction well. Why is there another 20% [the 
ineffectiveness rate]? [When designing the next RCT] we may 
need to consider further stratification [of the participants], 
narrowing the inclusion criteria or including the Chinese 
medicine characteristics into the eligibility.  
P-007 
因为西医来说的话，张三李四王麻子给你打地塞
米松，只要剂量是一样的，它效果就是一样的，
没有区别的，谁打都一样，护士打也一样。但是
中医不一样啊，中医张三李四王麻子开的同一个
方剂剂量一样，效果它是不一样。2.第一，这个
病人拿到方以后，他不同的药店去买药材或者在
医院买药材，这个药材质量就决定了疗效的一部
分效果啦是吧。比如说这个药材里面用的这个党
参是一极品，另外一剂药用的可能就是次级品那
怎么办。因为市场上中药的话，它分为几个品相
的。不同品相，它价格不一样，那效果也不一
样。西药又不会，地塞米松，我就这个浓度了，
In western medicine, dexamethasone injected by anyone, as 
long as it remains the same dose, has the same effect. Nothing 
differs. However, Chinese medicine is different. The same 
formula with the same dose prescribed by different people 
may have different effects. Then, patients may buy the herbs 
in different stores or hospitals after they receive the 
prescription. The herb quality decides part of the effect, right?  
[So the herbal source also contributes to effectiveness.]In 
addition, although placebo effect should be removed when 
conducting a research, placebo effect contributes to the 
effectiveness in clinical practice. We need to take great 
advantage of the placebo effect. For example, the formula 
prescribed by the senior practitioner has superior effectiveness 
to the same one prescribed by a young practitioner. That is 
 338 
 
都是这个浓度了是吧，我这个能保证啊。就存在
这种问题，而且其次还是说这个就说这个安慰剂
效应的问题，但是做研究就要排除安慰剂效应，
但是安慰剂效应的话，对于临床医生来说，它是
疗效啊。它是疗效，我们要充分地利用这个安慰
剂效应。就是一开方的话，一个老中医还可以，
年轻的医生，剂量一样方一样，但是开出来这个
老中医的效果可能会好一点，因为病人一开始从
就诊到治疗还要服药，他整个就产生一种非常强
的信赖感啊。 
because the patient has the strong trust [in the senior Chinese 
medicine practitioner] during his initial visit and therapy.  
P-003 
RCT，以前就觉得这个很客观，应该是这样说
吧，很真实很客观；但是呢，现在看起来仍然是
客观的，但是它不一定是适合中医研究的，因为
中医的可变性太大了。你要是看疗效，那就是说
影响的因素非常多。一个是药物本身，就已经是
非常不可控，因为它是由一个药方组成的，药方
里每味药它有数种有效成分，所以你就是要搞清
楚它们这个关系，它们的这个治疗的效果就是已
经是特别的困难。然后，但是中药应用的过程之
中又涉及到很多的因素，包括就是心理因素，心
理暗示因素，包括就是这个中国人的信仰这些问
题。还有就是实施过程之中，因为你这么一个复
方中药的应用过程，就是你的这个研究者啊，就
是可以控制，就是可变性也是比你单纯用一味西
药，譬如我单纯用这个舒乐安宁，让研究者给病
RCT, I previously thought it was objective, being true and 
objective. But it may not fit the research into Chinese 
medicine though it is objective because the variation of 
Chinese medicine is huge. There are many factors leading to 
the therapeutic outcome of a Chinese medicine therapy. First, 
the medication is out of control because it is a formula of 
multi-herb and every single herb has many active ingredients. 
So it is hard to know their causal relationship to the 
therapeutic outcome. Secondly, the practice of Chinese herbal 
medicine involves lots of factors, such as psychological 
factors and Chinese population’s belief. Thirdly, for the 
implementation, the use of a multi-herb formula by the 
research personnel is of more variability than the use of a 
single drug such as estazolamum. The way how research 
personnel provide with the therapy to the patient is a big 
difference. So I don’t think it might be the most appropriate 
method.  
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人用的差别是很大的。所以我觉得不一定是最适
合的一个方法。 
P-013 
做 RCT的话我不知道中医药那种，就一条方里面
不同的人，然后加减的那些，很变化，有有几个
要加减的，他样子符不符合。就是这种，如果我
们是西医的话呢它的 RCT肯定是很严格的，是
吧。他那些药的剂量啊，不管你那些这些品种都
是一样的，但是你中医，中医中药，你肯定要根
据不同人来加减，你不可能一条方每个人都这样
子用，所以你这样子做，做 RCT也，很，有点
怪。 
Concerning conducting an RCT, I have no idea whether the 
Chinese herbal medicine, modified for individuals meets the 
criteria [of an RCT] nor not. Western medicine sets strict 
criteria for an RCT, right? The dose and the brand of the drugs 
are exactly the same. But Chinese herbal medicine is 
commonly modified according to individuals. You can’t use 
one formula for everyone. If you did it in an RCT like this, it 
would be odd.  
P-001 
譬如有时候病人来了，你开了个方给他，例如开
了个酸枣仁汤对吧，你觉得他症状需要加一味大
黄进去，他下次来说好了，你把这种功劳归到大
黄身上，因为是你自己加进去的，不合适的，因
为他整个方都有吃的。但是你很麻烦啊，很难总
结每一味药加减的功效。但是没关系的，这种数
据慢慢积累，形成一个很大的 data的话，数据分
析的方法肯定能帮你分析出一个单条的点。譬如
说，对照组用酸枣仁汤，治疗组用酸枣仁汤加大
黄，这种经验总结的效率太慢，也不能现实；宁
愿真真实实的、每个病人用了什么药、多少克，
症状哪个改善了，把这些数据弄好，几千条肯定
是不行的，上几十万条之后，肯定不是一个医生
的能力啦，一片医生的能力、大数据，数据分析
For example, a patient visits you and you prescribe a formula, 
like Suanzaoren decoction. Then you add Dahuang, another 
herb to it because you think it fits his/her symptoms. The 
patient improves in his/her second visit. It is inappropriate to 
attribute the benefit to Dahuang only because the patient takes 
the whole formula. It is difficult to identify the contribution of 
each herb in every modification process. But when the data is 
accumulated to a big pool, the data-analysis can reveal it.  It is 
in low efficiency and not practical for having a study, like 
comparing Suanzaoren decoction to Suanzaoren decoction 
plus Dahuang. I would prefer to record the data that what herb 
and how many grams the patient takes as well as which 
symptom is improved [every time]. It may not work for only 
hundreds of records. Hundreds of thousands of records from a 
large group of doctors rather than a single doctor, a big data, 
 340 
 
的方法很快就会告诉你关联点在哪里。这样的经
验总结才会快。 
the data-analysis could tell you their relationship.  
 
 
 
